

# MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS NINE AND TEN YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1963 AND MARCH 1964)

ROBERT A. CONARD, M.D., LEO M. MEYER, M.D., WATARU W. SUTOW, M.D., AUSTIN LOWREY, M.D., BRADFORD CANNON, M.D., WILLIAM C. MOLONEY, M.D., ALVIN C. WATNE, M.D., ROBERT E. CARTER, M.D., AROBATI HICKING, PRACTITIONER, RICHARD HAMMERSTROM, PH.D., BYRON BENDER, PH.D., ISAAC LANWI, PRACTITIONER, EZRA RIKLON, PRACTITIONER, AND JETON ANJAIN, PRACTITIONER

Uplon, L. L. New York

REPOSITORY BALL RECORDS
COLLECTION UNARSHALL ISLAMDS
BOX NO. MEDICAL DEAT. POBLICATIONS



### BROOKHAVEN NATIONAL LABORATORY

ASSOCIATED UNIVERSITIES, INC.

under contract with the

UNITED STATES ATOMIC ENERGY COMMISSION

5005779

#### LEGAL NOTICE

This report was prepared as an account of Government sponsored work. Neither the United States, nor the Commission, nor any person acting on behalf of the Commission:

A. Makes any warranty or representation, expressed or implied, with respect to the accuracy, completeness, or usefulness of the information contained in this report, or that the use of any information, apparatus, method, or process disclosed in this report may not infringe privately owned rights; or

B. Assumes any liabilities with respect to the use of, or for damages resulting from the use of any information, apparatus, method, or process disclosed in this report.

As used in the above, "person acting on behalf of the Commission" includes any employee or contractor of the Commission, or employee of such contractor, to the extent that such employee or contractor of the Commission, or employee of such contractor prepares, disseminates, or provides access to, any information pursuant to his employment or contract with the Commission, or his employment with such contractor.

#### PRINTED IN USA PRICE \$5.00

Available from the
Clearinghouse for Federal Scientific and Technical Information
National Bureau of Standards
U.S. Department of Commerce
Springfield, Virginia

May 1965

1450 copies

# MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS NINE AND TEN YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1963 AND MARCH 1964)

#### **NINE-YEAR SURVEY**

ROBERT A. CONARD, M.D., LEO M. MEYER, M.D., WATARU W. SUTOW, M.D., WILLIAM C. MOLONEY, M.D., BRADFORD CANNON, M.D., AROBATI HICKING, PRACTITIONER, RICHARD HAMMERSTROM, Ph.D., AND EZRA RIKLON, PRACTITIONER

with the technical assistance of
WILLIAM A. SCOTT, DOUGLAS CLAREUS, IRVING JONES, ERNEST LIBBY,
LAWRENCE COOK, KOSANG MIZUTONI, SEBIO SHONIBER, AND KALMAN KITTIEN

#### TEN-YEAR SURVEY

ROBERT A. CONARD, M.D., LEO M. MEYER, M.D., AUSTIN LOWREY, M.D., ALVIN C. WATNE, M.D., ROBERT E. CARTER, M.D., AROBATI HICKING, PRACTITIONER, BYRON BENDER, Ph.D., ISAAC LANWI, PRACTITIONER, AND JETON ANJAIN, PRACTITIONER

with the technical assistance of
WILLIAM A. SCOTT, DOUGLAS CLAREUS, WILLIAM WAITHE, 10
KOSANG MIZUTONI, SEBIO SHONIBER, KALMAN KITTIEN, AND W. GAYS\*

\*Massachusetts General Hospital, Boston, Massachusetts

<sup>&</sup>lt;sup>1</sup>Brookhaven National Laboratory, Upton, New York <sup>2</sup>South Nassau Communities Hospital, Rockville Centre, New York <sup>3</sup>M.D. Anderson Hospital, University of Texas, Houston, Texas <sup>4</sup>Boston City Hospital, Boston, Massachusetts

<sup>\*</sup>Department of Public Health, Trust Territory of the Pacific Islands
\*American Foundation for the Blind, Washington, D.C.
\*University of West Virginia, Morgantown, West Virginia
\*State University of Iowa, Iowa City, Iowa

\*New York University, New York, New York

BROOKHAVEN NATIONAL LABORATORY UPTON, NEW YORK

#### **CONTENTS**

Introduction
Summary of Past Findings
Penetrating Radiation
Beta Irradiation of the Skin
Internal Irradiation
Other Studies
Difficulties Associated With the Examinations
Comparison Populations
Organization
1963 Survey (9 Years Post Exposure)
1964 Survey (10 Years Post Exposure)
Procedures
Physical Examinations
Laboratory Procedures
FINDINGS
Interval Medical History
Illnesses
Deaths
Births
Congenital Anomalies.
Miscarriages and Stillbirths
Physical Examinations
Adult Examinations
Anthropometric Studies
Pediatric Examinations.
Children Examined 1963
Children Examined 1964
Results of Physical Examinations.
Thyroid Nodules
Growth and Development Studies
Ophthalmological Findings
Residual "Beta Burns"
Laboratory Examinations.
Hematological
Rongelap Population
Leukocytes
Neutrophils
Lymphocytes
Eosinophils, Monocytes, and Basophils
Platelets
Erythropoietic Elements
Statistical Analysis of Rongelap Blood Data Over Past Four Years
Ailingnae Population
Utirik Population
Children of Exposed Parents
Bone Marrow Examinations
Red Cell Mass and Plasma Volume Studies

#### **CONTENTS**

Other La	boratory Studies	40
	osome Studies	
	ic Survey	
	gical Studies	
	ein Bound Iodine Determinations	
	Acid Determinations.	
	Ag System	
	chemical Analyses of the Urine	
	Discussion	
	rus	
Mortality		45
,		
	iscarriages, Stillbirths, and Genetic Effects	
	d Development Studies	
	nt of Thyroid Nodules	
	Y	
	s"	
	Absorbed Isotopes	
	ninations	
	MENTS	
Appendix 2.	at Various Times After Exposure	51
	at Various Times After Exposure	52
Appendix 3.	Utirik Group Mean Blood Counts at Various Times After Exposure	
Appendix 4.	Individual Hematological Findings, 1963	
Appendix 5.	Individual Hematological Findings, 1964	
Appendix 6.	Individual Basophil Determinations, 1963 and 1964	
Appendix 7.	Individual Adult Physical Findings	
Appendix 8.	Individual Children Physical Findings	
Appendix 9.	Anthropometric Study of Adult Marshallese	
Appendix 10.	Nausea and Vomiting Following Exposure	
	to Fallout of Marshallese, March 1, 1954	133
Appendix 11.		
	1957 Through 1964, on Rongelap Control (Unexposed) Children	134
Appendix 12.		
	1956 Through 1964, on Children Born to Exposed Parents	138
Appendix 13.		
	1954 Through 1964, on Rongelap Exposed Children	140
Appendix 14.	Supplementary Anthropometric Data, Rongelap Control Children	
Appendix 15.	Supplementary Anthropometric Data on Children Born to Exposed Parents	
Appendix 16.	Supplementary Anthropometric Data, Rongelap Exposed Children	
Appendix 17.	Serum Folic Acid Levels, 1963.	
Approvers 10	,	167

### MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS NINE AND TEN YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1963 AND MARCH 1964)


#### Introduction

The results of a medical survey of the people of Rongelap in the Marshall Islands, carried out in March 1963 and March 1964, 9 and 10 years after the accident, are presented in this report. These people had been accidentally exposed to fallout radiation following a detonation of a high yield thermonuclear device during experiments at Bikini in the Pacific Proving Grounds in March 1954. An unpredicted shift in winds caused a deposition of significant amounts of fallout on four inhabited Marshall Islands to the east of Bikini (see Figure 1) and also on 23 Japanese fishermen aboard their fishing vessel, the Lucky Dragon. Of the inhabitants of the island of Rongelap, 105 nautical miles away from the detonation, 64 received the largest fallout exposure: an estimated dose of 175 rads of whole-body gamma radiation, contamination of the skin sufficient to result in beta burns, and slight internal absorption of radioactive materials through inhalation and ingestion. Another 18 Rongelap people away on a nearby island (Ailingnae), where less fallout occurred, received only an external gamma dose of about 69 rads. There were 28 American servicemen on the island of Rongerik further to the east who received about the same amount of radiation as did the Rongelap people on Ailingnae. Lastly, 157 Marshallese on Utirik Island, about 200 miles further east, received about an estimated 14 rads of whole-body radiation. The fallout was not visible on this island and no skin effects developed.

The exposed people were evacuated from these islands by plane and ship about two days after the accident and taken to Kwajalein Naval Base about 150 miles to the south, where they received extensive examinations for the following three months. In view of the generally negative findings on the American servicemen, they were later returned to their duty stations. The Utirik people were also allowed to return to their home island, where

radioactive contamination was slight enough to allow safe habitation. Because Rongelap Atoll was considered to be too highly contaminated, a temporary village was constructed for the Rongelap people on Majuro Atoll several hundred miles to the south, where they lived for the following 3½ years and were examined at yearly intervals by a special medical team. In July 1957, after careful evaluation of the radioactive contamination situation, Rongelap Island was considered safe for habitation. A new village was constructed, and the Rongelap people were moved there by Navy ship. The annual medical surveys have since been carried out on Rongelap Island.

A group of more than 100 Rongelap people, who were relatives of the exposed people but had been away from the island at the time of the accident, moved back with the Rongelap people to their home island and have served as an ideal comparison population for the studies. This number has since increased to about 200. Following the initial survey of the Utirik people on Kwajalein in 1954, a repeat survey was carried out in March 1957. In addition, during the past survey,



(March 1, 1954), Marshall Islands.

Table 1
Summary of Marshallese Populations Examined Since 1954

	Group	No. in group	Series
	Сомр	ARISON POPULATIONS	
1954 April	Majuro	115 (adults and children)	700-817
1956	Rita	57	1000-1082
1957	Rongelap	100 "	801-900
1958	Rongelap	170 0 0	801-970
1964	Rongelap	801-1058	
	Ехр	osed Populations	
	Rongelap (175 r)	67 (includes 3 in utero; annual exams)	1-86
	Ailingnae (70 r)	19 (includes 1 in utero; annual exams)	1-86
	American servicemen	28 (examined 1954 only)	401-428
	Utirik (14 r)	157 (examined every 3 to 4 years)	2101-2257
	Unexposed Chil	dren ( $<$ 10 years as of 1964)	
	Rongelap & Ailingnae	45 (exposed parents)	87–136
	Rongelap	75 (unexposed parents)	801-1058
	Utirik	20 (exposed parents)	2258-2278

as in the previous surveys, a visit was made to Kwajalein and Majuro Atolls for examination of a number of Rongelap people, now residing at these atolls, and also groups of children who represent part of the control group used for the growth and development studies of the exposed children.

Table 1 lists the various populations that have been examined since 1954.

The accumulation of data from these surveys is becoming increasingly voluminous. Since conditions have not been favorable for performance of extensive statistical analyses or use of electronic computing procedures to store and manipulate the data, the annual survey reports published by this Laboratory are made as complete as possible. This report, therefore, includes a considerable amount of raw data, much of it in appendices, so that others may have an opportunity to make further calculations if desired.

#### **Summary of Past Findings**

Reports have been published on the findings of surveys made at the following times after exposure: initial examination, 6 months, 1 year, 2 years, 4 years, 5 4 years, 6 5 and 6 years, 7 years and 8 years. The following is a brief summary of the findings previously reported.

During the first 24 to 48 hr after exposure, about 3/3 of the Rongelap people experienced anorexia and nausea. A few vomited and had diarrhea. In appendix 10 the individual histories of nausea and vomiting are tabulated. Many also experienced itching and burning of the skin, and a few complained of lachrymation and burning of the eyes. Following this, the people remained asymptomatic until about 2 weeks after the accident, when cutaneous lesions and loss of hair developed, due largely to beta irradiation of the skin. It was apparent when the people were first examined, a few days after exposure, that the lymphocytes were considerably depressed and that significant doses of radiation had probably been received. In addition to the whole-body dose of radiation and the beta irradiation of the skin, radiochemical analyses of the urine showed that measurable amounts of radioactive material had also been absorbed internally. The effects of the radiation can best be summarized under three headings according to the mode of exposure: penetrating irradiation, skin irradiation, and internal irradiation.

#### PENETRATING RADIATION

One of the earliest findings indicative of significant exposure in these people was lowering of levels of leukocytes and platelets of the peripheral blood. This was most marked in the 64 people on Rongelap who had received 175 rads, and was less marked in the other groups receiving less exposure. The hemopoietic depression was roughly proportional to the dose of radiation received. Even in the 157 Utirik people who received only an estimated 14 rads, it was possible to distinguish slight platelet depression in the group as a whole. The smaller group on Ailingnae and Rongerik showed peripheral blood levels between those of the high and low exposure groups. The chronological records of blood findings in the Rongelap and Ailingnae groups are presented in Figures 20, 27, and 32 and in Appendices 1 and 2, and in the Utirik group in Appendix 3.

Lymphopenia of about half the level of the comparison Marshallese population was evident when the Rongelap people were first examined on their arrival at Kwajalein 3 days after exposure. In children <5 years of age the lymphocytes dropped to 25% of the levels in the comparison children, but showed a slight rise during the following weeks. The depressed level was maintained with only slight increase noted by one year. In the following year, mean counts approached the levels of the comparison population and have generally remained slightly below.

Neutrophil levels fluctuated considerably during the first month; possibly this was related to the prevalence of beta burns of the skin during that period. Neutrophil depression became evident by 5 and 6 weeks post exposure with levels reaching about half that of the comparison population in the adults and slightly lower in the children <5 years of age. This degree of neutropenia was insufficient to result in any apparent increased infectious processes, and indeed it was noted that neutrophilic leukocytosis was possible in people showing casual infections at this time. Neutrophil levels recovered more rapidly than lymphocyte levels and reached near control levels by one year. Subsequent annual surveys have revealed that recovery does not appear to be complete, particularly in younger and older age groups.

Platelet counts showed less fluctuation than other blood counts and fairly consistently showed increasing depression, reaching levels of about 30% that of the comparison population by the 4th week. A spurt of recovery to about 75% of comparison levels occurred during the following few

weeks, which was followed by slower recovery but with mean levels never reaching higher than 90 to 95% that of the comparison population during the 8 years post exposure.

Erythropoietic depression has not been a consistent finding as with the leukocytes and thrombocytes. Slight depression of red blood counts, hematocrits, and hemoglobin has been noted at times. No gross abnormalities of bone marrow smears were reported at 6 months post exposure. At 8 years, examination of 9 bone marrow aspirations from exposed people showed a reduced myeloid-erythroid ratio wth abnormalities of the erythroid and myeloid precursors in 5 cases.

Depression of peripheral blood elements in the Ailingnae and Rongerik groups was not so pronounced as in the Rongelap group. However, a slight lag in complete recovery in the Ailingnae peripheral blood count has also been noted.

The persistent depression of peripheral blood elements in the exposed people makes it appear likely that there is slight residual bone marrow damage.

A general anemic tendency has been evident in both exposed and unexposed Marshallese. Price-Jones curves, on the average, showed a slight microcytic tendency. Serum iron levels have generally been normal, and the cause of this anemic tendency has been undetermined.

Reticulocyte counts have been about the same in the exposed as in the unexposed people.

Except for radiation-induced lesions of the skin, patchy epilation, and early gastrointestinal symptoms, clinical examinations have revealed no disease processes or symptoms which could be related directly to radiation effects. No prophylactic or specific therapy of radiation effects was ever considered necessary or given. Epidemics of chicken pox and measles that occurred showed no greater incidence or severity in the exposed than in the unexposed Marshallese people.

During the first months post exposure about half of the exposed group exhibited loss of weight of several pounds. This may possibly have been related to their radiation exposure, although it is difficult to rule out effects possibly due to change of environment.

At 3 years post exposure the *immune response* to primary and secondary tetanus antitoxin was tested and found not to be significantly different in the exposed compared to the unexposed populations.

Five persons in the exposed population died of disease: (1) a 46-year-old man with hypertensive heart disease which had been present at the time of exposure, who died 2 years after the accident; (2) a 78-year-old man who died, 3 years after exposure, of coronary heart disease complicating diabetes; (3) a 35-year-old man who died of acute varicella, 4 years after exposure, who had received only 69 rads, having been on Ailingnae at the time of the fallout; (4) a 60-year-old woman who died of a cancer of the ovary at 5 years after exposure; and (5) a 78-year-old woman who died of traumatic vertebral fractures at 8 years after exposure. There was no apparent relationship between any of these deaths and radiation exposure. Four deaths have occurred in the comparison population. The five deaths that have occurred in the exposed people since exposure represent a mortality rate of 7.6 per 1000 population per annum, compared with 8.3 for the Marshall Islands as a whole.

Growth and development studies on the children (height, weight, anthropometric measurements, radiographic studies for bone age) have revealed that slight retardation in growth and development has occurred in the exposed boys who were under 12 years of age at the time of exposure, particularly those 12 to 18 months of age at exposure. Only slight immaturity was noted in the exposed female children. It was also noted that children born of exposed parents were slightly retarded and that they had slightly lower levels of neutrophils, lymphocytes, and platelets, compared with male children of unexposed parents. However, since the latter children were on the average 4 months older, the data did not justify a conclusion that the difference in stature was associated with the exposure of the parents.

It was difficult to evaluate the effects on fertility. However, a review of the birth rate of the exposed group over the past 8 years seems to indicate no noticeable effect of their exposure on fertility. The 35 births represent a rate of 53 per 1000 population per annum compared with 37.3 for the Marshall Islands (1957). The 25 births over a 5-year period for the comparison population represent a rate of 21.8 per 1000 population. A somewhat greater incidence of miscarriages and stillbirths was noted in the exposed women during the first 4 years after exposure, but because of the paucity of vital statistics on the Marshallese and the small number of people involved, the data are not readily amenable to statistical analysis.

A cardiovascular survey of the adults (1959)<sup>7</sup> showed no outstanding differences between the exposed and unexposed groups. The people appeared to have less hypertension on the whole than is noted in people in the continental United States.

An arthritis survey (1959)<sup>7</sup> showed no great differences between the exposed and the unexposed people, and about the same incidence as is seen in American populations.

Ophthalmological surveys showed no remarkable differences between the exposed and unexposed groups except possibly a slightly greater number of cases of pterygia, pingueculae, and corneal scars in the exposed group. It is not known whether this finding is of any significance in relation to their radiation exposure. Slit-lamp observations showed no opacities of the lens characteristic of radiation exposure. As a whole, visual and accommodation levels in the Marshallese appeared to be above the average in the U.S. population.

Dental surveys<sup>7</sup> showed no significant differences in caries rate between exposed and unexposed groups. However, the incidence and severity of peridontal disease was slightly greater in the exposed group. It is not known whether or not this finding is related to radiation effects. The poor oral hygiene generally observed in the Marshallese had its usual results, namely, high caries rate in teenage children, severe peridontal lesions in adults (heavy calculus and loss of alveolar bone), and edentulous mouths in the aged. Radiation exposure did not appear to have affected developing dentition in the exposed children.

Late effects of radiation. Various parameters usually associated with aging were measured or estimated on a 0 to 4+ scale (skin looseness, elasticity, and senile changes; greying of the hair and balding; accommodation, visual acuity, and arcus senilis; hearing; cardiovascular changes including blood pressure and degrees of peripheral and retinal arteriosclerosis; neuromuscular function; and hand strength). Comparison of these measurements in exposed and unexposed individuals of the same age groups showed no apparent differences. A biological age score was calculated for individuals and groups by use of an average percentage score. Life shortening effects of radiation have not been apparent. As noted, the mortality rate was about the same in the exposed as in the unexposed people.

The one case of cancer that developed in the exposed group occurred at 5 years after exposure, too soon, it is believed, to bear any particular relation to radiation exposure. Leukemia surveys including physical findings, studies of white cell counts and types, alkaline phosphatase staining, and basophil counts of 4000 white cells showed no evidence of leukemia or leukemic tendency. One child in the irradiated group has had slightly elevated basophils but no other positive findings. The cardiovascular and arthritis surveys, as well as the general results of the physical examinations, have not shown any apparent increased incidence of degenerative diseases in the exposed people. No radiation-induced cataracts have been observed in any of the exposed people.

Genetic effects have not been specifically studied because of the small number of people involved. No apparent radiation-induced genetic changes have been detected on routine physical examination in the first-generation children of exposed parents, with the possible exception of suggestive evidence of increased miscarriages and stillbirths in the exposed women and the slight retardation of growth noted in the male children of exposed parents.

#### BETA IRRADIATION OF THE SKIN

It was impossible to get an accurate estimate of the radiation dose to the skin. Beta burns of the skin and epilation appeared about 2 weeks after exposure, largely on parts of the body not covered by clothing. About 90% of the people had these burns, and a smaller number developed spotty epilation of the scalp. Most of the lesions were superficial; they exhibited pigmentation and dry, scaly desquamation, and were associated with little pain. Rapid healing and repigmentation followed. Some lesions were deeper, showed wet desquamation, and were more painful. A few burns became secondarily infected and had to be treated with antibiotics. Repigmentation of the lesions gradually took place in most instances, and the skin appeared normal within a few weeks. However, in about 15% of the people, deeper lesions, particularly noted on the dorsum of the feet, continued to show lack of repigmentation with varying degrees of scarring and atrophy of the skin. By 6 years the only residual effects of beta radiation of the skin were seen in 10 cases which showed varying degrees of pigment aberrations, scarring,

and atrophy at the site of the former burns. During the past several years an increased number of pigmented maculae and moles have been noted in previously irradiated areas of the skin, but these have appeared to be quite benign.

Numerous histopathological studies have been made, 1,4,5 and the changes found have been consistent with radiation damage. At no time have changes been observed either grossly or microscopically indicative of malignant or premalignant change. Spotty epilation on the heads was short lived, regrowth of hair occurring about 3 months after exposure and complete regrowth of normal hair by 6 months. No further evidence of epilation has been seen.

An interesting observation noted during the first few months after exposure was the development of bluish-brown pigmentation of the semilunar areas of the fingernails and toenails in about 90% of the people. By 6 months this pigmentation had disappeared, having grown out with the nail. The cause of this phenomenon has not been explained.

#### INTERNAL IRRADIATION

Radiochemical analyses of numerous urine samples of the exposed population showed internal absorption of radioactive materials, probably brought about largely through eating and drinking contaminated food and water and to a lesser extent through inhalation. During the first few days when the body levels were at their highest, the maximum permissible concentrations were approached or slightly exceeded only in the case of strontium-89 and the isotopes of iodine. The concentrations were believed to be too low to result in any serious effects. Body levels fell rapidly, so that by 2 and 3 years post exposure, they were far below the accepted maximum permissible level; by 6 months activity in the urine was barely detectable

In 1958 analyses of bone samples on one of the men who died showed 3.7 strontium-90 units/g calcium. Beginning in 1957, gamma spectroscopy by use of a low-level counting chamber was added to the techniques of radiochemical analysis. The return of the Rongelapese to their home island (which after careful survey was considered safe for habitation, despite a persisting low level of radioactive contamination) was reflected in a rise in their body burdens and increased urinary excretion of certain radionuclides. During the years

since the original contaminating event, additional weapons tests held in the area have contributed to the fission products in the environment. Since the diet includes a variety of imported foods, the people are not living in a "closed"environment, and therefore may not be rapidly approaching equilibrium with the environmental fission products, as might be expected under other circumstances.

Body burdens of gamma-emitting fission products (such as Cs<sup>137</sup> and Zn<sup>65</sup>) were measured in a whole-body counter and checked by radiochemical analysis of urine specimens. The levels of internal contamination per unit weight appeared to be about the same for juveniles as for adults, male and female. Wide variations in levels of contamination in any group were found, apparently due to differences in diet and metabolism.

Body burdens of Sr<sup>90</sup> were estimated from urinary excretion as determined by radiochemical analyses. Both the external dose measurements on Rongelap Island and the levels of radioactive isotopes in the food on the island indicated that some increase in Cs137, Zn65, and Sr90 body burdens was to be expected when the people returned there in 1957. The Cs<sup>137</sup> body burden in 1958 was about  $0.68 \mu C$ , about 60 times as great as in 1957, and the urinary Cs137 level rose by a factor of 140; the mean body burden for 1959 was 0.57  $\mu$ C. The mean body burden of Zn65 estimated from wholebody counting data was, in 1958, after the return to Rongelap,  $0.36 \mu C$ , 8 times as high as in 1957, and 0.44  $\mu$ C in 1959. In 1961 the mean Cs<sup>137</sup> body burden in adult males was 14.7 mµC/kg, which is not significantly different from the mean value of a similar group obtained in 1959; it was 300 times that of the medical team, who were measured at the same time for comparison. The Zn<sup>65</sup> level in adult males (1.51 m $\mu$ C/kg) dropped to 17% of the mean value measured in 1959. With a larger detector and a longer counting time than previously employed, it was possible to identify and quantify Co60 for the first time in these people; the mean level of Co60 was about 11% of the Zn65 level. A small amount of residual activity was still present after the subtraction of K40 and the above radionuclides from the total spectrum. The mean level of urinary excretion of Sr<sup>90</sup> was 7.2 pC/l or 14% higher than measured in the 1959 medical survey. In 1962 the mean urinary Sr<sup>90</sup> level was 114 pC/g Ca, giving an estimated body burden of 12.0 mμC. Analysis of bones from the deceased Rongelap woman (1962) gave an estimated body

burden of 11.4 m $\mu$ C. These levels represent about a sixfold increase in Sr<sup>90</sup> over the 1958 levels.

Little of the body burden of the exposed group is apparently due to their initial exposure, since at present there is little difference between the levels of the exposed and unexposed populations living on Rongelap Island. The body burdens are of small significance in terms of radiation hazard.

#### **OTHER STUDIES**

Studies of genetically inherited characteristics. Blood grouping studies in the Marshallese showed a relatively high B gene frequency, a high N gene frequency, an extremely high R1 gene frequency, and total absence of Kell and Diego factors.10 These characteristics differ from those of Polynesians and suggest relationship with Southeast Asians and Indonesians. Haptoglobin studies showed the frequency of the Hp1 gene to be higher than in European populations thus far tested and consistent with populations living near the equator. The distribution of haptoglobin types showed the population to be relatively homogeneous. Transferrins in all sera were type CC, the common European type. B-Amino-iso-butyric acid urinary levels showed the Marshallese to be the highest excreters of this acid of any population thus far reported. Levels in the exposed group were about the same as in the unexposed group, and no correlation was found with body burden level of radionuclides; this indicates that there is probably no correlation with radiation exposure. Hemoglobin types were considered normal (all had type AA2). Sickling tests showed no sickling tendency in any of the people. Glucose-6phosphate dehydrogenase of the red cells appeared to be normal in the Marshallese. Studies of Gm phenotypes showed the Marshallese to have 100% Gm<sup>(a+)</sup> and nearly 100% Gm<sup>(b+)</sup>. There was a complete absence of Gmx and a high frequency of Gm-like (Gm<sup>c</sup>). Considerable caution must be exercised in evaluating the results of these studies on genetically inherited characteristics because of the small number of samples tested. The data do seem to indicate relative homogeneity of the population and closest kinship with people of Southeast Asia. These data also may be useful as a base line should genetic changes appear in later generations, possibly related to radiation exposure.

Results of other laboratory studies included the following: Serum protein levels were generally on the high side of normal; electrophoretic patterns

showed the increase in proteins was largely due to an increase in the gamma globulin fraction. The reason for this is not apparent. Numerous chronic infections may be an explanation.

Sodium levels in the urine and food indicated about the same consumption of NaCl as in Americans. The generally lower incidence of hypertension in the Marshallese might be related to the fact that the former native diet was probably lower in salt content than the present, more westernized diet. It will be interesting to see whether the incidence of hypertension will later increase.

Serum cholesterol levels (1957, 1959) were somewhat lower in the exposed population than in the comparison or Utirik populations, but were in the low normal range. No abnormally low readings were noted.

Serum creatinine levels (1957) were in the normal range with no abnormal levels noted.

Serum vitamin  $B_{12}$  concentrations (1958, 1959) were generally significantly higher than American levels. The possibility of contamination of the samples with bacteria producing vitamin  $B_{12}$  must be considered, since myeloproliferative and liver diseases were not seen.

Serum protein bound iodine levels (1957, 1959, 1962) were generally slightly elevated. Evidence for thyroid dysfunction was not apparent in the people.

Glucosuria and elevated blood sugar were found in 8 people (1 exposed and 7 unexposed). An increased incidence of diabetes is prevalent in the Marshallese people.

A survey for intestinal parasites (1958) showed 75% of the people to be infected with various types.<sup>11</sup> For the three major pathogens found, the over-all infection rates were, for Entamoeba histolytica, 18.2%; for hookworm, 5.5%; and for Trichuris trichiura, 34.3%.

Eosinophilia >5% has consistently been noted in about half the people. The fact that half the cases with eosinophilia showed no helminthic infections at all suggests that other factors besides parasitic infections must be responsible. The eosinophilia may be related to chronic fungus and other infections, particularly of the skin.

Complement fixation studies for parainfluenza 1, 2, and 3, respiratory syncitial, psittacosis, and Q fever showed antibodies to all groups of viruses except that for Asian influenza, which probably had not yet seriously involved the people of the Marshall Islands. The antibody titers appeared to be somewhat lower in the exposed people.

Immunoelectrophoretic analysis showed neither a paraproteinemia nor a typical picture of antibodydeficiency-syndrome, but a high frequency of increases of some of the immunoglobulins was noted.

Blood volume studies with Cr<sup>51</sup>-labeled sodium chromate showed a significant reduction in red cell mass and/or plasma volume in 15 of 23 Marshallese.

## DIFFICULTIES ASSOCIATED WITH THE EXAMINATIONS

As mentioned in previous reports, several difficulties were associated with carrying out the examinations as well as interpreting the findings.

- 1. The language barrier made examinations difficult, since very little English is spoken by the Marshallese. However, there were sufficient English-speaking Marshallese to assist the medical team in most instances.
- 2. The lack of vital statistics or demographic data on the Marshallese imposed a serious difficulty in interpretation and evaluation of the medical data. Records of births, deaths, etc., have been made by the health aides or magistrates of the villages and supposedly forwarded to the district administrator; however, such records have been incomplete or lost in most instances, and vital statistics are therefore inadequate. Trust Territory officials are now attempting to assemble such data.
- 3. There is uncertainty on the part of some of the Marshallese as to their exact ages, particularly among the older group. This imposes certain difficulties in interpreting some of the studies to be outlined.

#### **COMPARISON POPULATIONS**

During the first 2 years, two separate groups of Marshallese people were used for comparison, each of comparable size to the exposed Rongelap group and matched for age and sex. However, this population was found to be unstable, with a large attrition rate over the 2 years, which made it unsatisfactory. At the time of the 3-year survey, it was found that during the preceding 12 months the Rongelap population at Majuro Atoll had doubled because of the influx of relatives who had come back from other islands to live with them. These people had been away from Rongelap Atoll at the time of the accidental exposure. This group matched reasonably well for age and sex and was





Figure 2. Medical survey team for 1963 (upper picture) and 1964 (lower picture). Many members of the team are Micronesians of the Trust Territory who work with the AEC medical specialists in carrying out the survey.



Figure 3. Trust Territory ship bringing team and medical equipment at anchor off Utirik Island.

Table 2

Location of Rongelap People, 1964

	Ex	posed		Une	exposed	
	Adults	Children	Children of exposed parents	Adults	Children	Total
Majuro	3	1	3	7	7	21
Kwajalein	9	6	11	37	40	103
Rongelap	34	20	29	72	49	204
Eniaetok	0	0	0	3	1	4
Other atolls	2	1	0	13	11	27
Total	48	28	. 43	132	108	359

of comparable size. Since the return of the people to Rongelap, however, this group has about doubled in size.

#### **Organization**

#### 1963 SURVEY (9 YEARS POST EXPOSURE)

Examinations were conducted on the following Rongelap people: 70 exposed, 35 children of exposed parents, and 196 unexposed (adults and

children of the comparison population). The majority of these people were examined on Rongelap Atoll, but about 100 of them were examined at Ebeye (Kwajalein Atoll) and a few at Majuro Atoll. In addition, Utirik Atoll was visited and 84 exposed people were examined there. The survey team consisted of 10 physicians and technicians from the United States and 6 from the Trust Territory of the Pacific Islands (see Figure 2). A Trust Territory ship, the M/V Roque, was used to transport the medical team to the Islands (Figure 3). The team lived ashore rather than on board ship

at Rongelap Village and also at Utirik Village while carrying out the examinations on these islands.

#### 1964 SURVEY (10 YEARS POST EXPOSURE)

The 1964 survey did not include Utirik, since these islanders are examined only every 3 to 4 years in view of the small exposure they sustained from the fallout. Examinations were carried out as in 1963 at Rongelap, Ebeye, and Majuro, the majority being done at Rongelap. Table 2 shows the distribution of Rongelap people on the various atolls. Examinations were conducted on 70 of the exposed Rongelap people, the 43 children of exposed parents, and 208 of the adults and children of the comparison population. The survey team consisted of 8 physicians and technicians from the United States and 8 from the Trust Territory (see Figure 2). The Trust Territory ships M/V Roque and M/V Ran Anim both aided in transporting the team and equipment to and from Rongelap Atoll. The team lived at Rongelap Village for the examinations on that island.



Figure 4. Marshallese man carrying a sack of copra. Copra is the main product in the economy of the Islands.

#### **Procedures**

#### PHYSICAL EXAMINATIONS

Since both the 1963 and 1964 surveys were similar in scope and procedures, they will be described together. Histories were taken by a Marshallese practitioner with particular emphasis on the interval history during the past year. During the 1964 survey Mr. Byron Bender, anthropologist from the Trust Territory, accompanied the medical team and carried out exhaustive studies on the genealogical background of the Rongelap people. These data are not published in this report, but are available to those interested. The pediatrician on the 1963 survey (W.W.S.) carried out further interviews with the Rongelap people in order to establish more closely the ages of some of the children, which were questionable.

Complete physical examinations on both children and adults were carried out in both years. In addition, anthropometric measurements were done on adults >19 years of age in order to determine certain ethnic characteristics of the Marshallese. During the 1963 examination extensive anthropometric measurements were also carried out on the children as part of the growth and development studies, and radiographs of their wrists were taken for the same studies.

In 1963 an ophthalmologist carried out complete ophthalmological examinations including slit-lamp observations.

Cancer detection, emphasized during examinations for both years, included an evaluation of the history, special physical examinations, and certain laboratory tests.\* The family history did not yield satisfactory information, since the incidence of familial diseases including cancer was generally unknown by the people. The history yielded some information on changes in weight, history of illness, and, in the case of women, menstrual, obstetric, and nursing history. In the physical examination particular emphasis was placed on examination of the skin, node-bearing areas, head and neck, chest, breast, abdomen, and external genitalia. Pelvic examinations were carried out on all mature females, and vaginal and cervical smears for Papanicolaou examinations were obtained.\*\* Rec-

<sup>\*</sup>Drs. E. Schackow and H.L. Atkins of Brookhaven National Laboratory interpreted the x-ray films.

<sup>\*\*</sup>We wish to thank Dr. Genevieve Bader of Memorial Sloan Kettering Cancer Center, New York, N.Y., for interpretation of the Papanicolaou smears.



Figure 5. Rongelap people awaiting examinations.



Figure 7. Slit-lamp examination of eyes for lens òpacities.



are 6. Aged Rongelap women eing carried in for examination.



Figure 8. Biopsy of the skin.



Figure 9. Typical Marshallese living conditions at Utirik.

tal examinations were carried out on all persons >40 years of age. This included in the case of men palpation of the prostate gland. Radiographs of the chest and other parts of the body were obtained as indicated. Hematological data were obtained and were available for evaluation.

In detection of possible leukemia (or preclinical evidence of incipient leukemia) the lymph nodes and spleen were carefully examined; hematological data were analyzed, including routine hemograms and percent basophils in 4000 white cell count; and alkaline phosphatase smears of the white blood cells where done were available for review.

#### LABORATORY PROCEDURES

Hematological studies included white cell counts with differentials, red blood counts, hematocrits, hemoglobins, platelet counts, serum proteins, blood smears for alkaline phosphatase, and basophil count studies. Techniques for these procedures have been described in previous reports. 1,2 Bone marrow aspirations for differential study were collected on 4 exposed and 2 unexposed individuals. Considerable effort was spent on chromosome studies in the past two surveys. Of particular interest was the possibility of studying the chromosomes of cells cultured from the "beta burn" areas of the skin. Some 50 skin biopsies were obtained and successfully grown in most cases. However, contamination of these cultures occurred under the field conditions of these studies, and unfortunately all were lost before they could be brought to

the stage of chromosome preparations. Chromosome studies of peripheral blood cultures, however, have been considerably more successful. During 1963 a large number of bloods were cultured successfully. However, the final chromosome spreads in many cases were not completely satisfactory, and the study was repeated during the 1964 survey. At this time successful 2- and 3-day blood cultures were obtained on 64 exposed people and 11 unexposed. Excellent growth and chromosome spreads were obtained, and the slides are now being evaluated.\*

Sera were collected both years on most individuals, and the following examinations were carried out in U.S. laboratories: protein-bound iodines on 9 exposed and 8 unexposed people and a few blood sugar determinations;\*\* serum folic acid levels on 52 exposed and 85 unexposed people.\*\*\*

During the 1963 survey 38 urine samples were collected, and during the 1964 survey 27 samples, for radiochemical analyses.<sup>†</sup> Most of these were 24-hour samples, though several pooled samples were obtained. Most were from people living on Rongelap Island, but some were obtained at Ebeye.

<sup>\*</sup>Assisting in these studies are Dr. Shields Warren and Dr. Hermann Lisco at the New England Deaconess Hospital, Miss Agnes Stroud at Argonne National Laboratory, and Miss Patricia Crumrine at the Women's Medical College, Philadelphia. We are grateful to Drs. Michael Bender and Carolyn Gooch of Oak Ridge, W.M. Court-Brown of Edinburgh, Scotland, and Kurt Hirshorn of New York University for advice.

<sup>\*\*</sup>Dr L.V. Hankes and the Clinical Chemistry Group in the Medical Department of Brookhaven National Laboratory were responsible for these analyses.

<sup>\*\*\*</sup>Dr. Thomas Lynch, Hackensack Hospital, Hackensack, N. J., did the folic acid determinations.

<sup>†</sup>Dr. Edward Hardy and others at the AEC Health and Safety Laboratory, New York, N.Y., carried out these analyses.

#### **Findings**

#### INTERVAL MEDICAL HISTORY

#### Illnesses

The outstanding medical event during the past 2 years on Rongelap was a poliomyelitis (type I) epidemic, which occurred early in 1963. The epidemic apparently was carried from atoll to atoll by the crew of a ship, since it broke out on each atoll within a week or two after that ship had departed. The epidemic occurred on Rongelap Atoll in January-February 1963 with 23 children and 3 adults stricken and one of the adults (an older exposed woman) succumbing. The children involved were all < 7 years of age. Eleven were children of exposed and 12 of unexposed parents. Mild residual facial or limb paralysis was present in 8 and more severe paralysis in 2 children. These cases will be further described under the Pediatrics Section. This epidemic was brought under control within a few months by widespread use of oral Sabine vaccine by medical personnel of the Public Health Service, Trust Territory, and Navy. Fortunately Utirik Atoll was spared the epidemic.

Other than the poliomyelitis epidemic, the interval medical history, both on Rongelap during the past 2 years and on Utirik for the past 4 years, did not reveal any epidemics or unusual diseases. Upper respiratory infections, gastroenteritis, and fungus and other infections of the skin predominated in the sickness inventory of the health aide. Only a few cases of fish poisoning and sickness from eating improperly prepared arrowroot were reported.

#### Deaths

Four deaths had occurred in the exposed group during 1962 and early 1963: (1) No. 30, female, 60 years of age. Died, July 1962, with a stated diagnosis of cancer of the cervix. Previous examinations had shown progressive loss of weight and increasing hypertension. On the past survey, bleeding was noted from the cervical os and a gynecological checkup had been recommended but death occurred before this was carried out. No autopsy was obtained. (2) No. 46, male, 84 years of age. Died July 1962. Had history of arteriosclerotic heart disease, a stroke a number of years ago, and senility. No autopsy was obtained. (3) No. 26, male, 21 years of age. Died in December 1962, two months after a fall from a coconut tree. Death was

preceded by disorientation and amnesia with convulsive seizures and finally coma. Autopsy showed meningeal damage grossly and histologically. Brain damage was the likely cause of death. Other findings were few, but of interest was notation of giant and multinucleated cells in the meninges area.\* (4) No. 52, female, 55 years of age. Died, February 1963, with laryngeal paralysis during the poliomyelitis epidemic. Death appeared to be from poliomyelitis with bulbar involvement. No autopsy was obtained.

There was one death of a child of an exposed parent: No. 107, female, 4 years of age. Died in October 1962 of acute gastroenteritis and dehydration. Child had a history of malnutrition and weakness, skin infections, loss of pigment in hair. No autopsy was done.

During 1963 one death occurred in the exposed group: the oldest Rongelap woman, estimated to be around 107 years of age; death was reported as due to "old age." Unfortunately, no autopsy was obtained. She had been known to be quite feeble and had cataracts and a considerable degree of arteriosclerosis.

A 54-year-old man in the comparison population died of asthma. No autopsy was done.

During the 10-year period, 10 deaths have occurred in the exposed Rongelap group, and 8 deaths have occurred in the comparison population since 1957 (when this group was first examined). Table 3 lists the deaths with probable causes in the two groups. The annual mortality rate per 1000 for the exposed group is thus about 12.2 compared with about 8.4 for the comparison population and 8.3 for the Marshall Islands as a whole (1960).

Poorly kept records made it difficult to get accurate demographic data on the Utirik people. It appeared, however, that during the past 4 years since they were last examined, about 5 deaths had occurred in the older people and 6 infant deaths had been recorded. The deaths were due to various causes such as pneumonia, infant diarrhea, and infections.

#### **Births**

In 1962, 3 healthy babies were born to exposed parents and 5 to unexposed parents. In 1963, 5 babies were born to exposed parents and 5 to unexposed parents.

<sup>\*</sup>Dr. Hans Cottier of Brookhaven National Laboratory reported on the histopathology.

Table 3

Mortality

			Exposed				Unexposed
Year	Subject No.	Age & sex	Probable cause	Year	Subject No.	Age & sex	Probable cause
1956	25	44 M	Hypertensive heart disease	1958	857	65 M	Cerebral thrombosis(?)
1957	38	76 M	Coronary heart disease, diabetes	1959	854	55 <b>F</b>	Infection urinary tract, diabetes
1958	31	35 M	Acute varicella	1960	933	56 M	Pneumonia secondary to influenz
1959	62	60 F	Ovarian cancer	1960	927	65 M	Pneumonia secondary to influenz
1962	30	60 <b>F</b>	Cancer of cervix*	1960	861	68 F	Diabetes, cancer cervix(?)
1962	46	84 M	Arteriosclerotic heart disease	1962	953	48 M	Status asthmaticus
1962	26	21 M	Brain damage following fall from tree	1962	848	41 F	Neurosyphilis(?)
1962	56	75 F	Fractured vertebrae	1963	886	54 M	Asthma(?)
1963	52	55 <b>F</b>	Poliomyelitis, bulbar				
1963	57	107 F	"Old age"(?)				

<sup>\*</sup>Not confirmed by autopsy or biopsy.

The birth rate for the past year was calculated as in the previous surveys from the number of births per woman of childbearing age (15 to 45 years). There were 23 such women in the exposed group and 39 in the unexposed group. (Not included in either group were 4 unexposed women whose spouses were exposed males.) For the 2-year period in the exposed group 8 babies were born, giving an average of 0.17 births per woman per year; in the unexposed group 10 babies were born, giving a slightly lower birth rate per woman (0.13 per year). The births were all full-term normal deliveries, except one case as noted below.

A review of the entire menstrual and obstetrical history of the women (examined in 1964) in the exposed and control groups is given in Table 4. In 20 exposed women there had been a total of 136 pregnancies, 19 women delivering 115 living children for an average of 4.8 babies per woman for the 24 women in the group. The same fecundity was noted in the control women, 32 of the 39 women having been pregnant 203 times and delivering 189 living babies, averaging 4.6 children per mother. The histories of the age of onset of menstruation and development of menarche were not too reliable, but the ages of onset for these events appear to be about the same in the exposed and the control women.

Table 5 lists the births and fetal deaths by year since 1954 of Rongelap people. Since it was uncertain whether the list of births on Utirik Atoll

obtained during the 1963 survey was complete, it was not possible to calculate an accurate birth rate for that group. However, the birth rate seemed to be about the same as noted in other Marshall Island populations.

#### **Congenital Anomalies**

A full-term stillbirth with congenital anomalies (ectromelus) was born to exposed parents in 1962. This anomaly is not very uncommon, and in view of the statistical evaluation the question of radiation implication must be left open. One 24-yearold exposed woman (No. 49) was operated on for ectopic pregnancy in 1962. A case of congenital heart defect had been noted in a child born of exposed parents several years ago. This child died at 4 months of age. Specific genetic studies have not been conducted on this relatively small population, and only routine examination of new births has been done. No unusual incidence of defects has been noted in the newborn. Some of the defects noted in both exposed and unexposed children include patent ductus arteriosus, congenital deformity of the hip, and congenital hypoplasia of the middle phalanx of the 5th finger.

#### Miscarriages and Stillbirths

Except for the one ectopic pregnancy, no miscarriages were reported during the past 2-year period. One neonatal death (at 1 month of age) due to infant diarrhea occurred in a twin born to

Table 4

Menstrual and Obstetrical History, Adults, 1964

		Exposed	i				Unexpose	ed	•
Subject No.	Age at men.	Age ' at meno.	No. preg.	No. live births	Subject No.	Age at men.	Age at meno.	No. preg.	No. live birth
1		40	12	12	826	7		6	5
12	13		5	4	829	12		7	6
13		48	0	0	832	13		6	6
14			9	9	835	12		7	7
18	12		13	12	841	14		7	7
<b>24</b>	12		2	2	843	13		6	6
28		58	10	10	844	13		12	11
34		35*	14	10	851		5 <b>4</b>	10	10
.43			4	4	852		40	0	0
45	13		11	9	858		49	3	3
49	13		6	3	859		50	9	6
51	17		2	0	865	13		10	9
58		64	12	10	867	18		9	9
59		41	2	1	893	15		13	11
60		45	0	Ô	894		45	0	0
61	12	10	2	$\overset{\circ}{2}$	895	17	15	_	_
63		44	13	10	896	13		3	3
64	12	••	10	9	898	13	45	4	4
66	13		0	0	908		5 <b>4</b>	15	14
67	13		0	ő	916	14	34	14	8
70	14		2	2	922	14		11	11
71	16		1	1	928	14	47	1	1
78	13		5	. 4	92 <b>0</b> 929		46	0	0
81	15		1	1	932	14	40	3	3
01	13		1	1	934	13		0	0
					934	13		3	3
					938	1.4		6	4
						14	5.0		
					941	10	53	11	10
					942	13		0	0
					945	13		1	1
					951	14		7	7
					956	12	• •	-	-
					957		46	2	1
					965	15		0	0
					970		47	0	0
					982	14		3	2
					991		54	1	1
					1001	13		7	6
					1042	17		6	4
					1043	14		<del>-</del>	<del>-</del>
					1050	18		1	1
					1052	13		5	3
Av	13.4	48.6	5.7	4.8		13.8	48.5	5.4	4.6
Total subs	. (14)	(7)	(24)	(24)		(28)	(13)	(39)	. (39)

<sup>\*</sup>Hysterectomy; not included in survey.

Table 5

Births and Fetal Deaths<sup>a</sup> by Year

				Chile	dren		
Year	Women aged 15-45	Total pregnancies	Live births	M	F	Miscarriagesa	% Pregnancies terminating in miscarriage
			Expose	D <sub>p</sub>			
1954°	19	1	0	0	0	1	100
1955	20	6	5	4	1	1	17
1956	20	6	4	0	4	2	33
1957	21	5	2	2	0	3	60
1958	22	14	8	4	4	6	43
1959	22	7	5	2	3	2	29
1960	24	10	9	5	4	1	10
1961	23	6	6	2	4	0	0
1962	24	4	3	0	3	1	25
1963	27	6	5	2	3	1	17
1964ª	26	2	1	1	0	0	0
			UNEXPOS	SED			
1956	29	9	7	6	1	2	22
1957	30	11	9	4	5	2	18 -
1958	30	9	8	5	3	1	11
1959	29	10	9	4	5	1	10
1960	29	10	8	5	3	2	20
1961	29	8	8	6	`2	0	0
1962	30	6	5	4	1	-1	17
1963	32	2	2	1	1	0	0
1964 <sup>d</sup>	32	3	. 3	2	1	0	0

<sup>\*</sup>Includes stillbirths and neonatal deaths.

<sup>c</sup>Includes only children conceived after March 1, 1954. <sup>d</sup>Includes data only through March 1964.

Table 6
Summary of Pregnancy Termination Data (women aged 15-45)

		1955ª	-1958		1959–1963					
	Exposed (22 femal		Unexposed (31 females)		Exposed <sup>b</sup> (30 females)		Unexposed (36 females)			
	Incidence	%	Incidence	%	Incidence	%	Incidence	%		
Women giving birth to living children	12	54	19	61	17	56	21	58°		
Women with miscarriages <sup>c</sup> but no live births	5	23	1	3	2	7	1	3		
Women with no recorded pregnancies	5	23	11	36	11	37	14	39		
Women with one or more miscarriages <sup>c</sup>	9	41	5	16	5	17	2	6		
Women with two or more miscarriages <sup>c</sup>	3	14	2	6	0	0	1	3		
Total miscarriages <sup>c</sup>	13	41	8	22	5	15	4	11		

<sup>\*</sup>Includes miscarriages occurring after March 1, 1954.

<sup>e</sup>Includes stillbirths and neonatal deaths.

<sup>&</sup>lt;sup>b</sup>Includes nonexposed females mated to exposed males.

<sup>&</sup>lt;sup>b</sup>Includes nonexposed females mated to exposed males.

Table 7

Physical Findings in Rongelap and Utirik Adult Populations

•		1963		19	64		1963			19	64
	R*	C	U	R	С		R*	C	U	R	С
No. examined	45	75	52	47	85	Hypertension (>140/90) Inguinal hernia	, 3	2	6	4	6
Adenopathy		1		3	10	Intestinal parasites	3	7	1		
Anemia, anemic tendency	4	2		3	6	Kyphosis, scoliosis	4	3	2	5	5
Arteriosclerosis, peripheral, mild	•	14	1	6	12	Leiomyoma, uterus					2
Arteriosclerosis, peripheral,			•	•		Leprosy, arrested	1			1	1
moderate to severe	12	10	3	6	5	Leukoplakia	i			•	. 2
Asthma	2	10	J	U	J	Liver, palpable	2	7	4	2	3
Auricular fibrillation with	_					Myocardial damage or	-		•	_	Ū
	,			1	1	insufficiency (EKG)	1	10	1	1	10
myocardial damage Bradycardia	1	1	1.	1	ı	Obesity	7	9	4	5	10
Bronchitis	1	4	3		4	Osteoarthritis	10	15	. •	10	13
Cardiac enlargement	3	3	J	1	4	Paralysis	1	13	1		1
	3	3			4	Parotid enlargement	1		•		. •
Cardiac murmur	٥	14	4	4 4	5	Perirectal abscess	1			1	
Cervical erosion, bleeding	8 4	5	7	5	3	Pharyngitis	•		2	8	20
Cervical lacerations	4	3		2	2	,	1	2	4	Ü	20
Cervical and vaginal atrophy				2	2	Pleural thickening or adhesions Pregnancies	6	5	2	2	6
Congenital defects						Prostatic hypertrophy	5	5	-	7	8
a) dislocation of hip	1 2	4		1 2	4	Proteinuria	J	. 4		′	1
b) prominent head of ulna	., 4	*		2	4	Pyorrhea		т.			2
c) bilateral shortening of	2	3		2	3	Rheumatic heart disease	1			1	_
5th finger	2			2		Senility	4	1		3	
d) polydactylism		1			1		2	2		1	1
e) shortened left thumb	1				•	Syphilis(?) arrested	4	1		1	1
f) flexion deformity, fingers		1			1	Thyroid enlargement		1		1	5
g) small 4th toe					1	Tinea circinata or versicolor		3		1	9
Cyst, Bartholin				1	•	Tonsilar hypertrophy, tonsilitis	1 5	3 8	1	3	4
Cyst, ovarian				c	1	Tumor, benign	3	0	1	3	1
Cystocele		2		2	~	Ulcer, leg			1		1
Diabetes mellitus		7			7	Urethral caruncle	1	1	1 2		
Dupuytren's contracture		1				Uterus enlargement, fibroids(?)			2		
Epididymitis					1	Uterus retroversion		I			
Furunculosis	1					Varicocele					1
Gynecomastia	1			1	1	Varicose veins	1				1
Hallux valgus	1	_		1		Vitiligo		l			
Hemorrhoids		2	1		1						

 $<sup>{}^{</sup>a}R = Rongelap \ exposed, including \ Ailingnae; \ C = Rongelap \ unexposed; \ U = Utirik \ exposed.$ 

exposed parents in 1962. A stillbirth (full term) with congenital anomalies which was born to exposed parents is described above. Tables 5 and 6 show the incidence of miscarriages and births in the exposed and comparison populations on a yearly basis and for the two 5-year periods.

The data on miscarriages and stillbirths in the Utirik population were not reliable.

#### PHYSICAL EXAMINATIONS

The major findings on physical examinations are listed in Table 7 for the adults and Table 13 for

the children. Appendix 7 contains findings on each individual adult and Appendix 8 contains such information on each child.

#### **Adult Examinations**

Table 7 does not show any significant difference in the abnormalities recorded between the exposed and the comparison populations. The exposed group did show a higher incidence of severe arteriosclerosis, which may be a reflection of the greater percentage of older people in this group. There was a slightly increased occurrence of cervical erosion and laceration in the exposed women. The ex-

<sup>&</sup>lt;sup>b</sup>Suspect.

posed group also showed an increase in kyphoscoliosis, which is probably also due to the age factor. A slightly increased incidence of prostatic hypertrophy was found among the exposed males. This will be given particular attention in the next survey. The unexposed population slightly exceeded the exposed in incidence of inflammatory diseases such as adenopathy, bronchitis, and pharyngitis. There are no obvious reasons for this difference. No malignant lesions were detected in either the exposed or unexposed groups. Papanicolaou examinations on vaginal secretions revealed several that were suspicious of malignancy. These women will be checked carefully on the next survey.

#### **Anthropometric Studies**

During the 1963 and 1964 physical examinations, anthropometric measurements were obtained on Rongelap adults examined (>19 years of age). These measurements included height and weight, and circumferences of shoulder girth, biceps, forearm, wrist, chest, abdomen, buttocks, thigh, knee, calf, and ankle. Dr. Albert R. Behnke, Jr.\* has been analyzing such data to provide in-

formation on body proportions and estimates of fat and muscle of various ethnic groups. His analysis of the Marshallese data compared with many individuals in other racial groups revealed that the young Marshallese adult male (age group 20 to 39) appeared outstanding in regard to muscle development. Table 8 shows a comparison of the anthropometric data on males of the Rongelap group and other groups. In contrast to the men, the data indicated that the women were either physically immature or had lost a considerable amount of lean tissue. These data as summarized by Dr. Behnke are presented in Appendix 9.

#### **Pediatric Examinations**

Children Examined 1963. During the 1963 survey, a total of 212 children were examined: 35 children exposed on Rongelap, 32 children exposed on Utirik, 35 children born after the fallout to exposed parents, and 120 controls.

In the Rongelap "exposed" group, two children examined in 1962 were not available in 1963. Three other children were transferred to the adult study (Table 9). The previous medical survey of children on Utirik had been done in 1959. Of the

Table 8

Anthropometric Data on Various Male Groups

Group	Number	Age,a years	Height, dm	Weight, kg	Factor, $F$ , $\sqrt{W/h^{0.7}}$	Sum of 11 circumferences <sup>b</sup>	K, sum of 11 circumferences/F
Rongelap (1)	19	20–39	16.25	60.7	2.936	581	197.9
Rongelap (2)	27	41-68	16.11	66. <b>0</b>	3.071	603	196.4
Turks	915	19-32	16.93	64.6	2.986	592°	198.3
Greeks	1084	18-30	17.05	67.0	3.033	603°	198.8
Italians	1358	19-44	17.07	70.3	3.106	613°	197.4
Oregon students	100	18-22	18.03	78.5	3.220	627	194,7
Lankenau	34	20-40	17.71	75.3	3.171	616	19 <b>4</b> .3
Navy	31	20-50	17.83	78.3	3.228	626	193.9
Air Force trainees	3000	18-34	17.41	68.5	3.045	593⁴	194.8
Air Force flyers	4000	18-45	17.56	74.4	3.164	$624^{d}$	197.2
Philadelphia YMCA	22	59-82	17.00	72.8	3.165	615	194.3
Baltimore indigents	20	57-93	16.47	60.9	2.927	578	197.5
Berkeley (1)	458	14.5	16.61	55.8	2.794	541	193.6
Berkeley (2)	454	15.3	17.11	61.1	2.893	561	193.9
Reference man			17.40	70.0	3.078	600	194.9

<sup>&</sup>lt;sup>a</sup>More than 90% of subjects are included in age range.

<sup>\*</sup>The University of California Medical Center, San Francisco.

<sup>&</sup>lt;sup>b</sup>The 11 circumferences are girth of the shoulders, chest, abdomen (average of waist, omphalion perimeters), buttocks, thigh; biceps, forearm, wrist, knee, calf, and ankle. Note the small variation in the K values.

<sup>&</sup>lt;sup>e</sup>Lower abdominal (omphalion) circumferences only were measured.

<sup>&</sup>lt;sup>d</sup>Forearm and knee circumferences calculated.

	·		Table 10					
Table 9 Exposed Rongelap Children Examine	ed in 1	963	Utirik Pediatric Population Samples Examined in 1959 and 1963					
Total number examined in 1962		30	Total number examined in 1959		60			
Not seen in 1963 (Nos. 44, 84)	2	2	Not exposed, not examined in 1963	10				
Transferred to adult study (Nos. 61, 76,	81) 3	3	Not exposed, examined in 1963	2				
Total number examined in 1963	,	25	Exposed, not examined in 1963	14				
			Exposed, graduated to adult study	7				
Table 11			Exposed, not examined in 1959 but					
Table 11			examined in 1963	3				
Control Pediatric Population, 1	963		Total number examined in 1963		. 32			
Total number examined in 1962		96	Table 12					
Not seen in 1963	4							
Graduated to adult study	2		Children Born After Fallout to Exp	posed Pa	arents			
Not seen in 1962, seen in 1963	5							
Total number old controls seen in 1963		85	Total number examined in 1962		37			
New babies added	4		Not seen in 1963	3				
New controls added (Ebeye) 2	29		Died since 1962	1				
New controls added (Rongelap)	2		New babies added in 1962	2				
Total number controls examined in 1963		120	Total number examined in 1963		35			

Table 13 Summary of Physical Findings in Children, 1963 and 1964

			•		Cor	ntrol			
	Rong	Exposed gelap			before 1955		after 1955		osed, born ed parents
	1963	1964	Utirik 1963	1963	1964	1963	1964	1963	1964
Number examined	25	22	30	38	44	51,	57	35	41
Active skin lesions	· 1	1	0	2	3	13	8	4	3
Adenopathy	5	2	0	4	1	9	5	2	5
Palpable liver	0	4	0	0	5	1	4	1	11
Palpable spleen	0	0	0	0	0	2	0	0	2
Upper respiratory infection	8	0	1	4	8	8	3	5	4
Blood pressure taken	19	22	29	30	43	3	28	2	19
Hypertension	1	0	0	0	0	0	0	0	0
Acute otitis media	6	1	1	2	6	2	5	1	4
Chronic otitis media	0	0	0	0	0	1	1	1	1
Molluscum	1	0	0	1	0	7	6	3	2
Tinea versicolor	2	2	3	5	0	1	1	0	0
Vitiligo	0	1	0	2	0	0	1	0	0
Warts	3	0	2	1	2	4	2	2	5
Papilloma	1	0	1	1	0	0	0	0	0
Cheilosis	0	1	1	0	0	0	0	0	1
Excoriation of lip	0	0	1	0	0	1	0	2	0
Black spots on tongue	2	1	0	1	2	0	0	0	0
Geographic tongue	0	0	0	0	0	1	0	0	0
Conjunctivitis	0	0	0	0	0	1	1	1	0
Thyroid nodule*	1	3	0	0	0	0	0	0	0
Tracheostomy scar	1	1	0	0	0	0	0	0	0
Thoracotomy scar	1	1	0	0	Ó	0	0	0	0
Pes excavatus	0	0	0	1	0	0	0	0	. 0
Infantile eczema	0	0	0	0	0	0	1	0	0
Rales in lungs	0	0	0	0	0	1	0	3	0
Systolic murmur (grade 2)	0	0	0	2	0	2	1	0	3
Extrasystoles	0	0	0	1	0	0	0	0	0
Spotted enamel on permanent teeth	0	1	0	0	0	0	0	0	0
Anisocoria	0	0	0	0	0	0	0	0	1

<sup>\*</sup>Subjects No. 17, 13½-year-old female; No. 21, 13½-year-old female; and No. 69, 13½-year-old female.

5 0 0 5 0 5 2

potentially available total of 41 children from the 1959 survey, 29 were re-examined in 1963 (Table 10). In the group of 60 children examined in 1959, there were 12 who because of their ages could not have been exposed either directly or in utero to the fallout radiation; two of these 12 were re-examined in 1963. More than one-fourth of the exposed pediatric sample on Utirik was lost to follow-up between the two examinations.

The fluctuations between examinations in the numbers of control children and of offspring of exposed parents are shown in Tables 11 and 12. The 29 children added to the control group were randomly selected from the Ebeye school population to provide an additional group comparable in ages to those Rongelap children who were exposed during infancy and early childhood years to the fallout radiation. Unfortunately, a study of the biographical information on these new subjects indicated the existence of the same uncertainties regarding actual chronological ages that had been encountered before. Verification or correction of the birth date on each of the children will be required before the data can be utilized for comparative purposes.

Children Examined 1964. During the 1964 survey, 22 exposed children, 41 children of exposed parents, and 101 control children were examined. The decrease in the number of exposed children examined in the Rongelap series from 1958 through 1964 results from temporary movement of subjects to other atolls and to graduation of children from the pediatric to the adult study. The increase in number of children of exposed parents examined results from new births.

Results of Physical Examinations. The incidence of abnormal physical findings in the exposed and control groups of children is summarized in Table 13. In general the health of the children seen during both surveys was good. Respiratory infections and skin infections were infrequent. The nutritional status of all children was adequate, the growth patterns were consistent with those seen in previous years, and the height increments for the period were consistent with the previous group trends.

During the epidemic on these atolls, 24 children in the study developed poliomyelitis. Residual weakness of muscle groups was evident in 11 of these children at the time of the 1963 examination (Table 14). Seven children continued to show residual paralysis of varying degree at the time of

Table 14

History of Poliomyelitis Among Children of Study Population, Rongelap and Ebeye

Subjects with positive history but no residual involvement at time of examination\*:

Nos. 102, 105, 113, 120, 126, 127, 930, 1012, 1025, 1031, 1040, 1504

Subjects with positive history and with residual involvement at time of examination:

Nos. 96, 98, 103, 106, 110, 870, 901, 903, 1030, 1037

\*One subject, No. 84, who had a history of poliomyelitis was not examined.

the 1964 survey (Nos. 95, 96, 98, 106, 870, 901, 903). In several instances, the degree of involvement appeared less than in the previous year.

The increase in palpable livers in exposed and control groups during the 1964 examinations is thought to result from variation between pediatric examiners. Liver enlargement exceeded 2 cm below the right costal margin in only two children, and in the remainder the liver was palpable at the costal margin only. In all but one additional category in Table 13, variation was considered to be within limits expected in sequential examinations of any pediatric age population.

Thyroid Nodules. Of particular interest was the development of thyroid nodules in three girls 9 and 10 years after exposure; two were 13 and one was 14 years of age at the time of detection. These girls were in the higher dose group in which there were 29 children (<18 years of age) exposed; 17 of the 29 were girls, with 6 girls in the 10 to 15year range. Of 75 unexposed comparison children, 37 were girls, and 21 of the girls were in the age range of 10 to 15 years. No thyroid nodules were noted in this group (only one diffuse thyroid enlargement has been detected in an unexposed adult). A small nodule was first detected in one of the girls in 1963, and nodules in the other two were first detected in March 1964. No lymph node involvement was grossly evident. The individuals were hospitalized and two had complete thyroidectomies and the third a partial thyroidectomy.\* Grossly the glands had a "bobblestone" appearance with multiple hard nodules and were at first


<sup>\*</sup>Captain C.A. Broaddus (MC) U.S.N. at the U.S. Naval Hospital in Guam performed the surgery.



Figure 10. Gross picture of sectioned thyroid gland from 14-year-old Marshallese girl (No. 69) showing nodules.

Figure 11. Microscopic section  $(10\times)$  of thyroid gland from same case as in Figure 10. These changes are characteristic of all three cases. Note the multiple, discrete nodules with wide variation in size and growth pattern. Some nodules consist of microfollicular tissue and others of colloid cysts, while still others show hyperplasia with papillary infolding of the epithelium.





70

Figure 14.

MEDIAN STATURES 1958-1963 BOYS

◆ EXPOSED

6 7 8 9 10 11 12 13 14 15 16 17 CHRONOLOGICAL AGE (YRS)

-o CONTROL

Figure 15.

3 4 5 6
CHRONOLOGICAL AGE (YRS)

MEDIAN STATURES 1958-1963 BOYS BORN AFTER FALLOUT

CHILDREN OF EXPOSED PARENTS.

- CHILDREN OF UNEXPOSED PARENTS.

110

100




Figure 16.

thought to be malignant. Sections of the tissues were reviewed by a number of pathologists,\* all of whom agreed that the nodules were not malignant and resembled in many respects adenomatoid goiters seen with iodine deficiency, with its characteristic regenerative rather than neoplastic proliferation. However, in the Marshall Islands, where fish and sea food are mainstays of the diet, iodine deficiency is not likely and goiters are rare. Figure 10 shows a picture of the gross appearance of the nodules and Figure 11 shows a microphotograph of one of the glands. The likelihood of these nodules being radiation induced is discussed in the Summarizing Discussion. The two girls who had complete thyroidectomies developed signs of hypoparathyroidism which responded to treatment. Parathyroid function returned in No. 17, but No. 21 still requires therapy including thyroid extract. In the third case (No. 69) only a partial thyroidectomy was done, and she requires no therapy.

Note: During the 11th-year survey now in progress (March 1965) 3 new cases of thyroid nodules in the exposed group have been detected. Two




Figure 17.

were in boys 12 and 17 years of age and one in an adult woman 41 years of age. The nodules appeared grossly similar to those described in the teen-age girls in this report, and these cases will receive study and treatment.

Growth and Development Studies. Analysis of the statural data from the 1963 survey indicated the persistence of the trends previously reported. As shown in Figures 12 and 13, no difference was apparent in median statures between the exposed and control groups among girls and between girls born to exposed and girls born to nonexposed parents.\* Among the boys, however, retardation in statural growth of the exposed group between the ages of 5 and 12 years as compared with that of the control group was again noted (Figure 14). The difference in median statures between boys born to exposed parents and those with nonexposed parents was also evident in 1963 (Figure 15). This difference has been attributed to the fact that the boys in the group with exposed parents were, on the average, 4 months younger than the boys in the group with nonexposed parents.

No statistically significant differences were noted in body weight curves between exposed and control children (Figures 16 and 17). In skeletal maturation, the trends reported in the previous studies

<sup>\*</sup>Sections of tissue were reviewed and reported on by Drs. S. Warren, New England Deaconess Hospital; G.H. Klink, Armed Forces Institute of Pathology; C. J. Stahl, U.S. Naval Hospital at Guam; H.A. Johnson, Brookhaven National Laboratory, and S. Lindsay, University of California Medical School.

<sup>\*</sup>Dr. K.M. Griffith of the M.D. Anderson Hospital did the statistical analyses.



Figure 18. Brothers. Marked retardation in statural growth is shown by the older (shorter) brother (No. 3, on the right) who was exposed at age 18 months. The younger by 21 months (No. 83, on the left) is taller by 13 cm. The retarded boy shows no evidence of hyperthyroidism or skeletal disease clinically, other than markedly delayed osseous maturation.

(7-year and 8-year surveys) have persisted. In comparison with the Greulich and Pyle standards, the skeletal development of Marshallese children was retarded at the same chronological age levels. In addition, the exposed children were less mature than control children. The retardation was most prominent among those exposed during infancy to the fallout radiation (see Figure 18). Skeletal age values during successive examinations of this particular group of children are shown in Table 15. These data covering the period since 1958 are being published in detail elsewhere. Complete tables of anthropometric measurements on the Marshallese children dating back to the early surveys are presented in Appendices 11 through 16.

#### **Ophthalmological Findings**

Ophthalmological examinations were carried out in 1964 on 68 exposed, 45 children of exposed, and 190 people in the comparison population; a total of 303 people.

As noted in previous surveys, there was an increased incidence of large corneas and enlarged tortuous retinal vessels and a lower incidence of myopia, strabismus, amblyopia ex anopsia, retinitis pigmentosa, retinoblastoma, and congenital glaucoma.

The incidence of arcus senilis is higher in the Marshallese than in similar age groups in the United States, which is in keeping with the gen-

Table 15

Skeletal Age Development in Children Born Between July 1952 and February 1953

Subject No.		Age at exposure, months	Skeletal age (S.A.) values at successive examinations, years						
	Sex		C.A.*=4  yr	C.A.=6 yr	C.A.=8 yr	C.A.=9 yr	C.A.=10 yr		
2	M	16	31/2	41/2	6	73/4	8½		
3	M	17	21/3	23/3	3	3	3		
5	M	16	3%	31/2	31/2	3¾	NE*		
6	M	16	3	51/2	6¾	81/2	9		
65	F	15	21/2	31/2	6	63/3	8		
33	F	20	5	61/2	91/4	10	NE		
<b>54</b>	M	12	3¾	NE	91/2	10	11		
955	F	$\mathbf{C}_{\bullet}$	NE	NE	10	10	10¾		
962	F	С	NE	NE	71/3	7%	91/4		
980	F	$\mathbf{C}$	NE	6%	81/3	NE	NE		
996	F	С	NE	NE	81/3	10	101/4		
814	M	C	NE	5¾	8	9 ,	10		

<sup>\*</sup>C.A.=chronological age; NE=not examined; C=not exposed (control).

eral observation that the Marshallese age faster than Americans. The incidence was higher in the exposed group (36%) than in the unexposed group (19%). However, recent analysis of aging criteria did not show any significant differences between exposed and unexposed groups.

Though diabetes mellitus has a moderately high incidence in the Marshall Islanders, only one case of diabetic retinopathy was noted. This is in keeping with the observation that the onset of diabetes in the Marshallese occurs largely in older individuals.

The incidence of pinguecula and pterygium is high in the Marshall Islands, and also slightly higher in the exposed group than in the unexposed (see Table 16). It has been postulated that the higher incidence in the exposed group may be related to contamination of the conjunctival sac with fallout material at the time of the accident.

The incidence of abnormalities of the crystalline lens is greater in the Marshall Islanders than in similar age groups in the United States. Furthermore, the incidence of such abnormalities was

Table 16

Ophthalmological Survey, 1964

No.			Children of exposed		Controls	
	%	No.	%	No.	%	
68		45		190	-	
1	1.40			1	0.52	
1	1.40					
25	36.70			37	19. <b>46</b>	
1	1.40					
				2	1.05	
3	4.20			3	1.57	
1	1.40					
2	2.80					
3	4.20			2	1.05	
1	1.40					
				1	0.52	
18	26.50			41	21.57	
1	1.40			3	1.57	
12	17.60			25	10.64	
	2.80			1	0.52	
1	1.40			1	0.52	
_				2	1.05	
-	*****				0.52	
					1.05	
1	1.40			_	4.00	
•	****			2	1.05	
11	16.20				8.44	
					19.98	
	40.10				0.52	
					0.52	
1	1 40		•	_	0.52	
				_	4.68	
					2.60	
				5	00	
•	1.10			1	0.52	
5	7 30				1.05	
3	7.50	1	22		0.52	
		•	<b></b>		1.57	
	1 1 25 1 3 1 2 3 1	1 1.40 1 1.40 25 36.70 1 1.40 3 4.20 1 1.40 2 2.80 3 4.20 1 1.40 18 26.50 1 1.40 12 17.60 2 2.80 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40	1 1.40 1 1.40 25 36.70 1 1.40 3 4.20 1 1.40 2 2.80 3 4.20 1 1.40 18 26.50 1 1.40 12 17.60 2 2.80 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40 1 1.40	1 1.40 1 1.40 25 36.70 1 1.40 3 4.20 1 1.40 2 2.80 3 4.20 1 1.40 18 26.50 1 1.40 12 17.60 2 2.80 1 1.40 1 1.40	1       1.40       1         1       1.40       37         25       36.70       37         1       1.40       2         3       4.20       3         1       1.40       2         2       2.80       3         1       1.40       3         12       17.60       25         2       2.80       1         1       1.40       1         1       1.40       2         1       1.40       2         1       1.40       38         1       1.40       1         4       6.00       9         2       2.80       5         1       1.40       1         4       6.00       9         2       2.80       5         1       1.40       1         4       6.00       9         2       2.80       5         1       1.40       1         4       6.00       9         2       2.80       5         1       1.40       1         1       1.40 <td< td=""></td<>	

somewhat greater in the exposed group in 1964 than in the unexposed comparison population. These abnormalities consist of polychromatic sheen, lenticular opacities of all degrees, and cataracts. The polychromatic sheen was noted as the earliest lens change and varied from a few fine granules in the earlier cases to large granular plaques in the more advanced cases. These plaques were situated on the posterior lens capsule in the zone of specular reflection. The earliest cases showed yellowish granules which in some cases appeared slightly darker with a "beaten brass" color. As the granules coalesce into a plaque, greenish and bluish hues appear – hence the name polychromatic sheen.

Whether the polychromatic sheen seen following irradiation has unique and specific characteristics is still a debatable question. Some investigators contend that similar appearing changes can be detected in patients with retinitis pigmentosa and the early stages of cataracts which might be a complication of endogenous ocular or systemic disease or intoxication. Such polychromatic sheens were seen in 21% of the unirradiated Rongelap group and 26.5% of the exposed group. This difference is thought to be too small to implicate irradiation exposure with any degree of certainty, particularly in view of the slightly greater number of older people in the exposed group. The incidence of lenticular opacities was also slightly greater in the exposed group (19%) than in the unexposed group (12%).

Only one child (an 8-year-old female) complained of defective night vision. This was thought to be due to vitamin A deficiency, since there were no pathological changes in the fundus of either eye. Several years ago 12 children were encountered who had great difficulty in seeing at night. These children responded promptly with vitamin A treatment and dietary changes.

Only two cases were noted with corneal pigmentation, previously seen in three cases (1962). This pigmentation was characterized by a fine, dark, linear streak of pigment lying close to or on Bowman's membrane in the horizontal axis between the limbus and pupillary edge. It is believed that these changes may have been induced from beta radiation contaminating margins of the eyelids at the time of the accident.

There were several findings which may be residual to the poliomyelitis epidemic of 1963: two

Table 17 Residual "Beta Burns"

Subjec No.	t Age	Sex	Data
2	12	M	Roughening and pigment variation on front of neck. Several pigmented macules ACF.* Perianal depigmentation.
3	11	M	Mottled pigmentation both axillae. Pigmented area behind left ear.
11	60	M	Pigment changes left ACF, dorsum first right toe; pigmented nevi axilla.
17	13	F	Scarring and pigmentation left ACF.
20	17	M	Pigmented patch back of neck.
23	14	M	Pigmented macules left axilla, front of neck and chest. Depigmented spots shaft penis.
24	23	F	Slight pigment variation on front of neck; several pigmented macules dorsum left foot.
34	55	F	Slight roughening and pigmentation back of neck. Moles on front of neck.
39	25	<b>F</b>	Slight roughening and pigmentation back of neck; pigment variations and slight hyperpigmentation dorsum right foot.
49	25	F	Numerous pigmented macules both sides of neck and a few on arms and ACF.
54	11	M	Mottled pigmentation and depigmentation on front of neck.
59	44	F	Mottled pigmentation and depigmentation on back of neck.
63	46	F	Slight rugosity and pigmented ridges on back of neck.
64	40	F	Mole back of neck; slight pigment variation and a few macules front of neck.
65	11	F	Pigment variation and roughening front of neck.
67	24	F	Depigmented scars dorsum left foot.
75	22	F	Slight pigmented area dorsum right first toe.
78	47	F	Numerous pedunculated moles on sides and front of neck.
79	49	M	Pigmented and depigmented scar posterior surface left ear.




Figure 19. Residual "beta burn" showing scarring and pigmentation (No. 79).



Figure 20. Residual "beta burn" scarring and pigment aberration in antecubital fossa (No. 17).



Figure 21. Pigmented nevus-like lesions in previous "beta burn" area of neck (No. 78).

cases with 7th nerve weakness involving the lids; two cases of anisocoria (unequal pupils); and an increased incidence of strabismus.

#### Residual "Beta Burns"

Persisting residual effects of "beta burns" were found to be present in 19 people, 6 children and 13 adults. These are outlined in Table 17. The skin changes consisted of hyperkeratosis, and varying degrees of atrophy, scarring, and pigment aberrations (see Figures 19 and 20). These changes were slight in most of the people. The development of lentigo-like and papular pigmented nevus-like lesions in areas of previous "beta burns" was first observed several years ago, and these lesions appear to have been increasing slightly

Figure 22. Section of skin from "beta burn" area on back of neck of 56-year-old woman (No. 34) at 10 years after exposure (100×). Note atrophy of epidermis with narrowing of stratum granulosum and finger-like projections of rete pegs. Slight atrophy of the sweat gland ducts is also present.

since that time (see Figure 21). Histological study of a biopsy of one of these lesions showed it to be a typical benign pigmented nevus.

The residual changes in the skin of the Marshallese who had sustained acute "beta burns" have shown neither fissure tissue breakdown in the affected areas as seen in chronic radiation dermatitis nor evidence of malignant change. Only one case showed a few spots of alopecia of the occipital area of the scalp as a residuum of epilation. Figure 22 shows histological residual changes in a lesion at 10 years after exposure.\*

#### LABORATORY EXAMINATIONS

#### **Hematological**

Summary tables of hematological data are presented in the tables and graphs in the text, and raw data on the individuals are presented in the appendices. The more heavily exposed Rongelap

\*Dr. David A. Wood of the University of California Medical Center, San Francisco, did the histological interpretations.




Table 18

Mean Levels of Rongelap Peripheral Blood Elements by Age and Sex, 1963

	Plate. ( <b>×10</b> <sup>-3</sup> )		WBC (×10⁻³)	Neut. ( ×10 <sup>-3</sup> )	Lymph. (×10 <sup>-3</sup> )	Mono. (×10 <sup>-3</sup> )
Males 9-15 yr						
Rongelap exposeda	$287 \pm 66 (9)$	,	$1.47\pm2.18$ (9)	$3.92\pm1.31$ (9)	$3.25 \pm 0.59 $ (9)	
Ailingnae exposed	194 (1)	,	5.64 (1)	2.79 (1)	3.19 (1)	, ,
' Utirik exposed	$419 \pm 93(12)$		$0.20\pm2.88(12)$	$4.57\pm1.83(11)$	$3.89 \pm 1.17(11)$	
Rongelap unexposed	286± 78(14)	) 8	$3.37\pm2.90(14)$	$4.07\pm1.96(14)$	$3.27 \pm 1.11(14)$	0.30(14)
Females 9-15 yr						
Rongelap exposed <sup>e</sup>	$300\pm 78 (8)$	,	$3.50\pm2.49$ (8)	$4.42\pm3.09$ (8)	$3.31 \pm 0.80 (8)$	
Ailingnae exposed	225 (2)		.15 (2)	3.69 (2)	2.97 (2)	
Utirik exposed	$402\pm116(14)$		$0.01\pm2.66(15)$	$4.81\pm2.04(15)$	$3.33 \pm 0.94(15)$	0.29(15)
Rongelap unexposed	$373 \pm 99(17)$	) 8	$1.82\pm2.29(17)$	$4.12\pm1.64(16)$	$3.86 \pm 0.77(16)$	0.26(16)
Males >15-40 yr						
Rongelap exposed	198± 71(11)	) 6	$6.58 \pm 1.49(11)$	$3.27\pm0.74(11)$	$2.82\pm0.89(11)$	0.19(11)
Ailingnae exposed			_	<del></del> .		_
Utirik exposed	$342 \pm 78(10)$	) 6	$5.55 \pm 1.47(10)$	$3.42\pm0.76(10)$	2.55±0.85(10)	0.27(10)
Rongelap unexposed	$294 \pm 66(21)$	) 7	$1.77 \pm 1.44(21)$	$4.07\pm1.86(21)$	$2.96\pm0.90(21)$	0.28(21)
Females >15-40 yr						
Rongelap exposed	$297 \pm 127(14)$	) 8	$0.02\pm2.18(14)$	$4.35\pm1.33(14)$	$2.86\pm0.84(14)$	0.29(14)
Ailingnae exposed	227 (4)		.96 (4)	5.45 (4)	2.05 (4)	
Utirik exposed	$410\pm 97(16)$		$1.17 \pm 1.39(16)$	$3.96\pm1.35(16)$	$2.67 \pm 0.66(16)$	
Rongelap unexposed	$294 \pm 66(23)$		$(.65\pm 1.47(23))$	$4.23\pm1.34(23)$	$2.83 \pm 0.78(23)$	
Males >40 yr	,	,	` /	,	,	` ,
Rongelap exposed	214± 87 (8)	) 6	$6.33 \pm 1.24$ (8)	$2.88\pm0.59$ (8)	$2.99 \pm 1.04$ (8)	0.15 (8)
Ailingnae exposed	245 (4		.38 (4)	3.23 (4)	2.46 (4)	, ,
Utirik exposed	344± 73(19)	•	.88±1.85(19)	$3.49\pm1.09(19)$	` '	
Rongelap unexposed	$294\pm 66(23)$		$6.65\pm1.40(23)$	$3.17 \pm 0.99(23)$	$2.85 \pm 0.67(23)$	
Females >40 yr	20122 00(20)	,		0.17 = 0.00 (10)	1,000.0. (10)	0.40(20)
Rongelap exposed	238± 98 (7)	5	.82±0.60 (7)	2.86±0.58 (7)	$2.56\pm0.63$ (7)	0.18 (7)
Ailingnae exposed	249± 47 (5)		$1.20\pm1.60$ (5)	$3.83 \pm 0.57$ (5)	$2.37\pm1.20$ (5)	, ,
Utirik exposed	$356\pm 90(16)$		$1.08\pm1.30(16)$	$3.47 \pm 1.13(15)$	$3.07 \pm 0.92(15)$	. ,
Rongelap unexposed	$318\pm 94(19)$		$1.21\pm1.40(19)$	$3.67 \pm 1.20(19)$	$2.98 \pm 0.94(19)$	
Males <9 yr	310= 34(13)	, ,	.21 = 1.40(13)	3.07 = 1.20(13)	2.30 ±0.54(15)	0.20(13)
Of exposed parents	374± 95(15)	1.0	$0.60\pm3.49(16)$	4.49±1.19(16)	$5.15\pm3.04(16)$	0.39(16)
Of unexposed parents	$374\pm 95(15)$ $375\pm119(29)$		$\pm 2.87(29)$	$4.49 \pm 1.19(10)$ $4.40 \pm 1.82(29)$	$5.19\pm3.04(10)$ $5.29\pm1.87(29)$	` ,
Females < 9 yr	373-119(29)	, 10	.31 _ 2.07 (23)	4.40 - 1.02(29)	3.23 - 1.07 (23)	0.40(23)
Of exposed parents	206 07/10	. 10	20-1-1-02/12\	4.76-1.00/10)	6 07 - 2 00 (10)	0.55/19\
	$386\pm 87(18)$		$1.20\pm1.92(18)$	$4.76\pm1.92(18)$	$6.07 \pm 3.00(18)$	, ,
Of unexposed parents	383±101(21)	) 10	.15±2.50(22)	3.83±1.23(22)	$5.31\pm1.60(22)$	0.36(22)
•		Baso.		RBC		Serum
	$(\times 10^{-3})$	×10 <sup>-2</sup> )	Hct., %	(×10 <sup>-4</sup> )	Hgb., g	protein, g
Males 9-15 yr						
Rongelap exposed	0.79 (9) 0.	74 (9)	39.1±2.0 (9)	429±45 (9)	13.8±0.5 (9)	7.7±0.5 (9)
Ailingnae exposed		0 (1)	36.0   (1)			
Utirik exposed		38(11)	$37.9 \pm 2.1(12)$	$377   (1)$ $442\pm23(12)$	` '	7.5 (1) $7.6 \pm 0.3(12)$
					$15.0\pm1.2(12)$	
Rongelap unexposed	0.69(14) 0.4	44(14)	$39.4 \pm 1.4(14)$	$433\pm34(14)$	$14.1 \pm 0.7(14)$	$7.8 \pm 0.4(12)$
Females 9-15 yr	0.49 (0) 0	46 (9)	20.5 + 2.0 (2)	440 + 24 (0)	120+00 (0)	00-04 (0)
Rongelap exposed		46 (8)	$39.5 \pm 2.0 (8)$	449±34 (8)	13.9±0.9 (8)	$8.0\pm0.4$ (8)
Ailingnae exposed		0 (21)	41.0 (2)	435 (2)	15.0 (2)	8.0 (2)
Utirik exposed		40(15)	$38.0 \pm 2.1(15)$	$427\pm29(15)$	$14.0\pm1.0(15)$	$7.9\pm0.4(14)$
Rongelap unexposed	0.48(16) 0.3	35(16)	$38.3\pm2.7(17)$	$424\pm40(17)$	$13.7 \pm 1.6(17)$	$7.9 \pm 0.5(17)$

Table~18~(cont'd) Mean Levels of Rongelap Peripheral Blood Elements by Age and Sex, 1963

	Eosin.	Baso.	RBC			Serum	
•	$(\times 10^{-3})$	$(\times 10^{-2})$	<b>H</b> ct., %	(×10 <sup>-4</sup> )	Hgb., g	protein, g	
Males >15-40 yr	· · · · · · · · · · · · · · · · · · ·						
Rongelap exposed	0.28(11)	0.25(11)	$45.5\pm2.4(11)$	$458 \pm 47(11)$	$16.1 \pm 1.3(11)$	$7.6\pm0.3(10)$	
Ailingnae exposed			<del>_</del>	_		_	
Utirik exposed	0.26(10)	0.48(10)	$44.6\pm2.5(10)$	$460\pm34(10)$	$16.2 \pm 0.7(10)$	$7.6\pm0.4(10)$	
Rongelap unexposed	0.40(21)	0.30(21)	$45.7 \pm 4.7(21)$	$473\pm32(21)$	$16.1\pm0.5(21)$	$8.0\pm0.4(21)$	
Females >15-40 yr	, ,	,	, ,				
Rongelap exposed	0.52(14)	0.25(14)	$37.9 \pm 4.8(14)$	$409\pm64(14)$	$13.2\pm1.8(14)$	$7.8\pm0.5(14)$	
Ailingnae exposed	0.19 (4)	0.32(4)	37.3 (4)	406 (4)	12.9 (4)	7.7 (4)	
Utirik exposed	0.32(16)	0.17(16)	$37.1 \pm 3.6(16)$	$405\pm41(16)$	$13.2 \pm 1.4(16)$	$7.6\pm0.4(16)$	
Rongelap unexposed	0.35(23)	0.23(23)	$38.3 \pm 2.8(23)$	$421\pm39(23)$	$13.6 \pm 1.0(23)$	$7.9\pm0.6(23)$	
Males >40 yr	` _	• ′		, ,	, ,		
Rongelap exposed	0.31 (8)	0.08 (8)	$41.3\pm5.4$ (8)	410±58 (8)	$14.5\pm0.5$ (8)	$7.6 \pm 0.4 (7)$	
Ailingnae exposed	0.35 (4)	0.06 (4)	44.0 (4)	469 (4)	15.8 (4)	7.6 (4)	
Utirik exposed	0.34(19)	0.28(19)	$41.3\pm2.2(19)$	$428\pm36(19)$	$14.8 \pm 0.9(19)$	$7.8\pm0.4(19)$	
Rongelap unexposed	0.36(23)	0.37(23)	$42.1\pm3.3(23)$	$429\pm47(23)$	$14.7 \pm 0.5(23)$	$7.9 \pm 0.5(23)$	
Females >40 yr	, ,	, ,	, ,	, ,	,	` ′	
Rongelap exposed	0.21(7)	0.09 (7)	$38.1\pm2.5$ (7)	376±38 (7)	$13.3\pm1.4$ (7)	$7.8 \pm 0.2 (6)$	
Ailingnae exposed	0.62 (5)	0.23 (5)	$38.0\pm2.6$ (5)	$403\pm41 (5)$	$13.9 \pm 1.1 (5)$	$8.4\pm0.4$ (5)	
Utirik exposed	0.32(15)	0.25(15)	$38.0\pm3.1(16)$	$405\pm28(16)$	$13.8 \pm 0.8(16)$	$8.1\pm0.6(16)$	
Rongelap unexposed	0.27(19)	0.37(19)	$38.3 \pm 1.7(19)$	$393\pm29(19)$	$13.7 \pm 0.9(19)$	$8.0\pm0.5(19)$	
Males <9 yr	` ′	, ,	` '	` ,	` ′	` ′	
Of exposed parents	0.56(16)	0.19(16)	$36.5 \pm 3.0(16)$	$438 \pm 64 (16)$	$12.6\pm1.1(16)$	$7.3 \pm 0.4 (6)$	
Of unexposed parents	0.79(29)	0.58(29)	$36.9\pm2.4(29)$	$434\pm30(29)$	$12.5 \pm 1.0(29)$	$7.3 \pm 0.2 (5)$	
Females < 9 yr	` ,	,	,	` '	, ,	` /	
Of exposed parents	0.79(18)	0.23(18)	$36.8 \pm 2.2(18)$	$424\pm32(18)$	$12.8 \pm 1.0(18)$	7.7 (3)	
Of unexposed parents	0.64(22)	0.03(22)	$37.6\pm1.7(22)$	$415\pm24(22)$	$13.0\pm0.9(22)$	$7.9\pm0.3(5)$	

<sup>&</sup>lt;sup>a</sup>Includes 2 children exposed in utero.

Table 19

Mean Levels of Rongelap Peripheral Blood Elements by Age and Sex, 1964

	Plate. $(\times 10^{-3})$	<b>WBC</b> (×10 <sup>-3</sup> )	Neut. (×10 <sup>-3</sup> )	Lymph. (×10 <sup>-3</sup> )
Males 10-15 yr				
Rongelap exposed <sup>a</sup>	$374\pm 35 (9)^{b}$	$8.01\pm2.10(9)$	$3.31\pm1.27$ (9)	$3.78 \pm 1.17$ (9)
Alingnae exposed	328 (1)	7.55 (1)	3.17 (1)	2.87 (1)
Rongelap unexposed	$389 \pm 158(15)$	$11.13 \pm 4.70(15)$	$5.96\pm5.03(\hat{15})$	$4.17\pm1.22(15)$
Females 10-15 yr	,	, ,	. , ,	` ,
Rongelap exposed	$398\pm110~(6)$	$7.53\pm1.10$ (6)	$3.39\pm0.52$ (6)	$3.34\pm1.06$ (6)
Ailingnae exposed	454 (1)	11.08 (1)	4.87 (1)	4.87 (1)
Rongelap unexposed	$397 \pm 106(18)$	$9.87 \pm 3.00(18)$	$4.74\pm2.25(18)$	$4.00\pm0.94(18)$
Males > 15-40 yr	, ,	` '	,	` /
Rongelap exposed	$287 \pm 78(11)$	$8.12\pm2.10(11)$	$3.90\pm1.44(11)$	$3.42\pm1.08(11)$
Ailingnae exposed	_ ` ´		<u> </u>	
Rongelap unexposed	$337\pm104(24)$	$9.40 \pm 3.40(24)$	$5.10\pm2.73(23)$	$3.45 \pm 1.15(23)$

<sup>&</sup>lt;sup>b</sup>Standard deviation and number of people in group.

<sup>&#</sup>x27;Includes 1 child exposed in utero.

Table 19 (cont'd)

Mean Levels of Rongelap Peripheral Blood Elements by Age and Sex, 1964

	Plate. $(\times 10^{-3})$		WBC ×10⁻³)	Neut. (×10 <sup>-3</sup> ) .	Lymph. (×10 <sup>-3</sup> )	
Females >15-40 yr						
Rongelap exposed	$372 \pm 73(15)$	$8.25\pm1.90(15)$		$4.32\pm2.13(14)$	$3.31\pm0.96(14)$	
Ailingnae exposed	382± 95 (5)	$6.80\pm1.60(5)$		$3.04\pm1.18$ (5)	$3.19\pm0.77$ (5)	
Rongelap unexposed	$382\pm110(29)$	9.16	$\pm 2.00(29)$	$5.29\pm1.87(29)$	$3.11\pm1.11(29)$	
Males >40 yr						
Rongelap exposed	$331\pm126$ (8)	7.83	$\pm 2.00$ (8)	$3.60\pm1.20$ (8)	$3.48\pm1.22$ (8)	
Ailingnae exposed	323 (4)	6.59	` '	3.03 (4)	3.03 (4)	
Rongelap unexposed	$348 \pm 114(19)$	7.75	$\pm 1.30(19)$	$3.93\pm1.14(19)$	$3.06\pm0.78(19$	
Females >40 yr						
Rongelap exposed	$346\pm159$ (6)	8.06	$\pm 2.20$ (6)	$3.74\pm2.02(6)$	$3.53\pm1.18$ (6)	
Ailingnae exposed	441±148 (5)	8.06	$\pm 2.00 (5)$	$4.32\pm0.91$ (5)	$2.80\pm1.15$ (5)	
Rongelap unexposed	$360 \pm 99(20)$	8.29	$\pm 1.9 (20)$	$4.01\pm1.41(20)$	$3.60\pm1.45(20$	
Males <10 yr						
Of exposed parents	$488\pm107(21)$	10.33	$\pm 2.20(21)$	$4.76\pm2.22(21)$	$4.65\pm1.38(21)$	
Of unexposed parents	$470\pm134(33)$	11.34	$\pm 2.80(33)$	$5.03\pm1.98(33)$	$5.24\pm1.77(33)$	
Females <10 yr						
Of exposed parents	$523\pm119(20)$		$\pm 1.90(20)$	$4.46\pm1.30(20)$	$5.38\pm1.31(20)$	
Of unexposed parents	468±133(24)	10.67	$\pm 2.80(24)$	4.28±2.10(24)	$5.47 \pm 1.50(24)$	
	Mono.	Eosin.	Baso.			
	( <b>×10</b> ⁻³)	$(\times 10^{-3})$	$(\times 10^{-2})$	Hct., %	Hgb., g	
Males 10-15 yr						
Rongelap exposed <sup>a</sup>	0.19 (9)	0.68 (9)	0.76 (9)	$40.4\pm6.1$ (9)	$12.5\pm0.4~(9)$	
Ailingnae exposed	0.45 (1)	0.98 (1)	0.80 (1)	37.0 (1)	12.1	
Rongelap unexposed	0.31(15)	0.66(15)	0.26(15)	$37.4 \pm 1.7(15)$	$12.5\pm0.8(\hat{1}5$	
Females 10-15 yr	` ,	` ′	` ,	` /	· ·	
Rongelap exposed	0.10 (6)	0.65 (6)	0.38 (6)	$39.5\pm2.4~(6)$	13.3±0.3 (6	
Ailingnae exposed	0.33 (1)	0.89 (1)	1.10 (1)	40.0 (1)	14.0 (1	
Rongelap unexposed	0.21(18)	0.88(18)	0.38(18)	$38.3 \pm 2.5(18)$	$12.4\pm0.8(18$	
Males >15-40 yr						
Rongelap exposed	0.25(11)	0.43(11)	0.46(11)	$43.8 \pm 5.5(11)$	$14.7 \pm 1.0(11)$	
Ailingnae exposed	<del>_</del>	_		_	_	
Rongelap unexposed	0.26(23)	0.57(23)	0.50(23)	$46.1\pm3.1(24)$	$15.2 \pm 1.1(24)$	
Females >15-40 yr						
Rongelap exposed	0.24(14)	0.37(14)	0.35(14)	$40.0\pm2.3(14)$	$13.1 \pm 0.7 (14$	
Ailingnae exposed	0.20(5)	0.33 (5)	0.36(5)	$38.0\pm6.1$ (5)	$12.3\pm2.5$ (5	
Rongelap unexposed	0.22(29)	0.49(29)	0.50(29)	$37.3 \pm 4.5(29)$	$12.4 \pm 1.6(29)$	
Males >40 yr						
Rongelap exposed	0.26 (8)	0.48 (8)	0.39 (8)	$43.0\pm2.7$ (8)	13.5±1.9 (8	
Ailingnae exposed	0.13 (4)	0.39 (4)	0.30 (4)	43.0 (4)	14.5 (4	
Rongelap unexposed	0.20(19)	0.47(19)	0.48(19)	$41.6 \pm 2.6(19)$	$14.0\pm1.0(19$	
Semales >40 yr						
Rongelap exposed	0.09 (6)	0.65 (6)	0.53 (6)	$37.3\pm3.9(6)$	$12.7 \pm 1.4$ (6)	
Ailingnae exposed	0.11 (5)	0.76 (5)	0.82 (5)	$38.3 \pm 1.8 (5)$	$12.7\pm0.7$ (5)	
Rongelap unexposed	0.23(20)	0.40(20)	0.63(20)	$39.6 \pm 1.0(20)$	$13.0 \pm 0.6(20)$	
Males < 10 yr						
Of exposed parents	0.23(21)	0.73(21)	0.63(21)	$36.6 \pm 2.5(21)$	$12.1 \pm 1.1(21)$	
Of unexposed parents	0.28(33)	0.66(33)	0.38(33)	$37.3 \pm 2.4(33)$	$12.1\pm0.9(33)$	
Females < 10 yr						
Of exposed parts	0.32(20)	0.76(20)	0.38(20)	$34.9 \pm 3.7(20)$	$11.5 \pm 1.4(20)$	
Of unexposed pare.	0.23(24)	0.62(24)	0.70(24)	$36.8 \pm 2.4(24)$	$12.1 \pm 1.0(24)$	

<sup>&</sup>lt;sup>a</sup>Includes 2 children exposed in utero.

<sup>&</sup>lt;sup>b</sup>Standard deviation and number of people in group.

group who received 175 rads are designated as "Rongelap exposed," the Rongelap people who received a smaller exposure of 69 rads as "Ailingnae exposed," and the larger unexposed comparison population of Rongelap as "unexposed." Because of the small number of people in the Ailingnae group, their data were not treated as fully as those for the Rongelap groups, and are briefly summarized in a separate paragraph. The Utirik data are summarized separately also. Because of certain differences noted in age and sex groups between the exposed and the unexposed, in addition to the comparisons of mean levels for entire groups, comparisons are also made of age and sex groups. Ages 9 to 15, 16 to 40, and >40 years for each sex are compared.

The hematological data are summarized in Tables 18 and 19 and in Figures 23 through 49. In Appendices 1, 2, and 3 are presented summaries of the mean blood counts of the exposed populations and of the various comparison populations since exposure in March 1954. In Appendices 4 and 5 are listed the individual blood counts for 1963 and 1964. In Appendix 6 basophil counts are presented.

Rongelap Population. Leukocytes. Mean levels of leukocytes in both exposed and comparison populations at 9 years post exposure were increased over the 8-year levels, and the 10-year levels were higher than those for either of the two preceding years. The exposed group had only slightly lower leukocytes than the unexposed (-4%) at 9 years, and at 10 years, lower by 9%. Most of the difference was due to lower neutrophil levels in the exposed group (see Figure 23).




Figure 23. Mean neutrophil and white blood counts of exposed Rongelap people from time of exposure through 10 years post exposure. Stars represent mean values of comparison population.

NEUTROPHILS. The neutrophil levels increased slightly at the time of the 9 and 10-year surveys in both exposed and comparison populations. At 9 years the neutrophil levels were about 5% lower in the exposed than in the comparison group, but at 10 years they were about 20% lower. Neutrophil levels are shown in Figures 23 through 29. The neutrophil deficit was greater in the exposed younger age groups (<40 years). The exposed older age groups (>40 years) did not share the deficit as much as has been noted in the past (Figures 26 through 29).

Lymphocytes. Lymphocyte levels were slightly higher in the exposed and unexposed groups during the 9 and 10-year surveys. In contrast to the 8-year survey results, the lymphocyte mean levels showed little difference between the exposed and unexposed groups during the 9 and 10-year surveys; however, some individual lymphocyte counts were lower in the exposed group. Lymphocyte levels are shown in Figures 24, 25, and 30 through 34.




Figure 24. Cumulative percent distribution curves for neutrophils, lymphocytes, and platelets, 1963.




Figure 25. Cumulative percent distribution curves for neutrophils, lymphocytes, and platelets, 1964.

Eosinophils, Monocytes, and Basophils. The levels of these cells were not remarkably different between the exposed and unexposed groups and were similar to the levels in past surveys.

PLATELETS. The platelet levels in the 9 and 10-year surveys both revealed greater deficit in exposed males than in exposed females. Compared with the unexposed groups the males had 20% less in 1963 and 12% less in 1964, and the females 7% less in 1963 and 2% less in 1964 (see Figure 35). In the scattergrams (Figures 36 through 39) and the accumulative distribution curves (Figures 24 and 25) the differences are clearly shown.

ERYTHROPOIETIC ELEMENTS. As in the past surveys no significant differences were noted in the red blood counts, hemoglobins, or hematocrits

preliminary report by Mr. Keith Thompson of Brookhaven National Laboratory. "A factorial analysis of variance of unweighted means was made for each of four blood components: platelets, white blood cells, neutrophils, and lymphocytes. For these preliminary analyses, the population was stratified into four factors: years

(1961, 1962, 1963, and 1964), sex, exposed Rongelap versus nonexposed, and age (5 to 15, >15 to 40, >40). Thus, for each of the blood compo-

nents, main effects and interaction effects were

between the exposed and unexposed groups. Fig-

STATISTICAL ANALYSIS OF RONGELAP BLOOD

DATA OVER PAST FOUR YEARS. These analyses

are in progress, and the following represents a

ures 40 through 49 demonstrate this point.




Figure 26. Neutrophil counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 27. Neutrophil counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1963.




Figure 28. Neutrophil counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1964.




Figure 29. Neutrophil counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1964.




Figure 30. Mean lymphocyte counts of exposed Rongelap people from time of exposure through 10 years post exposure. Stars represent mean values of comparison population.




Figure 31. Lymphocyte counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 32. Lymphocyte counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1963.

computed to obtain information about the effect of radiation over time in relation to sex, exposure, and age.

"A generally similar pattern was observed in these analyses for all four components. The variation among years was always highly significant, largely because of an increased count in all four components in 1964. This annual difference has been commented on in previous reports. Differences existed in 1961, 1962, and 1963, but these were not chronologically consistent among the components.

"A clear-cut and highly significant decrease in all four blood components was observed for the exposed population compared to the nonexposed. There was also a highly significant decrease in




Figure 33. Lymphocyte counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1964.




Figure 34. Lymphocyte counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1964.

counts of all four components with increasing age at the time of radiation. There was no evidence at the 5% level of any sex difference for any of the blood components except platelets, for which the male count was significantly lower (1% level) than the female count.

"There was no evidence at the 1% level that any of the two- or three-factor interactions (years, sex, exposed versus nonexposed, age groups) were significant. For lymphocytes there was evidence at the 5% level of an interaction between exposure and sex, and for neutrophils there was evidence at the 5% level of an interaction between exposure and year. The four-factor interaction was treated as error, an assumption which appeared justified upon examination of the variances. Since these data are being further analyzed, no interpretation as to biological significance of the above interactions is justified at present."




Figure 35. Mean platelet values of exposed Rongelap people from time of exposure through 10 years post exposure. Stars represent mean values of unexposed comparison population.




Figure 36. Platelet counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 37. Platelet counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1963.




Figure 38. Platelet counts of exposed Rongelap males plotted against age. Solid line represents mean level of unexposed male population, 1964.




Figure 39. Platelet counts of exposed Rongelap females plotted against age. Solid line represents mean level of unexposed female population, 1964.




Figure 40. Hematocrit values of exposed males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 41. Hematocrit values of exposed females plotted against age. Solid line represents mean level of unexposed female population, 1963.




Figure 42. Hematocrit values of exposed males plotted against age. Solid line represents mean level of unexposed male population, 1964.




Figure 43. Hematocrit values of exposed females plotted against age. Solid line represents mean level of unexposed female population, 1964.




Figure 44. Hemoglobin values of exposed males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 45. Hemoglobin values of exposed females plotted against age. Solid line represents mean level of unexposed female population, 1963.




Figure 46. Hemoglobin values of exposed males plotted against age. Solid line represents mean level of unexposed male population, 1964.




Figure 47. Hemoglobin values of exposed females plotted against age. Solid line represents mean level of unexposed female population, 1964.

Ailingnae Population. The 16 people in the Ailingnae population that were examined during these two years showed blood counts similar to those of the higher dose Rongelap group. The 10-year platelet counts in the Ailingnae women were considerably higher than the previous counts; the reason for this is not apparent. The blood data on this group of people are summarized in Tables 18 and 19 and Appendix 2.

Utirik Population. The people of Utirik Atoll who had been exposed to a very low dose of radiation (an estimated 14 rads of whole-body gamma radiation) had leukocyte, neutrophil, and lymphocyte counts of about the same levels as seen in the unexposed comparison population of Rongelap (Table 18 and Appendices 3 and 4). However, it




Figure 48. RBC values of exposed males plotted against age. Solid line represents mean level of unexposed male population, 1963.




Figure 49. RBC values of exposed females plotted against age. Solid line represents mean level of unexposed female population, 1963.

was of interest that the platelet counts for all age groups averaged considerably higher in the Utirik people than in the Rongelap unexposed population. The explanation for this is not apparent. The erythrocytes, hemoglobin, and hematocrit levels were about the same as in the unexposed Rongelap people.

Children of Exposed Parents. Blood counts of children of exposed parents compared with those of the children of parents in the comparison population showed no significant differences. These data are tabulated in Tables 18 and 19 and Appendices 4 and 5. During the 7th and 8th-year surveys these children had shown slightly lower levels of leukocytes and platelets compared with children of unexposed parents. This difference is not apparent at this time.




Figure 50. Bizarre mitosis in a myelocyte.



Figure 51. Binucleated normoblast.

#### **Bone Marrow Examinations**

The differential counts of bone marrow aspirations on 6 individuals, 4 exposed and 2 unexposed, are listed in Appendix 18. The differential counts showed that in 3 of 4 exposed persons there was an alteration in the myeloid-erythroid ratio manifested by an increased number of red cell precursors. In addition to hyperplasia, abnormalities of chromatin material with double nuclei and increased numbers of mitotic figures were seen in the normoblastic series (Figures 50 and 51). One of the exposed (No. 63) and one of the unexposed (No. 948) showed increased lymphocytosis of 33% and 27% respectively. This was reflected in the peripheral blood counts in which the total number of leukocytes was normal but the lymphocytes were increased to 51% and 56%. The significance of this finding remains obscure, but repeat bone marrow examinations will be carried out in both these cases during the 1965 survey.

## Red Cell Mass and Plasma Volume Studies

During the 1961 and 1962 surveys blood volume studies were performed on a group of Marshallese subjects and on a small number of Caucasians who had been living on the islands for one year or longer. Sodium chromate labeled with Cr<sup>51</sup> was used to tag the erythrocytes. With body weight as a criterion, it appeared that 15 of 23 subjects, both Marshallese and Caucasian, showed a significant reduction in red cell mass and/or plasma volume.

In order to establish the relationship of blood volume to lean body mass tritiated water was administered orally to each of 21 Marshallese subjects during the 1963 survey. In addition, determinations were made of red cell mass and blood volume by using Cr<sup>51</sup>-labeled sodium chromate.

Table 20

Total Blood and Red Cell Volume Data
(WT.=gross weight; TBW=total body water; FAT=fat as % gross weight; LBM=lean body mass; RCV=red cell volume; BV=blood volume)

Subject No.	WT., kg	TBW, I	TBW, %	FAT, %	LBM, kg	RCV, I	B.V., 1	RCV/LBM, ml/kg	BV/LBM, ml/kg
822	54.54	38.1	68.8	4.4	52.1	1.402	3.260	26.9	62.6
832	46.36	25.0	53.0	26.4	34.1	0.849	2.358	24.9	69.2
836	56.36	35.3	61.7	14.3	48.3	1.428	3.320	29.6	68.7
838	66.13	41.7	62.2	13.6	57.1	2.108	4.053	36.9	71.0
841	66.81	31.9	47.0	34.7	43.6	1.150	3.196	26.4	73.3
873	61.36	43.2	69.4	3.6	59.1	1.670	3.631	28.3	61.4
881	68.63	32.8	47.1	34.6	44.7	1.996	4.247	44.7	95.0
882	54.77	39.9	71.8	0.3	54.6	1.131	3.426	20.7	62.7
885	61.81	41.0	65.3	9.3	56.1	1.760	3.825	31.4	68.2
895	55.90	29.0	51.5	28.5	40.0	1.070	2.488	26.8	62.2
916	63.63	32.6	50.4	30.0	44.5	1.091	3.031	24.5	68.1
928	57.27	29.4	50.5	29.9	40.2	0.927	2.505	23.1	62.3
932	46.30	26.2	55.7	22.6	35.8	1.274	2.963	35.6	82.8
938	40.00	22.0	54.1	24.9	30.1	688.0	2.331	29.4	77.4
942	57.72	27.6	47.1	34.6	37.8	0.860	2.150	22.8	56.9
959	60.00	32.2	52.8	26.7	44.0	1.151	2.877	26.2	65.4
960	38.63	24.8	63.1	12.4	33.9	0.774	2.150	22.8	63.4
1007	71.36	41.2	56.9	21.0	56. <b>4</b>	1.620	4.155	28.7	73.7
1043	41.81	26.4	62.3	13.5	36.2	1.066	2.664	29.4	73.6
1501	66.81	43.3	64.0	11.2	59.3	1.843	3.840	31.1	64.8
Jeton	63.18	39.8	61.9	14.0	54.4	1.310	2.675	24.1	49.2
	Av	33.5				1.303	3.102	28.3	68.2

 $\frac{Av RCV (1)}{Av TBW (1)} = 0.039; \quad \frac{Av BV (1)}{Av TBW (1)} = 0.092$ 




Figure 52.

After 4 hours, urine samples were collected and lyophilized, and tritium in the water portion was counted in a Nuclear-Chicago liquid scintillation counter. From these values of total body water, fat was estimated by the formula % fat =100 -(% TBW/0.72). The % TBW is total body water (in kg) as percent of gross weight. Lean body mass (LBM) was taken as the difference between gross weight and fat (kg).

The data are shown in Table 20. According to Siri (personal communication) the values for total body water, fat, or lean body mass are not different from averages for Caucasian subjects in the San Francisco area. Figure 52 shows the values of blood volume (liters) and red cell volume (liters) plotted against total body water. Regression lines drawn for Caucasians by Moore<sup>13</sup> and Siri (unpublished) disclose that with the exception of one case the values of Marshallese fall far below those described by the authors. The average red cell volume for Marshallese is 28.3 ml per kg LBM as compared to 35 ml/kg (Siri, unpublished).

Whether these findings represent a genetic difference or are the result of environment and/or diet cannot be stated at present. It is hoped that studies will be continued in 1965 with examina-

Table 21 Protein Bound Iodine, 1963 and 196-

Protein Bound	Iodine,	1963 and 1964	
Subject No	).	PBI, γ %	
Marshallese F	RESIDING	G ON RONGELAP	
1		9.4	
6		7.9	
10		12.0	
14		8.2	
86		8.2	
17		6.8	
21		8.1	
69		10.2	
865		8.2	
	Av	8.8	
Marshallese	RESIDI	ING ON EBEYE	
12		8.8	
829		7.1	
944		2.0	
938		5.6	
982		6.3	
950		6.7	
1005		7.9	
1043		5.8	
	Av	6.3	
Americans Residi	ng in M east I Y		
ALLI	EASI I I	LAK	
		6.2	
		5.5	
		5.0	
		5.6	
		6.1	
		5.5	
		4.4	
	Av	5.5	

MEDICAL TEAM

4.7 4.7 5.1 5.5 5.2 2.5 6.0 4.5 4.2 6.9

tions of blood volume and total body water in Caucasians living in this area for one year or more.

Av

# Other Laboratory Studies

Chromosome Studies. Microscopic examination of smears from peripheral blood cultures is in progress, including chromosome counts, enumeration of aberrations, and karyotype analysis by paste-ups of photographs. A few dicentric chromosomes and certain other aberrations have been noted in the examined group, but insufficient control material has been analyzed for any positive statements to be made at this time.

Diabetic Survey. Based on blood sugar determinations as part of the routine urine analyses and fasting blood sugar determinations, it was found that 6 people had a diabetic tendency. The following had elevated fasting blood sugars (mg %): No. 853, 247; No. 893, 279; No. 936, 187; No. 991, 248; No. 1042, 180; No. 835 had a 3+ urine sugar but no blood sugar determination was done. As has been noted, the incidence of diabetes is fairly high in the Marshallese. It is, however, of the type that develops in older people since no cases have been seen in younger people.

Serological Studies. PROTEIN BOUND IODINE DETERMINATIONS. Protein bound iodine levels were determined in several groups of people during the past two surveys. The groups included 9 Marshallese living on Rongelap Atoll, 8 Marshallese living on Ebeye Island (Kwajalein Atoll), 10 members of the medical team, and 7 Americans who had been residing in the Marshall Islands for at least a year. The results are presented in Table 21. Again the Marshallese values are higher than the Caucasian values. Though the number of samples involved is too small for any positive statement to be made, the lower levels of the Marshallese living on Ebeye may have some meaning, since their environment is quite different from that of the Rongelap residents (more westernized in food, etc.). A difference between the medical team who had only been in the Islands a few weeks and the Americans who had resided there for at least a year is probably not significant. It is anticipated that this aspect of the problem will be further investigated on the next survey.

Folic Acid Determinations. Folic acid levels were below or in the low range of normal in 29% of the 129 Rongelap people tested. Fifteen percent were below 4 mµg/ml and 16% in the borderline range of 4 to 7 mµg/ml. The unexposed comparison population had slightly lower values than the exposed population. The generally low level of these Island people is attributed to a dietary deficiency of foods containing folic acid, mainly leafy vegetables. The levels were not sufficiently low to result in any hematological changes or apparent clinical effects. The individual values for folic acid are presented in Appendix 17.

The Ag System. The following statements were made by Dr. B.S. Blumberg\*: "The sera of patients who have received multiple transfusions may contain antibodies against normal human serum components." The first example of such antibodies was reported in a patient (C.deB.) who had received  $\approx 50$  transfusions for the treatment of a refractory anemia of unknown etiology. By means of the Ouchterlony double-diffusion technique, it was shown that the antibody formed a precipitin with  $\approx 55\%$  of normal U.S. white and Negro sera. By twin, family, and population studies. It was shown that the presence or absence

<sup>\*</sup>Associate Director for Clinical Research, Institute for Cancer Research, Philadelphia, Pa.

Table	22
Serum	Tests

		Antisera reactors								
		C.de	В.	New York						
Population	Location	Total No.	% Pos.	Total No.	% Pos.					
Micronesian	Rongelap Atoll	187	98	181	38					
U.S. White	Maryland	120	59	120	97					
U.S. Negro	Georgia	149	68	149	99					
Greek	Greece	203	72	203	93					
Quechua Indian	Peru	102	70	102	86					
Sioux Indian	South Dakota	143	91	143	78					

of the reacting antigen was under genetic control. Individuals with a dominant gene designated  $Ag^4$ in single or double dose (genotypes  $Ag^A/Ag^A$ ,  $Ag^{A}/Ag$ ) were reactors [phenotype Ag(a+)] and those homozygous for the recessive allele Ag nonreactors [Ag(a-)]. The antigen or antigens that react with the antibodies present in the serum of the frequently transfused patient are serum low density  $\beta$ -lipoproteins. 17 A serum from a second ), the New York antiserum, was also patient ( found to react with a low density  $\beta$ -lipoprotein. Preliminary family studies indicated that reactors were homozygous or heterozygous for a second gene, while nonreactors were homozygous for the alternate recessive allele. Immunologic, genetic, and population studies showed that the lipoproteins selected by the two antisera were antigenically distinct and controlled by different genes.18

"Sera collected from the inhabitants of Rongelap Atoll in 1962 were tested with both the C.deB. [anti-Ag(a+)] and the New York antisera. The total results compared with those on several other populations are shown in Table 22. There is a much higher frequency of C.deB. antiserum reactors and a much lower frequency of New York antiserum reactors in the Rongelap population than in U.S. whites and Negroes. The reasons for these differences are not known, but may depend on differences in past or present selective forces which affect the balance of the polymorphisms.

"Because of the lower frequency of New York antiserum reactors, the Rongelap population was useful for family studies. From these studies it was tentatively concluded that reactors with the New York antiserum were either homozygous or heterozygous for a dormant gene, and nonreactors were homozygous for its alternate allele."

Radiochemical Analyses of the Urine. Determinations of body burdens of gamma emitting isotopes (principally Cs<sup>137</sup> and Zn<sup>65</sup>) by whole-body gamma spectroscopy were not done during the past two surveys. Data in 1961, by that technique, indicated that the body burdens of Cs<sup>137</sup> were not significantly different from those of two years before, and Zn<sup>65</sup> levels had dropped by a factor of about 10. It was decided, therefore, to defer whole-body counts until the 1965 survey.

Results of radiochemical urine analyses for Cs<sup>137</sup> and Sr<sup>207</sup> on 38 urine samples for 1963 and 27 samples for 1964 are presented in Tables 23 and 24. The data are divided into the following groups:

exposed and unexposed of ages <15 and >15 years, living on Rongelap, Ebeye, and Utirik.

Sr<sup>300</sup> urine levels for 1963 and 1964 have not increased over the 1962 levels. In 1962, the mean Sr<sup>300</sup> values from the individual adult 24-hr samples were 12.45 pC/l or 114 pC/g Ca. From these values, on the basis of previous calculations, <sup>6,19</sup> the body burden was estimated as 12.0 m $\mu$ C for adults and 28.4 m $\mu$ C for children. On the same basis, the estimates for 1963 body burden levels of Sr<sup>300</sup> are 11.3 m $\mu$ C (adults) and 21.8 m $\mu$ C (children); and for 1964, 10.7 m $\mu$ C (adults) and 23.1 m $\mu$ C (children). As shown in Table 23, the levels of both Cs<sup>137</sup> and Sr<sup>500</sup> are lower for the people living on the uncontaminated island Ebeye at Kwajalein Atoll.

Thus the return of the Rongelap people to their home island was reflected in annual increases to 1962 in estimated body burdens of  $Sr^{90}$  based on urinary excretion values. The annual estimates in  $m\mu$ C for adults were as follows: 2.0 in 1958; 6.0 in 1959; 6.9 in 1961; 12.0 in 1962; 11.3 in 1963; and 10.7 in 1964. The present body burdens are about 5 to 6% (adults) to about 10% (children) of the maximum permissible concentration (MPC) of  $Sr^{90}$  (200 m $\mu$ C) for non-industrial populations. It appears now that equilibrium with the environmental contamination of  $Sr^{90}$  has been reached in the people living on Rongelap Island, and the previously estimated equilibrium value of 23 m $\mu$ C will not be reached.

No bone samples were obtained from autopsy material during the past two years for Sr<sup>90</sup> analysis. Estimates of body burdens from previous analyses of bone samples had shown fairly good correlation with those obtained from urine analyses.

In view of the paucity of the previous data on Cs<sup>137</sup> urinary levels, it is difficult to interpret the present levels in terms of body burden. However, the levels are generally less than the mean 1958 Cs<sup>137</sup> urinary level of about 4 nC/l. This is in accord with the finding by gamma spectrographic determinations that the whole-body burdens of Cs<sup>137</sup> in 1961 had not increased.

Analyses of three coconut crabs for  $Sr^{90}$  and  $Cs^{137}$  are shown in Table 25. Though the levels of  $Sr^{90}$  (pC/g Ca) are lower than in the crabs analyzed in 1962, they are still sufficiently high to necessitate continuation of the ban on their consumption by the people of Rongelap. It is interesting that the  $Cs^{137}$  levels are also quite high in these crabs.

Table~23 Radiochemical Urine Analysis for  $Sr^{90}$  and  $Cs^{137},\,1963$ 

Group	Subject No.	Age	Sex	Sample vol., ml	Sr <sup>90</sup> , pC/l	Ca, g/l	$Sr^{90}$ , $pC/g$ $Ca$	Cs137, nC/
Rongelap								
Unexposed, age $< 15$	818	12	M	790	19.3	0.072	268	6.73
	820	14	M	1180	6.4	.020	320	3.32
	814	i 1	M	1490	12.0	.168	71	2.60
	913	12	M	590	17.1	.188	91	1.52
	912	10	M	1630	11.4	.117	98	2.68
	815	13	M	550 ·	4.9	.012	408	4.69
	911	10	F	1050	5.9	.046	137	1.54
	955	10	F	465	4.1	.022	186	3.14
			F					
	816	13		1050	6.3	.035	180	2.12
	821	14	F	705	12.5	.172	73	4.69
Mean				950	10.0	0.085	183	3:31
Exposed, age <15	19	12	M	1160	4.8	0.031	155	1.81
zasposou, ugo 💜 10	23	13	M	987	5.6	.046	122	2.24
	69	13	F	987	9.6	.031	310	6.11
	42	12	F	1060	17.5	.076	230	2.84
	17	12	F	340	33.6	.076	442	3.08
			F					
	8	11	r	1150	16.8	.074	227	1.10
Mean				947	14.6	0.056	248	2.86
Unexposed, age >15	822	16	M	1280	6.4	0.069	93	2.02
e neaposed, age > 15	865	30	F	795	11.8	.072	164	2.41
Mean			_	1037	9.1	0.070	128	2.21
	40	20						
Exposed, age>15	40	38	M	700	14.6	0.167	88	7.33
	7	45	M	875	9.1	.218	42	1.73
	41	53	M	1500	2.0	.040	50	0.57
	27	35	M	1400	6.3	.177	36	1.67
	14	34	$\mathbf{F}$	990	6.9	.038	182	0.48
	66	38	F	650	8.9	.137	65	2.58
	39	24	F	530	4.0	.015	267	4.45
	18	30	F	725	7.2	.171	42	7.96
	61	17	F	1025	15.3	.104	147	2.68
Mean				933	8.3	0.118	102	3.27
Pool	A			2060	4.5	0.051	88	1.58
F 001	В							
	C			1820	3.5	.071	49	1.62
	C			1990	4.7	.065	73	1.49
Mean				1956	4.2	0.062	70	1.56
Евече Pooled				1400	5.9	0.073	75	0.65
Utirik (Exposed)								
	2256	14	F	625	8.5	0.149	57	0.95
Age < 15			r F					
	2251	12	Г	350	1.9	.031	52	0.15
Mean				487	5.2	0.090	55	0.55
Age > 15	2168	28	M	730	2.6	0.363	7	1.26
50 / .0	2137	24	M	800	3.2	.178	15	0.70
Mean	-107			765	2.9	0.271	11	0.98
								,
Summary Rongelap, all <15					11.8	0.074	207	3.14
						.114	107	3.08
Rongelap, all >15					8.3			
Ebeye					5.9	.073	75 = =	0.65
Utirik, all <15					5.2	.090	55	0.55
Utirik, all >15					2.9	.271	11	0.98

5005825

Table 24

Radiochemical Urine Analysis for Sr<sup>90</sup> and Cs<sup>137</sup>, 1964

Group	Subject No.	Age	Sex	Sample vol., ml	Sr <sup>90</sup> , pC/l	Ca, g/l	$Sr^{90}$ , pC/g Ca	Cs <sup>137</sup> , nC/
Rongelap								
Unexposed, age <15	818	13	M	2000	22.4	0.165	136	6.90
Exposed, age <15	19 69	13 14	M F	1280 490	4.5 21.1	0.020 .071	225 297	4.12 12.0
Mean				885	12.8	0.046	261	8.06
Unexposed, age >15	822	17	M	2880	9.0	0.114	79	2.97
	865 896	31 24	F F	3260 2180	6.7 7.4	.077 .0 <b>40</b>	87 1 <b>8</b> 5	2.96 3.62
Mean	-00		_	2773	7.7	0.077	117	3.18
Exposed, age >15	15	17	F	1100	6.6	0.028	236	2.94
	41	54	M	1940	3.5	.035	100	2.34
	40	39	M	2000	9.5	.230	41	4.59
	7	46	M	1890	11.1	.206	54	4.33
	16	49	M	1880	4.6	.069	67	3.55
	50	44	M	2100	6.0	.122	49	3.14
	14	35	F	1580	8.7	.032	271	4.52
	18	31	F	860	14.5	.181	80	6.40
	27	36	M	1340	3.6	.083	43	2.95
	59	44	F	1000	7.2	.200	35	3.60
Mean				1569	7.5	0.119	98	3.84
Pooled	Α			8920	3.7	0.080	46	0.96
,	В			2050	9.3	.107	87	2.94
Mean				5480	6.5	0.093	66	1.95
Евече								
Unexposed, age <15	909	14	F	770	4.4	0.130	34	0.15
Exposed, age < 15	32	13	M	1160	9.0	0.083	108	1.49
possa, ugo (15	23	14	M	285	16.3	.189	86	3.34
	20	••						
Mean				722	12.6	0.136	98	2.41
Unexposed, age $>15$	895	34	F	1180	3.5	0.030	117	0.08
. F	843	35	F	2000	8.6	.130	66	2.80
	893	46	F	3680	5.3	.052	102	1.25
Mean			-	2287	5.8	0.071	95	1.37
Exposed, age >15	28	78	F	1200	2.4	0.092	26	1.17
Exposed, age > 15	39	25	F	740	7.6	.078	97	1.86
Mean				970	5.0	0.085	61	1.51
Summary								
Rongelap, all <15				1257	16.0	0.085	219	7.67
Rongelap, all >15				1846	7:5	.101	102	3.69
Ebeye, all <15				738	9.9	.134	76	1.99
Ebeye, all >15				1760	5.5	.077	81	1.45

Table 25
Analysis of Coconut Crabs for Sr <sup>90</sup> and Cs <sup>137</sup>

			Per kg		Total					
Crab No.	Tissue .	Sr <sup>90</sup> , pC	Cs <sup>137</sup> , pC	Ca, g	Sr <sup>90</sup> , pC	Cs <sup>137</sup> , pC	Ca, g	Sr <sup>90</sup> , pC/g Ca		
1	Liver	4,400	2,679	6.88	999	608	1.56	639		
	Exoskeleton	172,502	94,074	198.39	68,285	37,239	78.53	869		
	Muscle (edible)	5,757	4,994	6.57	1,708	1,482	1.95	876		
	Remaining soft parts	5,631	4,470	6.56	516	410	0.60	858		
	Total crab	70,703	39,292	81.71	71,508	39,739	82.64	865		
2	Liver	4,428	2,287	5.80	571	295	0.75	764		
	Exoskeleton	123,318	95,724	197.75	45,287	35,154	72.62	623		
	Muscle (edible)	3,980	5,757	5.50	937	1,355	1.30	723		
	Remaining soft parts	5,711	3,414	6.92	497	297	0.60	825		
	Total crab	57,766	45,318	91.94	47,292	37,101	75.27	628		
3	Liver	8,650	5,431	10.21	335	502	0.48	847		
	Exoskeleton	146,956	143,758	187.90	30,817	30,146	39,40	782		
	Muscle (edible)	6,010	12,716	7.74	978	2,069	1.26	776		
	Remaining soft parts	4,316	6,475	6.23	211	316	0.30	692		
	Total crab	64,847	66,234	83.09	32,341	33,033	41.44	780		

# **Summarizing Discussion**

## **HEALTH STATUS**

Medical evaluation of the health status of the exposed Rongelap people over the years since the accident has revealed about the same incidence of illness and disease as in the unexposed population with the exceptions noted below. General health and nutrition has continued to be satisfactory and comparable to that of the unexposed comparison population. Annual hematological follow-up studies have revealed that the levels of white cells and platelets of the peripheral blood in the exposed group have never quite reached the levels of the unexposed comparison population. This was again demonstrated in the 9 and 10-year surveys and can be readily seen in the accumulative distribution curves (Figures 23 and 35).

Bone marrow examinations of a few individuals at 9 and 10 years post exposure showed a reduced myeloid-erythroid ratio with slight increase of immature red and white cells in some cases. There has been no indication that these findings have impaired the general health or response to disease in the exposed people.

# **MORTALITY**

There were 10 deaths in the exposed population over the 10-year period. Of these, two deaths were due to malignancies. Neither of these could be ascribed reasonably to radiation exposure. The somewhat higher death rate in the exposed group is partly offset by the higher proportion of older people, those >65 years of age being 20% in the exposed group and only 7% in the unexposed group. This mortality rate is also higher than in the Marshallese as a whole, but not significantly so. Evaluation of effects of exposure on longevity in this group must await future findings.

# **AGING**

No specific aging studies were carried out during the past two surveys, but attempts were made during several previous surveys to put on a quantitative basis various criteria of aging (skin elasticity, skin looseness, hand strength, blood pressure, arteriosclerosis, accommodation and arcus senilis of the eyes, greyness of hair, degree of baldness, etc.). No detectable radiation-induced aging effects have been noted. Aging scores evaluated at 6

and 7 years after the accident were about the same for exposed and unexposed persons of comparable age.<sup>20</sup>

# FERTILITY, MISCARRIAGES, STILLBIRTHS, AND GENETIC EFFECTS

Effects on fertility were not apparent as judged by comparison of birth rates for the exposed and unexposed populations. During the first 4 years after exposure an increase in miscarriages and stillbirths was noted in the exposed women, 41% of the births (13 in 32 births) in this group terminating in nonviable offspring compared with 21% (8 in 38 births) in the unexposed women. Since that time, the incidence has been about the same in the two groups. One cannot be certain that this effect is actually due to radiation exposure because of the small number of women involved.

No specific genetic studies have been carried out, but differences in incidences of abnormalities in children of exposed compared with those of unexposed women have not been observed. The generally negative results of large-scale genetic studies on the offspring of exposed Japanese<sup>21</sup> indicated that detailed studies on the Marshallese would not be fruitful.

#### **GROWTH AND DEVELOPMENT STUDIES**

Comparison of exposed with unexposed children of the same ages indicated slight retardation effects in the exposed males. The boys exposed at ages 1 to 5 showed retardation of statural growth as well as bone age. This was most marked in those exposed at 15 to 18 months of age. The average skeletal maturation in the exposed boys was about 7 months behind that of their unexposed peers. Though weight gain also appeared slightly retarded in this group, it was not statistically significant. The exposed girls showed no significant differences compared with unexposed girls.

The slight retardation of growth in the male children who were exposed when <5 years of age as compared with unexposed males of the same age suggests that radiation may be a causal factor although possible mechanisms are not clear. The dose to bones from internally absorbed isotopes is believed to have been too small to have affected bone growth. Adverse effects on growth and development of Japanese children exposed to the atomic bomb have been reported by Greulich,<sup>22</sup> Reynolds,<sup>23</sup> and Nehemias.<sup>24</sup> However, the evaluation of such effects in these Japanese children

was complicated by physical and psychic trauma and by malnutrition factors not operative in the case of the Marshallese children. The 175-rad gamma dose would seem to be too small to cause any direct effect on bone growth, and the estimated dose to the bones from internally absorbed isotopes probably can also be disregarded since this source contributed only about 3 to 4 rads over a 10-year period. Bone growth studies in weanling rats given sublethal exposures have shown an indirect effect on subsequent growth of shielded legs, but this appears to be based largely on a radiationinduced lowered food consumption.25 It is of interest that 25 of 31 exposed children were noted to lose several pounds of weight during the first 6 to 8 weeks following exposure. However, the influence of change in environment in producing this effect cannot be ruled out.

#### **DEVELOPMENT OF THYROID NODULES**

Thyroid nodules were removed from 3 teen-age exposed girls after the 10-year survey. Most pathologists consulted did not feel that radiation could be implicated as the etiologic agent on the basis of the pathological findings alone, though some considered the findings typical of the lesions seen in children treated medically with radioactive iodine. However, the evidence is strong that the thyroid nodules in the Marshallese girls were induced by radiation. Correlation of the thyroid nodules with radiation exposure was substantiated by statistical analysis which showed the difference in thyroid nodule incidence between the exposed and the unexposed children to be significant at the 1% level.\* Moreover, Sheline et al. 26 and Lindsay et al.27 have reported the development of thyroid nodules 5 to 11 years after treatment of children with radioiodine for thyrotoxicosis. Dr. Lindsay reported that the sections of the glands removed from the Marshallese girls were similar to the glands of children who had been given I131 therapy. On the basis of a calculated dose of  $\approx 150$ rads<sup>1</sup> to the adult thyroids from isotopes of iodine, it was estimated that the smaller thyroid glands of the girls exposed at 3 to 4 years of age received a total dose of the order of 1000 rads\*\* (probable

<sup>\*</sup>Mr. Keith Thompson of Brookhaven National Laboratory carried out the  $\chi^2$  test.

<sup>\*\*</sup>Mr. Ralph James and Dr. John Gofman, Lawrence Radiation Laboratory, Livermore, California, re-examined the early data and recalculated the thyroid doses.

range 700 to 1400 rads). The fact that a part of the total dose to the thyroid (175 rads) was due to whole-body gamma exposure (including the pituitary gland) may be of some significance.

The fact that all three Marshallese developing the thyroid nodules were girls is in accord with the experience of others that thyroid neoplasia and goiters predominate in females. In the report by Sheline et al. 26 referred to above, 8 cases among 256 patients treated with  $I^{131}$  developed thyroid nodules. All 8 cases were females: the ages at the time of treatment in 6 were < 18 (4 aged < 10 and 2 between 20 and 30). In the Marshallese girls, the stress of puberty may have been a factor in the development of the nodules.

Note: During the 11th-year survey now in progress (March 1965) 3 new cases of thyroid nodules in the exposed group have been detected. Two were in boys 12 and 17 years of age and one in an adult woman 41 years of age. The nodules appeared grossly similar to those described in the teen-age girls in this report, and these cases will receive study and treatment.

#### MALIGNANCY

Two older women who had been exposed died with a diagnosis of cancer, one at 67 years of age of ovarian malignancy at 5 years post exposure and the other at 60 years of age of probable cancer of the cervix at 8 years post exposure. The diagnosis in the latter case was not confirmed by autopsy or biopsy. One unexposed older woman died possibly of cancer of the cervix, but the diagnosis was not confirmed. No other cases of malignancy have been noted in the unexposed population.

No cases of leukemia have been detected in either the exposed or unexposed Rongelapese. Peripheral blood smears were studied closely for leukemic cells, including examinations for alkaline phosphatase and basophil counts.

The three cases of thyroid nodules plus the two earlier cases of cancer in older exposed women raise the question whether an increased frequency of cancer may be expected in future years. However, in evaluating the role of radiation, it must be kept in mind that one case of cancer in the exposed group occurred at 5 years after exposure – too soon, it is believed, to be related to radiation exposure – and in the second case it was not possible to obtain autopsy or biopsy material for con-

firmation of the diagnosis. Atomic Bomb Casualty Commission studies have conclusively demonstrated an increased incidence of leukemia in Japanese exposed to the atom bomb radiation.<sup>28-30</sup> An increased incidence has also been noted in patients who had received radiation therapy for ankylosing spondylitis.31 There are many reports of the late development of neoplasia, particularly cancer of the thyroid gland, following radiation exposure of infants and children. 32-36 Increased instances of cancer of the thyroid gland and adenomata have been reported in the Japanese heavily exposed to ionizing radiation from the atomic bombs.37-39 The Marshallese will be carefully observed for such a possibility in future surveys. The question of increased incidence of malignancy in the irradiated Marshallese must be left open for the present.

#### "BETA BURNS"

During the past several years, increased numbers of pigmented nevus-like lesions have been noted in previously irradiated areas of the skin, but these have appeared to be quite benign. Neither chronic radiation dermatitis nor cancers of the skin have been noted.

## **INTERNALLY ABSORBED ISOTOPES**

Radiochemical urine analyses and whole-body gamma spectrometric analyses revealed that the level of body burdens of radioisotopes in the exposed Rongelapese fell rapidly, so that by 2 and 3 years post exposure the levels were far below the stated maximum permissible level.4.5 The return of the Rongelapese to their home island was associated with a rise in their body burdens of Cs<sup>137</sup>, Zn<sup>65</sup>, and Sr<sup>90</sup>. By 1961, the whole-body content of Cs<sup>137</sup> had apparently reached an equilibrium with the environment at a value of about 14.7 mμC/kg body weight or about 300 times the mean of the medical team measured at the same time. Zn<sup>65</sup>, which had risen to about 9.9 mµC in 1959, fell by 1961 to 1.5 mμC/kg body weight, or about 100 times that measured in members of the medical team. The levels of Sr<sup>90</sup> in 1962 and 1963 hovered around the 12.0-mµC level in adults and about 22 mµC in children, about 5 and 10% of the maximum permissible level (for members of the population at large). It thus appears that body burdens of Sr<sup>90</sup> have reached equilibrium with the environmental Sr<sup>90</sup>. Little or none of the present body burden of the exposed group can be considered residual from their initial exposure, since little difference has been noted between the body burdens in exposed and unexposed populations living on Rongelap Island. The possible relation of internal absorption of radioiodines initially in the fallout to the recent development of thyroid nodules has been referred to above. No other effects of such exposure have been detected.

#### OTHER EXAMINATIONS

Ophthalmological examinations showed no clear-cut evidence of radiation-induced changes in the eyes. Slit-lamp studies revealed no increase in incidence of lens opacities which might be attributed to radiation. Cytogenetic studies of the chromosomes of leukocytes and peripheral blood cultures obtained in 1964 are in progress and will be reported at a later date. Anthropometric studies revealed that young adult Rongelap males were superior in muscular development compared with many populations. This was not true, however, for the young adult females. Blood volume and red cell mass determinations using tritiated water and Cr51 revealed values in the Marshallese which were considerably lower than found in American Caucasians. However, there is some indication that Americans living in the Islands for more than one year may also have slightly lower values. This finding will be further investigated on future surveys. Protein bound iodine studies during the past two years confirmed the previous findings of levels higher in the Marshallese than generally found elsewhere. No explanation is apparent. Folic acid levels were found to be somewhat low in the Rongelap population and probably reflected low dietary folic acid. Serum studies for the Ag system reveal that the Rongelapese compared with other world populations have a high frequency of C.deB. antiserum reactors and a low frequency of New York antiserum reactors.

# **Acknowledgments**

The cooperation of many agencies and persons was necessary to carry out these surveys successfully. The authors are deeply grateful to many

individuals, too numerous to name, for valuable assistance.

Many officials of the Atomic Energy Commission, particularly Dr. Charles L. Dunham, Dr. H.D. Bruner, and many of their staff of the Division of Biology and Medicine, and Mr. W.H. Brummett, Jr. and Mr. G.P. Steffy of the San Francisco Operations Office were most helpful in the coordination of arrangements with various governmental agencies and in supporting these surveys in every possible way.

We are grateful to the officials of the Department of the Interior, particularly to Mrs. Ruth Van Cleve and the officials of the Trust Territory of the Pacific Islands, including the High Commissioner, Mr. M.W. Goding; the Director of Medical Services, Dr. J.W. Sampson; the District Administrator for the Marshall Islands, Mr. Peter Coleman; the Director of the Marshall Islands Memorial Hospital, Dr. John Iaman, and members of his staff; and the Representative of the High Commissioner at Kwajalein, Mr. R. Mc-Kay. Mr. Don Davis and his crew of the Trust Territory Ship Ran Anim and Mr. L. Roberts and the crew of the Roque were most helpful.

As in the past, the Department of Defense, particularly the Department of the Navy, contributed most vitally to the mission. The Pacific Missile Range Facility at Kwajalein was of great assistance in furnishing necessary airlifts and materials to be used on the survey. Drs. G. Temple, C. Cunnington, and Y.C. Smith at the Kwajalein Hospital were extremely helpful.

Drs. L. Donaldson and E. Held at the University of Washington have aided in coordination of their studies with these.

We are grateful to Dr. K. Tsuhamoto, Director of the Japanese National Institute of Radiological Sciences, and to Dr. Dunham for arranging the visit of the senior author to Japan to observe the annual examinations of the irradiated Japanese fishermen and for having Dr. T. Kumatori visit Rongelap for the 10-year survey.

At Brookhaven National Laboratory, contributions were made by many individuals in many departments including Medical, Instrumentation and Health Physics, Photography and Graphic Arts, the Shipping Section, and others. We are grateful to the following people for their support and advice: Dr. Maurice Goldhaber, Director; Dr. J.B.H. Kuper, Chairman of the Instrumenta-

tion and Health Physics Department; Dr. V.P. Bond, Chairman of the Medical Department, and others in this department including Drs. D.D. Van Slyke, E.P. Cronkite, J.S. Robertson, S. Cohn, L.K. Dahl, H.A. Johnson, H. Cottier, and Mr. A. Finn and Mr. W. J. Walsh.

We wish also to thank Miss B.R. Brezisky for her secretarial assistance and Mrs. M. Dienes for editorial help.

# References

- 1. CRONKITE, E.P. ET AL., The Effects of Ionizing Radiation on Human Beings: A Report on the Marshallese and Americans Accidentally Exposed to Radiation From Fallout and a Discussion of Radiation Injury in the Human Being, U.S. Government Printing Office, Washington, D.C., 1956.
- Bond, V.P., Conard, R.A., Robertson, J.S., and Weden, E.A. Jr., Medical Examination of Rongelap People Six Months After Exposure to Fallout, WT-937, Operation Castle Addendum Report 4.1A, April 1955.
- 3. CRONKITE, E.P., DUNHAM, C.L., GRIFFIN, D., Mc-PHERSON, S.D., AND WOODWARD, K.T., Twelve-Month Postexposure Survey on Marshallese Exposed to Fallout Radiation, BNL 384 (T-71), August 1955.
- CONARD, R.A., HUGGINS, C.E., CANNON, B., LOWREY, A., AND RICHARDS, J.B., Medical survey of Marshallese two years after exposure to fallout radiation, J.A.M.A. 164, 1192-7 (1957).
- CONARD, R.A., MEYER, L.M., RALL, J.E., LOWREY, A., BACH, S.A., CANNON, B., CARTER, E., EICHER, M., AND HECHTER, H., March 1957 Medical Survey of Rongelap and Utirik People Three Years After Exposure to Radioactive Fallout, BNL 501 (T-119), June 1958.
- CONARD, R.A. ET AL., Medical Survey of Rongelap People, March 1958, Four Years After Exposure to Fallout, BNL 534 (T-135), May 1959.
- CONARD, R.A. ET AL., Medical Survey of Rongelap People Five and Six Years After Exposure to Fallout, BNL 609 (T-179), September 1960.
- CONARD, R.A. ET AL., Medical Survey of Rongelap People Seven Years After Exposure to Fallout, BNL 727 (T-260), May 1962.
- CONARD, R.A. ET AL., Medical Survey of Rongelap People Eight Years After Exposure to Fallout, BNL 780 (T-296), January 1963.
- Sussman, L.N., Meyer, L.M., and Conard, R.A., Blood groupings in Marshallese, Science 129, 644-5 (1959).
- GOLDMAN, M. AND CARVER, R.K., An intestinal parasite survey on Rongelap Atoll in the Marshall Islands, Am. J. Trop. Med. Hyg. 8, 417-23 (1959).
- SUTOW, W.W., CONARD, R.A., AND GRIFFITH, K.M., Growth status of children exposed to fallout radiation on Marshall Islands, *Pediatrics*, in press.

- 13. Moore, F., The Body Cell Mass and Its Supporting Environment, Saunders, Philadelphia, 1963.
- Blumberg, B.S., Bernanke, A.D., and Allison, A.C., A human lipoprotein polymorphism, J. Clin. Invest. 41, 1936 (1962).
- Allison, A.C. and Blumberg, B.S., An isoprecipitation reaction distinguishing human serum-protein types, *Lancet* 1961-I, 634.
- Blumberg, B.S., Dray, S., and Robinson, J.C., Antigen polymorphism of a low density beta-lipoprotein. Allotypy in human serum, *Nature* 194, 656 (1962).
- 17. Blumberg, B.S., Iso-antibodies in humans against inherited serum low density beta-lipoproteins. The Ag system, Ann. N.Y. Acad. Sci. 103, 1052 (1963).
- Blumberg, B.S. and Riddell, N.M., Inherited antigenic differences in human serum beta-lipoproteins. A second antiserum, J. Clin. Invest. 42, 867 (1963).
- 19. Environmental Contamination, Annex D, Report of the United Nations Scientific Committee on the Effects of Atomic Radiation, General Assembly Official Records, Supplement No. 17 (A/3838), 1958.
- 20. CONARD, R.A., An attempt to quantify some clinical criteria of aging, J. Gerontol. 15, 358-65 (1960).
- NEEL, J.V. AND SCHULL, W. J., Editors, The Effect of the Atomic Bombs on Pregnancy Termination in Hiroshima and Nagasaki, Publ. No. 461, Natl. Acad. Sci., Natl. Res. Council, Washington, D.C., 1956.
- GREULICH, W.W., The physical growth and development of children who survived the atomic bombing of Hiroshima and Nagasaki, J. Pediat. 43, 121 (1953).
- 23. REYNOLDS, E.L., Growth and Development of Hiroshima Children Exposed to the Atomic Bomb. Three Year Study (1951-1953), Atomic Bomb Casualty Commission, Tech. Rept. 20-59, p. 157, 1954.
- 24. Nehemias, J.V., Multivariate analysis and the IBM 704 computer applied to A.B.C.C. data on growth of surviving Hiroshima children, *Health Phys.* 8, 165 (1962).
- 25. CONARD, R.A., Indirect effect of x-irradiation on bone growth in rats, Ann. N.Y. Acad. Sci. 114, 335 (1964).
- 26. Sheline, G.E., Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine, J. Clin. Endocrinol. Metab. 22, 8-18 (1962).
- LINDSAY, S. AND CHAIKOFF, I.L., The effects of irradiation on the thyroid gland with particular reference to the induction of thyroid neoplasias: A review, Cancer Res. 24, 1099-1107 (1962).
- MOLONEY, W.C. AND LANGE, R.D., Leukemia in atomic bomb survivors. II. Observations in early phases of leukemia, *Blood* 9, 663-85 (1954).
- HEYSSEL, R., BRILL, A.B., AND WOODBURY, L.A., Leukemia in Hiroshima atomic bomb survivors, Blood 15, 313 (1960).
- Wald, N., Leukemia in Hiroshima City atomic bomb survivors, Science 127, 699-700 (1958).
- 31. COURT-BROWN, W.M. AND DALL, R., Leukemia and Aplastic Anemia in Patients Irradiated for Ankylosing Spondylitis, London, H.M. Stationery Office (Med. Res. Council, Special Rept. Series No. 295), 135 p., 1957.

- 32. DUFFY, B. J. JR. AND FITZGERALD, P. J., Thyroid cancer in childhood and adolescence, a report on 28 cases, *Cancer* 3, 1018 (1950).
- 33. Clark, D.E., Association of irradiation with cancer of the thyroid in children and adolescents, *J.A.M.A.* 159, 1007 (1955).
- SIMPSON, C.L., HEMPELMANN, C.H., AND FULLER, L.M., Neoplasia in children treated with x-rays in infancy for thymic enlargement, Radiology 64, 840 (1955).
- 35. ROONEY, D.R. AND POWELL, R.W., Carcinoma of the thyroid in children after x-ray therapy in early childhood, *J.A.M.A.* 169, 1 (1959).
- 36. WARREN, S., ALVIZOURI, M., AND COLCOCK, B.P., Carcinoma of the thyroid in childhood and adolescence, *Cancer* 6, 1139 (1953).
- 37. Socolow, E.L., Thyroid carcinoma in man after exposure to ionizing radiation, *New Engl. J. Med.* **268**, 406 (1963).
- 38. ZELDIN, L. J., JABLON, S., AND ISHIDA, M., Current status of ABCC-NIH studies of carcinogenesis in Hiroshima and Nagasaki, Ann. N.Y. Acad. Sci. 114, 225-50 (1964).
- 39. HOLLINGSWORTH, D.H., Thyroid disease: A study in Hiroshima, Japan, *Medicine* 42, 47-71 (1963).

APPENDIX 1

Rongelap Group and Control Mean Blood Counts at Various Times After Exposure

	WBC Neutrophils $(x10^{-3})$ $(x10^{-3})$			Lymphocytes Platelets (x10 <sup>-3</sup> ) (x10 <sup>-4</sup> )						Hem	atocri %	i <b>t,</b>	RBC (x10 <sup>-6</sup> )			
Postexposure day	< 5	> 5	<5	> 5	<5	> 5		Male >10	Female all ages		Male <15		Female all ages			Female all ages
3	9.0	8.2	6.4	4.7	1.8	2.2										
7	4.9	6.2		1					ol. o	a). 0						
10	6.6	7.1	3.5	4.5	2.6	2.1	28.2	22.7	24.9	24.8						
12 15	5.9 5.9	6.3 6.5	3.5 3.2	3.9 4.1	2.1 2.4	1.7 1.9	27.1	21 2	21.7	22.5						
18	5.9 6.7	7.2	3.4	4.7	2.4	2.1	21.8		21.7	21.0						
22	7.0	7.4	4.3	5.0	2.6	2.1	16.8		15.2	15.3	37.5	43.9	39.0			
26	5.7	6.1	3.0	3.9	2.3	1.8	13.2		10.9	11.9	36.3	41.6	37.5			
30	7.6	7.8	4.0	5.3	3.2	2.1	14.1		11.8	12.3	37.9	42.2	37.1			
33	6.5	6.2	3.1	3.8	3.2	2.0	17.9		15.1	16.0	37.4	42.2	36.8			
39	5.7	5.5	3.0	3.3	2.6	2.0	25.5		22.4	22.8	37.8	42.4	37.4			
43	5.2	5.2	2.0	2.6	2.9	2.3	26.8		23.2	23.2	37.3	41.8	37.6			
47	5.9	5.8	2.6	3.3	3.1	2.4	24.6		23.9	23.1	39.0	43.4	38.3			
51	6.7	5.6	2.6	3.5	3.4	2.1	22.1	17.5	21.2	20.3						
56	7.0	6.0	3.5	3.5	3.7	2.4										
63	7.7	6.0	3.9	3.6	3.7	2.3	23.1	18.2	20.2	20.1						
70	7.6	6.5	3.8	4.0	3.3	2.2										
74								21.7	24.7	24.1						
6-mo survey	8.5	6.6	4.6	4.2	3.6	2.2	24.4		23.2	22.6	38.0	41.7	38.2			
1-yr survey	10.1	8.1	4.7	4.8	4.6	2.8	26.6		27.6	24.9	37.5	41.1	36.9			
2-yr survey	11.8	8.6	5.9	4.8	4.7	3.1	30.0		25.5	24.7	38.7	41.2	38.1			
3-yr survey	8.6	6.9	4.1	3.7	3.7	2.7		22.1	28.1		35.6	38.7	35.4			
4-yr survey	8.9	7.5	3.3 6.9	3.4 4.8	4.6 6.0	3.6		27.1	30.8		35.6	41.0	35.8	4.45	4.71	4.21
5-yr survey	13.5	9.5 6.5	0.9	3.5	0.0	4.0 2.7	32.3	24.4	27.6					4.42	4. (1	4.51
6-yr survey 7-yr survey		7.4		3.9		2.9		24.6	27.3		37.6	41.7	37.0	4.54	4.45	4.11
8-yr survey		6.9		3.6		2.6		32.8	32.1		38.5	43.0	39.3	4.68	4.67	4.44
9-yr survey		7.4		3.7		3.0		23.1	28.4		39.1	43.7	38.4	4.29	4.38	4.12
0-yr survey		8.2		3.8		3.5		32.8	37.2		40.4	43.5	39.3			
Majuro controls	13.2	9.7	4.8	4.8	7.4	4.1	41.2		36.5	33.4	39.6	46.0	39.9			
Rita cont. 6 mo	10.7	7.6	5.4	5.2	4.7	3.7			30.9 29.4	30.4						
Rita cont. 1 yr							37.5	27.3	29.4	27.6		1.0.				
Rita cont. 2 yr Rong.cont. 3 yr	14.0 9.8	8.9 6.9	7.0	4.4 3.4	5.6	3.6 2.9	35.5	24.2	31.2 30.0	29.5	38.9 35.6	42.1 41.0	39.8 35.9			
Rong.cont. 3 yr Rong.cont. 4 yr	11.2	8.0	4.0	3.6	4.7 6.2	3.7	38.8	24.2 26.9 30.7	34.0		35.5	42.8	35.1			
Rong.cont. 5 yr	13.7	10.1 7.8	6.2	5.2	6.2	4.1	35.8	28.O	33.6					4.60	4.80	4.40
Rong.cont. 7 yr		7.8		4.2		3.1		28.5 3 34.8	31.4		37.2	44.4	37.0	4.52	4.68	4.12
Rong.cont. 8 yr Rong.cont. 9 yr		7.7		4.2 3.9		2.9 3.1		29.1	34.5		38.3 39.4	44.1 43.8	39.0 38.3	4.60 4.33	4.90 4.50	4.47 4.13
Rong.cont.10 yr		9.1		4.8		3.5		35.4	37.9		37.4	44.1	38.3	T+ JJ	7.70	ر <del>.</del>

aIncludes all males >7.

APPENDIX 2

Ailingnae Group and Control Mean Blood Counts at Various Times After Exposure

	WBC Neutrophils Lymph (x10 <sup>-3</sup> ) (x10 <sup>-3</sup> ) (x1			nocytes 10 <sup>-3</sup> )	Platelets (x10 <sup>-4</sup> )				Hematocrit,			RBC (x10 <sup>-6</sup> )				
Postexposure day	<5	>5	< 5	>5	< 5	> 5	Male <10	Male ≥10	Female all ages		Male <15	Male >15	Female all ages	Male ≺15	Male >15	Female all age
3	6.0	7.0	3.0	5.0	2.8	2.2										
.7	5.5 6.3 6.3	6.8	4.2	4.2	1.9		~~ -									
10 12	6.3	7.3	1.8	4.7	3.1	2.2	22.5	22.6	20.9	21.5						
15	7.1	7.0	2.3	4.5	4.2	2.2	29.0	20.2	24.6	23.9						
18 22 26	6.8	7.8	2.9	5.0	3.5	2.4	27.5	21.7	24.9	24.3						
55	8.9 8.4	8.7 7.0	5.3 4.8	5.4 4.4	2.7 3.2	2.9	23.5	17.0	22.9	21.3 16.7	37.5 36.5	43.7	39.2 36.8			
	9.6	8.6	5.3	6.2	3.7	2.0	20.0	13.8 12.8	17.4 18.2	16.8	36.0	43.2 44.6	36.7			
30 33 39 43 47	7.7	7.8	3.3	5.2	3.5	2.2	19.5 24.0	15.8	22.7	17.6	36.0 35.5	43.8	37.3			
39	7.5 6.9	6.2	2.9 2.7	4.2	4.7	1.9	26.5	20.8	27.0	25.2	35.0	45.6	37.4			
43 47	7.3	$6.\overline{5}$	3.5	3.6 3.8	3.9 3.4	2.7 2.7	28.0 27.0	19.6 20.0	25.3 26.1	24.0 24.5	36.0	45.2 46.5	36.8 40.2			
51 54	8.4	6.3	3.8	3.6	4.0	2.2	32.0	18.2	25.0	23.9		+0.7	10.2			
_	4.6	6.3	2.8	3.5	3.2	2.5	37.0	19.8	23.8	24.2						
6-mo survey	7.7	6.5	4.8	3.9	2.7	2.2	25.2	19.2	23.9	22.7	37.5	40.1	37.3			
l-yr survey	11.1	7.8	4.2	4.7	6.5	5.6	38.7	21.4	28.3	27.5	33.0	44.6	36.2			
2-yr survey 3-yr survey	11.0 12.1	9.1 7.0	4.9 5.5	5.1 3.9	4.8 5.6	3.2 2.6	51.2 40.8	17.4 22.4	26.4	26.7	35.7	44.4 40.6	37.5			
4-yr survey	11.5	7.5	2.8	3.7	7.0	3.3	33.2	24.7	31.2 33.6		37.5 36.1	40.0	35.6 35.7			
5-yr survey		9.7		5.1		3.7	40.9	26.3	26.8		JU. 1		32+1	4.46	5.15	4.31
6-yr survey		7.3		3.6		3.0										
7-yr survey		7.7		4.1		3.1		25.6ª	28.1		36.0	44.2	37.0	4.56	5.11	4.19
8-yr survey		6.5		3.4		2.6		33.4b			37.0	42.5	37.8	4.51	5.12	4.35
9-yr survey 0-yr survey		7.1 7.5		4.0 3.6		2.4 3.1		23.5° 32.4	23.6 41.5		36.0	44.0 43.0	38.3 38.3	3.77	4.69	4.10
Majuro controls	13.2	9.7	4.8	4.8	7.4	4.1	41.2	25.8	36.5	33.4	37.0 39.6	46.0	39.9			
Rita cont. 6 mo	10.7	7.6	5.4	5.2	4.7	3.7	35.0	27.3	30.9	30.4	J7.0		J7•7			
Rita cont. 1 yr							37.5 35.5	24.5	29.4	27.6		7				
Rita cont. 2 yr Rong. cont. 3 yr	14.0 9.8	8.9	7.0 4.0	4.4 3.4	5.6 4.7	3.6	35.5	24.2 26.9	31.2	29.5	38.9	42.1	39.8			
Rong. cont. 3 yr Rong. cont. 4 yr	11.2	8.6	4.0	3.6	6.2	2.9 3.7	32.6 38.8	30.7	30.0 34.0		35.6 35.5	41.0 42.8	35.9 35.1			
Rong. cont. 5 yr		10.1	6.2	5.2	6.2	4.i	35.8	28.0	33.6					4.60	4.80	4.40
Rong. cont. 7 yr		7.8		4.2		3.1		28.5ª	31.4		37.2	44.4	37.0	4.52	4.68	4.12
Rong. cont. 8 yr		7.7		4.2		2.9		34.8 b	34.5		38.3	44.1	39.0	4.60	4.90	4.47
Rong. cont. 9 yr		7.7		3.9 4.8		3.1		29.1 c 35.4	32.5		39.4	43.8	38.3	4.33	4.50	4.13

aIncludes all males >7.

APPENDIX 3

Utirik Group Mean Blood Counts at Various Times After Exposure

		WBC Neutrophils I $(x10^{-3})$ $(x10^{-3})$			Lympi			Platelets (x10 <sup>-4</sup> )			Hematocrit,			RBC (x10 <sup>-6</sup> )		
Postexposure day	< 5	> 5	<5	>5	<5	>5	Male <10	Male ≻10	Female all ages	Male <15	Male >15	Female all ages	Male <15	Male >15	Female all ages	
4	9.4	8.2	4.7	4.2	4.9	3.2			•						•	
14	10.0	8.6	4.1	3.2	5.1	2.9										
19							38.9	28.1	35.6							
29	10.1	9.7	4.9	5.8	4.8	3.2	34.5	<b>25.</b> 6	31.7	39.9	45.	39.4				
3-yr survey	9.8	6.9	4.0	3.4	4.7	2.9	32.6	26.9	30.0	35.6	41.	0 35.9				
9-yr survey		7.0		3.9		3.0		36.5*	38.9	37.9	42.	4 37•7	4.4	2 4.3	9 4.12	

<sup>\*</sup>Includes all males >9.

APPENDIX 4 Individual Hematological Findings, 1963

Subject	Plate.		Neut.	Lymph.	Mono.	Eosin.		Hct.,		Нgb.,	Serum
No.	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	(x10 <sup>-4</sup> )	g	protein,					
	R	ongelap E	xposed Ma	ales, Ag	e 9-15						
2	224	8.03	5.06	2.41	0.16	0.24	1.60	37	402	13.2	8.0
3	285	9.71	4.66	3.20	0.48	1.16	1.94	39	370	13.6	8.8
5	440 251	11.90 6.03	6.07 2.89	4.28 2.41	0.95 0.30	0.36 0.42	2,38 0.0	38 41	381 508	13.6 13.6	7.8
19 23	344	7.12	2.71	3.34	0.30	1.00	0.0	36	449	12.8	7.3 7.4
32	222	7.29	3.43	3.06	0.07	0.66	0.70	39	413	14.0	6.8
54	307	6.97	2.72	3.69	0.28	0.28	0.0	41	459	14.0	7.6
83 <b>*</b>	253	11.90	5.12	3.45	0.95	2.38	0.0	41	422	14.8	7.8
85*	257	7.29	2.62	3.43	0.66	0.58	0.0	40	456	14.4	7.6
Mean	287	8.47	3.92	3 <b>.25</b>	0.44	0.79	0.74	39.1	429	12.9	
	±66**	±2.18	±1.31	±0.59		12	•••	±2.0	± 45	13.8 ± 0.5	7.7 ±0.5
	<u>A</u> :	ilingnae	Exposed A	Males, Ag	ge 9-15						
6 mean	194 194	6.64 6.64	2.79 2.79	3.19 3.19	0.06 0.06	0.60 0.60	0.0	36 36.0	377 377	12.4 12.4	7•5 7•5
	Ro	ongelap E	xposed Fe	emales, /	Age 9-15						
17	427	14.70	12.20	2.06	0.15	0.29	0.0	43	481	15.2	8.3
21	370	7.15	2.72	3.00	0.21	1.14	0.70	42	507	14.8	7.4
33	355	8.25	2.97	4.21	0.08	0.91	0.80	39	457	13.2	8.8
42	328	8.31	3.66	4.24	0.25	0.17	0.0	39	409	14.8	8.0
65	268	7.92	3.64	3.41	0.32	0.48	0.80	36	403	12.4	7.5
69 70	203	7.05	2.61	3.81	0.21	0.35	0.70	39	432	13.6	7.8
72 86*	203 247	7.27	3.27	3.42	0.44	0.07	0.70	39	456 448	14.0	8.5
	•	7-33	4.25	2.35	0.29	0.44	0.0	39	440	13.6	7-5
mean	300	8.50	4.42	3.31	0.24	0.48	0.46	39.5	449	13.9	0.0
	±78	± 2.49	± 3.09	± 0.80	•••		••••	± 2.0	-		8.0
				_				- 2.0	± 34	± 0.9	± 0.4
	¥Ŧ	lingnae I	exposed F	emales,	Age 9-15	<u> </u>					
8	203	7.05	3.38	3.03	0.21	0.42	0.0	40	415	14.4	8.0
48	248	7.25	3.99	2.90	0.22	0.15	0.0	42	456	15.6	8.0
mean	225	7.15	3.69	2.97	0.22	0.28	0	41.0	435	15.0	8.0

<sup>\*</sup>Exposed in utero.
\*\*Standard deviation.

Subject	Plate.	WBC (x10 <sup>-3</sup> )	Neut.	Lymph.	Mono.	Eosin. (x10 <sup>-3</sup> )	Baso.	Hct.,	RBC (x10 <sup>-4</sup> )	Hgb.,	Serum protein, g
. NO.	(X10 )	(X10 )	(XIO )	(X10 )	(XIO )	(XIO )	(XIO )		(XIO )	g	protein, g
	Ro	ongelap E	kposed Ma	ales, Age	>15-40						
9	128	7.25.	3.26	3.77	0.15	0.07	0.0	47	518	16.0	8.0
1Ó	320	5.91	2.84	2.54	0.18	0.30	0.60	46	442	15.2	8.0
20	102	4.91	2.41	2.06	0.25	0.20	0.0	50	531	17.9	8.0
27	113	7.82	3.36	4.30	0.0	0.16	0.0	43	416	16,4	
36	231	5.00	2.35	2.05	0.15	0.45	0.0	42	486	15.2	7.5
37	270	6.47	3 <b>.</b> 36	2.46	0.13	0.52	0.0	45	446	16.0	7.4
40	231	7.98	4.31	3.43	0.16	0.08	0.0	43	392	14.8	7.1
47	232	5.45	2.83	2.13	0.16	0.33	0.0	ነተነተ	395	16.9	7.7
73	183	5.17	2.95	1.76	0.26	0.16	0.50	50	508	17.4	7,1
76	138	9.73	4.77	3.99	0.29	0.58	1.00	45	416	15.2	7.6
77	230	6.71	3 <b>.</b> 56	2.55	0.34	0.20	0.70	46	487	16.4	8.0
mean	198	6.58	3.27	2.82	0.19	0.28	0.25	45.5	458	<b>1</b> 6.1	7.6
	±71	±1.49	±0.74	±0.89	0.19	0,20	0.27	±2.4	±47	±1.3	
								15.4	-71	-1.3	±0.3
	Re	ongelap Ex	cposed Fe	emales, A	\ge >15-	40					
12	625	7.80	4.76	2.65	0.39	0.0	0.0	25	240	9.1	7.1
14	250	7.70	4.47	2.85	0.23	0.15	0.0	38	373	13.2	8:4
15	345	7.66	3.98	3.14	0.38	0.15	0.0	40	415	13.2	7.7
18	208	4.88	2.78	1.81	0.20	0.10	0.0	36	401	13.2	7.3
22	208	7.14	4.21	1.93	0.07	0.93	0.0	39	426	14.4	7.7
24	260	5.78	2.25	2.59	0.35	0.52	0.60	40	477	14.8	7.8
39 49	133	7.40	4.37	2.15	0.22	0.67	0.0	34 36	400	11.8 12.4	7.5
49 61	322 373	6.39 8.87	3.20 3.64	2.75 4.70	0.13 0.0	0.26 0.44	0.60	36	374 489	14.4	7.8 8.5
64	193	8.87	5.41	2.84	0.44	0.18	0.90 0.0	43	331	10.9	7.1
66	219	8.39	3.69	3.78	0.59	0.10	0.0	33 38	419	13.6	7.3
71	265	9.26	5.93	2.32	0.37	0.65	0.0	41	456	15.2	8.0
74	465	14.30	7.44	4.15	0.14	2.43	1.40	42	469	14.4	8.8
75	288	7.97	4.78	2.39	0.32	0.48	0.0	45	456	14.4	8.5
mean	297	8.02	4.35	0.06							
	±122	+ 2 18	±1.33	2.86	0.29	0.52	0.25	37.9	409	13.2	7.8
	- <b>-</b>	_ 2.10	-1.33	±0.84				±4.8	±64	±1.8	±0.5
	<u>Ai</u>	lingnae E	xposed F	emales,	Age >15-	-40					
51	241	6.55	4.00	2.29	0.13	0.0	1.30	42	390	15.2	7.3
53	291	7.53	3 • 5 4	3 <b>.7</b> 7	0.15	0.15	0.0	41	445	14.4	8.8
70	243	8.82	7.23	1.06	0.26	0.26	0.0	30	442	9.4	7.4
81	131	8.94	7.06	1.07	0.45	0.36	0.0	35	346	12.4	7.3
mean	227	7.96	5.45	2.05	0.25	0.19	0.32	37-3	406	12.9	7.7

Subject No.	Plate. (x10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct.,	RBC (x10 <sup>-4</sup> )	Hgb.,	Serum protein, g
	Re	ongelap E	xposed Ma	ales, Ag	e > 40						
4 7 11 55 68	245 113 103 208 293	8.02 5.86 5.34 5.36 4.75	2.73 2.70 2.40 2.57 2.00	5.21 2.81 2.78 2.41 2.04	0.08 0.0 0.05 0.16 0.29	0.0 0.29 0.11 0.21 0.43	0.0 0.60 0.0 0.0	47 38 43 30 43	507 381 403 291 420 464	16.4 14.0 15.2 10.9 14.4	8.4 7.8 7.1 7.0
79 80 82	133 306 307	7.01 8.00 6.29	3.51 3.60 3.52	2.87 3.68 2.08	0.21 0.08 0.31	0.42 0.64 0.38	0.0 0.0 0.0	48 42 39	408 402	16.9 14.4 14.0	7.3 7.7
mean	214 ±87	6.33 ±1.24	2.88 ±0.59	2.99 ±1.04	0.15	0.31	0.08	41.3 ±5.4	410 ÷58	14.5 +-0.5	7.6 ÷0.4
	<u>A i</u>	ilingnae	Exposed M	ales, A	ge > 40						
16 29 41 50	203 356 104 318	4.78 9.10 4.70 6.94	1.96 5.55 1.97 3.47	2.53 2.46 2.07 2.78	0.0 0.55 0.19 0.35	0.29 0.36 0.47 0.28	0.0 0.18 0.0 0.07	749 777 745 747	543 419 453 461	14.4 15.2 16.0 17.4	7.4 7.8 7.7 7.4
mean	245	6.38	3.23	2.46	0.27	0.35	0.06	44.0	469	15.8	7.6
	RO	ongelap E	xposed Fe	males,	\ge >40						
13 3 <sup>1</sup> 4 57 58 60 63 78	404 226 286 115 284 135 219	5.37 6.31 5.69 6.71 6.36 4.66 5.62	2.36 3.34 3.76 2.82 2.48 2.14 3.09	2.42 2.40 1.82 3.56 3.24 2.00	0.21 0.25 0.11 0.20 0.25 0.23	0.38 0.32 0.0 0.14 0.32 0.28 0.06	0.0 0.0 0.0 0.64 0.0	37 38 37 39 34 43	340 362 358 389 343 459 381	12.4 13.2 11.8 14.8 12.1 16.0	8.0 8.1 7.5 7.5 7.8 7.9
mean	238 ±98	5.82 ±0.60	2.86 ±0.58	2.56 ±0.63	0.18	0.21	0.09	38.1 ±2.5	376 - 38	13.3 ±1.4	7.8 ÷0.2
	<u>Ai</u>	lingnae	Exposed I	emales,	Age >40						
1 28 43 45 59	206 204 268 330 235	8.20 6.40 5.34 7.11 8.96	4.42 2.94 4.17 3.98 3.67	3.28 2.43 0.64 1.85 3.67	0.08 0.26 0.21 0.21 0.99	0.41 0.70 0.27 1.07 0.63	0.0 0.64 0.53 0.0	40 35 42 36 37	402 459 428 363 365	14.4 15.2 13.6 13.6 12.8	8.3 9.2 8.4 8.0 7.9
mean	249 ±47	7.20 ±1.60	3.83 ±0.57	2.37 11.20	0.35	0.62	0.23	38.0 ±2.6	403 ±41	13.9 ±1.1	8.4 <u>+</u> 0.4

Subject	Plate (x10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct.,	RBC (x10 <sup>-4</sup> )	Hgb.,	Serum protein, g
	<del> </del>	<del></del>									
	4	ale Child	ren or E	xposed P	arents, /	rke <a< td=""><td></td><td></td><td></td><td></td><td></td></a<>					
88	323	10.30	4.22	5.46	0.0	0.52	1.03	35	403	12.2	7.2
89	358	9.78	4.60	3.81	0.20	1.17	0.0	38 36	438	14.4	7.0
90	347	11.70	5.15 6.09	3.74 2.76	0.35 0.19	2.46 0.38	0.0 0.95	36 37	428 395	12.8 12.4	7.2 7.5
9 <b>1</b> 93	293 310	9.51 10.90	6.00	4.14	0.19	0.33	0.0	37 36	398	12.8	(•)
98	202	7.18	3.09	2.87	0.72	0.50	0.0	35	429	12.4	7.2
102		8.23	3.79	3.79	0.33	0.33	0.0	41	454	13.2	
104	392	8.00	3.28	4.32	0.16	0.24	0.0	38	483	13.6	7.8
109	478	19.20	4.99	12.29	0.77	1.15	0.0	32	434	10.6	
110	283	7.93	5.00	2.62	0.32	0.0	0.0	39	510	12.8	
111 113	5 <b>74</b>	7.65	2.91	4.13 4.41	0.30	0.30	0.0	39	428	12.8	
115	423 453	10.50 17.80	5.67 3.92	12.82	0.21 0.71	0.11 0.36	1.05 0.0	41 31	489 369	13.2 11.2	
116	490	9.31	2.89	5.96	0.19	0.28	0.0	37	459	13.6	
118	272	13.60	6.53	5.44	0.95	0.68	0.0	38	419	12.8	
126	417	8.03	3.69	3.85	0.32	0.16	0.0	31	472	10.0	
mean	374	10.60	4.49	<i>-</i>	0.00						
	±95	±3.49	-	5.15	0.39	0.56	0.19	36.5	438	12.6	7.3
			±1.19	±3.04				±3.0	<u>+</u> 64	±1.1	<u>+</u> 0.4
4			_								•
	1	Female Chi	ldren of	Exposed	Parents	, Age <9					
87	352	9.79	4.41	4.60	0.49	0.29	0.0	37	414	13.2	7.9
92	258	7-73	4.02	2.40	0.62	0.70	0.0	37	445	12.4	7.8
94	485	13.80	7.45	4.69	0.69	0.97	0.0	39	478	14.4	
95	414	12.50	7.25	4.63	0.50	0.13	0.0	37	456	13.2	7.3
101 103	438 268	25.80 11.10	7.74 5.88	16.00 4.00	1.03	1.03	0.0	40 26	<u> </u> 412	14.0	
105	386	11.50	5.64	5.41	0.22 0.23	1.00 0.23	0.0 0.0	36 40	412 436	13.2 13.2	
106	307	8.52	3.07	4.60	0.51	0.26	0.0	35	432	12.1	
108	423	19.40	8.15	5.24	0.58	5.24	1.94	36	442	12.1	
112	458	9.08	4.99	3.54	0.36	0.09	0.91	36	405	12.8	
117	343	8 <b>.</b> 78	4.04	3.95	0.53	0.26	0.0	35	341	10.9	
119	508	13.70	5.62	5.89	0.69	1.51	0.0	36	435	12.1	
120	305	10.30	2.37	6.59	0.72	0.62	0.0	40	448	12.8	
122	419	12.20	2.56	8.42	0.61	0.61	0.0	36	413	13.2	
124 125	468 220	12.90	3.23	8.64 5.89	0.13 0.28	0.90	0.0	38 36	398 401	11.8 12.8	
127	220 520	9.35 12.50	3.18 3.75	7.50	1.00	0.0 0.13	0.0 1.25	36 30	398	10.6	
128	3 <b>7</b> 9	10.70	2.35	7.28	0.75	0.32	0.0	38	438	14.8	
				-		_		-	-		
mean	386	12.20	4.76	6.07	0.55	0.79	0.23	36.8	424	12.8	•
	±87	±4.29	±1.92	±3.00		••	_	±2.2	±32		7 7
				<del>-</del> '					ےر -	<u> </u>	7.7

Subject			Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.		Hgb.,	Serum
No.	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	$(x10^{-3})$	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	(x10 <sup>-4</sup> )	g	protein,
	Co	ontrol Ma	les, Age	9-15							
813 814 815 818 819 820 863 913 919 921 931 981	254 252 218 307 460 283 209 370 284 133 355 258	8.24 11.20 5.69 11.60 4.57 6.91 11.30 7.78 5.25 8.10 11.90 13.60 5.29	3.71 4.59 2.22 6.50 1.69 2.21 7.35 5.45 2.78 4.21 5.83 6.39 2.01	3.46 5.38 3.07 3.94 2.24 3.11 3.16 1.95 1.68 2.92 3.09 5.58 2.86	0.49 0.34 0.11 0.81 0.05 0.14 0.0 0.31 0.32 0.48 0.54 0.11	0.49 0.78 0.28 0.35 0.59 1.38 0.79 0.08 0.37 0.56 2.38 1.09 0.26	0.82 1.12 0.0 0.0 0.0 0.69 0.0 1.05 0.81 1.19 0.0	37 39 37 40 38 42 38 40 39 31 41	376 415 362 441 420 460 448 472 419 451 420 486	13.2 14.0 13.6 13.2 140 144 15.2 14.0 14.0 14.4 15.6 14.4	7.4 8.4 7.5 7.5 7.5 7.7 7.8 7.8 7.3
1036	352	5.81	2.03	3.37	0.12	0.29	0.0	39	469	14.8	8.1
mean	286 ±78	8.37 ±2.90	4.07 ±1.96	3.27 ±1.11	0.30	0.69	O* <del>ji ji</del>	39.4 ±1.4		14.1 ±0.7	7.8 ±0.4
	Co	ntrol Fer	males, Ag	e 9-15					•		
811 812 816 821 891 909 911 925 926 937 946 955 959 960 962 996 1035	527 310 318 234 243 560 361 513 383 410 428 318 335 250 466 263	10.60 6.68 7.38 9.65 13.60 8.83 6.03 7.41 13.60 8.66 9.43 8.59 7.64 8.92 5.51 9.68 7.77	3.82 2.81 2.80 5.50 8.30 3.62 1.69 3.41 7.48 5.66 3.51 4.28 4.65 3.11	5.62 2.81 4.06 3.76 4.08 2.91 3.98 3.98 3.56 4.08 3.13 4.37 2.76 4.45 3.57	0.21 0.27 0.37 0.10 1.22 0.35 0.0 0.22 0.14 0.0 0.09 0.22 0.49 0.19 0.23	0.95 0.73 0.15 0.19 0.0 1.85 0.36 0.22 0.54 0.0 0.34 0.69 0.27 0.22 0.39 0.78	0.0 0.67 0.0 0.97 0.0 0.89 0.0 0.0 0.0 0.76 0.0 0.75 0.0	35 38 40 37 40 39 37 39 41 37 43 40 34 34 34 34 34 34 34 34 34 36 37	355 462 389 429 441 415 470 520 461 399 433 395 467 453	12.4 12.7 14.0 12.1 15.6 14.0 13.2 13.6 16.4 12.8 16.0 14.4 11.5 11.5	7.5 7.8 7.6 7.4 7.5 7.6 8.4 9.0 7.7 7.6 8.2 7.9 8.1 7.8 8.5
mean	373 ±99	8.82 ±2.20	4.12 ±1.64	3.86 ±0.77	0.26	0.48	0.35	38.3 ±2.7	740 454	13.7 ±1.6	7.9 ±0.5

Subject	Plate.		Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	RBC	Hgb.,	Serum
No.	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	(x10 <sup>-4</sup> )	g	protein, g					
	<u>c</u>	ontrol Ma	les, Age	>15-40							
822	286	6.04	2.78	2.96	0.18	0.12	0.0	<del>1</del> 11	436	14.0	8.0
823	195	5.68	3.24	2.10	0.06	0.23	0.60	42	425	14.8	7.4
830	293	7.66	5.06	1.23	0.31	1.07	0.0	48	424	16.4	7.4
831	327	7.60	3.50	2.74	0.30	1.06	0.0	51	509	17.9	8.0
833	249	5.66	2.66	2.89	0.0	0.11	0.0	47	513	16.0	7-4
834	381	7.24	2.24	3.69	0.22	1.01	0.72	44 1	448	15.2	8.0
836	233	8.73	4.19	3.75	0.35	0.44	0.0	45	430	14.8	8.5
8 38 840	224 244	8.79 6.74	2.55	5.71	0.18 0.40	0.35	0.0	51 44	509	18.9	8.3
842	400	8.82	3.37 2.82	2.97 4.15	0.40	0.0 1.15	0.0 1.76		501.	16.0 18.4	8.0 8.0
872	345	7.38	4.50	2.66	0.22	0.0	0.0	49 47	499 486	16.4	8.4
874	293	13.40	10.59	2.68	0.0	0.13	0.0	37	434	13.2	7 <b>.</b> 8
881	282	8.63	5.78	2.24	0.35	0.26	0.0	47	459	15.6	8.2
882	179	5.72	2.35	2.97	0.23	0.17	0.0	33	454	15.2	7.1
885	225	9.26	6.11	2.41	0.65	0.0	0.93	46	483	16.0	8.0
944	31.Ó	7.89	3.55	3.16	0.24	0.16	0.0	47	523	16.4	8.8
958	358	8.67	5.20	2.51	0.35	0.43	1.73	41	436	14.0	7.7
967	340	8.54	3.84	3.59	0.34	0.77	0.0	52	484	17.4	7.8
971	413	7.20	4.46	2.16	0.43	0.14	0.0	47	469	16.9	8.6
1500	283	7.38	3.91	2.66	0.15	0.67	0.0	50	505	17.4	7.8
1501	283	6.16	2.83	2.90	0.31	0.06	0.60	48	499	16.4	8.0
mean	294	7.77	4.07	2.96	0.28	0.40	0.30	45.7	).72	-( -	0 -
	<u>±</u> 66	±1.44	±1.86	±0.90	0.20	0.40	0.00		473	16.1	8.0
								± 4.7	±32	±0.5	±0.4
	c	ontrol Fe	males, A	ge >15 <b>-4</b>	<u>0</u>						
825	355	8.02	3-93	3.69	0.40	0.0	0.0	40	466	12.8	8.9
826	358	5.39	3.56	1.35	0.16	0.32	0.0	34	408	12.4	8.2
829	330	7.23	3.98	2.89	0.07	0.29	0.0	33	355	12.1	8.0
832	240	6.06	2.85	2.97	0.12	0.12	0.0	37 36	451	14.0	8.3
841	264	6.34	2.98	3.04	0.13	0.19	0.0	36	424	12.8	8.0
843	253	6.43	2.96	2.96	0.19	0.32	0.0	35	376	13.6	7.0
865	263	6.17	3.58	2.34	0.06	0.12	0.60	38	396	12.8	7.2
895	320	6.69	2.54	3.48	0.20	0.47	0.0	45	487	16.4	8.5
896 914	393 268	7•35 7•88	3.68	2.87	0.29	0.44	0.70	42	474	14.8	8.7
914 916	200 378	4.84	4.33 2.47	2.84	0.32 0.15	0.16	2.36 0.48	37	407	13.6	7.2
922	411			1.79 1.85		0.39 0.49		36	425 567	13.6	7.5
932	198	9.73 9.21	7.01 6.45	2.30	0.39 0.0	0.49	0.0	41 43	467	14.0 12.1	8.7
934	246	7.39	3.99	2.73	0.30	0.40	0.0		330 414	12.1	7.1 7.0
938	170	10.80	5.40	3.13	0.54	1.73	0.0	37 30	402	14.0	7.9 8.7
950	280	8.83	3.36	5.03	0.0	0.44	0.0	39 38	428	14.0	7.8
951	264	9.75	6.34	2.44	0.59	0.39	0.0	36	396	12.4	7.1
965	288	7.16	4.80	1.93	0.07	0.36	0.0	39	367	14.0	7.8
993	3 <b>0</b> 8	7.51	3.76	3.38	0.15	0.23	0.0	39 43	462	15.6	7.8
9 <b>9</b> 8	245	6.29	3.46	2.45	0.19	0.06	1.26	38	419	14.8	8 <b>.</b> 9
1001	258	9.24	5.82	3.05	0.18	0.18	0.0	37	420	12.4	70
1043	414	9.78	6.26	2.64	0.39	0.49	0.0	40	455	13.2	7.5 8.8
1502	265	7.88	3.78	3.86	0.16	0.08	0.0	38	451	13.6	8.8
mean	294	7.65	4.23	2,83	0.22	0.35	0.23	38.3	421	126	7.0
	<u>+</u> 66	±1.47	±1.34	±0.78	E	V•37	V.E.)	±2.8		13.6 ±1.0	7.9 +0.6
•			-					_2.0	±39	12.0	±0.6

853	ect	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	RBC	Hgb.	Serum
849 375 8.58 4.12 3.86 0.17 0.43 0.0 46 461 853 328 6.84 3.15 3.21 0.14 0.34 0.0 38 389 855 253 6.38 3.32 2.55 0.13 0.32 0.64 41 362 856 293 5.52 2.21 2.70 0.06 0.55 0.0 39 410 862 240 7.02 4.21 2.39 0.28 0.07 0.70 44 400 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 575 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 6.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.29 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.19 0.13 0.0 573 2.20 47 459 947 338 7.77 4.04 2.72 0.16 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.47 0.10 0.0 0.47 489 947 338 7.77 4.04 2.72 0.16 0.47 0.10 0.0 0.47 489 947 338 7.77 2.37 2.02 0.23 1.04 1.15 45 471 964 178 5.88 3.07 2.12 0.11 0.10 0.0 0.9 38 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 178 5.88 3.07 2.12 0.11 0.11 0.56 35 376 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 38 383 899 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 887 1.34 35 5.86 3.17 2.85 0.20 0.77 0.0 39 398 894 284 1.0 5.88 2.94 2.65 0.0 0.29 0.0 39 379 988 894 288 7.32 4.41 3.81 0.09 0.35 0.18 0.0 38 383 899 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 288 7.32 6.65 3.17 2.85 0.20 0.77 0.0 39 398 894 288 7.32 6.65 3.18 2.89 0.65 0.20 0.0 40 393 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 288 7.32 6.65 4.41 3.81 0.09 0.35 0.18 0.0 36 381 899 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 288 7.32 6.65 3.17 2.85 0.20 0.77 0.0 39 398 894 283 3.60 3.34 1.99 0.35 0.18 0.0 36 381 899 894 283 3.66 3.44 1.381 0.09 0.35 0.08 0.0 38 383 899 894 286 5.97 1.49 3.88 0.66 0.30 0.00 39 379 994 126 6.65 3.17 2.85 0.30 0.00 0.35 0.00 39 379 994 128 283 8.90 5.16 3.12 0.29 0.77 0.0 39 398 894 283 8.65 4.41 3.81 0.09 0.35 0.00 0.00 39 379 994 128 283 8.90 5.16 3.12 0.26 0.39 0.00 39 392 393 393 393 393 393 393 393 393	0.	(x10 <sup>-5</sup> )	(x10 <sup>-5</sup> )	(x10°)	(x10°)	(x10 <sup>-5</sup> )	(x10°)	(x10 )	<b>%</b>	(x10 ')	g	protein,
853 328 6.84 3.15 3.21 0.14 0.34 0.0 38 389 855 253 6.38 3.32 2.55 0.13 0.32 0.64 41 362 856 293 5.52 2.21 2.70 0.06 0.55 0.0 39 410 862 240 7.02 4.21 2.39 0.28 0.07 0.70 44 400 873 363 10.70 5.89 3.96 0.32 0.54 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.39 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 6.25 3.50 2.44 0.19 0.13 0.0 553 918 6.25 3.50 2.44 0.19 0.13 0.0 553 918 7.77 4.04 2.72 0.16 0.73 2.20 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 941 0.56 88 3.07 2.12 0.15 0.41 0.21 0.69 43 461 961 198 5.18 2.49 1.76 0.21 0.67 0.78 38 359 94 10 5.88 2.49 1.76 0.21 0.67 0.52 40 35 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.18 0.0 36 481 482 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 0.0 41 442 886 989 410 5.88 2.94 2.65 0.0 0.20 0.0 38 383 383 859 410 5.88 2.94 2.65 0.0 0.20 0.0 38 383 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 379 371 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 828 79 891 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 0.0 41 442 898 3317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 428 7.72 4.61 2.27 0.15 0.0 0.29 0.0 39 379 379 371 5.86 3.34 1.99 0.35 0.18 0.0 36 341 899 3317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 428 7.22 4.61 2.27 0.15 0.0 0.29 0.0 39 379 379 387 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 899 3317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 286 5.97 1.49 3.82 0.50 0.50 0.70 0.0 39 398 894 286 5.97 1.49 3.82 0.50 0.30 0.77 0.0 39 398 894 286 5.97 1.49 3.82 0.50 0.30 0.0 38 373 998 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 998 286 5.97 1.49 3.82 0.36 0.30 0.0 38 373 998 383 6.01 3.37 2.16 0.06 0.36 0.30 0.0 39 398 394 286 6.59 7.149 3.82 0.36 0.30 0.0 39 398 394 100 6.42 4.11 1.73 0.26 0.39 0.0 39 38 413 992 160 6.42 4.11 1.73 0.26 0.39		<u>Cc</u>	ontrol Ma	les, Age	>40							
855 253 6.38 3.32 2.55 0.13 0.32 0.64	49	375	8.58						46		16.9	8.0
866 293 5.52 2.21 2.70 0.06 0.55 0.0 39 410 862 240 7.02 4.21 2.39 0.28 0.07 0.70 4.4 400 873 363 10.70 5.89 3.96 0.32 0.54 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 488 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 489 947 338 7.77 4.04 2.72 0.16 0.78 36 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.07 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 335 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 36 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 428  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 893 317 9.66 6.43 2.11 0.29 0.07 0.0 39 379 871 343 5.86 3.34 1.99 0.05 0.50 0.70 0.0 38 383 899 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.05 0.50 0.70 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.66 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.66 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.66 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 0.9 0.0 36 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.80 0.31 0.26 0.39 0.0 39 399 942 160 6.42 4.11 1.73 0.26 0.39 0.0 37 399 941 260 6.42 2.73 3.89 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 37 39 942 160 6.42 4.11 1.73 0.26 0.39 0.0 37 39 943 6.01 3.77 5.77 0.08 0.08 0.00 0.0 36 419	53								38		13.6	8.5
873 363 10.70 5.89 3.96 0.32 0.54 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442 166 \$18 7.19 3.24 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 0.0 41 442 166 \$1.40 \$10.99 \$10.67 \$23.3 \$17 0.32 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 883 389 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 39 379 398 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 39 379 398 893 337 8.65 4.41 3.81 0.09 0.35 0.0 39 379 398 893 333 8.65 4.41 3.81 0.09 0.35 0.0 39 379 398 893 333 8.65 4.41 3.81 0.09 0.35 0.0 39 379 398 893 333 8.65 4.41 3.81 0.09 0.35 0.0 38 333 398 228 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.50 0.0 39 379 941 263 8.90 5.16 3.12 0.06 0.36 0.00 39 379 941 263 8.90 5.16 3.12 0.06 0.36 0.00 39 379 941 263 8.90 5.16 3.12 0.06 0.36 0.00 39 399 399 398 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 40	55	253	6.38	3.32	2.55		0.32	0.64	41		14.0	8.0
873 363 10.70 5.89 3.96 0.32 0.54 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 941 5.88 2.49 1.76 0.21 0.67 0.78 38 359 461 295 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442 166 \$1.40 \$10.99 \$10.67 \$23.3 \$147 \$1.40 \$1.50 \$	56	293		2.21	2.70	0.06	0.55	0.0	39	410	14.0	7.8
873 363 10.70 5.89 3.96 0.32 0.54 0.0 46 440 875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442 106 107 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442 106 107 333 5.86 3.34 1.99 0.57 0.20 0.0 41 442 106 106 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.36 0.37 42.1 428.7 466 \$1.40 \$1.0.99 \$1.067 \$2.30 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 389 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 389 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 398 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 383 383 385 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 389 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 389 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 398 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 389 899 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 398 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 803 317 9.60 6.12 3.18 2.26 0.31 0.31 0.61 40 361 428 424 424 424 428 428 428 428 428 428		240	7.02		2.39	0.28	0.07	0.70	44		14.4	7•5
875 196 5.16 2.73 2.17 0.10 0.10 0.52 48 483 878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.86 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 845 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.9 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 331 9.96 6.12 2.71 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.18 0.0 36 341 989 333 8.65 4.41 3.81 0.09 0.35 0.18 0.0 36 341 989 333 8.65 4.41 3.81 0.09 0.35 0.18 0.0 36 341 989 333 8.65 4.41 3.81 0.09 0.35 0.18 0.0 38 373 980 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 988 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 989 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 998 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 988 268 5.97 1.49 3.82 0.36 0.30 0.0 39 399 996 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 991 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 992 343 6.01 3.37 2.16 0.06 0.30 0.08 0.0 39 392 996 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 997 197 8.44 2.70 5.57 0.08 0.08 0.0 36 0.0 36 419	<b>7</b> 3	363	10.70	5.89		0.32	0.54	0.0	46	440	16.0	7.2
878 232 5.65 2.49 2.77 0.34 0.06 0.0 40 418 880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.67 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  ■mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 ±66 ±1.40 ±0.99 ±0.67   Control Females, Age ≥40   Control Females, Age ≥40   Control Females, Age ≥40   Control Females, Age ≥40  Control Females, Age ≥40   Control Females, Age ≥40  Control	75	196	5.16	2.73	2.17	0.10	0.10	0.52	48	483	17.4	7.4
880 308 7.66 3.75 3.29 0.38 0.23 0.0 47 487 883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 466 ±1.40 ±0.99 ±0.67   Control Females, Age >40   844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.20 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 898 268 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 941 283 8.90 5.16 3.12 0.36 0.36 0.30 0.0 38 373 941 283 8.90 5.16 3.12 0.36 0.39 0.0 39 379 941 283 8.90 5.16 3.12 0.36 0.39 0.0 39 389 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 39 392	78		5.65		2.77				40	418	14.0	8.0
883 238 5.86 1.88 3.05 0.29 0.06 0.0 43 406 884 418 8.29 4.06 3.48 0.33 0.33 0.83 41 406 886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 4.56 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 3.8 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 ±66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 363 859 410 5.88 2.94 2.65 0.0 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 389 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 889 333 6.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 889 333 6.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 833 3.65 4.41 3.81 0.99 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 393 908 260 6.12 3.18 2.26 0.30 0.00 38 343 934 288 5.97 1.49 3.82 0.36 0.30 0.0 38 343 935 259 457 1.49 3.82 0.36 0.30 0.0 38 373 941 283 8.99 5.16 3.12 0.36 0.39 0.0 39 399 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 399 941 283 8.99 5.16 3.12 0.36 0.17 0.0 37 379 941 283 8.99 5.16 3.10 0.25 0.36 0.17 0.0 37 379 941 283 8.99 5.16 3.12 0.36 0.17 0.0 37 379 941 283 8.99 5.16 3.10 0.25 0.36 0.17 0.0 37 379 941 283 8.99 5.16 3.10 0.25 0.36 0.07 0.08 0.08 0.09 38	<b>80</b>	308								487	16.4	8.0
884	83		5.86	ĭ.88	3.05						14.8	7-5
886 388 8.13 4.47 3.41 0.0 0.24 0.0 38 401 915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.11 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age >40   Rul 234 6.43 3.60 2.70 0.06 0.0 0.64 38 363 859 410 5.88 2.94 2.65 0.0 0.29 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.99 0.35 0.18 0.0 36 341 893 317 9.60 6.42 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 381 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 941 283 8.90 5.16 3.01 2.25 0.36 0.17 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.08 0.0 39 392	84	418		4.06	3.48						14.0	8.5
915 292 4.86 2.09 1.75 0.05 0.97 0.0 42 386 917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7				4.47							13.2	8.8
917 183 6.25 3.50 2.44 0.19 0.13 0.0 553 918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 ±66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   Control Females, Age > 40  Control Femal			4.86						42		14.8	7.8
918 260 7.32 2.78 3.44 0.15 0.73 2.20 47 456 935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 1.98 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   Control Females, Age > 40   Control Females, Age > 40											A-110	8.2
935 324 5.12 2.15 2.46 0.41 0.10 0.0 47 489 947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7	า้อ		7 32	2 78		0.15			47	1156	16.4	7.8
947 338 7.77 4.04 2.72 0.16 0.78 0.78 38 359 948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   Control Females, Age > 40  Control Females, Age O.30  Co.30  Co.30  Co.30  Co.30  Co.30  Co.30  Co.30  Co.30  Co.30											16.4	8.4
948 177 6.88 3.23 3.23 0.14 0.21 0.69 43 461 961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67   Control Females, Age > 40   844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419	コノ カマ	328		7. 17							12.8	7.9
961 245 5.77 2.37 2.02 0.23 1.04 1.15 45 471 964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.67 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442    mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 ±66 ±1.40 ±0.99 ±0.67 ±3.3 ±47   Control Females, Age > 40  844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 39 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419		177	6.88						)(2	3/9	15.2	7.6
964 198 5.18 2.49 1.76 0.21 0.67 0.52 40 376 969 417 5.58 3.07 2.12 0.11 0.11 0.56 35 376 1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442 mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 +66 ±1.40 ±0.99 ±0.67 ±3.3 ±47     Control Females, Age > 40   Control Females,	40 61	フリト			3.43						15.6	
969	O1 ∠),		2.11									7.2
1007 333 5.87 2.64 2.88 0.18 0.18 0.0 38 428 1041 358 6.51 2.08 3.97 0.26 0.20 0.0 41 442  mean 294 6.65 3.17 2.85 0.20 0.36 0.37 42.1 428.7 ±66 ±1.40 ±0.99 ±0.67 ±3.3 ±47   Control Females, Age > 40  844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 388 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.30 0.0 38 373 929 343 8.90 5.16 3.12 0.36 0.30 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	<del>6</del> 4	190									14.0	7.5
1041   358   6.51   2.08   3.97   0.26   0.20   0.0   41   442			2.50	3.07	2.12				35		11.8	7.1
Mean   294   6.65   3.17   2.85   0.20   0.36   0.37   42.1   428.7   ±66   ±1.40   ±0.99   ±0.67   ±3.3   ±47   ±3.3   ±47   ±3.3   ±47   ±466   ±1.40   ±0.99   ±0.67   ±3.3   ±47   ±		333							38		13.2	8.1
Control Females, Age > 40  844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 379 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419	041	358	6.51	2.08	3.97	0.26	0.20	0.0	41	442	14.4	8.6
Control Females, Age > 40  844 234 6.43 3.60 2.70 0.06 0.0 0.64 38 366 846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419	ean	294 +66				0.20	0.36	0.37			14.7 ±0.5	7.9 ±0.5
844       234       6.43       3.60       2.70       0.06       0.0       0.64       38       366         846       518       7.19       3.24       2.88       0.50       0.50       0.72       41       421         851       241       6.49       2.53       3.37       0.32       0.19       0.65       35       350         852       457       10.80       5.94       3.89       0.65       0.32       0.0       38       383         859       410       5.88       2.94       2.65       0.0       0.29       0.0       39       379         871       343       5.86       3.34       1.99       0.35       0.18       0.0       36       341         893       317       9.60       6.43       2.11       0.29       0.77       0.0       39       398         894       298       7.32       4.61       2.27       0.15       0.0       2.93       42       424         898       333       8.65       4.41       3.81       0.09       0.35       0.0       40       393         908       260       6.12       3.18       2.26 <t< td=""><td></td><td>Co</td><td>ntrol Fer</td><td>nales, Ag</td><td></td><td></td><td><del>,</del></td><td></td><td><del></del></td><td></td><td></td><td></td></t<>		Co	ntrol Fer	nales, Ag			<del>,</del>		<del></del>			
846 518 7.19 3.24 2.88 0.50 0.50 0.72 41 421 851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419								- 61	-0	-66	0	0 =
851 241 6.49 2.53 3.37 0.32 0.19 0.65 35 350 852 457 10.80 5.94 3.89 0.65 0.32 0.0 38 383 859 410 5.88 2.94 2.65 0.0 0.29 0.0 39 379 871 343 5.86 3.34 1.99 0.35 0.18 0.0 36 341 893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419					2.70				38		12.8	8.7
859			7.19								14.4	8.5
859	51		6.49		3 <b>-</b> 37				35	350	12.8	7.4
893 317 9.60 6.43 2.11 0.29 0.77 0.0 39 398 894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 36 419				5.94					38	383	12.8	7.8
893       317       9.60       6.43       2.11       0.29       0.77       0.0       39       398         894       298       7.32       4.61       2.27       0.15       0.0       2.93       42       424         898       333       8.65       4.41       3.81       0.09       0.35       0.0       40       393         908       260       6.12       3.18       2.26       0.31       0.31       0.61       40       361         928       268       5.97       1.49       3.82       0.36       0.30       0.0       38       373         929       343       6.01       3.37       2.16       0.06       0.36       0.60       40       448         936       253       8.26       3.72       3.88       0.41       0.25       0.0       37       379         941       283       8.90       5.16       3.12       0.36       0.18       0.89       38       413         942       160       6.42       4.11       1.73       0.26       0.39       0.0       39       392         956       315       5.78       3.01       2.25       <				2.94					39	379	14.0	7.7
894 298 7.32 4.61 2.27 0.15 0.0 2.93 42 424 3 898 333 8.65 4.41 3.81 0.09 0.35 0.0 40 393 3 908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 3 928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 3 929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 3 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 3 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 3 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 3 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419		343		3.34	1.99	0.35	0.18	0.0		341	12.4	8.0
898       333       8.65       4.41       3.81       0.09       0.35       0.0       40       393         908       260       6.12       3.18       2.26       0.31       0.31       0.61       40       361         928       268       5.97       1.49       3.82       0.36       0.30       0.0       38       373         929       343       6.01       3.37       2.16       0.06       0.36       0.60       40       448         936       253       8.26       3.72       3.88       0.41       0.25       0.0       37       379         941       283       8.90       5.16       3.12       0.36       0.18       0.89       38       413         942       160       6.42       4.11       1.73       0.26       0.39       0.0       39       392         956       315       5.78       3.01       2.25       0.36       0.17       0.0       37       370         957       473       6.59       2.90       3.30       0.13       0.26       0.0       36       410         970       197       8.44       2.70       5.57       <	93			6.43					39	398	15.2	8.7
908 260 6.12 3.18 2.26 0.31 0.31 0.61 40 361 3928 268 5.97 1.49 3.82 0.36 0.30 0.0 38 373 3929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 3936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 3941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 3942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 3956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 3957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 3970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	94	298	7.32								14.0	8.4
928       268       5.97       1.49       3.82       0.36       0.30       0.0       38       373         929       343       6.01       3.37       2.16       0.06       0.36       0.60       40       448         936       253       8.26       3.72       3.88       0.41       0.25       0.0       37       379         941       283       8.90       5.16       3.12       0.36       0.18       0.89       38       413         942       160       6.42       4.11       1.73       0.26       0.39       0.0       39       392         956       315       5.78       3.01       2.25       0.36       0.17       0.0       37       370         957       473       6.59       2.90       3.30       0.13       0.26       0.0       37       410         970       197       8.44       2.70       5.57       0.08       0.08       0.0       36       419	98	333								393	15.2	8.6
929 343 6.01 3.37 2.16 0.06 0.36 0.60 40 448 936 253 8.26 3.72 3.88 0.41 0.25 0.0 37 379 941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419		260	6.12	3.18	2.26				40		14.0	7.5
929       343       6.01       3.37       2.16       0.06       0.36       0.60       40       448       1         936       253       8.26       3.72       3.88       0.41       0.25       0.0       37       379       1         941       283       8.90       5.16       3.12       0.36       0.18       0.89       38       413       1         942       160       6.42       4.11       1.73       0.26       0.39       0.0       39       392       392         956       315       5.78       3.01       2.25       0.36       0.17       0.0       37       370<			5.97	1.49	3.82	0.36	0.30		38	373	13.2	8.7
936       253       8.26       3.72       3.88       0.41       0.25       0.0       37       379       379       379       379       379       379       379       379       379       379       379       379       379       379       379       370       <	29	343	6.01		2.16	0.06	0.36	0.60	40	1118	15.2	8.5
941 283 8.90 5.16 3.12 0.36 0.18 0.89 38 413 1 942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 1 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 1 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 1 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	36			3.72	3.88	0.41		0.0	37	379	13.6	8.1
942 160 6.42 4.11 1.73 0.26 0.39 0.0 39 392 3 956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 3 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 3 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	41	283			3.12				38		14.0	7.5
956 315 5.78 3.01 2.25 0.36 0.17 0.0 37 370 1 957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 1 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	42		6.42		1.73				39		13.2	7.4
957 473 6.59 2.90 3.30 0.13 0.26 0.0 37 410 3 970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419	56								37		12.8	7.5
970 197 8.44 2.70 5.57 0.08 0.08 0.0 36 419		473							37		14.0	7. É
			8.44						36		12.8	7.5
1072 ) 0 0 32	045	338	6.32	3.16	2.78	0.19	0.19	0.0	37	440	13.6	8.6
						/	/			- · · <del>-</del>	J	•
mean 318 7.21 3.67 2.98 0.26 0.27 0.37 38.3 393	ean					0.26	0.27	0.37	38.3	393	13.7	8.0
TON 19 10 10 10 10 10 10 10 10 10 10 10 10 10		I94	<del>1</del> 1.40	±1.20	±0.94		•				±0.9	±0.5
					- *				1	7	/	

	Plate.		Neut.	Lymph.	Mono.	Eosin.		Hct.,	RBC	Hgb.,	Serum
No.	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	% 	(x10 <sup>-4</sup> )	g	protein,
	<u>c</u>	ontrol Ma	les, Age	<u>&lt;9</u>							
801	552	10.30	3.09	5.46	0.41	1.34	0.0	39 38	453	13.2	7.4
802	459	8.61	4.82	3.01	0.34	0.34	0.86	38	440	14.0	6.8
803	388	9.21	4.88	3.50	0.55	0.28	0.0	35	382	12.8	7.5
806	450	12.60	6.30	3.40	0.38	2.52	0.0	38 38	424	14.0	
807	307	11.10	4.55	5.00	0.44	1.00	1.10	38	412	12.2	. 7•3
809	400	12.90	6.19	4.77	0.26	1.68	0.0	37	455	14.0	
870	336	10.50	5.78	3.57	0.63	1.26	1.05	38	445	14.0	7.3
904	452	14.40	10.80	2.30	0.0	1.30	0.0	39	405	12.4	
905	208	12.90	6.32	5.55	0.65	0.39	0.0	39	426	12.1	
952	583	12.30	4.92	4.80	0.86	1.72	0.0	39	424	12.4	
1002	428	19.30	6.37	8.49	0.0	4.25	1.93	36	462	12.1	
1004	155	16.30	4.89	9.94	0.65	0.0	8.15	37	439	11.8	
1006	330	8.27	2.56	4.88	0.08	0.74	0.0	39 38	419	13.4	
1009	447	8.14	3.26	4.23	0.24	0.41	0.0	38	438	12.8	
1010	545	10.70	5.46	4.71	0.32	0.21	0.0	37	398	13.6	
1014	313	12.80	4.74	6.66	0.38	1.02	0.0	36	71,717	12.4	•
1015	167	12.20	2.81	7.81	0.85	0.61	1.22	41	520	14.4	
1017	416	9.62	4.62	4.62	0.38	0.0	0.0	33	433	11.8	
1024	223	6.09	2.19	3.41	0.18	0.18	1.21	33	413	11.8	
1027	311	9.15	4.21	4.76	0.09	0.09	0.0	39	419	12.1	
1030	466	14.00	5.04	8.26	0.56	0.0	1.40	40	493	12.1	
1037	235	7.87	2.51	4.09	0.16	1.10	0.0	35	425	12.1	
1038	376	9.66	2.41	6.67	0.39	0.19	0.0	33	438	9.7	•
1040	258	8.64	3.71	4.23	0.35	0.35	0.0	34	413	11.5	
1045	545	12.70	3.43	8.26	0.76	0.25	0.0	35	439	10.6	
1046	508	10.70	2.89	6.74	0.64	0.86	0.0	35	442	11.5	
1047	435	7.22	2.96	3.61	0.29	0.29	0.0	32	368	11.8	
1503	251	8.59	2.15	5.50	0.60	0.34	0.0	39	448	12.8	
1504	348	9.53	3.81	5.15	0.29	0.29	0.0	39	456	13.2	
mean	<b>37</b> 5	10.91	4.40	5.29	0.40	0.79	0.58	36.9	l al		<u>.</u> _
	±119	±2.87	±1.82	±1.87	0.40	0.15	0.50	±2.4	434	12.5	7.3
			-					_ 2.4	±30	<u>+</u> 1.0	±0 <b>.2</b>
	C	ontrol Fe	males, A	ge <9	-						
	_										
808	520	9.74	5.06	4.09	0.29	0.29	0.0	40	396	14.0	8.5
810	520 283	10.30	5.25	4.02	0.62	0.41	0.0	39	396 439	14.0 14.0	8.5 7.7
810 8 <b>6</b> 6	520	10.30 6.12	5.25 2.02	4.02	0.62 0.06	0.41	0.0	39 40	439 403	14.0 14.0 14.4	7.7 7.7
810 866 900	520 283 368	10.30 6.12 8.60	5.25 2.02 3.61	4.02 3.55 4.30	0.62 0.06 0.34	0.41 0.49 0.34	0.0 0.0 0.0	39 40 40	439 403 4 <b>1</b> 3	14.0 14.4 13.6	8.5 7.7 7.7 8.0
810 866 900 901	520 283 368	10.30 6.12 8.60 12.60	5.25 2.02 3.61 3.91	4.02 3.55 4.30 7.43	0.62 0.06 0.34 0.38	0.41 0.49 0.34 0.76	0.0 0.0 0.0	39 40 40 37	439 403 413 446	14.0 14.4 13.6 13.2	7.7 7.7
810 866 900 901 902	520 283 368 392 298	10.30 6.12 8.60 12.60 10.40	5.25 2.02 3.61 3.91	4.02 3.55 4.30 7.43	0.62 0.06 0.34 0.38 0.10	0.41 0.49 0.34 0.76 1.98	0.0 0.0 0.0 0.0	39 40 40 37 33	439 403 413 446 382	14.0 14.4 13.6 13.2 10.9	7.7 7.7
810 866 900 901 902 903	520 283 368 392 298 348	10.30 6.12 8.60 12.60 10.40 8.71	5.25 2.02 3.61 3.91 3.54 4.18	4.02 3.55 4.30 7.43	0.62 0.06 0.34 0.38 0.10	0.41 0.49 0.34 0.76 1.98 1.05	0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37	439 403 413 446 382	14.0 14.4 13.6 13.2 10.9 14.0	7.7 7.7
810 866 900 901 902 903 906	520 283 368 392 298 348 269	10.30 6.12 8.60 12.60 10.40 8.71 7.67	5.25 2.02 3.61 3.91 3.54 4.18 3.22	4.02 3.55 4.30 7.43 4.78 3.48 4.07	0.62 0.06 0.34 0.38 0.10 0.0	0.41 0.49 0.34 0.76 1.98 1.05 0.31	0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40	439 403 413 446 382	14.0 14.4 13.6 13.2 10.9 14.0 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923	520 283 368 392 298 348 269	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44	4.02 3.55 4.30 7.43 4.78 3.48 4.07	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18	0.41 0.49 0.34 0.76 1.98 1.05 0.31 0.98	0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40	439 403 413 446 382	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2	7.7 7.7
810 866 900 901 902 903 906 923 930	520 283 368 392 298 348 269 493 414	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51	4.02 3.55 4.30 7.43 4.78 3.48 4.07 3.29 4.26	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21	0.41 0.49 0.34 0.76 1.98 1.05 0.31 0.98 0.42	0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 438 436	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995	520 283 368 392 298 348 269 493 414	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34	4.02 3.55 4.30 7.43 4.78 3.48 4.07 3.26 5.90	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19	0.41 0.49 0.34 0.76 1.98 1.05 0.31 0.98 0.42	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 438 436 454	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012	520 283 368 392 298 348 269 493 414 293 368	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34	4.02 3.55 4.30 7.43 4.78 3.48 4.07 3.26 5.90	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23	0.41 0.49 0.34 0.76 1.98 1.05 0.31 0.98 0.42 0.94 0.83	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 438 436 454	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020	520 283 368 392 298 348 269 493 414 293 368 433	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74	4.02 3.55 4.30 7.43 4.78 3.48 4.07 4.29 4.26 5.90	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47	0.41 0.49 0.34 0.76 1.98 1.05 0.98 0.42 0.94 0.83 0.23	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.75	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 436 454 394 382	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021	520 283 368 392 298 348 269 493 414 293 368 433 420	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74	4.02 3.55 4.30 7.43 4.78 3.48 4.07 4.29 4.26 5.90	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46	0.41 0.49 0.34 0.76 1.98 1.05 0.98 0.42 0.94 0.83 0.23 2.62	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.75 0.0	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 438 454 394 382 419	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021	520 283 368 392 298 348 269 493 414 293 368 433 420 297	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74 5.08 1.47	4.02 3.55 4.30 7.43 4.78 4.07 4.26 5.90 7.25 7.24 5.06	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46 0.37	0.41 0.49 0.76 1.98 1.05 0.98 0.42 0.94 0.83 0.23 2.62 0.44	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.75 0.0	39 40 40 37 33 37 40 37	439 403 413 446 382 390 389 438 454 394 382 419	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 13.6	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20	5.25 2.02 3.61 3.91 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74 5.08 1.47 6.64	4.02 3.55 4.30 7.43 4.78 4.07 4.26 5.90 7.25 7.24 5.06	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46 0.37	0.41 0.49 0.76 1.98 1.05 0.98 0.42 0.83 0.23 2.62 0.44 0.32	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.75 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 389 389 438 454 394 393 419 393 439	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 13.6 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12	5.25 2.02 3.61 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74 6.64 2.92	4.02 3.55 4.78 4.78 4.07 4.26 5.90 7.24 5.99 7.24 5.59 4.47	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46 0.37 0.65 0.41	0.41 0.49 0.76 1.98 1.05 0.98 0.42 0.83 0.62 0.44 0.32 0.34	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.75 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 389 438 438 454 392 419 393 439 392	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.4 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50	5.25 2.02 3.61 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74 6.64 2.92 3.75	4.02 3.55 4.78 4.78 4.07 4.26 5.90 7.24 5.99 7.24 5.59 4.47	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46 0.37 0.65 0.41	0.41 0.49 0.76 1.98 1.05 0.98 0.42 0.83 0.62 0.34 0.34 0.38	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40 37	439 403 413 446 389 389 438 454 392 419 393 439 439 449	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.4 12.8 12.1	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028 1029	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10	5.25 2.02 3.61 3.54 4.18 3.22 4.44 5.51 2.34 2.33 3.74 6.64 2.92 3.75	4.02 3.55 4.78 4.78 4.07 4.26 5.90 7.24 5.90 7.24 7.77 8.59 4.75 6.77	0.62 0.06 0.34 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.46 0.37 0.63 0.56	0.41 0.49 0.76 1.98 1.05 0.98 0.94 0.83 0.62 0.34 0.38 0.34 0.38	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 40 37 33 37 40	439 403 413 446 389 438 438 454 389 419 399 419 399 416	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.4 12.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028 1029 1031	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293 318	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10	5.25 2.02 3.61 3.54 3.54 3.54 3.74 5.51 2.34 5.64 2.75 3.75 4.41	4.02 3.55 4.78 4.78 4.07 4.26 5.90 7.24 5.90 7.24 7.75 8.59 4.47 6.10	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.63 0.56 0.45	0.41 0.49 0.76 1.98 1.05 0.98 0.94 0.83 0.62 0.34 0.34 0.34	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 37 33 37 40 37 39 37 39 35 38 34 36 37 39	439 403 413 446 389 389 438 454 392 419 393 439 439 449	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.1 12.1 12.1	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028 1029 1031 1034	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293 318 624	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10	5.25 2.02 3.61 3.54 3.54 3.54 3.74 5.34 5.34 2.33 3.78 2.75 3.75 3.44 3.90	4.02 3.55 4.78 4.78 4.07 4.26 4.26 5.90 7.24 7.29 7.24 7.77 7.06 4.30 4.30	0.62 0.06 0.34 0.38 0.10 0.08 0.18 0.19 0.21 0.47 0.46 0.37 0.46 0.56 0.45 0.43	0.41 0.49 0.76 1.98 1.05 0.98 0.98 0.98 0.98 0.34 0.34 0.34 0.34 0.34 0.34 0.34	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 37 33 37 40 37 39 37 39 35 38 34 36 37 39 40	439 403 413 442 389 438 439 439 439 439 439 439 446 453	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.1 12.1	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028 1029 1031	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293 318 624 591	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10	5.25 2.02 3.61 3.54 3.54 3.54 3.74 5.51 2.34 5.64 2.75 3.75 4.41	4.02 3.55 4.78 4.78 4.07 4.26 5.90 7.24 5.90 7.24 7.77 8.59 4.75 6.77	0.62 0.06 0.34 0.38 0.10 0.0 0.08 0.18 0.21 0.19 0.23 0.47 0.63 0.56 0.45	0.41 0.49 0.76 1.98 1.05 0.98 0.94 0.83 0.62 0.34 0.34 0.34	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 37 33 37 40 37 39 37 39 35 38 34 36 37 39	439 403 413 446 389 438 439 439 439 439 439 439 446 456	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 13.2 12.4 12.8 12.4 12.8 12.1 12.1 12.1	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1022 1025 1026 1028 1029 1031 1034	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293 318 624 591	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10 11.30 10.70	5.25 2.02 3.61 3.54 3.54 3.54 3.74 5.34 5.34 5.47 6.92 3.75 5.41 3.83 3.83	4.02 3.55 4.78 4.78 4.02 4.02 4.02 4.02 4.02 4.02 4.03 4.05	0.62 0.06 0.34 0.38 0.10 0.08 0.18 0.19 0.21 0.47 0.46 0.37 0.46 0.56 0.45 0.43	0.41 0.49 0.76 1.98 1.05 0.98 0.98 0.98 0.98 0.34 0.34 0.34 0.34 0.34 0.34 0.34	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 37 33 37 40 37 37 37 37 37 37 37 37 40 37 37 37 37 37 37 37 37 37 37 37 37 37	439 403 413 443 459 459 459 459 459 459 459 459 459 459	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.4 12.8 12.4 12.8 12.1 12.1 12.1 12.1 13.2 14.8 11.8	7.7 7.7 8.0
810 866 900 901 902 903 906 923 930 995 1012 1020 1021 1026 1028 1029 1031 1034 1044	520 283 368 392 298 348 269 493 414 293 368 433 420 297 378 296 347 293 318 624 591	10.30 6.12 8.60 12.60 10.40 8.71 7.67 8.88 10.40 9.37 7.52 11.70 15.40 7.34 16.20 8.12 12.50 11.10 11.30 10.15 ±2.50	5.25 2.02 3.61 3.54 3.54 3.54 3.74 5.51 2.34 5.64 2.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3	4.02 3.55 4.78 4.78 4.02 4.26 4.29 5.99 7.24 7.50 6.10 4.30 4.30 4.75 6.10	0.62 0.06 0.34 0.10 0.08 0.19 0.47 0.46 0.43 0.45 0.45 0.45 0.45 0.45 0.45	0.41 0.49 0.76 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	39 40 37 33 37 40 37 37 39 37 39 38 38 38 39 39 39 39 39 39 39 39 39 39 39 39 39	439 4013 444 4389 4384 4384 4384 4384 4384 4384	14.0 14.4 13.6 13.2 10.9 14.0 12.8 12.2 12.4 12.8 12.4 12.8 12.1 12.1 12.1 12.1	7.7 7.7 8.0

Subject No.	Plate. (x10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )		Hct.,	RBC (x10 <sup>-4</sup> )	Hgb.,	Serum protein,
	<u>U1</u>	irik Mal	es, Age '	9-15							
2102 2106 2115 2124 2136 2142 2151 2155 2174 2179 2188 2242	543 363 280 326 568 418	9.84 15.10 13.40 7.57 6.18 7.87 7.20 7.89 12.10 8.30 6.10 8.86	3.54 7.55 7.37 4.39 2.90 3.70 3.02 3.95 6.78 4.65 2.44	5.93 5.74 4.96 2.73 2.72 3.78 3.46 2.76 4.11 3.32 3.23	0.10 0.45 0.40 0.23 0.19 0.08 0.14 0.32 0.36 0.08 0.24	0.30 1.36 0.40 0.15 0.37 0.24 0.58 0.87 0.85 0.25	0.0 0.0 2.68 0.76 0.0 0.79 0.0 0.0 0.0	38 39 35 38 41 36 33 39 40	419 449 455 425 428 472 418 456 494	14.8 14.4 15.2 13.6 14.4 15.2 17.4 14.8 14.0 14.8	7.9 7.9 7.2 8.0 7.1 7.5 7.7 7.7 7.9
mean	419 ±93	9.20 <u>+</u> 2.88	4.57 ±1.83	3.89 ±1.17	0.24	0.50	0.38	37.9 ±2.1	419 442 ±23	14.0 15.0 ±1.2	7.2 7.6 ±0.3
2111 2113 2126 2130 2160 2197 2210 2213 2218 2225 2226 2227 2228 2251 2255 2256	291 411 395 360 460 255 526 712 325 259 424 393 326 413 481	11.60 9.65 8.01 13.40 8.35 6.42 7.56 8.70 9.31 9.69 5.75 15.20 7.77 10.40 6.48	6.84 7.04 3.68 7.91 4.68 2.63 3.48 4.70 3.72 3.78 2.88 9.73 4.27 5.10 3.76	3.60 1.83 3.68 4.42 2.67 3.27 2.80 3.05 4.19 5.33 2.81 2.30 4.41 2.72 3.85	0.35 0.48 0.32 0.54 0.17 0.19 0.38 0.35 0.19 0.29 0.24 0.29 0.15 0.31 0.13	0.70 0.29 0.32 0.40 0.75 0.26 0.76 0.61 1.11 0.29 0.12 0.29 0.91 0.39 1.04 0.19	1.16 0.0 0.0 0.0 0.84 0.0 1.66 0.0 0.93 0.0 0.0 0.0 0.78 1.04	39 39 37 39 32 39 39 40 36 38 39 37 37 42	418 471 424 416 398 369 475 475 390 410 436 433 409	14.0 14.0 15.2 14.0 14.0 12.1 14.4 14.4 16.0 13.3 12.4 14.0 14.4 14.0	8.2 8.7 8.0 7.6 7.3 7.3 8.3 7.8 7.6 8.0 8.1 7.7
mean	402 ±116	9.01 +2.66	4.81 ±2.04	3.33 ±0.94	0.29	0.53	0.40	38.0 ±2.1	427 ±29	14.0 ±1.0	7.9 ±0.4

No.	Plate. (X10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct., %	RBC (x10 <sup>-4</sup> )	Hgb.,	Serum protein, g
	, <u>U</u> 1	irik Mal	es, Age >	15-40							
2108	398	6.23	2.36	2.36	0.50	0.75	2.49	43	449	16.4	7.7
2135	468	9.20	5.06	3.13	0.46	0.46	0.92	45	396	16.0	8.4
2137	310	5.61	2.75	2.52	0.17	0.11	0.56	42	467	14.8	8.0
2150	257	6.97	3.83	2.65	0.28	0.21	0.0	<del>ነ</del> ነት	492	16.4	7.4
2156	318	4.80	3.07	1.30	0.24	0.19	0.0	45	455	16.4	7.2
2157	415	5.81	2.91	2.56	0.23	0.12	0.0	43	409	15.2	7.4
2167	283	7.68	3.69	3.53	0.23	0.23	0.0	43	487	16.4	7.1
2176	420	6.44	3.35	2.64	0.39	0.06	0.0	51	512	17.4	7.7
2235	307	8.14	3.91	3.74	0.08	0.33	0.81	45	470	16.4	7.5
2152	240	4.60	3.22	1.10	0.09	0.18	6.0	45	459	16.4	7.8
mean	342	6.55	3.42	2.55	0.27	0.26	0.48	44.6	460	16.2	7.6
	±78	±1.47	±0.76	±0.85	0.2,	0.20	0.40	±2.5	±34	±0.7	+0.4
			•							- 0.1	
	<u>U</u>	tirik Fen	ales, Age	>15-40							
2104	375	5.84	3.85	1.69	0.06	0.23	0.0	36	396	12.8	7.8
2119	385	5.79	2.55	2.84	0.06	0.35	0.0	40	ЙЙИ	13.2	8.1
2128	573	8.31	3.91	3.99	0.08	0.33	0.0	30	418	10.0	8.0
2129	412	8.59	4.81	3.09	0.43	0.26	0.0	37	408	13.6	7.6
2149	400	6.13	2.15	3.13	0.43	0.31	1.23	37	360	12.8	7.7
2158	398	6.29	3.33	2.70	0.06	0.19	0.0	35	389	12.8	7.5
2164	324	9.51	6.94	2.09	0.19	0.29	0.0	39	415	14.4	8.ó
2172	449	5.82	2.44	2.74	0.23	0.41	0.0	41	436	14.4	7.5
2189	417	8.25	4.04	3.63	0.33	0.25	0.0	42	438	15.2	7.7
2195	301	5.32	3.19	2.02	0.11	0.0	0.0	38	408	13.2	6.8
2217	391	7.20	5.18	1.73	0.14	0.14	0.0	29	276	10.3	6.6
5559	316	6.93	4.02	2.49	0.27	0.14	0.0	4 <b>1</b>	445	15.2	7.5
2246	321	9.25	6.48	2.59	0.09	0.09	0.0	41	435	14.4	7.7
2247	401	8.17	3.92	3.35	0.16	0.74	0.0	36	379	13.2	7.8
2248	413	7.73	3.63	2.40	0.39	1.16	1.55	35	400	12.8	7.7
2249	683	5.61	2.86	2.19	0.39	0.17	0.0	37	425	13.2	8.2
mean		7.17	3.96	2.67	0.21	0.32	0.17	37.1	405	12.0	<b>7</b> 6
	±97	±1.39	±1.35	±0.66		٠. ا	J. 1	±3.6		13.2	7.6
		- ··		20000				- 3.0	<u>+</u> 41	±1.4	±0.4

Subject	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	RBC	Hg♭.,	Serum
No.	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	(x10 <sup>-4</sup> )	g	protein,
•	<u>U1</u>	irik Mal	es, Age>	40							
2101 2105 2110 2112 2114 2121 2125 2145 2146 2166 2169 2175 2181 2186 2206 2211 2214 2240 2253	296 371 437 317 306 324 467 539 308 352 264 275 243 368 323 384 355 308	11.80 8.62 6.06 5.70 7.34 5.26 8.56 7.77 5.90 5.91 6.31 3.95 7.19 5.51 6.74 5.35 5.09 8.81 8.77	6.37 4.31 3.39 3.74 3.05 3.77 3.07 3.03 1.90 4.55 2.97 2.55 4.55 3.44 5.35	4.96 3.19 2.55 1.60 2.94 1.95 4.11 3.65 2.36 2.25 1.80 2.26 2.97 1.82 2.97 2.41 2.29 4.23 2.81	0.24 0.26 0.06 0.11 0.07 0.16 0.17 0.39 0.35 0.12 0.19 0.16 0.36 0.11 0.61 0.37 0.05 0.18 0.26	0.24 0.76 0.06 0.63 0.59 0.11 0.51 0.47 0.06 0.08 0.43 0.61 0.20 0.05 0.20 0.97	0.0 0.86 0.0 0.0 0.0 0.78 0.59 0.59 0.63 0.72 0.55 0.0 0.54 0.0	30 42 45 45 45 45 45 45 45 41 41 43 44 43 44 43 44 44 45 46 46 46 46 46 46 46 46 46 46 46 46 46	389 438 393 408 487 418 453 455 454 450 368 358 456 445 493 442	13.2 15.6 14.8 14.4 16.0 14.4 14.8 15.6 15.2 14.4 14.4 12.1 16.0 15.6 15.2	8.4 8.0 7.7 8.0 8.6 8.6 7.5 7.3 7.3 7.5 7.5 7.5 7.5 7.5
mean	3 <del>ԿԿ</del> <u>+</u> 73	6.88 ±1.85	3.49 ±1.09	2.80 +0.91	0.22	0.34	0.28	41.3 ±2.2	428 <u>+</u> 36	14.8 ±0.9	7.8 +0.4
	<u>U</u> -	tirik Fem	ales, Age	>40							
2139 2140 2146 2162 2182 2191 2193 2196 2200 2212 2215 2216 2224 2238 2244	349 254 358 294 315 309 315 289 320 312 283 516 425 308 527 510	6.62 5.29 6.22 6.99 4.79 7.43 6.07 9.13 6.85 8.47 8.59 7.71 8.17 5.99 8.75 6.27	3.02 2.18 3.29 1.58 5.20 2.85 3.65 3.22 3.56 4.12 4.01 5.88 3.17 4.20 2.19	2.01 3.73 3.01 2.92 1.63 3.04 4.47 2.81 4.32 3.87 3.01 1.96 1.80 3.94 3.57	0.05 0.06 0.21 0.10 0.22 0.06 0.55 0.34 0.25 0.31 0.16 0.12 0.18	0.16 0.19 0.49 0.14 0.22 0.06 0.46 0.34 0.26 0.39 0.16 0.84 0.13	0.0 0.0 0.48 1.49 0.61 0.0 0.0 0.0 0.0 0.60 0.63	38 39 35 35 35 39 42 38 42 38 37 35 39 40	410 419 415 398 383 359 394 414 430 402 480 416 395 382 416	13.6 14.8 14.4 12.8 13.2 14.0 14.8 14.0 14.8 14.0 13.2 14.4	8.0 8.0 8.3 8.0 8.3 7.3 7.3 8.5 7.7 8.2 8.3 7.5 6.8 8.7
mean	356 <u>+</u> 90	7.08 ±1.30	3.47 ±1.13	3.07 ±0.92	0.22	0.32	0.25	38.0 ±3.1	405 <u>+</u> 28	13.8 ±0.8	8.1 ±0.6

APPENDIX 5 Individual Hematological Findings, 1964

Subject	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	Hgb.
No.	$(x10^{-3})$	$(x10^{-3})$	$(x10^{-3})$	$(x10^{-3})$	$(x10^{-3})$	$(x10^{-3})$	(x10 <sup>-2</sup> )	%	g
	Ronge	lap Expose	ed Males, A	ge 10-15					
2 3	430	7.65	3.52	3.52	0.15	0.31	1.50	38	13.2
3	396	12.03	6.13	3.85	0.48	1.44	1.20	36	12.1
5	365	6.25	3.13	2.88	0.13	0.13	0.0	37	12.1
19 23	380	4.68	1.92	1.82	0.19	0.75	0.0	μ̈́ġ	12.8
23	365	7.40	3.03	3.18	0.0	1.11	0.70	39	12.8
32	<b>30</b> 6	9.10	3.09	5.10	0.18	0.46	2.70	39	12.8
54	368	7-35	2.21	4.19	0.29	0.59	0.70	57	11.8
83*	350	9.20	4.32	3.68	0.0	1.20	0.0	37	12.4
8 <u>4</u> *	404	8.40	2.49	5.76	0.26	0.09	0.0	38	12.8
mean	374	8.01	3.31	3.78		- (0		11	
	±35**	<u>+</u> 2.10	±1.27	· ·	0.19	0.68	0.76	40.4	12.5
				±1.17				<u>+</u> 6.1	±0.4
•	Ailin	gnae Expos	sed Males,	Age 10-15					
6	3 <b>2</b> 8	7-55	3.17	2.87	0.45	0.98	0.80	<b>37</b> .	12.1
mean	328	7.55	3.17	2.87	0.45	0.98	0.80	37.0	12.1
	Ronge	lap Expose	d Females,	Age 10-15					
17	309	6.35	3.11	2.67	0.13	0.44	0.0	39	13.6
21.	275	7.00	3.01	2.52	0.07	1.33	0.70	42	13.2
33	585	8.63	3.11	4.83	0.09	0.52	0.90	40	14.0
42	440	9.20	4.23	4.42	0.09	0.46	0.0	37	13.6
65	378	7.40	3.85	2.29	0.15	1.04	0.70	38 38	12.4
69	403	6.60	3.04	3.30	0.07	0.20	0.0	41	12.8
mean	398	7-53	3.39	3.3 <sup>4</sup>			0		
	+110	+1.10	+0.52		0.10	0.65	0.38	39.5	13.3
		11.10	10.52	<u>+</u> 1.06				±2.4	±0.3
	<u>Ailin</u>	gnae Expos	ed Females	, Age 10-1	5				
8	454	11.08	4.87	4.87	0.33	0.89	1.10	40	14.0
mean	454	11.08	4.87	4.87	0.33	0.89	1.10	40.0	14.0
	-		•	•					

<sup>\*</sup> Exposed in utero.
\*\* Standard deviation.

Subject No.	Plate. (x10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct.,	Hgb.,
			d Males, A						<del></del>
10	388	11.30	6 <b>.20</b>	3.73	0.57	0.79	0.0	46	14.0
20	265	7.83	5.01	2.03	0.31	0.39	0.80	50	16.0
27	256	7.00	3.92	2.38	0.07	0.49	1.40	41	14.8
35	162	6.20	2.85	3.04	0.25		0.60	49	16.0
36	218	10.60	6.15	3.50	0.21	0.74	0.0	种	13.6
37	285	5.85	2.75	2.63	0.23	0.18	0.60	45	15.6
40	425	7.53	2.33	5.04	0.08	0.08	0.0	40	13.2
47	305	8.50	2.72	4.50	0.17	0.17	0.90	45	15.2
73	315	8.28	3.97	3.56	0.33	0.33	0.80	49	15.2
76	209	10.90	4.58	5.01	0.33	0.98	0.0	<del>11</del> 4	13.6
77	330	5.32	2.39	2.23	0.16	0.53	0.0	29	14.0
mear		8.12	3.90	3.42	0.25	0.43	0.46	43.8	14.7
	<u>+</u> 78	<u>+</u> 2.10	±1.44	<u>+</u> 1.08	-	J		±5.5	±1.0
	Ronge	elap Expose	ed Females,	Age >15-4	<u>o</u>				
12	395	6.45	2.45	3.81	0.06	0.06	0.60	41	13.2
14	355	7.15	4.22	2.65	0.21	0.07	0.0	36	12.1
15	331	7.75	3.33	3-57	0.47	0.39	0.0	38	13.2
18	257	6.93	4.22	1.87	0.48	0.28	0.70	40	13.6
24	505	6.05	1.88	3.51	0.06	0.61	0.0	42	13.2
39	406	7-55	2.79	3.85	0.23	0.53	1.50	37	11.8
39 49	385	8.25	5.20	2.39	0.17	0.50	0.0	39	12.8
61	445	9.03	5.69	2.61	0.18	0.54	0.0	43	14.0
64	295	7.10	2.98	3.20	0.28	0.43	2.10	38	12.4
66	448	8.00						40	12.8
67	295	8.20	4.26	3.44	0.25	0.25	0.0	42	13.6
71	425	9.00	5.76	2.70	0.27	0.27	0.0	40	14.0
72	360	8.40	2.67	5.68	0.17	0.09	0.0		-
74	263	9-55	4.68	4.39	0.29	0.19	0.0	45	14.8
75	423	14.40	10.37	2.73	0.29	1.01	0.0	39	12.4
mear	- 71-	8.25	4.32	3.31	0.24	0.37	0.35	40.0	13.1
	±73	<u>+</u> 1.90	±2.13	±0.96				<u>+</u> 2.3	±0.7
	Aili:	ngnae Expos	sed Females	, Age >15-	·40				
48	295	7.13	2.57	3.92	0.07	0.50	0.70	42	14.8
51	415	9.40	4.98	4.04	0.28	0.09	0.0	44	14.0
53	5 <b>31</b>	6.30	2.90	3.09	0.19	0.06	0.60	40	13.2
70	320	5.15	1.80	2.32	0.26	0.72	0.50	26	7.6
81	348	6.03	2.95	2.59	0.18	0.30	0.0	<b>3</b> 8	11.8
mear	_	6.80	3.04	3.19	0.20	0.33	0.36	38.0	12.3
	±95	±1.60	<u> </u>	±0.77			•	±6.1	±2.5
									-6.7

Subject	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	Hgb.,
No.	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	g					
	Ronge	elap Expose	d Males, A	ge > 40					
4	134	10.15	3.65	5.89	0.30	0.30	0.0	43	15.2
7	445	8.10	4.62	2.84	0.08	0.57	0.0	41	13.2
11	390	6.33	3.42	2.34	0.32	0.13	1.30	38	12.4
55	351	6.05	2.18	3.5 <b>1</b>	0.18	0.12	0.60	46	9.3
55 68	210	5.90	2.71	2.01	0.06	1.12	0.0	47	15.6
79	266	6.70	3.08	3.15	0.40	0.07	0.0	44	14.8
8o	319	11.50	5.98	3.91	0.46	1.03	1.20	42	14.0
82	538	8.00	3.12	4.16	0.24	0.48	0.0	43	13.2
mean	331	7.83	3.60	3.48	0.26	0.48	0.39	43.0	13.5
	±126	+2.00	±1.20	±1.22	0.20	0.40	0.39	±2.7	±1.9
	Aili	ngnae Expos	ed Males,	Age > 40					
16	386	6.33	2.59	3.10	0.13	0.51	0.0	46	14.0
29	235	7.70	5.24	2.23	0.0	0.23	0.0	40	14.0
41	225	5.98	1.79	3.35	0.24	0.49	1.20	42	14.8
50	448	6.35	2.48	3.43	0.13	0.32	0.0	44	15.2
mean	323	6.59	3.03	3.03	0.13	0.39	0.30	43.0	14.5
	+110	±0.80	±1.52	±0.55	0.13	0.39	0.30	±2.2	±0.5
	Ronge	lap Expose	d Females,	Age >40					
13	628	5.45	2.56	2.02	0.05	0.82	0.0	30	10.0
34	253	9.80	3.72	4.90	0.0	1.08	1.00	38 38	12.8
3 <sup>4</sup> 58 60	295	6.73	2.22	4.30	0.07	0.13	0.0	40	14.0
60	250	9.80	3.63	4.41	0.29	1.47	0.0	35	11.8
63	250	6.20	2.60	3.16	0.0	0.31	1.20	41	13.6
63 78	704	10.40	7.70	2.39	0.10	0.10	1.00	40	14.0
mean	346	8.06	3.74	3.53	0.09	0.65	0.53	27 2	10 =
	<u>+</u> 159	+2.20	+2.02	±1.18	0.09	0.09	0.93	37•3 ±3•9	12.7 ±1.4
	Ailir	ignae Expos	od Eemales	A = 0 > 40	•				-1.4
1	313	8.30	4.40	1.74	0.33	1.66	1.70	41	14.0
28	663	7.98	5.34	2.31	0.08	0.16	0.80	36	12.1
43	353	5.28	2.90	2.27	0.05	0.05	0.0	39	12.1
45	520	7.80	4.13	2.96	0.08	0.47	1.60	39 38	12.8
59	355	10.95	4.81	4.71	0.0	1.44	0.0	37	12.4
mean	441	8.06	4.32	2.80	0.11	0.76	0.82	38.3	12.7
	<u>+</u> 148	<b>±2.00</b>	±0.91	<u>+</u> 1.15		• -		±1.8	±0.7

	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	Hgb.,
No.	$(x10^{-3})$	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	g
	Male	Children o	f Exposed	Parent(s),	Age <10				
88	355	10.50	4.20	5 <b>.5</b> 6	0.32	0.42	. 0.0	36	11.8
89	395	10.93	6.77	3.17	0.33	0.44	2.20	40	14.4
90	380	11.00	5.17	4.18	0.11	1.43	1.10	37	11.8
91	298	9.85	5.32	3.94	0.10	0.49	0.0	38	12.8
93	503	13.00	8.58	<b>3.3</b> 8	0.26	0.78	0.0	37	11.5
96	619	15.18	8.35	5.01	0.30	1.37	1.50	36	12.1
97	6 <del>7</del> 8	8.50	3.40	3.57	0.26	1.19	0.90	37	12.4
98	528	11.20	5.49	3.81	0.45	1.46	0.0	36	10.9
102	600	8.45	2.03	6.25	0.17	0.0	0.0	40	13.2
104	429	12.65	6.45	4.43	0.38	1.27	1.30	39	13.2
109	410	10.90	4.47	5.56	0.22	0.55	1.10	34	11.2
110	440	9.80	4.41	4.90	0.20	0.20	1.00	38	12.1
111	635	6.35	1.65	4.00	0.06	0.64	0.0	35	11.5
113	490	7.78	3.34	3.34	0.31	0.78	0.0	39	13.2
115 116	400 385	12.15	4.74	5.95	0.49	0.85	1.20	36	11.5
118	585	10.90	3.60	6.98	0.0	0.33	0.0	36	11.8
126	433	11.65 8.60	3.84	7.57	0.12	0.12	0.0	39	12.8
130	485	7.85	2.24 4.16	5.85	0.17	0.34	0.0	35	11.5
131	670	13.95		2.59	0.24	0.86	0.80	37	10.9
132	470	7.98	9•77 2 <b>.</b> 07	2.79 4.86	0.28	0.98	1.40	35	11.8
<b>عر</b> ـد	•		2.01	4.00	0.16	0.80	0.80	28	9.7
mean		10.33	4.76	4.65	0.23	0.73	0.63	36,6	12.1
	±1777								
	±107	±2.20	<u>+</u> 2.22	±1.38	0125	01,15	0.05	+2.5	+1.1
		±2.20 Le Children	<u>+</u> 2.22	±1.38			0.05		
87	Fema!	le Children	±2.22 of Expose	±1.38	), Age <10	2	_	+2.5	<u>+</u> 1.1
	<u>Femal</u> 378	le Children	+2.22 of Expose 5.15	±1.38 ad Parent(s) 5.50	), Age <10	0.57	1.10	±2.5 38	±1.1 12.4
87 92 94	Fema!	le Children 11.45 9.10	†2.22 of Expose 5.15 4.82	±1.38 ed Parent(s) 5.50 3.46	0.11 0.18	0.57 0.55	1.10	±2.5 38 40	±1.1 12.4 13.6
92 94 <b>100</b>	Fema. 378 520	le Children	±2.22 of Expose 5.15 4.82 5.62	±1.38 ed Parent(s) 5.50 3.46 4.82	0.11 0.18 0.34	0.57 0.55 0.69	1.10 0.90 0.0	±2.5 38 40 39	12.4 13.6 12.8
92 94 100 101	Femal 378 520 675 633 623	le Children 11.45 9.10 11.48	±2.22 of Expose 5.15 4.82 5.62 2.77	±1.38  td Parent(s)  5.50  3.46  4.82  3.10	0.11 0.18 0.34 0.20	0.57 0.55 0.69 0.53	1.10 0.90 0.0 0.0	+2.5 38 40 39 35	+1.1 12.4 13.6 12.8 11.5
92 94 100 101 103	Femal 378 520 675 633 623 583	11.45 9.10 11.48 6.60	±2.22 of Expose 5.15 4.82 5.62 2.77 4.75	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64	0.11 0.18 0.34 0.20 0.33	0.57 0.55 0.69 0.53 0.33	1.10 0.90 0.0 0.0	±2.5 38 40 39 35 36	+1.1 12.4 13.6 12.8 11.5 11.8
92 94 100 101 103 105	Femal 378 520 675 633 623 583 433	11.45 9.10 11.48 6.60 11.05 10.90 11.65	±2.22 of Expose 5.15 4.82 5.62 2.77	±1.38  cd Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67	0.11 0.18 0.34 0.20 0.33 0.11	0.57 0.55 0.69 0.53 0.33 0.76	1.10 0.90 0.0 0.0 0.0	38 40 39 35 36 36	+1.1 12.4 13.6 12.8 11.5 11.8 12.8
92 94 100 101 103 105 106	Femal 378 520 675 633 623 583 433 417	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60	±2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25	±1.38  cd Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78	0.11 0.18 0.34 0.20 0.33 0.11 0.47	0.57 0.55 0.69 0.53 0.33 0.76 0.58	1.10 0.90 0.0 0.0 0.0 1.10	38 40 39 35 36 36 36 37	12.4 13.6 12.8 11.5 11.8 12.8 12.1
92 94 100 101 103 105 106 108	Femal 378 520 675 633 623 583 433 417 490	11.45 9.10 11.48 6.60 11.05 10.90 11.65	±2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83	±1.38  cd Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40	0.11 0.18 0.34 0.20 0.33 0.11 0.47	0.57 0.55 0.69 0.53 0.33 0.76 0.58 0.74	1.10 0.90 0.0 0.0 0.0 1.10 0.0	±2.5 38 40 39 35 36 36 37 37	12.4 13.6 12.8 11.5 11.8 12.8 12.1
92 94 100 101 103 105 106 108 112	Femal 378 520 675 633 623 583 433 417 490 648	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50	±2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09	±1.38  cd Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53	0.57 0.55 0.69 0.53 0.33 0.76 0.58 0.74 1.19	1.10 0.90 0.0 0.0 0.0 1.10 0.0	±2.5 38 40 39 35 36 36 37 37 36	12.4 13.6 12.8 11.5 11.8 12.8 12.1 12.8
92 94 100 101 103 105 106 108 112	Femal 378 520 675 633 623 583 433 417 490 648 631	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83	+2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32	0.11 0.18 0.34 0.20 0.33 0.11 0.47	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0	±2.5 38 40 39 35 36 36 37 36 36 36	12.4 13.6 12.8 11.5 11.8 12.8 12.1 12.8 11.8
92 94 100 101 103 105 106 108 112 117	Femal 378 520 675 633 623 583 433 417 490 648 631 378	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75	+2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.33	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32  4.46	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.38	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20	±2.5 38 40 39 35 36 37 36 36 36 37	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119	Femal 378 520 675 633 623 583 433 417 490 648 631 378 417	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40	+2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.33 3.74	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32  4.46  4.99	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.38 0.12	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0	38 40 39 35 36 37 36 36 37 36 36 33 35	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120	Femal 378 520 675 633 623 583 433 417 490 648 631 378 417 531	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25	+2.22  of Expose  5.15  4.82  5.62  2.77  4.75  4.25  5.83  4.13  6.34  2.09  5.44  3.33  3.74  3.14	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32  4.46  4.99  4.46	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.38 0.12 0.53	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20 0.0	38 40 39 35 36 37 36 37 36 36 33 35 36 37	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123	Femal 378 520 675 633 623 583 417 490 648 631 378 417 531 328	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60	+2.22  of Expose  5.15  4.82  5.62  2.77  4.75  4.25  5.83  4.13  6.34  2.09  5.44  3.33  3.74  3.14  6.53	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32  4.46  4.99  4.46  4.62	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.38 0.12 0.53 0.12	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20 0.0	38 40 39 35 36 36 37 36 36 37 36 36 37 37 34	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125	Femal 378 520 675 633 623 583 433 417 490 648 631 378 417 531 328	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63	+2.22  of Expose  5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.33 3.74 4.53	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  5.32  4.46  4.99  4.46  4.62  5.53	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.38 0.12 0.53 0.12 0.53 0.12 0.53 0.11	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44 1.35 0.50 1.90 0.43	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20 0.0 1.00	38 40 39 35 36 37 36 36 37 36 36 37 34 34	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125	Femal 378 520 675 633 623 583 417 490 648 631 378 417 531 328 528 565	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63 13.48	+2.22  of Expose  5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.33 3.74 4.57 3.77	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.15  5.99  5.32  4.46  4.99  4.46  4.62  5.53  9.03	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.12 0.53 0.12 0.53 0.12 0.54 0.11 0.0	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44 1.35 0.50 1.90 0.43	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20 0.0	38 40 39 35 36 37 36 36 37 36 36 37 34 34 37	12.4 13.6 12.8 11.5 11.8 12.1 12.8 11.8 11.8 11.8 11.8 11.9
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125 127	Femal 378 520 675 633 623 583 437 490 648 631 378 417 5328 528 565 350	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63 13.48 11.70	+2.22  of Expose  5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.33 3.74 4.57 3.16	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.67  4.78  5.40  5.15  5.99  4.46  4.99  4.46  4.62  5.53  9.03  7.37	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.12 0.53 0.12 0.53 0.12 0.54 0.11 0.0 0.83	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44 1.35 0.50 1.90 0.43 0.67 0.23	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.00 1.20 0.0 1.00	38 40 39 35 36 37 36 36 37 36 36 37 34 34	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125 127 128 134	Femal 378 520 675 633 583 433 417 490 648 631 378 417 531 328 528 565 350 719	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63 13.48 11.70 11.40	+2.22  of Expose  5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.74 4.57 3.14 6.53 4.57 3.16 3.42	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  4.46  4.99  4.46  4.62  5.53  9.03  7.07	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.12 0.53 0.12 0.53 0.12 0.54 0.11 0.0 0.83 0.23	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.44 1.35 0.67 0.67 0.68	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.20 0.0 1.00	+2.5 38 40 39 35 36 37 36 37 36 37 34 37 32 33 39 39 39 39 39 39 39 39 39	12.4 13.6 12.8 11.5 11.8 12.8 11.8 11.8 11.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125 127 128 134 135	Femal 378 520 675 633 623 583 417 490 648 631 378 417 531 328 528 565 350 719 628	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63 13.48 11.70	+2.22 of Expose 5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.04 3.74 3.74 3.74 3.74 6.53 4.57 3.77 3.42 6.42	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.67  4.78  5.40  5.15  5.99  4.46  4.99  4.46  4.62  5.53  9.03  7.37	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.12 0.53 0.12 0.53 0.12 0.54 0.11 0.0 0.83	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.83 0.44 1.35 0.50 1.90 0.43 0.67 0.23	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.20 0.0 1.00 0.0 0.0	12.5 38 40 39 35 36 37 36 37 36 37 34 37 32 33	12.4 13.6 12.8 11.5 11.8 12.1 12.8 11.8 11.8 11.8 11.8 11.8
92 94 100 101 103 105 106 108 112 117 119 120 122 123 125 127 128 134	Femal 378 520 675 633 583 433 417 490 648 631 378 417 531 328 528 565 350 719	11.45 9.10 11.48 6.60 11.05 10.90 11.65 10.60 13.20 9.50 11.83 8.75 10.40 8.25 13.60 10.63 13.48 11.70 11.40	+2.22  of Expose  5.15 4.82 5.62 2.77 4.75 4.25 5.83 4.13 6.34 2.09 5.44 3.74 4.57 3.14 6.53 4.57 3.16 3.42	±1.38  td Parent(s)  5.50  3.46  4.82  3.10  5.64  5.67  4.78  5.40  5.15  5.99  4.46  4.99  4.46  4.62  5.53  9.03  7.07	0.11 0.18 0.34 0.20 0.33 0.11 0.47 0.32 0.53 0.12 0.53 0.12 0.53 0.12 0.54 0.11 0.0 0.83 0.23	0.57 0.55 0.69 0.53 0.76 0.58 0.74 1.19 0.95 0.44 1.35 0.67 0.67 0.68	1.10 0.90 0.0 0.0 0.0 1.10 0.0 0.0 1.20 0.0 1.20 0.0	38 40 39 39 36 37 36 37 36 37 37 38 39 39 39 39 39 39 39 39 39 39 39 39 39	12.4 13.6 12.8 11.5 11.8 12.1 12.8 11.8 11.8 11.8 11.8 11.8

Subject	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	Hgb.,
No.	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	g					
	Unex	posed Males	, Age 10-1	<u>5</u>				-	
813	405	6.65	2.06	4.19	0.27	0.13	0.0	36 36	13.2
814	285	10.80	5.51·	4.43	0.54	0.32	0.0	36	12.4
815	200	8.05	2.25	5.15	0.24	0.40	0.0	<b>3</b> 8	12.8
818	505	9.95	5.27	3.88	0.50	0.30	0.0	39 .	12.1 12.4
819	273	5.45	2.45	2.18	0.05	0.71	0.50	38 40	
820	412	23.20	20.42	2.32	0.46	0.0	0.0	40	13.2 13.6
863	730	9.00	4.59	3.96	0.09	0.27 1.44	0.90	<del>3</del> 6	11.2
912	215	12.00	7.32	3.12	0.12		0.0		12.8
913	340	8.40	4.45	3.70	0.17	0.08	0.0	39 34	10.6
921	335	19.50	14.43	3.51 6.86	0.39 0.40	1.17 3.83	0.0 1.30	3 <del>4</del> 36	12.4
931	465	13.20	1.98			0.62	1.20	38	12.8
981	410	12.40 7.90	5.58 3.71	5.70 4.03	0.37 0.16	0.02	0.0	38	14.0
1033		11.00	5.28	5.06	0.44	0.22	0.0	37	12.4
1036 1052	151 495	9.40	4.14	4.51	0.38	0.38	0.0	36	12.1
1022	<del>4</del> 97	9.40	4.14	4.71	0.30	0.30	0.0	,,,	
mean		11.13	5.96	4.17	0.31	0.66	0.26	37.4	12.5
	±158	±4.70	±5.03	±1.22	_			±1.7	<u>+</u> 0.8
	Unex	posed Femal	es, Age 10	<u>-15</u>	,			-	
805	458	11.38	4.55	5.35	0.34	1.14	0.0	41	12.1
811	433	11.70	6.44	4.10	0.12	1 .05	0.0	35	12.1
812	333	8.80	4.14	2.82	0.35	1.23	2.60	<b>3</b> 8	12.1
816	334	8.68	3.12	4.86	0.17	0.52	0.0	37	11.8
909	325	5.95	2.32	2.62	0.18	0.77	0.60	42	12.8
911	416	8.48	5.17	3.05	0.08	0.16	0.0	36	11.8
925	275	6.60	2.71	3.63	0.07	0.13	0.70	40	12.4
926	360	11.85	6.75	3.91	0.24	0.95	0.0	40	13.6
937	570	17.80	10.32	4.98	0.36	2.14	0.0	37	12.1
946	335	8.55	3.33	3.76	0.26	1.11	0.90	40	13.2
955	538	7.80	3.28	3.98	0.31	0.16	0.80	39 38	13.2
959	448	11.05	7.29	2.76	0.11	0.88	0.0	38	12.8
960	390	9.25	4.16	4.53	0.09	0.46	0.0	37	12.1
962	365	6.70	2.01	4.02	0.0	0.54	1.30	35	11.2 12.8
978	218	7.80	2.26	4.52	0.0	1.01	0.0	39	12.0 12.4
980	283	8.40	3.86	2.69	0.42	1.43	0.0	41	10.6
996 1035	629 433	14.33 12.50	7•59 6 <b>•00</b>	5.73 4.62	0.57 0.13	0.43 1.75	0.0	33 42	14.0
mean	397	9.87	4.74	4,00	0.21	0.88	0.38	38.3	12.4
	<u>±106</u>	±3.00		±0.94	0144	••••		±2.5	±0.8

Subject	Plate. (x10 <sup>-3</sup> )	WBC	Neut.	Lymph. (x10 <sup>-3</sup> )	Mono.	Eosin.	Baso.	Hct.,	Hgb.,
No.		(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )		(x10 <sup>-3</sup> )	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	g
	Unex	osed Males	, Age >15-4	10					
822	628	14.15	10.33	3.11	0.14	0.57	0.0	44	14.0
823 8 <b>2</b> 7	346 339	15.65 8.75	10.48 5.08	3.13 2.45	0.47 0.44	1.41	1.60	42 1.4	13.6
828	339 428	13.28	8.36	4.51	0.40	0.79 0.0	0.0 0.0	46 46	14.8 15.2
830	360	5.78	2.98	2.35	0.06	0.23	1.10	45	15.2
831	353	9.00	2.88	4.41	0.45	1.17	0.90	54	16.9
833	428	6.45	2.71	3.48	0.26	0.0	0.0	47	16.0
836	453	7.50	3.52	3.38	0.15	0.45	0.0	46	14.4
840	308	7.68	4.30	2.92	0.08	0.38	0.0	47	15.6
842 864	528 300	9.70	3.10	4.66	0.20	1.65	1.00	50	17.4
881	32 <b>2</b> 333	9•95 7•90	4.08 3.32	4.48 4.19	0.50	0.90 0.08	0.0	47	14.8 14.8
882	175	6.49	2.72	3.44	0.32 0.13	0.06	0.0 1.30	45 44	14.8
885	203	11.03	6.28	4.08	0.22	0.44	0.0	45	15.6
892	295	7.90	2.37	4.03	0.24	1.11	1.60	43	15.6
918	205	7.15	2.43	4.00	0.21	0.43	0.70	47	16.0
919	308	7.80	4.68	2.11	0.47	0.55	0.0	39	12.1
939	220	10.80	8.53	1.62	0.11	0.54	0.0	43	14.4
944 966	313	6.15	3.44	2.40	0.12	0.12	0.60	45	14.4
900 971	270 403	8.55 18.95	5.73 10.42	1.97 6.82	0.09 0.57	0.68	0.90 1.90	47 1.7	15.2 15.6
1005	330	8.60	10.42	0.02	0.57	0.95	1,70	47 50	16.4
1500	275	6.80	3.13	2.99	0.20	0.48	0.0	51	16.4
1501	258	9.68	6.39	2.90	0.20	0.20	0.0	46	14.8
mean	337	9.40	5.10	3.45	0.26	0.57	0.50	46.1	15.2
	<u>+</u> 104	±3.40	±2.73	+1.15		•		<b>‡3.1</b>	±1.1
·	Unexp	osed Female	s. Age > 15.	<b>-4</b> 0	<del> </del>				
							, 00	20	10.0
821	425	8.53	3.92	4.18	0.09	0.26	0.90 1.60	38 35	12.8 11.5
826 829	315	8.25 10.83	5.86 7.14	1.65 2.81	0.25 0.22	0.33 0.65	0.0	38 38	12.1
832	315 358	7.25	4.35	2.54	0.07	0.29	0.0	39	12.4
835	340	10.30	5.25	4.02	0.10	0.93	0.0	37	12.4
841	430	10.40	6.55	3.12	0.0	0.62	1.00	29	10.0
843	400	6.85	5.07	1.30	0.14	0.34	0.0	31	10.6
845	345	9.10	4.28	4.28	0.27	0.18	0.90	<b>11</b> 1	13.6
865	575	7.33	4.91 4.25	1.83	0.22	0.37	0.0	33	10.9 12.1
867	484	8.18 8.33	2.66	3.11 4.16	0.33 0.17	0.41 1.33	0.0 0.0	39 41	14.4
89 <b>1</b> 8 <b>95</b>	235 613	10.55	5.38	4.64	0.21	0.32	0.0	45	15.6
896	390	11.00	6.60	3.96	0.22	0.11	1.10	35	10.9
916	465	11.23	7.18	2.58	0.67	0.67	1.10	38	12.1
922	457	6.13	3.19	2.21	0.18	0.49	0.60	36	12.4
932	525	12.88	8.24	3 - 35	0.0	1.16	1.30	33	11.2
934	393	9.00	4.41	4.05	0.09	0.36	0.90	40	13.2
938	309	10.88	9.14	0.87	0.11	0.76	0.0 0.0	30 46	10.0 15.6
945	478	7.05	4.51 2.28	1.76	0.35 0.13	0.42 0.52	1.30	40 41	14.0
950	75 390	6.50 9.30	4.84	3.45 3.91	0.09	0.37	0.90	41	13.2
95 <b>1</b> 965	424	8.80	5.10	3.17	0.26	0.26	0.0	37	12.1
907 977	422	12.95	<b>8.1</b> 6	3.63	0.26	0.91	0.0	28	8.8
993	445	10.10	3.33	5.55	0.40	0.71	1.00	40	12.8
998	326	10.88	5.98	4.24	0.54	0.11	0.0	40	14.0
1001	280	5.83	3.20	2.04	0.17	0.41	0.0	39 40	13.2 13.2
1043		7.00	3.22	3.01 2.45	0.35 0.0	0.42 0.40	0.0 <b>0.80</b>	40 38	12.1
1050 1502		7.90 12.43	4.98 9.32	2.45	0.37	0.25	1.20	32	11.5
mean	- 0 -	9 <b>.1</b> 6	5.29	3.11	0.22	0.49	0.50	37.3	12.4
00585	3 ±110	+2.00		±1.11	V. C.L.	J. 77	,-	±4.5	±1.6

Subject No.	Plate. (x10-3)	WBC (x10-3)	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct., %	Hgb.,
		posed Males							<del></del>
849				2 20		. 0.5			/
853		7.70	3.47	3.39	0.0	0.85	0.0	<del>7</del> 7	15.6
856	675	8.30 8.73	3.24 4.80	3.65	0.25	0.16	1.60	39	13.6
868	278	8.50	5.36	2.79 2.64	0.17 0.26	0.87 0.26	0.90	39	12.8
878	303	7.90	2.92	4.50	0.20	0.40	0.0	45 40	15.2
880	324	7.80	3.59	3.43	0.55	0.23	0.80 0.0	46	13.2 14.8
884	321	10.75	5.48	4.19	0.21	0.75	1.10	41	13.2
897		8.30	4.15	3.65	0.25	0.25	0.0	43	14.0
899	288	5.40	2.97	1.84	0.22	0.32	0.50	40	13.6
915	5 538	8.40	5.29	2.18	0.25	0.67	0.0	37	12.1
947	380	7-55	4.00	3.02	0.08	0.38	0.80	40	14.0
948		5-95	1.84	3.33	0.30	0.36	1.20	44	16.0
961		7.30	2.56	3 <b>.</b> 72	0.07	0.88	0.70	45	14.8
964		5.63	2.87	1.80	0.23	0.68	0.60	<b>3</b> 8	13.2
969		7.83	3.99	3.29	0.23	0.31	0.0	40	12.8
973 975		8.53	4.43	3.07	0.17	0.77	0.90	44	14.0
100		7.05 6.40	5.01 2.88	1.69	0.14	0.21	0.0	14 14	15.2
104	1 428	9.15	5.86	3.14 2.75	0.13 0.18	0.26 0.37	0.0	40 42	14.0 14.4
<b></b>	20	J• ± J	7.00	2.17	0.10	0.31	0.0	42	14.4
mea	n 348	7.75	3.93	2.06	0.00	a 1.m	- 10	1	-1 -
	±114	±1.30	±1.14	3.06	0.20	0.47	0.48	41.6	14.0
			_1.14	±0.78				<u>+</u> 2.6	±1.0
	Unex	posed Femal	es, Age >40	2					
814)4		8.93	5.00	3.21	0.62	0.09	0.0	1414	14.0
851	205	8.10	1.62	5.67	0.16	0.65	0.0	<del>36</del>	12.1
852	443	10.20	4.28	4.90	0.20	0.71	1.00	35	11.2
858	468	8.00	3.28	4.00	0.32	0.32	0.80	<b>3</b> 8	11.8
859	525	7.75	2.95	4.34	0.0	. 0.47	0.0	40	13.6
893	328	10.50	5 <b>.7</b> 8	4.20	0.0	0.42	1.10	37	12.1
894	426	7.88	4.80	2.13	0.16	0.71	0.80	44	14.0
898 9 <b>0</b> 8	263	6.48	3.24	2.33	0.19	0.58	1.30	41	12.1
928	173 435	6.13 6.65	2.45	3.31	0.0	0.37	0.0	41	12.8
929		6.35	3.26 3.18	2.53	0.27	0.47	1.30	35	12.1
936	275	8.93	3.84	2.79 4.55	0.25	0.13	0.0	41	14.4
941		6.50	4.36	1.69	0.09 0.26	0.36	0.90	37	13.2
942		6.73	2.89	3.30	0.20	0.20 0.20	0.0 0.70	40 40	13.2 12.8
956		7.53	4.59	2.18	0.38	0.38	0.0	<b>3</b> 6	11.8
957		8.60	3.78	4.30	0.34	0.17	0.0	39	13.2
970	450	11.80	3.66	7.79	0.12	0.12	1.20	37	12.1
982		8.40	5.29	2.69	0.08	0.25	0.80	43	14.0
991		13.05	8.22	3.13	0.52	1.04	1.30	47	16.0
104	2 370	7.25	3.77	2.54	0.36	0.44	1.40	40	13.6
mean	n 360	8.29	4.01	3.60	0.23	0.40	0.63	20 6	12.0
	±99	±1.9	+1.41	±1.45	0.23	0.40	0.03	39.6 <u>+</u> 1.0	13.0
	_	<b>-</b>	-					31.0	±0.6

Subject	Plate.	WBC	Neut.	Lymph.	Mono.	Eosin.	Baso.	Hct.,	Hgb.,
No.	(x10 <sup>-3</sup> )	(x10 <sup>-2</sup> )	%	g					
	Male	Children o	f Unexposed	Parents,	Age <10		· · · · ·		
801	399	8.83	3.26	4.85	0.09	0.62	0.0	40	13.2
802	265	10.68	5.23	4.91	0.21	0.32	0.0	40	13.6
803	299	11.95	8.37	2.99	0.24	0.24	1.20	38	12.4
807	454	13.58	5-43	5.70	0.27	2.17	0.0	36	12.4
809	300	8.90	3 <b>.5</b> 6	3.56	0.27	1.42	0.0	35	11.5
870	483	5.85	2.11	3 <b>.1</b> 6	0.18	0.41	0.0	35	11.8
904	435	11.00	5.28	4.84	0.44	0.44	0.0	40	13.2
905	640	14.53	10.60	3.20	0.15	0.44	1.40	37	10.6
952	610	16.40	6.40	7.71	0.49	1.80	0.0	37	12.4
1002		14.45	7.95	4.05	0.29	2.02	0.14	35	11.8
1004		12.83	5.13	7.31	0.26	0.13	0.0	37	12.4
1006	553	16.90	8 <b>.28</b>	6.93	0.68	1.01	0.0	37	11.8
1009	280	8.05	3.70	3.46	0.40	0.40	0.80	38	12.4
1010	613	11.50	3.22	7.71	0.12	0.35	1.20	37	12.1
1013	3 548	9.90	6.73	3.07	0.10	0.0	0.0	34	10.3
1014		8.60	4.64	3.10	0.09	0.69	0.90	42	11.5
1018		12.80	4.99	5.25	0.26	2.18	1.30	36	12.4
1024		8.50	4.68	3.15	0.0	0.68	0.90	34	11.5
1026	575	11.15	3.68	6.02	0.11	1.34	0.0	34	11.8
1027	423	9.15	4.30	4.39	0.09	0.37	0.0	39	11.5
1030	) 5 <b>1</b> 0	9.65	5.31	3.38	0.39	0.48	1.00	36	12.4
1037		8.03	2.33	4.73	0.24	0.72	0.0	37	12.4
1038		10.70	4.07	6.10	0.32	0.11	1.10	35	10.6
1039		14.10	6.91	6.49	0.28	0.42	0.0	44	12.4
1040		9.58	5.17	3.54	0.29	0.58	0.0	37	12.1
1046	520	10.45	3.97	5.85	0.0	0.63	0.0	34	11.2
1047		17.70	8.32	8.32	0.53	0.35	1.80	35	10.6
1049	400	11.15	3.12	7.36	0.56	0.11	0.0	39	12.8
1053	490	8.25	3.47	4.04	0.17	0.50	0.80	<b>3</b> 8	12.4
1054		13.80	4.97	8.00	0.41	0.41	0.0	39	14.4
1058		8.20	2.54	4.76	0.49	0.41	0.0	37	14.4
1503		12.25	3.80	8.33	0.12	0.0	0.0	40	13.6
1504		11.95	4.42	6.69	0.60	0.24	0.0	37	12.8
mean		11.34	5.03	5.24	0.28	0.66	0.38	37.3	
	±134	<u>±</u> 2.80	±1.98	±1.77	0.20	0.00	0.30	±2.4	12.1
	-		/-	11				<u> </u>	±0.9

Subject	Plate. (x10 <sup>-3</sup> )	WBC (x10 <sup>-3</sup> )	Neut. (x10 <sup>-3</sup> )	Lymph. (x10 <sup>-3</sup> )	Mono. (x10 <sup>-3</sup> )	Eosin. (x10 <sup>-3</sup> )	Baso. (x10 <sup>-2</sup> )	Hct.,	Hgb.,
	Fema.	le Children	of Unexpos	sed Parent	s, Age <1	0			
810 866 901 902 903 906 923 930 954 979 995 1011 1012 1022 1025 1024 1031 1041 1051	461 203 543 264 419 455 423 651 328 386 350 283 2478 373 629 665 635 575 440 525 440 410 410 410 410 410 410 410 410 410	8.40 6.20 19.50 9.90 13.80 7.83 10.65 8.60 11.60 9.70 8.30 11.45 7.20 11.10 14.85 8.20 13.73 11.15 8.75 10.90 9.40 11.03 11.20	4.87 2.42 11.12 2.97 8.14 2.58 5.33 3.78 4.18 4.66 2.74 4.24 2.23 3.66 2.87 3.66 2.87 3.68 2.36 3.57 3.68	2.52 3.341 5.55 4.55 4.56 4.58 4.52 2.17 4.59 5.18 4.52 5.17 6.59 6.50 6.50	0.84 0.06 0.20 0.0 0.41 0.08 0.43 0.09 0.23 0.0 0.33 0.14 0.11 0.0 0.18 0.22 0.38 0.34	0.88 0.37 0.68 0.558 0.57 0.58 0.59 0.74 0.57 0.58 0.57 0.57 0.57 0.57 0.57 0.57 0.57 0.57	0.80 0.0 1.95 0.0 0.0 0.80 1.10 0.0 0.0 1.70 1.10 0.0 1.10 1.50 0.0 2.70 0.0 0.0 0.0 0.0 1.10	39 37 35 38 38 38 38 38 37 37 38 39 39 39 39 39 39 39 39 39 39 39 39 39	12.8 12.1 10.9 10.9 12.8 11.8 12.4 13.6 12.4 12.4 12.4 11.2 12.1 12.8 13.6 11.8 10.9 12.4 13.6 13.6 13.6
1057 mean	١. ٢٠	12.60 10.67 <u>+</u> 2.80	3.78 4.28 ±2.10	7.94 5.47 ±1.50	0.38	0.50 0.62	0.0 0.70	36.8 ±2.4	10.6 12.1 ±1.0

APPENDIX 6

Individual Basophil Determinations, 1963 and 1964

Cubine	% Baso./4000	cell count	Subject	% Baso./40	000 cell count
Subject No.	1963	1964	No.	1963	1964
1	0.45	0.40	63	0.30	0.50
2	0.65	0.75	64	0.40	0.48
2 3 4	1.00	1.60	65 66	0.45	0.23
	0.52	0.75	66	0.30	0.52
5 6 7 8	0.50	0.55	. 67	` <del>-</del>	0.23
6	0.38	0.30	68	0.35	0.28
7	0.40	0.30	69	0.38	0.23
8	0.55	0.62	70	0.25	0.18
9 <b>1</b> 0	0.42	~ =0	71	0.25	0.38
	0.65	0.58	72	0.58	0.32
11	0.25	0.50	73	0.72	0.38
12	0.38	0.50	74	0.28	0.25
13	0.58	0.52	75 76	0.18	0.35
14	0.72	0.55	76	0.25	0.28
15 16	0.30	0.42	77 78	0.32	0.20
	0.25	0.30	78 78	0.20	0.23
17 18	0.35 0.60	0.30 0.45	79 80	0.35 0.25	0.28 0.28
19	0.50	0.52	80	0.42	0.20
20	0.55	0.58	81	0.38	0.30
21	0.45	0.50	82 83	0.15	0.23
22	0.30	0.70	84		0.38
23	0.30	0.25	85	0.13	
24	0.48	0.38	85 86	0.42	
27	0.52	0.28	87	0.48	0.45
28	0.42	0.30	88	0.48	0.25
29	0.30	0.38	89	0.30	0.38
32	0.52	0.60	90	0.40	0.38
33	0.45	0.38	91	0.28	0.30
34	0.48	0.50	92	0.20	0.25
35 36		0.30	93	0.40	0.15
36	0.25	0.23	94	0.18	0.23
3 <b>7</b>	0.45	0.30	9 <b>5</b> 96	0.25	
39	0.50	0.40	96		0.48
40	0.55	0.50	97		0.52
41	0.50	0.50	98	0.45	0.35
42	0.60	1.05	100		0.35
43	0.62	0.45	101	0.45	0.50
45 1.07	0.52	0.70	102	0.38	0.58
47 48	0.40	0.45	103	0.42 0.48	0.25
	0.55	0.48	104	0.40	0.38
49 50	0.50	0.45	105	0.42	0.42 0.42
50 53	0.35 0.45	0.30 0.38	106 108	0.35	0.45
51. 53	0.45	0.50	109	0.35	0.45
73 5h	0.30	0.50	1109	0.25	0.48
77 55	0.50	0.45	111	0.42	0.50
54 55 56		U.T.J	112	0.50	0.38
57	0.25		113	0.55	0.50
5 <b>7</b> 58	0.20	0.30	115	0.25	0.48
59	0.20	0.25	116	0.35	0.28
60	0.28	0.20	117	0.35	0.40
61	0.48	0.35	118	0.42	0.40
- <b></b>		3/			,

0.15	% Baso./400	00 cell count	0.1.	% Baso./40	00 cell count
Subject No.	1963	1964	Subject No.	1963	1964
119	0.52	0.45	843	0.35	0.28
120	0.28	0.20	844	0.38	0.23
121			845		0.38
122	0.38	0.25	846	0.30	
123		0.25	849	0.40	0.23
124	0.45		85 <b>1</b>	0.40	0.35
125	0.28	0.40	85 <b>2</b>	0.30	0.28
126	0.23	0.25	85 <b>3</b>	0.28	0.28
127	0.40	0.28	855	0.28	
128	0.25	0.28	856	0.23	0.23
130		0.40	858		0.25
131		0.32	859	0.30	0.20
132		0.40	862	0.25	U,20
133		0.23	863	0.20	0.28
134		0.25	864		0.18
135		0.25	865	0.35	0.28
801	0.28		866		0.25
802	0.30	0.30	867	0.30	
803	0.42	0.30	868		0.20
805		0.23		0.00	0.25
806	0.30 0.35	0.38	870	0.38	0.20
807		0.25	871	0.23	
808	0.50	0.35	872	0.28	
809	0.23	0.00	873	0.28	
810	0.15	0.23	874	0.18	
811 811	0.38	0.28	8 <b>75</b>	0.40	2.1.0
812	0.25	0.23	8 <b>78</b>	0.30	0.40
813	0.48	0.40	880	0.28	0.25
814	0.30	0.30	881	0.38	0.20
815	0.25	0.20	882	0.42	0.35
816	0.23	0.20	883	0.38	0.10
818	0.23 0.28	0.28	884	0.28	0.42
		0.40	885	0.30	0.38
819 820	0.40	0.38	886	0.25	
82 <b>1</b>	0.52	0.40	891	0.23	0.25
822	0.32	0.28	892		0.30
8 <b>23</b>	0.23	0.28	893	0.35	0.30
	0.30	0.23	894	0.55	0.23
825 8 <b>26</b>	0.18	~**-	895	0.32	0.30
	0.25	0.32	896	0.50	0.38
827		0.15	897		0.30
8 <b>2</b> 8	0.00	. 0.42	898	0.25	0.28
829	0.28	0.35	89 <del>9</del>		0.35
83 <b>0</b>	0.38	0.38	900	0.30	
831	0.20	0.38	901	0.35	0.28
832	0.15	0.25	902	0.35	0.18
833	0.23	0.18	903	0.25	0.32
834 835	0.32		904	0.38	0.23
835	0.20	0.25	905	0.20	0.25
836	0.30	0.30	906	0.25	0.35
838	0.35		908	0.35	0.35
840	0.38	0.35	909	0.42	0.28
841 842	0.28	0.40	911	0.38	0.52
042	0.50	0.30	912	0.45	0.28

Cub to -+	% Baso./400	00 cell count	CL 24	% Baso./4	000 cell count
Subject No.	1963	1964	Subject No.	1963	1964
913	0.25	0.38	977		0.20
914	0.45		978		0.28
915	0.38	0.30	979		0.20
916	0.35	0.30	9 <b>80</b>		0.38
9 <b>17</b>	0.28		981	0.35	0.30
9 <b>1</b> 8	0.42	0.45	98 <b>2</b>		0.30
9 <b>1</b> 9	0.52	0.40	9 <b>91</b>		0.35
921	0.38	0.30	993	0.40	0.35
922	0.25	0.35	995	0.28	0.25
923	0.28	0.35	996	0.30	0.23
925	0.40	0.25	998	0.42	0.30
926 927	0 <b>.</b> 25 0.32	0.28	1001	0.30	0.38
928	0.23	0.38	1002 1004	0.38 0.48	0.35
929	0.35	0.30	1004	0.40	0.30
930	0.25	0.23	1007	0.2)	0.30
931	0.30	0.32	1008	U+ 32	0.23 0.50
932	0.18	0.38	1009	0.30	0.28
934	0.42	0.30	1010	0.38	0.28
935	0.30		1011		0.35
936	0.30	0.30	1012	0.38	0.23
937		0.35	1013		0.28
938	0.32	0.25	1014	0.28	0.30
939		0.23	1015	0.40	
94 <b>1</b>	0.40	0.23	1017	0.38	
945	0.38	0.30	1018		0.30
944	0.32	0.25	1019		0.40
945		0.25	1020	0.20	0.25
946	0.30	0.28	1021	0.28	
947	0.38	0.32	1022	0.40	0.32
948	0.38	0.28 0.40	1024	0.45	0.25
9 <b>50</b>	0.28 0.40	0.30	1025	0.28	0.30
95 <b>1</b> 9 <b>52</b>	0.25	0.40	1026 1027	0.35 0.42	0.30
954	0.2)	0.28	1028	0.42	0.30 0.18
955	0.35	0.28	1029	0.38	
956	0.30	0.35	1029		0.28 0.25
957	0.25	0.25	1030	0.35 0.35	0.30
958	0.52		1033	0.40	0.32
959	0.40	0.32	1034	0.30	0.28
960	0.30	0.25	1035	0.35	0.38
96 <b>1</b>	0.45	0.38	1036	0.30	0.38
962	0.35	0.28	1037	0.38	0.28
964	0.50	0.42	1038	0.23	0.23
965	0.23	0.50	1039		0.30
966		0.30	1040	0.28	0.35
967	0.30		1041	0.25	0.25
96 <b>9</b>	0.32	0.30	1042	0.40	0.25
9 <b>70</b>	0.30	0.38	1043	0.23	0.28
9 <b>71</b>	0.25	0.25	1044	0.23	0.30
9 <b>72</b> 9 <b>73</b>	0.30	0.25	1045	0.28	
975		0.32	1046	0.32	0.30
フリノ	<b>-</b>	٠٠ ا	1047	0.38	0.30

Cubicat	% Baso./40	00 cell count	Subject	% Baso./40	000 cell count
Subject No.	1963	1964	No.	1963	1964
1049		0.38	2164	0.20	
1050		0.25	2 <b>1</b> 66	0.23	
1051		0.25	2167	0.25	
1052		0.28	2168	0.32	
1053		0.23	2169	0.38	
1054		0.30	2172	0.30	
1057		0.20	2174	0.30	
1500	0.30	0.30	2175	0.25	
1501	0.23	0.28	2176	0.32	
1502	0.28	0.28	2179	0.28	
1503	0.10	0.20	2181	0.40	
1504	0.28	0.20	2182	0.35	••••
2101	0.25	0.20	2186	0.45	
2102	0.32		2188	0.40	
2104	0.23		2189	0.30	
2105	0.38		2191	0.40	
2106			2193	0.42	
	0.35		2195	0.25	
2108	0.70		2196	0.30	
2110	0.30			0.25	
2111	0.40		2197		
2112	0.30		2200	0.35	
2113	0.38		2206	0.25	
2114	0.25		2210	0.60	
2115	0.50		2211	0.40	
2119	0.48		2212	0.30	_++-
2121	0.23		2213	0.20	
2124	0.30		2214	0.30	
2125	0.25		2215	0.32	
2126	0.30		2216	0.38	
2128	0.38		2217	0.25	
2129	0.38		2218	0.35	
2130	0.35		5551	0.38	
2135	0.40		2224	0.45	
2136	0.25		2225	0.25	
2137	0.35		2226	0.25	
2138	0.30		2227	0.32	
2140	0.30		2228	0.23	
2142	0.38		2229	0.28	
2145	0.40		2235	0.30	
2146	0.30		2238	0.23	
2148	0.45		2240	0.30	
2 <b>1</b> 49	0.45		2242	0.38	
2150	0.35		2244	0.38	
2151	0.25		2246	0.23	
2152	0.25		2247	0.20	
2155	0.35		22148	<b>0.</b> 48	
2156	0.32		2249	0.30	
2157	0.28		2251	0.38	
2158	0.35		2253	0.30	
2160	0.30	= =	2255	0.25	
2162	0.30		2256	0.30	
2102	V• 3V	- <del></del>	22,0	<b>0.00</b>	

	NO., AGE, SEX	PAST HISTORY	in jur ies	WE IGHT POUNDS HE IGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	1 64 F	Obesity. URI. Menopause age 40. Grav. 12, para. 12.	Fixation left elbow.	157	190/100 Hypertension.	Macular degenera tion and lenti- cular opacties.	Mild cystocele.	
	78 M	URI, cough. Mild polio '63.	Trau. amp. distal phalanx left index finger.	143	128/80	Pterygium and lenticular opacities bilat. Arcus 4+.		2 cm. cyst on back over D5; removed surgically.
	7 46 M			128	110/74	Bilat. pterygium Arcus 1+. Bilat. small neck nodes.	Slightly enlarged prostate	,
	9 32 M	Hx. of trichomonas.		156	116/70	Strabismus.		
	10 34 M			139	110/60	Pterygium left eye.	·	
	11 60 M	Slight pain and stiffness in joints.		112	115/90 Hypertensive 170/100 '63	Argylle-Roberson pupil bilat. Pterygium left eye. 3+ retinal arteriosclerosis		Burn scars rt. shoulder and chest, healing. Ulcer rt. ankle (treated).Resi- dual "beta burn!
	12 28 F	Menarche age 13. Para. 5, grav.4. IMP June 1962.		127 '63	110/70 '62	Choroiditis	Pregnant, no pelvic 1963.	Nevi on back '63.
	13 68 F	Menopause age 48(?). Pars. O, grav. O. Poor vision.	Struck in left eye 7-8 years ago, ulceration.	76	118/60	R.E.: 20/70, old chorioretinitis, arcus,lenticular opacity.L.E.: 20/ staphyloma 5x6mm endophthalmitis.	koo.	
	14 35 F	IMP 3/63. Para. 9, grav. 9. Lactating 12/63 to present.		127	90/60	Pingueculae(?) left eye.		"Beta burn" scars rt. elbow left axilla,and left neck.
	16 49 M			124	108/68	Arcus 2+. Rt. pterygium.	Prostate 1+.	
	18 31 F	Menarche age 12. IMP 1/63. Para. 13, grav. 12. Lactating 10/63 to present.		108	100/68	Pinguecula rt, pterygium left. Throat inflamed.	Rectocele, cystocele. Healed cervical lacerations.	
	22 27 <b>F</b>	Cough.		101 '62 98 '63	95/60 162 84/50 163			
	24 23 F	Menarche age 12. Para. 2, grav.2. Itching of skin.		90 100 '63	104/68	Small nodes right neck.		Mottled depig. front of neck. Biopsy scar rt. ACF.
	30	Chest pain.		141 134 '63	106/60 Pulse 52/min. Bradycardia			
500b	28 78 F	Menopause:age50. Para. 10, grav. 10. URI.		84 111 '61	138/68 pulse 82, regular 160/90 '63 180/90 '62	Arcus 4+. Pterygium bilat. Senile cata- racts,bilat.	Liver palpable one finger breadth.	

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	8,300	41	313	PBI 9.4 '63. Chest X-Ray: Cardiac enlarg., aortic arteriosclerosis'63. Pap.: Negative for malignant cells; marked inflammation with inflammatory atypia.	Hypertension. Chesity.
	10,200	43	133	Chest X-Ray neg. '63.	Bone marrow taken for general study.
Deformed upper lobe left har. Tumor left buttock 63.	8,100	41	445		Prostatic hypertrophy. Neck adenopathy.
	7,200	47	125		1963 examination. No 1964 examination.
Lipoma left shoulder '63.	11,300	46	388	PBI 12.0 '63.	
Romberg +.	6,300	38	390	Cardiolysin slide flocculation test: reactive, titer 2. Reiter protein complement fixation test: reactive.	Arrested hues. Arteriosclerosis. Rec. Kahn test.
	6,500	41	395	PBI 8.8 '63	1963 examination. Hematology only 1964.
Atrophic vagina, 75° kyphosis, right scoliosis. Tumor left labia 1963.	5,500	30	628	Pap.: Negative for malignant cells; inflammation; some squamous atypia noted; ? trichomonas vaginalis infestation; high estrogenic level for age and menstrual history.	Kyphoscoliosis. Evaluate for possible ca. of bowel at Maju
Prominent ulnar styloid bilat.	7,200	36	355	FBI 8.3 '63. Pap.: Negative for malignant cells; inflammation; endocervical cell atypia.	
Minimal arteriosclerosis, weak right dorsalis pedis pulse. Hypoactive reflexes.	6,300	46	386		Artericsclerosis. Prostatic hypertrophy.
Hypoactive reflexes.	6,900	40	257	Pap.: Negative for malignant cells; marked inflammation with inflamma- tory atypia.	
	7.1	39	208	Chest X-Ray negative '62.	1963 examination. No 1964 examination. Pregnant 2-3 months '63.
	6,000	42	505	Pap.: Negative for malignant cells; severe inflammation; marked squamous atypia; well- preserved spermatozoa noted.	Neck adenopathy.
	7,000	41	256		
Severe arteriosclerosis. Mild kyphosis and right scoliosis. Prominent rt. ulnar styloid.	8,000	36	663	Pap.: Negative for malignant cells; trichomonas vaginalis infestation with inflammation; mild endo- cervical cell atypia.	Aged and feeble, arterioscler kyphoscoliosis. Repatomegaly. Rec. cataract removal.

NO.,	PAST HISTORY	in jur ies	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
29 75 M	Blind in left eye. Right eye fair.		110	110/64 Pulse 80, reg.	Rt. cataract hyper-mature. Left aphakia.	Prostate 2+, firm left lobe.	Numerous nevi on shoulders.
34 55 F	Menopause-hys- terectomy '49. Para. 14, grav. 10. Pain in legs.		126	106/70	Arcus 4+. Left pterygium. Rt. pingueculae. 1+ retinal scler csis.	Mid-line surg. scar. Erosion of cervix.	Pigmented moles back and neck.
35 23 M			125 '62	110/60 '62			
36 18 M	-		134	115/60	Throat slight inflammation.		Tinea circinata back, abd., legs and arms.
37 30 M			146	120/70	Arcus 1+. Bilat.pinguecula	<b>.</b>	
39 · 25 F			109 '62	90/60 162	Corneal scar left eye '63.		Sl. roughening and pig. back of neck. Pig. var. and sl.hyperpig dorsum right foot.
40 39 м	Fistula in ano (corrected surgically '64). Low back pain.	Traumatic deform- ity right index finger.	125 115 '63	110/70	Arcus 2+. Pingueculae and exophoria.	Fistula in ano with perirectal abscess '63. Leukoplakia '63.	Dermatitis right hand.
42 54 M	Lump right arm.		116	110/70	Arcus 3+.2+ ret. inal arterio- sclerosis.Circum papillary ring o choroid degenera tion.	r	
43 76 F	Menopause: time unknown. Para. 4, grav. 4.		68	130/72 Grade I ays. m.	Bilat. pterygium Bilat. cataracts Throat slight inflammation.		
45 42 F	Menarche age 13. IMP 3/7/64. Para. 11, grav. 9. Low back pain.	_	117	120/70	Arcus 2+. Left pingueculae. Right pterygium.		
47 18 M			135	110/70	Throat slight inflammation.		
49 25 F	Menarche age 13. IMP 2/5/64. Para. 6, grav. 3. Pain in joints, obese, URI.		166 137 '63	96/64	Throat inflamed.	Rt. paramedian scar. Severe lat. cervical tears, lx3 cm. cervical erosion.	Pig. macs. both sides of neck, ACF.
77 W			185	120/70	Arcus 3+. Scar nose septum.		Scars on upper rt. arm (not "beta burns").
51 35 F	Menarche age 17. Para. 2, grav. 0. IMP 3/7/64.		99	90/60		Healed cervical tear. Bartholin cyst left labia.	Mole on abdomen.
55 85 M	Backpain. Blind- ness, partial.		134 '61	100/65 Pulse 86, reg.	4+ arcus. Blind, partial. Throat inflamed. Node left neck. Cataract OD) 163 Aphakia OD)	Prostate 1+.	

MISCELLANEOUS, NEUROLOGICAL, TUNORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Slight gynecomastia. Mild kyphosis	7,700	40	235		Prostate suspicious for ca. Consider removal rt. cataract.
	9,800	38	253	Fap.: Negative for malignant cells; inflammation with marked squamous atypia, possibly on an inflammatory basis.	Cervical erosion.
	6,200	49	162	Chest X-Ray, negative 1962.	
	10,600	1414	218	Chest X-Ray negative 1963.	
	5,800	45	285		
	7,600	37	407	Chest X-Ray negative 1962.	1963 examination. Partial 1964 examination.
	7,500	40	425	Chest X-Ray negative 1963.	Surgical correction fistula in ano.
Minimal arteriosclerosis. 3 cm. mass over right biceps. Both 5th fingers short. Congenital dis- located hip 1963?	6,000	42	225		Appears older than 54 years. Arteriosclerosis.
Severe arteriosclerosis.  Mod. kyphoscoliosis.	5,300	39	353	Pap.: Negative for malignant cells; post menopausal atrophic type smear.	Senile, arteriosclerosis, kyphoscoliosis. Recent removal right cataract.
	7,800	38	520	PBI 9.1 '64. Chest X-Ray; rt. tenting diaphragm, old pleurisy? '63. Pap.: Negative for malignant cells; inflammation; high estrogenic level; degenerating glandular cells noted.	
	8,500	45	305		
	8,300	39	385	Chest X-Ray: Soft tissue dens. lat. 1/3 rt. clavicle (lipoma?); elev. pul. seg. '63. Pap.: Neg. for malignant cells; fresh blood; severe inflammation with mild inflammatory atypia.	Large cervical erosion. Obese, gaining weight.
Bilat. hallux valgus.	6,400	չեր	448		
	9,400	74.74	415	Pap.: Negative for malignant cells; marked inflammation with histiocytic reaction; single atypical squamous cell noted.	
	6,000	46	351		Senile, examined at home.

NO., AGE, SEX	PAST HISTORY	IN JUR IES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
57 110 F	Hearing poor,			134/70 '62 Arteriosclerosis 96/60 '63	Vis. L.P. '63 Cataracts 0 S'63		
58 69 <b>F</b>	Menopause age 64. para.12, grav.10		110 103 '63	120/66	Harcus, strabis- mus, left cataract Rt. lenticular cpacities. Throat inflammed.	Atrophic vagina, bled during exam.	Moles front and side of neck.
59 44 F	Menopause age 41. Para.2,grav. 1. URI and cough.		82	110/70	Bilat. choroidal degeneration.	Blood at cervical os.	Biopsy scar back, Nevi both breasts.
60 66 F	Menopause age 45. Para.0, grav. 0. Obese.		138 147 '63	190/90,170/75'63 Hypertension. Harsh systolic M.		Atrophic vagina.	Mole on forehead.
61 18 F	Menarche age 12. L M P 2/15/64. Para.2,grav.2. Obese		168 154 '63	120/78	Slight inflam. throat.	Cervical erosion '63. Palp. liver '63.	Scar right breast.
63 46 F	Menopause age 44. Para.13,grav.10. Dyspnea, pain in joints.		115	100/60			Biopsy scar left neck. Irreg. pig. back neck.
64 40 F	Menarche age 12. L M P May 1963, Para.10,grav.9. Lactating since May 1963.		157	110/70 ,	2 pterygium right eye.	Uterus enlarged 5.0 cm dia.	Mole back of neck; sl. pig var. front of neck.
66 40 <b>F</b>	Menarche age 13. LMP 3/5/64. Para.0,grav.0. URI.		139	110/70	Arcus 2+. Left pterygium.	Liver edge palp. 1 F B. Scar right labia.	
67 24 F	Menarche age 13. L M P 3/10/64. Para.O,grav.O.		127	Pulse 96 Split 1st sound.		No pelvic exam.	"Beta burn" scars dorsum left ft.
68 55 <b>M</b>	Pain in legs and feet. Poor vision		132	130/80 Split 2nd sound.	Rt.Light only. Left 20/600. Rt. Aphakia, left senile cataract.	Prostate 2+	
70 27 F	Menarche age 14. L M P Feb. 1964. Para. 2, grav. 2.	<del>-</del>	115	104/56		Multiparous cervix.	
71 38 F	Menarche age 16. L M P 2/25/64. Para.1,grav.1. URI.		124	124/84	Bilat pingueculae Throat inflammed.	•	Few pig. spots
73 28 <b>M</b>			157 160 '63	140/90 Hypertensive 110/68 '63		Few groin nodes.	
74 26 F	Menarche age 12. L M P Dec. 1961. Para. 6,grav. 6. Lactating.		180 161 '63 Obese	100/60		Lat. cervical tears. Ant. and post. erosions.	
75 22 F			122 115 '63	90/60		8 mos.pregnant, fetal heart sounds.	Biopsy scar left neck. Pig area dorsum r lst toe.

	BLOOD				COMMENTS &
MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.	WBC	OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	RECOMMENDATIONS
Kyphoscoliosis, oster- arthritis, subcutaneous mass both hips, short left thumb, wasting lower extremities 1963.	5,400	34	286	Chest X ray neg. '61, '63	Died of old age 1963. No other information available concerning death.
Minimal arteriosclerosis.	6,700	40	<b>2</b> 95	Chest X-ray: Cong. scalloping diaphragm, elongated aorta '63. Pap:Clusters of somewhat suspicious glandular cells, both endometrial and endocervical in a background of fibrinated blood.	Atrophic vagina, bled on exam Rec. cataract removal.
Minimal arteriosclerosis	11,000	37	355	Pap: Negative for Malignant Cells. Scanty smears showing fairly low estrogenic level (consonant with history of IMP - 2 years ago).	Postmenopausal bleeding. Rec. recheck of bleeding at intervals.
Mod. arteriosclerosis, slight kyphosis	9,800	35	250	Pap: Flaques of squamous epithelium showing marked atypia. High estrogenic level for age.	Artericsclerotic heart disease Hypertension.
Vaccination rt. arm. Temp. 100.2°	9,000	43	445	Pap: Negative for Malignant Cells. High estrogenic level. Smears Have a relatively clean background.	Vaccination, febrile.
	6,200	41	250	Pap: Negative for Malignant Cells. Inflammation with mild inflamma- tory atypia.	Bone marrow taken for gen. study.
	7,100	38	295	Pap: Negative for Malignant Cells. Marked inflammation with in- flammatory atypia. Fresh blood.	Possible pregnancy.
	8,000	40	448	Chest X-ray: Elevated pul.seg.; congen. heart(?); rt.apical & lt. subclavicular densities of infl. nature (TBC?) '63. Pap: Negative for Malignant Cells.	
	8,200	42	295	,	
Moderate arteriosclerosis	5,900	47	210		Unsuccessful surgery rt. eye 1963. Arteriosclerosis. Bone marrow taken for gen. study.
	5,200	26	320	P.B.I. 8.7 '63. Pap: Negative for Malignant Cells. Trichomonas Vaginalis infestation with inflammation. Much amorphous debris.	Anemia Rec. Iron and Vitamin C.
	9,000	40	425	Chest X-ray neg. '63. Pap: Negative for Malignant Cells. Inflammation. Marked keratinization of squamous cells with atypia. ? Trichomonas Vaginalis infestation	
	8,300	49	315		Developed hypertension. Bone marrow taken for gen. study.
	9,600	45	263	Pap: Negative for Malignant Cells. Moderate estrogenic level. Smears have a clean background.	2 pair of twins. Obese.
	14,400	39	423		

NO., AGE, SEX	PAST HISTORY	in jur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
76 21 <b>M</b>			145 141 '63	145/50 cardiomegaly Gr. IV dias. M. 120/70 '63			
77 36 <b>m</b>	U R I. Hansen's disease			110/70	Pterygium left eye '63.		Scars of Hansen's disease.
78 47 <b>F</b>	Menarche age 13. LMP 3/7/64. Para.5,grav.4. Pain in joints.		146	110/70	Arcus 2+, rt pterygium	Menses, no pelvic exam.	Papillomas of neck and trunk.
79 49 <b>M</b>			133	130/80	Arcus 2+. Bilat. pingueculae.		Bilat inguinal scar. Rt. abd. and rt. arm sca: Pig. scar back l ear from "Beti burn".
80 56 <b>M</b>		1st left toe deformed 1963.	126 135 '62 129 '63	120/80 Extrasystoles	Arcus 2+. Rt. pingueculae, lei pterygium, rt. cataract, left opacity.	t Prostate 1+.	1/2" diam. raised lesions of front of chest, 1. arm and leg. (Fungus?).
81 18 F	Menarche age 15. IMP Mar. 1964 Para.1,grav.1.	,	99	Mitral systolic M		Rt. adnexa thickened.	Mole left breast. Vaccination scar rt. arm.
82 60 M	Old facial paralysis '63.		132 128 '63	112/68	Arcus 4+. Bilat Pterygium, choroidal atropt lenticular opacities.	y, Prostate enlarged '63.	
823 20 M	URI .		139 134 '63	115/60	Rt. pterygium. Exophoria.		
825 21 M			111 '62	82/50 '62 104/60 '63		Liver edge down 1 cm. '63. cervical errosion? '63.	
826 27 F	Menarche age 7. L M P 2/25/64. Para.6,grav.5.		88	90/56	Bleeding gums.	Lat. cervical tears.	Patchy depigmentation
827 24 <b>M</b>			127	114/78	Corneal scars. Throat inflammed.		Impetigo scar over pubis.
828 24 <b>M</b>			118	115/70	Pyorrhea. Throat inflammed		
829 25 F	Menarche age 12. IMP Sept. '63. Para.7,grav.6. Lactating.		111 141 '63	100/68	Throat inflammed	Severe cervical lacerations.	
830 25 M			151	106/60		•	
831 24 M	Abd. Pain		132	110/60	Rt. tonsil inflammed.		

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	10,900	<b>.</b>	209		Encumatic heart disease, compensated Rec. Mitral valvulctomy.
Absent fingers and toes from leprosy. Hypoactive right knee. Healed ulcers on soles of both feet.	5,300	29	330		Examined at home.
Short 5th fingers observed '63.	10,400	40	404	Chest X-ray: Cardiac enlarg; aortic arteriosclerosis '63.	
Mod. arteriosclerosis. Pipestem brachial art.	6,700	44	266 -	Chest X-ray: Elevated pul. seg.; emphysema (?) '63.	Arteriosclerosis.
	11,500	42	319		Rec. rt. cataract removal following cardiac evaluation. Poss. heart block.
	8,900	38	348	Pap: Negative for Malignant Cells. Moderately high estrogenic level. Mild squamous and endocervical cell atypia.	Cardiac murmur.
Minimal arteriosclerosis	8,000	43	538		Arteriosclerosis.
Inguinal and cervical nodes.	15,600	42	346		
	8,000	40	355	Chest X-ray neg. '62. Urine prot. 100 mg. '62.	'63 examination. No '64 examination.
15° contracture both ring and little fingers. Displacement of patellas.	8,300	35	315	Pap: Negative for Malignant Cells. Marked inflammation. Relatively high estrogenic level.	Contraction and deformity of fingers and knees. Rec. X-ray eval.
Few Inguinal nodes.	8,800	46	339		
Few nodes right neck.	13,300	46	428		
	10,900	38	315	PBI 7.1 '63. Serum Iron 120 '63. Pap: Negative for Malignant Cells. Inflammation. Mild endocervical cell atypia.	·
	5,700	45	360		
	9,000	54	353	Chest X-ray neg. 163.	
5	<del>10 6 </del>	<del>! S</del>	<del>68</del>	<u> </u>	

NO.,	PAST HISTORY	IN JUR IES	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gym	SKIN
832 26 F	Menarche age 13. IMF Jan. '63. Fara.6,grav.6. Lactating.		101	96/70		5 cm mass L.L.Q. (probably ovariar cyst in left adnexa).	
833 31 M	URI		135	104/70	Chalazion left lower lid.		
834 30 M	5		118	115/60 '63	Pterygium rt.		
835 30 F	Menarche age 12. IMP Dec. '63. Para.7, grav.7. Lactating since May 1962		96	106/70		Uterus 4 fingers above pubis.	
836 31 M	Weight loss.	•	126 122 '63	125/70	Corneal scar rt. eye. Node left neck.		
838 31 M			144 '63	100/68 '63		-	
. 840 34-м			156	100/60	Bilat.pterygium.		
841 31 F	Menarche age 14. IMP June '63. Para.7,grav.7. Lactating since March 4, 1964.		136	112/70		Uterus 4 cm above pubis, involutional. Rt. lat.cervical tear.	
842 40 <b>M</b>		Amp. rt. little and left index fingers.	154	112/70	Pingueculae bilat. Throat inflammed		Mole left cheek.
843 35 F	Menarche age 13. IMP Sept. '63. Para.6,grav.6. 6 mos.pregnant.		128-1/2	96/60	Left pingueculae	1 cm. ant. cervical erosion. Uterus at umbilicus.	Scar back of neck, left elbow.
844 45 F	Menarche age 13. LMP Feb.15,'64. Para.12,grav.11. U R I		100 109 '62 103 '63	110/70	Rt. pterygium, left pingueculae	Liver edge palp. IFB	l cm. mole left breast.
845 34 M			154 140 '61	110/70	l+ arcus. Rt. pingueculae, left pterygium.		
В49 45 м	Skin itch. Obese.		218 207 '62 213 '63	125/70	l+ Arcus, Bilat. pterygium, retinal arteriosclerosis		Scars on legs.
851 55 F	Menopause Jan. 16 Para. 10, grav. 10. U R I	<b>3</b> -	167 166 '63	130/80	4+ Arcus. Bilat.pterygium.		Scar right arm.
852 60 F	Menopause-20 yrs ago. Para.0, grav.0. U R I		94	124/70	4+ Arcus. Bilat. pterygium.	Anal tag.	Mole on nose, left lip, cheek Skin tags in inguinal area.

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Short 5th finger both hands.	7,300	39	358	Pap: Negative for Malignant Cells. Very high estrogenic. Keratiniza- tion of squamous cells.	Rec. Removal ovarian cyst.
Prominent left ulnar styloid. Healed acne on back.	6,500	47	428		
				Chest X-ray neg. '63.	'63 examination. No '64 examination.
Left breast 1 x larger.	10,300	37	340	Pap: Negative for Malignant Cells Trichomonas Vaginalis infestation with severe inflammation and histocytic reaction.	3 mos. pregnant.
	7,500	46	453		
	8,800	51	224	Chest X-ray neg. '62.	'63 examination. No '64 examination.
	7,700	47	308		
	10,400	29	430	Chest X-ray neg. '63. Pap: Negative for Malignant Cells. Marked inflammation with in- flammatory stypia. ? Fibrinated blood.	6 days post partum. Rec. Iron and Vit. C.
	9,700	50	5 <b>28</b>		
	6,900	31	400	Pap: Negative for Malignant Cells. Inflammation with inflammatory atypia. Vaginal smear QNS.	6 mos. pregnant.
Left neck nodes.	8,900	ý ý f	485	Pap: Negative for Malignant Cells. Severe inflammation with mild endocervical cell atypia. Vaginal smear is scanty.	Losing weight. Hepatomegaly. Rec. hysterectomy; enlarged uterus.
	9,100	ĦĦ	345		
	7,700	1414	203		Obese.
	8,100	36	205	Pap: Negative for Malignant Cells. Trichomonas Vaginalis infestation with marked inflammation. Squamous and endocervical cell atypia noted.	Obese.
Minimal arteriosclerosis	10,200	35	443	Pap: Negative for Malignant Cells. Trichomonas Vaginalis infestation with inflammation. Red blood cells present.	

NO., AGE, SEX	PAST HISTORY	injuries	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
853 59 <b>M</b>	URI		155 145 '63	158/90 Hypertensive. 120/70 '63.	4-Arcus. Bilat. pterygium, chor- cidal degenerati retinal arterio- sclerosis 2+. Throat inflammed	on, Prostate 1+.	Tinea versi- color.
856 65 <b>м</b>	URI. Blind, Rt. back pain.		119 120 '63	164/80 128/64 '63.	Rt. cataract. Left lenticular opacities and scar.		
858 69 F	Menopause 20 yrs ago. Para. 3, grav. 3. Back pain.		92	120/74	3+ Arcus. Bilat. pterygium,lenti- cular opacities. Throat inflammed 5x5 cm.thyroid mass, midline.		
859 71 F	Menopause 20+ yrs ago. Para.9, grav.6.		136 137 '63	146/96 Hypertensive. 120/80 '63.	4+ Arcus. Bilat. pterygium, lenti cular opecities.		Nevi on neck rt. chest.
860 74 M			11 <sup>1</sup> 4 121 '61	108/68	Blind in left ey Rt. eye 8/200. Left phthisis bulbi.	<b>.</b>	
864 38 m	URI.		155	118/80	Bilat.pterygium	•	Cyst left some verruca of no 3 nevi right face.
865 31 F	Menarche age 13. LMP May '63. Para.10, grav.9. U R I.		97	100/68	Bilat.pinguecula	External hemorr- e. hoids. Uterus involutional.	
867 36 F	Menarche age 18. IMP 3/18/64. Para.9,grav.9. Tubal ligation'62.		116 102 '62	110/74	Throat inflammed	Rt. Paramedian scar. No pelvic, menses.	Nevi neck, chest and ab
868 41 <b>M</b>	Poor vision		199 182 '61	110/70	l+ Arcus.		
875 47 м							
877 26 M		•					
878 64 <b>n</b>	URI. Back pain.		193	148/94 Pulse 64.Hyper- tensive. 140/90 '63.	3+ Arcus. Bilat. pterygium. Ethmoiditis. Vitrecus opaciti	es.	
880 43 M			191 188 *63	120/70	Rt. pterygium.		Papilloma ch and back. Scar abdomen
381 5 V	URI.		169	116/74			
882 31 M			122	90/50	Throat inflammed		Appendectomy scar.

Miscellaneous,	BLOOD COUNTS		w= . =	LAB DATA, Urine, Pap.,	COMMENTS &
NEUROLOGICAL, TUMORS, ETC.	WBC	HCT	PLAT	X-ray, etc.	RECOMMENDATIONS
Minimal arteriosclerosis. 2 x 3 cm. ulcer right tibia.	8,300	39	3 <sup>1</sup> 43	B. Sugar 247 '63 F.B. sugar 187 '64 Chest X-ray neg. '63	Diabetes. Hypertension. Arteriosclerosis. Leg ulcer. Tinea versicolor. Prostatic hypertrophy.
	8,700	39	675		Rec. cataract removal, rt.
Mod. kyphosis	8,000	38	468	Pap: In cervical smear there are two clusters of cells suspicious for carcinoma of cervix or endocervix.	Non-toxic nodular goiter 20 + years.
Mod. arteriosclerosis, small rt. 3rd toe.	7,700	40	525	Pap: Negative for Malignant Cells. Inflammation. High estrogenic level for age.	Hypertension. Rec. glasses.
Moderate arteriosclerosis. Weak d.p. pulse left foot. Marked kyphosis, hallux valgus.					Arteriosclerosis. Kyphosis, hallux valgus. No hematology '63 or '64.
Small inguinal nodes.	10,000	47	322		
	7,300	33	575	PBI 8.2 '63. Serum Iron 117 '63. Pap: Negative for Malignant Cells. Very marked inflammation with histiccytic reaction and marked squamous atypia.	1 mo. post partum.
	8,200	39	484		
	8,500	45	278		Obese.
					Not examined since '62.
					Not examined since '61.
	7,900	40	303		Hypertension. Nasal irritation.
	7,800	46	324		Obege.
	7,900	45	333	Chest X-ray neg. '63.	
Nodes in neck and inguinal area.	6,500	Щ	175	006872	

	NO.,	PAST HISTORY	INJURIES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	883 52 <b>M</b>	Facial asymetry.		138	120/80	Corneal opacity, left.		
	884 69 <b>M</b> •	Poor vision.		152	120/80 136/70 '63	4+Arcus. Bilat. pterygium, rt. chalazion, lenti- cular opacities.	Prostate 1+. Anal tags.	Scar right groin Tinea versicolor Nevi on face.
	885 24 M	Leg and chest pain.		139	110/60 Systolic M	Throat inflammed.		Tinea versicolor
	888 35 F							
	889 39 F	-						
	893 44 F	Menarche age 15. IMP 2/10/64. Para.13,grav.11. 8 mos. since last menses.		103	85/60 90/60 163.	Arcus 1+. Pterygium, Lenticular opacities.		
	894 67 F	Menopause age 45.		98	ll0/70, split first sound, p.80. Irregular fine rales both lungs.	4+ Arcus. Left Lenticular opacities, rt. cataract. Throat inflammed.	Questionable hepatomegaly. Anal tag.	Nevi and cyst on face.
	895 34 F	Menarche age 17. Pelvic surg. '63 U R I.		120	96/60	Bilat.pingueculae	Cervix O.K., adnexa thick, uterus anteflexes	
	896 24 F	Menarche age 13. IMP 2/25/64. Para.3,grav.3.		100	100/60			Scar on neck.
	897 66 м		and the second s	171 154 '62	155/80 120/60 162	Arcus 4+. Bilat. pterygium, left cataract.		Nevi on back. Tinea versicolor on face.
	898 66 F	Menopause age 45. Para.4,grav.4. Vag. bleeding after exam.		170 172 '63	112/78	4+ Arcus. Bilat. pterygium, Lent. opacities.	Atrophic cervix.	Scars over ti
	899 70 M	Poor vision		125	160/80, Grade 1 sys.M.	3+Arcus. Bilat. pingueculae, lent opacities, reti- nal arterioscle- rosis 2+.	Liver edge palp. Prostate 1+.	
	908 74 F	Menopause age 54. Para.15,grav.14. Dyspnea, fainting.		117 102 '63	170/96 Hypertensive. 180/90 '62 150/80 '63	4+ Arcus. Bilat. pterygium and lent. opacities.	Anal tags.	
	910 61 M			120	110/64	2+ Arcus. Melanoma left iris.		
	914 29 F			89	90/60			
500b8	915 7 3 <sup>67 M</sup>	U R I. Pain elbows.		119	100/60	3+ Arcus. Bilat. lent opacities.	Prostate 1+.	·

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	5,800	43	238	Chest X-ray: ? Heart enlarg, '63.	'63 examination. No '64 examination.
Minimal arteriosclerosis	10,800	41	321		Fundi not examined. Arteriosclerosis. Prostate hypertrophy.
Bilat. inguinal nodes.	11,000	45	203		Cardiac murmur.
					Not examined since '62.
					Not examined since 162.
Painful right shoulder- osteoarthritis.	10,500	37	328	B. Sugar 379 '63. Pap: negative for Malignant Cells. Trichomonas Vaginalis infestation with in- flammation and histicoytic re- action. Fresh blood. Mild squamous atypia.	RX diabetes.
Mod. arteriosclerosis. Mod. kyphoscoleosis.	7,900	<u>դ</u> վե	426	Pap: Negative for Malignant Cells. Atrophic post menopausal type smear.	ASHD, poss.decompensation Rec. EKG and workup.
	10,600	45	613	Pap: Negative for Malignant Cells. Mild inflammation. Glandular cell atypia.	Surg. '63, Tubal ligation?
Rt. leg 4 cm. shorter than left leg. Arthritis rt. knee.	11,000	39	390	Pap: Negative for Malignant Cells. Severe inflammation with histic- cytic reaction. Probable Tricho- monas Vaginalis infestation.	Rt. slipped femoral epiphyis.
	8,300	43	340		Rec. cataract removal.
. "	6,500	41	263	Pap: Negative for Malignant Cells. Fresh blood, Mild inflammation. Smears are somewhat dry.	Obese.
Mod. arteriosclerosis. + Romberg. Weak rt. biceps. Pupils react to light. Dupuytren's contracture.	5,400	40	288		ASHD. Paralysis right arm. + Romberg - hues?
Min. arteriosclerosis. Kyphoscoliosis.	6,100	41	173	Chest X-ray neg. '63.  Pap: Inflammation with histiocytic reaction. Atypical glandular cells noted. Few giant histiocytes also seen.	Hypertension. Rec. glasses.
Few neck and groin nodes. Min. arteriosclerosis. d.p. pulse weak on right.					Arteriosclerosis. No hematological exam '63 or '64.
	7,900	37	268		'63 examination. No '64 examination.
	8,400	37	538		Prostatic hypertropny.
5005874		L			

	NO., AGE, SEX	PAST HISTORY	injur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	916 40 F	Menarche age 14. IMP Oct. '63. 5 mos. pregnant. Para.14,grav.8.		143	90/60		Uterus to umbili- cus. Fetal heart sounds.	
	917 45 <b>M</b>	Abd. pain. Myocardial damage (EKG '59)		184 175 '63	120/78 pulse 72, reg.	Bilat.pingueculad	Appendectomy scar.	
	918 66 <b>m</b>	Diabetes. Obese.		188 182 '63	120/70 Grade 1 sys- tolic M.	4+ Arcus. Bilat. pterygium, lent. opacities. Leukoplakia of mouth.	Left varicocele.	
	920 32 m							
	922 40 F	Menarche age 14. IMP 2/5/64. Para.ll,grav.ll.		107	110/80		Uterus 4FB above pubis, irregular, firm.	Nevi left face
	928 51 F	Menopause age 47. Para.l,grav.l. Pain abd. and joints.		124	110/70	3+ Arcus. Bilat. pterygium, scars of chorioretinit		Scars left breast.
	929 66 F	Menopause age 46. Para.0,grav.0. Poor vision		129	110/74 '63	Rt. pterygium an lent. opacities. Left cataract.	Atrophic cervix.	
	932 29 <b>F</b>	Menarche age 14. IMP Jan. '64. Para.3,grav.3. U R I		104	90/54		1 x 2 cm. cervical erosion.	Scar right chest.
	93 <sup>4</sup> 29 F	Menarche age 13. IMP 3/8/64. Para.0,grav.0.		141 121 163	110/70		No pelvic exam, menses.	
	935 66 <b>M</b>				110/64		? Enlarged liver.	
	936 73 F	Menopause - 4 mos. ago? Para.3, grav.3. Nocturia.		118	110/60, no m. M detected '62.	4+ Arcus. Bilat chorioretinitis scars and lent. opacities.	Liver palp. IFB. Cervical discharge.	Wart left eyelid.
	938 25 F	Menarche age 14. IMP Nov. '63. 4 mos. pregnant. Para.5,grav.4.		92	95/50 fine rhonchi left lung.		Uterus to umbilicus.	
	941 63 F	Menopause age 53. Para.ll,grav.10.		109	120/70 140/90 '61 122/72 '63	4+ Arcus. Bilat. pingueculae. Leukoplakia of hard palate. Rt. cataract.	Liver edge palp. IFB.	
	942 49 F	Menarche age 13. LMP Feb. '64. Para.0,grav.0.		134	110/70	l+ Arcus. Bilat.pingueculae		Scar left scapula.
	943 36 M							
068	15_							

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	11,200	38	465	Pap: Negative for Malignant Cells. Moderate estrogenic level. -Heavy T. Vaginalis.	5 mos. pregnant.
	6,300		183	Chest X-ray: Card. enlarg. '63.	Caining weight. No hematological exam '64.
Varicose vein right leg.	7,200	47	205		Cral leukoplakia. A S H D with sys. murmur. Variocele and varicose veins. RX diabetes.
					Not examined since '61.
	6,100	36	457	Pap: Negative for Malignant Cells. Inflammation. Mild endocervical cell atypia. High estrogenic level.	Leiomyoma of uterus.
	6,700	35	435	Pap: Negative for Malignant Cells. Inflammation. Mild endocervical cell atypia. Vaginal smear is scanty.	
Mod. arteriosclerosis	6,400	41	439	Pap: Negative for Malignant Cells. Inflammation with histiccytic reaction. Fresh blood. Atypical glandular cells noted.	Arteriosclerosis. Atrophic cervix.
Node right neck.	12,900	33	525	B. Sugar 79 '63. Pap: Negative for Malignant Cells. Inflammation. Fresh blood. Mild endocervical cell atypis.	
	9,000	40	393		
	5,100	47	324		'63 examination. No '64 examination.
Left 5th toe absent	8,900	37	275	Pap: High estrogenic level for age. Marked inflammation with histic- cytic reaction. Some very atypical glandular cells present in vaginal smear raising question of endo- metrial lesion.	Questionable vaginal bleeding. RX diabetes.
6 toes right foot.	10,900	30	30 <del>9</del>	PBI 5.6 64. Pap: Negative for Malignant Cells. Severe inflammation with histocytic reaction. Atypical glandular cells noted probably endometrial.	4 mos. pregnant. Rec. Iron & Vit. C.
Minimal arteriosclerosis	6,500	40	235	Pap: Negative for Malignant Cells. Mild inflammation. Relatively high estrogenic level for age and menstrual history.	Leukoplakia. Hepatomegaly. Arteriosclerosis. Rec. rt. cataract removal.
Deficient eyebrows. Absent knee reflexes.	6,700	40	390	Chest X-ray neg. '63.  Pap: Negative for Malignant Cells.  Inflammation with inflammatory atypia. High estrogenic level for age.	
5005876					Not examined since '62.

NO., AGE, SEX	PAST HISTORY	in jur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
39 M			182 176 '62 179 '63	130/80	Melanoma left iris. Rt. pin- gueculae, rt. pterygium.		Nevi on abdomen.
945 39 <b>F</b>	Menarche age 13. IMP 3/1/64. Para.1,grav.1. U R I.		88	130/80 no m. ?murmur '63	Pterygium, left lent. opacities.		Scar dorsum left hand.
9 <sup>4</sup> 7 56 м	URI.		110	190/100, grade 1 sys. M. 140/96 '63. Hypertensive.	4+ Arcus. Bilat. pterygium, rt. esotropia, rt. cataract, lt. lent. opacities.	Enlarged prostate '63, not signi- ficant '64.	Nevi on back. Scar left arm.
948 56 <b>M</b>			176 162 '63	140/84 120/50 '63	3+ Arcus. Bilat. pterygium.	Prostate 1+.	Scars back and shoulders.
951 31 F	Menarche age 14. Para. 7, grav. 7. Lactating.		136	120/80	Horizonal nystagmus, rt.pingueculae.		
956 55 F	Menarche age 12. IMP 2/20/64. U R I		125	128/80 Crepitation left lower lung.	Rt. pterygium.		Tinea versicolon Nevi right shoulder.
957 56 F	Menopause age 46. Para.2,grav.1. Obese.		164 162 '63	116/80	Bilat.pterygium, left lent. opacities.Throat inflammed.		
958 32 <b>M</b>	Chr. bronchitis.		120	140/80			
961 71 M	Gen. pain. Mouth sores		139 144 '63	130/70	4+ Arcus. Bilat. pterygium, left lent. opacities.	Prostate 1+	
963 46 м	Abd. pain. Worms		138	104/60	Bilat.pterygium.		
964 88 m	Back pain.		135	160/90 pulse58, regular. Hypertensive 140/80 '63	4+ Arcus. Premature cataracts and lent. opacities.	Prostate 2+	
965 20 F	Menarche age 15. IMP 3/20/64. Para.0,grav.0.		112	Pulse 110	Throat inflammed	No pelvic exam.	
966 32 <b>M</b>			148	110/70	Bilat. pingueculae.	·	-
967 21 M			149	108/70			
969 46 M	URI. Cough.	n n b 3 7 7	116	llo/66 Grade l sys.M.	Rotary nystag- mus. Rt.pig- mented nevi. Throat inflammed	1.	Nevi on trunk

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.	WBC	BLOOD COUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	6,200	45	313	PBI 2.0 '64.	Repeat FBI.
	7,000	46	478	Pap: Negative for Malignant Cells. Marked inflammation. Degenerating glandular cells seen. High estrogenic level noted.	
	7,600	40	380	Chest X-ray: Min. card. enlarg., aortic arteriosclerosis '63.	Evaluate + RX hypertension. Rec. cataract removal?
Minimal arteriosclerosis.	6,000	44	298		Arteriosclerosis. Prostatic hypertrophy. Bone marrow taken for gen. stud
	9,300	41	390	Pap: Negative for Malignant Cells. Inflammation.	
	7,500	36	330	Pap: Negative for Malignant Cells. Severe inflammation with histio- cytic reaction. Squamous and endocervical cell atypia. ? Tri- chomonas Vaginalis infestation. Vaginal smear QNS.	Rec. surgery rt. pterygium.
Minimal arteriosclerosis.	8,600	39	350	Pap: Negative for Malignant Cells. Relatively low estrogenic level noted. One or two giant cells seen.	Rec. glasses.
	8,700	41	358	Chest X-ray: 'Density rt. hilus with sm. central radiclucency, inflam. nature? '63.	'63 examination. No '64 examination.
	7,300	45	253		Prostatic hypertrophy.
					'63 examination, no hematology. No '64 examination.
Slight gynecomastia. Minimal arteriosclerosis. Marked kyphoscoliosis. Lipoma above left knee.	5,600	38	203		Arteriosclerosis and hypertensi Prostatic hypertrophy. Kyphoscoliosis. Rec. cataract removal?
	8,800	37	424		
	8,600	47	270		
	8,500	52	340		'63 examination. No '64 examination.
5005878	7,800	40	439	Chest X-ray neg. '63.	Cardiac murmur. Nystagmus.

NO., AGE, SEX	PAST HISTORY	INJURIES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
970 50 <b>F</b>	Menopause age 47 Para.0,grav.0.		108 101 '63	110/60 Rhonchi and rales left lower lung.	Bilat,pterygium. Throat inflammed.	Atrophic cervix.	Scars both legs.
971 21 M			128	110/70	Left pterygium.		Scar rt.
973 55 M	Losing weight.		129 133 '61	112/70 Rales right chest.	2+ Arcus. Rt. immature cataract Left lent. opa- cities. Pingue- culae. Throat inflammed.	Old rt. epididymitis.	Rt. inguinal and left leg scars.
975 41 <b>M</b>							
982 43 F	Menarche age 14. IMP, present. Para. 3,grav. 2. Abd. pain.		181 140 '62	180/115 Hypertension. 170/108 '62.	Pterygium, bilat.	Menses, no pelvic exam.	Nevi left shoulder.
984 32 F							·
991 56 <b>F</b>	Menopause age 54. Para.1,grav.1. Obese. Diabetes.		175 173 '61	120/80	Bilat.pingueculae rt. senile cata- ract,left lent. opacities.	,	
1001 30 F	Menarche age 13. IMP 12/15/63. Para. 7,grav. 6.		129	100/64		Uterus 3 FB above pubis. 3mos pregnant.lx3 cm ant. cervical erosion.	
1005 31 M		Absent right thumb.	176	130/70			
1007 53 M			155	120/80	2+ Arcus. Bilat. pterygium.	Prostate 1+	Absent lat. po tion of eyebro Scar right ear Scar right inguinal area.
1041 59 <b>M</b>	Chest pain URI		184 '63	120/46 Rales left lung	Rt. pterygium.		
10 <sup>1</sup> +2	Menarche age 17. IMP Feb. '64. Para.6,grav.4. Losing weight.		120 133 '63	130/80	3+ Arcus. left pterygium. Scarred right ear drum. Caricus teeth.	2 midline scars 1x3 cm.Cervical erosion.Uterus 6-8 cm. above pubis.	Tinea versicolo
1043 29 F	Menarche age 14. IMP 3/5/64.		96	105/60	l+ Arcus. Bilat. pterygium.		
1050 C. F	Menarche age 18. IMP 2/15/64. Para.l,grav.l. Abd. pain.		138	120/78	Duane's syn- drome. Throat inflammed.		Scar right biceps.
1500 33 M			117 108 '63	120/70	Throat inflammed		Nevi right shoulder.

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Minimal arteriosclerosis.	11,800	37	450	Pap: Negative for Malignant Cells. Inflammation with some glandular cell atypia. Occassional anucleated squamous cell noted. Good estrogenic level.	Artericsclerosis. Rales in lung. Rec. chest X-ray and glasses.
Adenopathy '63.	18,900	47	403	Chest X-ray: Plural thickening lt. apex; increased bronchovasc. Markings from lt. hilus into apex (TEC?) '63.	
	8,500	14.24	415		Rales chest.
	7,000	1414	283		'64 hematological exam only. No other exam since '62,
	8,400	43	283	PBI 6.3 '64.	Obese. Hypertension.
					No examination since '61.
Minimal arteriosclerosis.	13,000	47	323	F B S 248 mg % '64. Pap: Negative for Malignant Cells. Moderately high estrogenic level for age. Smears have a relatively clean background.	Arteriosclerosis. Cataract. RX diabetes.
1 x 1.5 cm. mass dorsum right wrist.	5,800	39	280	Pap: Negative for Malignant Cells. Inflammation with histiocytic reaction.	Pregnant. Rec. removal ganglion rt. wrist
1 x 2 cm. subcutaneous mass rt. hypochondium. Swelling left knee.	8,600	50	330	PBI 7.9 '64.	Lipoma? Arthritis of knee?
Ulnar nerve palpable. Hansen's disease?	6,400	140	302		Prostatic hypertrophy. Hansen's disease questioned. Bone marrow taken for gen. stud
	9,200	142	427	B. Sugar 106 '63.	Resp. infection RX'd.
	7,300	40	370	B. Sugar 180 '63. Pap: Negative for Malignant Cells. Trichomonas Vaginalis infestation with marked inflammation and histiccytic reaction Endocervical cell atypia.	Cervical erosion and leiomyoma of uterus.
	7,000	40	324	P B I 5.8 '64. Pap: Negative for Malignant Cells. Mild inflammation. High estrogenic level. Cervical smear is scanty.	
	7,900	38	330	Pap: Negative for Malignant Cells. Mild inflammation. Degenerating endometrial cells present.	Duane's syndrome.
5005880	6,800	51	275		

	NO., AGE, SEX	PAST HISTORY	INJURIES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	1501 27 M	URI. Abd. pain.		147	106/60			
	1502 25 F	Menarche age 13. IMP July '63. Para.5,grav.3. 7 mos.pregnant.		124	100/60	Throat inflammed	Uterus 3FB below xiphoid.Cervical erosion.	
		-						
							-	
								·
				!				
	,							
•	·							
5005 <b>6</b>	8							

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	9,700	46	258	Chest X-ray: Card. enlarg., mainly lt. '63.	
	12,400	32	216	Chest X-ray neg.'63. Pap: Negative for Malignant Cells. Trichomonas Vaginalis infestation with severe inflammation, with inflammatory atypia and histocytic reaction.	Pregnant, 7 mos.
		-			
					· · · · · · · · · · · · · · · · · · ·
<u> </u>					
5005882					

<del> </del>		_ <del></del>	WEIGHT		!		
NO., AGE, SEX	PAST HISTORY	in jur ies	POUNDS HE IGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
2 11 M	URI		65-1/4 133.1	92/60 Gr II systolic m '62; no m '64			Perianal depig- mentation; scars and depigmentation on neck
3 11 M	URI		68.2 114.2	112/80	Myopia		Demigmented areas axillae & perianal areas; pig. area behind l. ear
5 א בו א	? Blood in stools '64		51.0 113.6	102/58 Systolic m '54; no m '64			Neg.
6 11 M	Recent cut on 1. big toe; pneumo- nia '54; inf. hepatitis date?		61-1/4 127.9	86/48 Gr. I systolic m	Trach. scar	Both testes down liver edge palp.	Neg.
8 12 F	URI		75.2 139.7	112/80 Systolic m '63; no m '64	Old impetigo scars	#3 breast devel- opment	Cafe au lait spo thigh; molluscum impetigo scalp 77 thigh lesion look more like a pig- mented nevus now '64
15 17 F	Moles on face		119-1/2 158.1	112/82 Gr I systolic m at mitral area			Neg.
17 13 F	Epigastric pain; nocturia; neg. '64.		99 <b>-</b> 3/4 115.8	80/60 Gr I systolic m	2.0 cm nodule in left lobe of thyroid; tongue papillae pigmen- ted		Depigmented area 1. ante-cubital fossa
19 15 M	Epigastric pain '60; scars on head & arm from known childhood injuries		84 149. 4	122/72 Gr I systolic m	Mole upper lip; scar 2-1/2x0.5 cm on scalp;kel- oid on arm;brown spots on teeth		Neg.
20 17 M	Headaches; bronchitis; melena & worms; neg. '64		117-3/4 159.4	140/92 RA 138/90 LA Recheck 124/82 Gr I systolic m	Corneal pigmenta tion; FB in eye- lid rt. ('56); neg. '64	-	Pig. patch back neck; biopsy pig. spots 1. neck
21 13 F	Earaches; URI's; sores in mouth '64		87-1/4 145.3	96/60	1.5x2.5 cm firm movable nodule i 1. lobe of thy- roid; no cerv. nodes	n	Pigmented pat back of neck
23 13 M	Pain in rt. knee; cough; swelling of feet ('59); abd. pain ('58); mild URI '64		97-1/4 147.4	106/48 Gr I systolic m '62; no m '64			Area of depi, on shaft of penis
32 14 M	Chest and abd. pain '58; no complaints '64		71.0 136.9	96/70 Gr I systolic m	Tonsils 2+	Testes down	Pig. nevus 3.5 cm on chest; depig. lesions on skin
, 33 12 F	Occ. cough; pain 1.knee & elbow ('63); worms '61; no complaints '64		81-1/4 147.1	116/84 No m			Scars on legs; small 1.5 cm nevus on neck- pale in color
42 13 F	URI; abd. pain; no complaints '64		68 138.5	102/60 No m	Scarred rt. TM		Impetigo scars; leg and neck warts
<b>т</b> † <b>м</b>	Colds; constipa- tion; earaches	·	63-3/4 130.8('61	90/50('59) Systolic m '59' gr I	Draining rt. ear '54		

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	7,650	38	430	PPD - '57 BCG - '57 Chest OK '62	
Head 51.5 cm; odd appearance to face; short stature	12,025	36	396	PPD neg. '57 BCG '57 Chest OK '62	Odd physical appearance - ? cretinoid; husky voice
Short stature - stubby fingers	6,250	37	365	Prominent aortic arch on '54 x-ray head of humerus deformed bilat. '62; PPD neg. '57; BCC '57	;
	7,550	37	328	PPD neg. '57 BCG '57 Chest OK '62 PBI 7.9 ('63)	
	11,075	40	454	PPD neg. '57 BCG '57	
	7,750	38	331	PPD neg. '57 BCG '57 Chest OK '62	
	6,350	39	309	PPD neg. '57 BCG '57 Chest OK '62 FBI 6.8 '64	
	4,675	40	380	PPD neg. '57 BCG '57 Chest OK '62	
	7,825	50	265	UA OK (?) Chest OK '62	
	7,000	42	275	PPD neg. '57 BOG '57 Chest OK '62 PBI 8.1 ('64)	
	7,400	39	365	PFD neg. '57 BOG '57 Chest OK '62	
	9,100	39	306	PPD neg. '57 Chest OK '62	
,	8,625	40	585	PPD neg. '57 Chest OK '62	
Deciduous upper lateral incisor persists	9,200	37	440	PPD neg. '57 BCG '57 Chest OK '62	
5006884	7.65	36	366	(61 counts)	Not examined since '61

NO., AGE, SEX	PAST HISTORY	IN JUR IES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
48 16 F	No complaints		103-3/4 155-0	138/78 Gr I systolic m '62; no m '64	Teeth fine	Liver at costal	Pig. patch rt.
53 18 F	Abd. pain daily; dysuria; hepa- titis (date?); lumps in abdo- men '64		101-3/4 155.0	126/70	Corneal opacities (posterior) date ?		Tinea
54 10 M	No sig. hx. '64		81-3/4 140.2	110/62 Gr I systolic m			Mottled pig. & depig. neck (fr. beta burn); biopsy '64
65 11 F	Mild URI '64		52.0 123.7	90/54 Gr I systolic m '62; no m '64	Vascular anomaly upper margin of disc OS	Liver 2 cm down	Neck scars noted
69 14 F	URI's; occ. abd. pain '58; worms; neg. '64		101 155.4	108/72 Gr I systolic m '63; no m '64; no cardiomegaly	Small nodule in		Neg.
72 17 F	ок 164		136-1/2 157.2	130/68 Gr I m in prd area		Abdomen OK	Acne on face
83 10 F	No hx. '64		64-1/4 113.3	100/74	Rt. TM red; dental caries-5; cervical nodes	Neg.	
84 10 M	No sig. hx. '64		57-1/2 124.0	82/60		ok	Scars
85 9 <b>M</b>	Worms; URI's		48 120.9		Assym. skull; rhinitis		Impetigo face '57
86 9 F	Otitis		44 116.3	95/50('62) Gr I sys m '62, '59; no m '56	Caries; generalized nodes '62		Papilloma 1. thumb; mole face; mollus '59
87 9 F	No complaints		48 118.3	78/58 Gr I sys m	URI		
88 9 <b>M</b>			52-1/2 118.0	82/60 Cr I sys m		Sore abdomen; diarrhea	Scars
89 9 M	No sig. hx. 164		45-1/2 115.2	92/68 Gr I sys m	OM bilateral	Testes down	Scar rt. axilla
90 9 <b>м</b>	Hosp. with bloody diarrhea '57		54 120.0	No murmur heard '64	Few bilat. cerv. nodes	Pigeon breast 162; liver 5 cm	
91 9 <b>M</b>	No sig. hx. 164	·	55-1/2 124.1	100/74 Gr I sys m	URI; rhinorrhea		

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	7,125	42	295	Chest OK '62 PPD neg. '57 BCG '57	
	6,300	40	531	Chest OK '62	
Lesion on back resembles a simple pigmented nevus	7,350	57	368	Chest OK '62	
Question of Sturge Weber raised '58	7,400	38	378	Chest OK '63 PPD neg.'56	
	6,600	41	403	PBI 12.2 '63 PPD neg. '56 PBI 10.2 ('64)	
Scars of impetigo	8,400		360	Chest OK '62	
	9,200	37	350	Chest CK '62 PPD neg. '57	
	8,400	38	<del>1</del> О4	PBI 9.3 ('64)	
	7,287	40	257	PPD neg. '57 BCG '57	Examined '63 No exam. '64
Cafe au lait spot abdomen	7,328	39	247	Chest OK '62 PPD neg. '57 BOG '57	Examined '63 No exam. '64
	11,450	38	378	Chest OK 163	
	10,500	36	355	Chest OK '63	
	10,900	40	395	PPD neg. '57 BOG '57	
	11,000	37	380	Chest OK '63 PPD neg. '57 BCG '57	
00588 <b>5</b>	9,850	38	298	Chest OK '63 PPD neg. '57 BCG '57	

NO., AGE, SEX	PAST HISTORY	in jur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
92 8 F	? Inf. hepatitis submandibular abcess '57; URI		48-1/2 117.0	Gr I sys m RSR	Caries		Scars
93 7 M	No sig. hx. '64		45-1/2 115.8	96/56	Active otitis media; cervical nodes	Liver 1 cm down	Warts on legs
94 7 F	Chronic cough; hosp. for malnu- trition in '57; no sig. hx. '64		40 107.1	88/60			
95 8 F	Polio		40-3/4 114.0		Caries	Small umb. hernia	1
96 6 <b>π</b>	Polio 3/63; omphalitis '58		41 106.4	76/58 Gr I apical sys m		Liver and spleen are not palpable	
97 6 <b>m</b>	URI '64' rhinorrhea		41 113. 3	No m		Scars on legs	
98 6 <b>M</b>	Polio ?; no sig. hx. '64		37 101.3	84/50 Gr II sys m at apex & base P <sub>2</sub> = A <sub>2</sub>		Scars on legs	
100 8 F	Abd.pain; bronch pneumonia '56; no complaints '6		50-1/2 117-3	98/50 Gr II apical sys m			
101 6 F	Pneumonia '63		37 <b>-</b> 3/4 101.2			Liver 1 cm down	Scars
102 6 <b>M</b>	URI '64; polio? kerosene inges- tion ('60); rectal bleeding ('60)		37-1/4 110.7	88/40 Gr II sys m	Microcephalic (47.2 cm); flat back to head; mental retarda- tion; active URI		Impetigo sca
103 6 F	Polic - arm weakness; sores on corners of mouth '64		36.0 105.6	92/62 Gr I sys m P <sub>2</sub> = A <sub>2</sub>	LTM red; pharynx injected		
104 5 <b>M</b>	Neg. except for URI '64		34-3/4 104.9	Gr I sys m	URI with left OM		Warts rt. foot
105 5 <b>F</b>	Polio; URI		39-3/4 107.0	76/40	Ant. cervical & axillary nodes		OK except for scars
106 4 F	Previous polio		35 102.7	90/60 Gr I sys m	Ant. & post. cervical nodes		Liver 1 cm down
108 5 F	Pinworms		33-1/2	Sys m gr I '63	Cerv. nodes	Liver 3 cm '61	Furuncles

	Γ			·	
MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	9,100	40	520	PPD neg. '57 BCG '57	
	13,000	37	503	Chest OK '62	
	11,500	39	675		
Bilateral lower extr. paralysis (polio)	12,500	37	414	Chest OK '62 PPD neg'57 BCG '57	Examined '63; no examination '64
Total flacid paralysis of left leg with atrophy of gluteals as well	15,200	36	619		Rec. polio rehabilitation at Ebeye or Majuro
Small head (47.2 cm); flat occiput	8,500	37	678		
Very sl. lower rt. facial paresis persists	11,200	36	528	Epiphyseal dysplasia on X-ray of chest (hum.)	Rec. iron and Vit. C
	6,600	35	633		
	11,100	36	623		
	8,450	40	600		RX tonsilitis; rec. exam for retardation
No arm weakness found	10,900	36	583		
	12,600	39	429	Chest X-ray OK '63	
	11,650	37	433		
Very questionable rt.	10,600	37	417		
	13,200	36	490		
<u> 500638</u>	<u> </u>	L	<u> </u>	L	L

	NO.,	PAST HISTORY	IN JUR IES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	109 4 <b>M</b>	URI	. ,	38-1/2 114.0	Sl. pharynx injection	•		
	110 4 M	Polio?; melena & diarrhea '61; skin lesions '64		33-3/4 98. 3	88/46 Nom		·	Impetigo legs and chest
	111 5 M	No sig. hx. 164		29-3/4 95.7	No m. RSR	Ant. cervical nodes; purulent nasal discharge		Wart on leg
	112 6 F	Otorrhea; ? abd. pain '64		29 <b>-</b> 3/4 93.0	78/60 Gr I sys m	Cervical nodes	Liver 1 cm down	
	113 3 M	uri '64		30	No m			Scars; mole on upper lid OD
	115 4 M	No sig. hx. 164		32-3/4 87.0	Gr I sys m P <sub>2</sub> = A <sub>2</sub>			Scars on legs; molluscum arm
	116 4 M	Neg. history		32-1/2 95.3		Tonsils 2+		
	117 3 F	No complaints '64		25 <b>-</b> 1/4 89.1	Gr I sys m	Ant. cervical nodes		Scars
	118 3 M	Conjunctivitis; URI		29 91.7	86/42 Nom			Mongoloid spot rt. shoulder
	119 4 F			31-3/4 92.4	No ma	Draining 1. ear		Scars
	120	No hx. '64		31-3/4 92.7	No m			
	122 4 <b>F</b>	No hx. 164		29-3/4 93.8	No m	L. TM sl. red	Liver 1 cm down	
	123 2 F			23-1/2 81.3	88/56			
	124 2 F							
50058	125 3 F	No hx. of sig- nificance 164		29.0 88.4	No m		Liver not palp.	Scars on legs warts on feet

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.	α	LOOD DUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Fullness in LLQ	10,900	34	410		
	9,800	38	<b>ħ</b> ħ0		
	6,350	35	635		
	9,500	36	647		
	7,800	39	490		
	12,100	36	400		
	10,900	36	385		
	11,800	33	631		
	11,600	39	585		
	8,750	35	378		
No detectable paresis of left leg; measurements same for both legs (calf, thigh); reflexes OK	10,400	37	417	,	
	8,250	34	531		
	13,600	34	328		
	12,900	38	468		1963 examination; no examination '64
5005890	10,600	37	528		

NO., AGE, SEX	PAST HISTORY	injur ies	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
126 2 M	?Polio		24-1/4 81.0			Tip of spleen only	
127 2 F	?Polio; no hx. '64		21-1/4	Gr I systolic m '63; no m audible at this time ('64)			Small nevus 1. cheek
128 F	Congenital hemangioma rt. ankle; no hx. '64		16-3/4				Hemangiomas of neck and back
130 1 M	-	·		No na			
131 1 M			13	No m.			
132 . 1 M			13-1/4	No m			
134 1 F			17-3/4	No m			
135 2 F				No m			
801 8 M	Occ. abd. pain; repeated URI		39.0 108.4	88/64 Systolic m '62; no m '64	Head 49 cm	Liver not palpable	Warts on hand and legs
802 8 m	URI; abscess on back '56		48.0 118.1	Systolic m '62; no m '64	Inguinal & ant. cerv. nodes		No active impetigo
8 мі 803	URI; abd. pain occ.		46 118.1	Systolic m '63; no m '64	Head 51.1 cm	Both testes decended now	Scars of impetigo
805 10 F	Cardiac surg. '57; patent ductus; URI		61 129.9	98/82 Gr I sys m '63; no m '64,however P <sub>2</sub> is very loud	-2D myopia bilaterally		Warts on right foot (sole)
806 9 M			47.5 118.3	Gr I sys m '61	General adenopathy		Nevus 1. hand
807 10 M	No sig. hx. '64		41-1/4 116.7	102/64 Gr I systolic m '62; no m '64	Caries and pyorrhea; sub- mandibular node from caries; head 48.7 cm		
808 9 F	Abd. pain '59; ? worms		49 117.8		Tonsils #; genl.	Liver 1.5 cm '62	

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	8,600	35	433		
No apparent muscle weakness	13,500	32	565	,	Rec. iron and Vit. C
	11,700	33	350		Rec. iron and Vit. C
	8,750	37	485		
	13,950	35	670		
	8,000	28	470		Rec. iron and Vit. C
	11,400	29	719		Rec. iron and Vit. C
	13,650	23	628		Rec. iron and Vit. C
	8,800	40	398		
	10,700	40	265	Chest OK '62 PPD - '57	
	11,900	38	299	PPD - '57 BOG - '57	,
	11,400	41	458	Chest - pul. seg. prominent '62 (cause ?); FPD - '57	
	12,600	38	450	Chest OK '63 PPD - '57 BOG - '57	1963 examination; no examination '64
	13,600	36	454	Chest OK '62 PPD - '57 BCG - '57	Very poor teeth
5005392	9,738	40	520	Chest OK '62	1963 examination; no examination '64

NO., AGE, SEX	PAST HISTORY	IN JUR IES	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
809 8 м			48-1/4 123.9	82/60 Very faint sys m		Testes down	Scars
810 9 <b>F</b>	URI		56.5 131.6	102/62 Gr I apical systolic m - functional	-2D myopia OD; marked cupping of discs bilat.; serous rt. otiti media	9	·
811 10 F	Occ. URI's		56-1/2 125.0	92/60 Gr I apical sys m - functional	Serous nasal discharge		
812 9 F	Night blindness; convulsion '57 - cause?		58 <b>-</b> 1/2 129.7	118/76 Gr I sys m	Tonsils 2+		Tinea; impetigo scar active impeti on face
813 10 M	Pinworms; URI		55 125.9	104/72 P <sub>2</sub> > A <sub>2</sub> ; no m'64	URI; tonsils #	Liver 1 cm down on inspiration	Impetigo scar
814 12 M	ROM '61; neg.'64		69.0 13 <sup>4</sup> -3	92/68 No m	Mild URI	Liver 1 cm down; testes down	
815 13 M	Painful inguin. mass '63; abd. pain '59 ('57?)		89.0 149.4	108/52 No m	Eyes neg.; teeth good		Skin clear
816 14 F			104 152.3	112/52 Systolic m '63; no m '64 A <sub>2</sub> > P <sub>2</sub>	Tonsils 1+; ant. cerv. nodes		Skin scars only
818 12 M	URI		81-3/4 146.3	122/88 Gr I sys m '62; no m '64 A <sub>2</sub> > P <sub>2</sub>	Tonsils 1+; ant. cerv. nodes		Scars only
819 15 M	LOM '62. Occ. diarrhea; occ. abd. pain; neg. '64		123 164.5	108/68 No m '64; gr I sys m '59	Ant. cerv. nodes		
820 15 M	Worms '58; URI		109 116.1	110/70 No m, P <sub>2</sub> = A <sub>2</sub>	Ing. node 1 cm on right; URI. TM's red		Scars
821 17 F	Fever occ. '59; poor night vision; neg. '64		126-1/2 147.7	98/62 No m '64; gr I sys m '63	Exophoria		Skin neg.
. 822 17 <b>M</b>	Perforated L/IM '59; pul. TBC by hx.		169 159.9	92/40 Extrasystoles with bradycardia '63; no m, (pulse 92)		Liver edge pelp.	
863 14 M	No sig. hx. '64		85.0 147.0	126/78 Nom'64; gr I sysm'62			Acne
866 9 F	URI		46-1/2 119.2	82/50 Gr II sys m '63; split P <sub>2</sub> - no audible sys m	Thickened TM's; ant. cerv. nodes hard to see left fundus		· · · · · · · · · · · · · · · · · · ·

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD UNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	8,900	35	300	Chest OK '62 PPD - '57 BCG - '57	
	8,400	39	461	Chest OK '62 PPD - '57 BCG - '57	
	11,700	35	433	Chest OK '62	
	8,800	38	333	Chest OK '63 -PPD - '57 BCG - '57	
	6,650	36	405	FPD - '57	Chest X-ray
Head shape OK; size 50.7 cm	10,800	36	285	Chest OK '62 PPD - '57 BCG - '57	
	8,100	38	200	PPD - '57 BOG - '57	
	8,700	37	33 <sup>1</sup> 4	Chest OK '62 PPD - '57 BCG - '57	
	9,900	39	505	Chest OK '62 PPD - '56	
	5,450	38	273	Chest OK '62 PPD - '57 BOG - '57	·
	23,200	40	411	Chest OK '62 PPD - '57 BCG - '57	Rec. achromycin for otitis med
	8,500	38	425	PPD - '57 BCG - '57	
,	14,200	44	628	Chest OK '62	
	9,900	40	730	Chest OK '62	
<del>1 N O 5 S N H</del>	6,200	37	203	PPD + '57	

NO., AGE, SEX	PAST HISTORY	in jur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
870 8 <b>M</b>	Polio		46-3/4 120.9	92/66 Gr I sys m			Scars
874 17 M	Substernal pain		119 168.3	118/60 Pul. sys m '58			Healed skin lesion
879 9 F	Occ. diarrhea; sore on 1. foot		54.0 126.3	86/60 Gr I apical sys m	Liver 1 cm down		Marked warts on 1. foot; impetigo scars
887 18 M			116 169 '62	110/70	Hemangicma near disc - not thought to be Sturge Weber		Ch. impetigo
891 16 F	Pain in joints; neg. '64		90-3/4 151.9	100/68 No m			
892 19 M	Occ. abd. pain; no sig. hx. '64		114-3/4 161.3	92/50			
900 7 F			110	·	Caries; cerv. nodes '62		Sores on legs; impetigo '59
901 7 F	Polio; URI and cough '64		42 110.7	80/48	Canals OK		Molluscum on back
902 6 F	No sig. hx. '64		40-3/4 110.2	78/50 Gr I sys m with loud venous hum under rt. clavicle	Left TM sl. retracted		Impetigo lesion on elbow
903 6 F	Polio; foreign body ear; (deaf 1. ear '63); poor hearing only '64		38-1/4 107.4	76/40 Gr I sys m '62; Gr I apical sys m with change c position	Both TM's are thick and prob- ably have fluid behind them; tonsils 1+		
904 6 <b>m</b>	Abd. pain '63; worms '61; occ. abdominal pain '64		44-1/2 113.2	92/56 Gr I sys m '63, '62, '61; rales in chest; clear chest-nc m audible '64			Molluscum on face
905 5 <b>M</b>	No sig. hx. '64		35 106.1	88/60 Gr I apical sys m with musical quality			Ulcers leg; nevus left leg '57
906 6 F	Anorexia		34-1/2 107.4	76/40 Sys m Gr I '62; no murmurs audible - split P <sub>2</sub> '64		Liver edge at costal margin	
909 14 F			78.0 14.14	110/70 No m	Infected throat	•	
911 95 11 F	Broken wrist '59; no sig. hx. '64	·	77 135.0	112/40 Gr II sys m at apex '63; gr I systolic m at apex '64			Vitiligo or persisting tinea

<del></del>				<u></u>	Τ
MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Slight rt. lower facial paresis	5,800	35	483	PPD - '57 Chest OK '62	
	13,400	37	293	PPD + '56	1963 examination; not examined *64
					1962 examination; not examined '63 or '64
	8,300	41	235		
	7,900	43	295		
					Partial exam '63; not examined '64
Rt. leg Lt. leg  Mid thigh 28 23.4  Mid calf 23.4 22.0  Length 6.1 61  (ant. spine to heel)	19,500	35	543	Chest X-Ray OK '63	Rec. iron and Vit. C
tant. spine to neel/	9,900	314	264		Rec. iron and Vit. C
Rt. deltoid weakness again noted '64	13,800	39	419	General cardiomegaly '63-X-ray	Rec. audiometric workup for deafness; tympanotomy and drainage
	11,000	40	435		
	14,500	37	640		
	7,800	36	455		
	6,000	42	325		
500599b	8,500	36	416	Chest OK '61	

			····	WEIGHT				
	NO., AGE, SEX	PAST HISTORY	INJUR IES	POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	912 11 M	No significant history '64		58 130.8	88/56	Ant. cervical nodes; parotids do not seem enlarged		
	913 13 M	No hx. '64		70 138.0	106/64 Gr I sys m '62; no m, M <sub>1</sub> split in '64	Clear	Genitalia 2	Scars of impetigo
	919 16 M	Swelling of rt. wrist; abd. pain '62		77-1/2 150	80/50			
	921 10 <b>M</b>	URI'64		56-1/4 125.0	108/50 Gr I sys m	Tonsils +++		
	923 9 <b>F</b>	LOM '61-'63; loss of hearing; occasional earaches '64		46-1/2 116.3	82/60 Sys m gr I '63; no m '64	Carious teeth	Liver 2 cm '62; neg. '64	Numerous scars
	924 9 <b>M</b>			107 cm '62			?Undescended rt testis '62	
	925 14 F	ITP '59 Kwaj. Hosp.; no sig. hx. '64		84-3/4 145.9	102/60 Gr I sys m '62; no m '64	Sl. infection of throat		
	926 13 F	Night blindness in '63; URI '64		71.0 140.6	82/60 Sys m gr I '59; no m '64			Patch of impetigo on 1
	930 8 F	Polio, ?piles in '59; URI and leg pain '64		50-1/2 120.7	78/58 Gr I sys apical m			
	931 10 M	URI '64	-	53 122.9	98/56			Tinea on trunk
	937 11. F			77 137				Molluscum('
	939 18 <b>M</b>	No sig. hx. '64		149-1/4 163.7	118/58 No m		RLQ scar	
	940 15 <b>M</b>	Deafness '62; otorrhea '61		81-3/4 146.5	90/50 Gr I sys m '62	Caries + '62	RIQ scar, cause	r
	946 13 F			91-1/2 147.8	106/62			Scars
500389	950 20 F	No complaints'64		158-1/2 155.4	1.22/82		Obese	

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	12,000	36	215	Chest OK '63	
	8,400	39	340	Chest OK '62	
?Arthrogryposis '62	7,800	39	308	Chest OK '63; FPD + '56	
Cervical nodes	19,500	314	335	Chest OK '63	
	10,600	38	423	Chest OK '62	
Clonus and hyperactive reflexes '62					Not examined since 1962
	6,600	40	275	Chest OK '62; Platelets ('59) 340 ('61) 453	
	11,800	40	360		
	8,600	36	651	Chest OK '62	
	13,200	36	465		
Temp. 101, probably due to impetigo lesions on lega	17,800	37	570	Chest OK '62	
	10,800	43	220	PPD '56, neg.	
					Not examined since '62
	8,500	40	335	Chest OK '62	
5006898	6,500	41	75	Chest X-ray '62; prom. pul conus infiltrate rt. base PBI 6.7 ('64)	

NO.,	PAST HISTORY	IN JUR IES	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
952 7 M	Joint pains '61; no sig. hx. '64		43-3/4 115.0	84/52	Caries .		Scars only
954 7 F	URI		39.0 109.3	72/40	ROM & LOM '61; malformed 1. pinna '63	Liver edge palp.	Active impetie
955 12 F	No sig. hx. '64		98.0 145.0	116/82			Tinea spots
959 16 F	Fainting spells, edema of feet 63; neg. '64		127.0 150.0	120/82 Gr I sys m '62; no m '64	l+ tonsils		
960 13 F	No sig. hx. '64		97-1/4 148	104/70 Gr II-III sys m '63, '62; no m audible '64		·	
962 11 F	Worms '61; joint pain '61; nausea in '64		61-1/4 130.1	84/50 Gr I sys m '63; no m '64			
972 9 <b>M</b>	Otitis and abd. pain '61		45-1/2 117.2	80/40	Caries		Molluscum '61
977 18 F			109-1/2 157.5	122/76			
978 13 F	No sig. hx. '64		101-1/2 151.3	88/70	·		Scars of impetigo
97 <b>9</b> 9 F	No sig. hx. <sup>164</sup>		42-3/4 115.1	·			,
980 11 F	Occ. myalgia '61; ? piles '59; no sig. hx. '64		85.0 114.3	86/60		Liver edge at costal margin	
981 10 M	URI '64		51-1/2 125-3	86/50 Gr I sys m		Liver 1 cm down	Molluscum '6; scar on iliac crest (burn); active impet:
987 7 <b>M</b>	Worms 61		98 cm. '61.			Liver 2.5 cm '61	Impetigo
989 19 M				120/60 Gr I sys m '59			Molluscum - chest
992 6 F	Admitted to hosp. with diarrhea '59		32-1/4 99.2	Gr II sys m '62		Liver 3 cm '59	Impetigo

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD DUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
Cervical and axillary nodes	16,400	37	610		
	11,600	38	328		
	7,800	39	538	Chest OK '62	
	11,100	38	1448	PPD + '51 Chest '62 infiltrate rt. base; Chest '63 neg.	
	9,250	37	390	PPD - '51 Chest Neg. '62	
	6,700	35	365	Chest neg. '62	
	6,874	39	364	Chest neg. '63	1963 examination; not examined 1964
	13,000	28	422		5 mo. pregnant; rec. iron and Vit. C.
	7,800	39	218		
	9,700	40	386		
	8,400	41	283		
	12,400	38	410	Chest neg. '62	
					Not examined since 1961
					Not examined since 1962
<b>6</b> 006900	-				Not examined since 1962

NO., AGE, SEX	PAST HISTORY	INJURIES	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gym	SKIN
993 17 F.	No sig. hx. '64		114-3/4 154.6	94/60 No m			Lump under 1. ear 1 cm '62; wart rt. axill '62; scars '64
995 7 F	URI		42 110.9				Excoriation of lip, mole on cheek '63; time on face '64
996 11 F	Joint pains at night for yrs., no hx. of further joint pain '64		62-3/4 133.1	106/60 No m erect; gr I m prone; seems entirely func- tional	Exophoria '59	Breast devel. #3	Bilat. acute otitis media
998 17 F	Infectious hepa- titis '58(?); no hx. of sig.'64		119.0 155.9	128/80 No m	Prominent papillae on tongue, dark in color		
1002 9 M	URI '64		43 113.1	94/66 Gr I sys m	Cervical nodes		Active impeti
1004 6 µ м	Joint pain '61; no hx. except URI '64		36.0 104.0	Gr I sys m	Tonsils ++++		Scars through
1006 6 M	Abd. pain after eating; poor appetite '64		36-1/4 106.2	82/60 Gr I sys m '63, '62; no m '64	Liver edge at costal margin; l+ tonsillar hypertrophy		
1009 5 M			37.0 99.1	Gr I sys m	Liver 1 cm down		Scars
1010 4 M	Earaches; no sig. hx. '64		33-1/4 99.6	Gr I sys m,		Liver 1 cm	Vaccination scar (fresh)
1011 5 F	No significant hx. '64		33 <b>-</b> 3/4 97.0	No m			Molluscum
1012	Polio (?); occ. abd. pain; neg. except URI '64		41-3/4 110.8	90/60			Scars
1014 8 m			39-1/4 113.4	88/46 Gr II m in apical and mitral area			
1015 3 M			29 #	·			
1017 6 м	Joint pain '61		28-3/4 95.6		Tongue desqua- mated '62	Umbilical hernia '62	
1018			30-3/4 92.8	Sys gr I m '62; no m '64			Skin ulcers ( leg '62; scar on legs '64

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD DUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
,	10,100	40	445	Chest OK '62	
	8,300	38	350	Chest OK '63	·
	14,300	33	629	PPD '56, negative; chest x-ray '62 - prom. pul. conus	Recheck X-ray; rec. iron and Vit. C
	10,900	40	326	Chest neg. '62	
Inguinal nodes 1 cm	14,500	35	363		
Nodes throughout	12,800	37	681		
	16,900	37	553		
	8,100	38	280		
	11,500	37	613		
	11,400	38	283		
	7,200	35	478		
	8,600	42	225		
	12,200	41	167		1963 examination; not examined '64
	9,600	33	416		1963 examination; not examined '64
5005902	12,800	36	649		

NO., AGE, SEX	PAST HISTORY	injur ies	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
1019 4 F	URI		30 <b>-</b> 3/4 95 <b>.2</b>		Bronchitis; liver edge palpable		Active impetigo
1020 5 F	Red eyes 1 yr.; eyes still red'64		28 <b>-</b> 3/4 94.5		Conjunctivitis '63; bulbar conjunctival vessels injected in '64		Impetigo; keloid-like lesion on neck
1021 5 <b>F</b>			22 # 161				Impetigo '61
1022 4 F			32-1/4 99.1		· ·		
1024 4 M	Diarrhea with blood '61; neg		39-1/4 100.0	Gr I sys m '63; no m '64			Scars
1025 5 F	Draining ears; polio; neg. hx.		29.0 93.5	Sys Gr I m	·		Skin neg.
1026 4 F	Hx. neg. 164		29-3/4 96.7	Gr I sys m			Skin neg.
1027 3 M	No sig. hx. '64		27 87.0	Gr I sys m, very faint			Scars only
1028 3 M	Occ. diarrhea with bld. or pus '63		21-1/2#				
1029 3 F			29 <b>-</b> 1/4 90.5				
1030 3 M			29-1/4 90.2	Gr I apical sys m			Vitiligo-li spots on bc inguinal sc contracture hand
1031 3 F	Polic; no sig. hx. '64		30-1/2#	Gr I sys m			Molluscum on trunk; impeti on legs
· 1032	Neg. exam. '62	:					
1033 14 M	Neg. '64		105 150.0	110/78 Gr I sys '63,'62; no m '64			
1034 6 F	Worms, poor appetite '63; URI only '64		38 <b>-</b> 3/4 112.5	90/60 Gr I sys m - P <sub>2</sub> > A <sub>2</sub>	Tonsils 1+		Scars

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		LOOD DUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
	11,100	34	373		
	14,850	37	629		RX infected neck scar (Bacitracin ointment)
	15,400	35	420		1963 examination; not examined *64
	8,200	37	665		
	8,500	34	400		
	13,700	40	635		
	11,200	34	575		
	9,100	39	423		
	12,500	36	347		1963 examination; not examined in '64
Molluscum on body; wart on hand	8,750	37	440		
	9,600	<b>3</b> 6	510		
Hemangioma chest wall '62, '63; genl. adenopathy; no leg weakness	10,900	38	525		
					Not examined since '62
Adolescent breast enlargement rt. '63; breasts	7,900	38	613		
5005901	9,400	39	410		

NO., AGE, SEX	PAST HISTORY	IN JUR IES	WE IGHT POUNDS HE IGHT CENT IMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
1035 15 F	No sig. hx. '64		107.0 146.3	116/78 Gr I sys m - mitral area			Scars
1036 12 M	No sig. hx. '64		66-3/4 134.1	106/64 Gr I sys m '62; no m '64		Liver at costal margin	Scars
1037 2 M	Polio between '62 and '63; no interval hx. '64		24=3/4#			3 cm inguinal hernia	
1038 2 M	Cold only '64		27-1/4 84.0				Scars and active impetig
1039 2 M	URI - mild '64			Gr I sys m not transmitted '64			Scars
1040 3 M	No sig. history '64; polio '63; rashes on neck in '63		28 <b>-</b> 3/4 87.0			-	Scars
1044 2 F	No sig. hx. '64		20#			Liver edge palpable	Skin neg.
1045 2 M						Spleen 2 cm '63	
1046 1 M			17-3/4#	No m	Ears neg.		Skin neg.
1047 2 M	No sig. hx. '64		18=3/4#			Spleen 2 cm '63	
1049 4 M	No sig. hx. '64		35.0 97.9	No m			
1051 9 F	URI		59 123.6	104/56			
1052 11 M	URI		58 132.1	106/74 Gr I sys m	Tonsils 3+		
1053 5 M	No sig. hx. '64		33-1/2 99.0	92/58 Gr I sys m	Tonsils 1+	Liver 1 cm down	
1054	No sig. hx. '64		15#	Gr I sys m - RSR			

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.		BLOOD OUNTS HCT	PLAT	LAB DATA, Urine, Pap., X-ray, atc.	COMMENTS & RECOMMENDATIONS
	12,500	42	433	Chest X-ray neg. '62	
	11,000	37	151		
Fresh vaccination scar	8,025	37	681		
	10,700	35	500		
	14,100	44	493		
	9,600	37	603		
	11,000	29	635		Rec. iron and Vit. C
	12,700	35	545		1963 examination; not examined *64
	10,500	34	520		
	17,700	35	634		
				·	
	11,200	39	494		
	9,400	36	495		
	8,300	38	490		
5006906	13,800	39	225		
<del>-                                    </del>	<del></del>				·

				···				····
	NO., AGE, SEX	PAST HISTORY	injuries	WEIGHT POUNDS HEIGHT CENTIMETERS	BLOOD PRESSURE HEART & LUNGS	EENT	ABDOMEN Gu or Gyn	SKIN
	1055 1 F							
	1056 1 M			8-3/4#				·
ļ	1057 1 F			15#	No m			
	1058 1 M			8-1/2 #	No m			
	1503 6 м	Sores on nostrils; no hx. of sig. '64		30-1/4 96.1	78/58 Gr I apical sys			Scars
	1504 2 M	Polio (?) date?; no sig. history aside from leg pains '64		25-1/4 85.2	Gr I apical sys			
		-						
·								
						·		
							· · ·	
			· ·					
500b9	Γ Ο							

MISCELLANEOUS, NEUROLOGICAL, TUMORS, ETC.	1	BLOOD COUNTS WBC HCT		BLOOD COUNTS		LAB DATA, Urine, Pap., X-ray, etc.	COMMENTS & RECOMMENDATIONS
					Not examined '64		
a	12,600	36	636		Eczema from cows milk, change to rice or Jugarco		
	8,200	37	550				
	8,588	39	251				
No evidence of paresis; reflexes normal							
					·		
500690	1						

### APPENDIX 9

## ANTHROPOMETRIC STUDY OF ADULT MARSHALLESE

Albert R. Behnke, Jr., M.D.

Unifying Principle Underlying Anthropometric Measurements.

F, a factor derived from  $\sqrt{W/h^{0.7}}$  is proportional to the sum of 11 circumferences, and the sum of the 11 circumferences divided by F is a biologic constant, approximately 195 (194 to 197) for widely differing groups of males. If the mean value for each measurement is divided by F, then the quotient (Mean/F or d) can be used for comparison of measurements. The d values are the raw measurements converted to a common basis for comparison of relative body size.

Analysis of Data.

#### RONGELAP FEMALES MEAN VALUES\*

	Group 1 N- 10 Age 30.3 yr. Weight 52.4 kg. Height 15.10 dm F** = 2.797	Group 11 N =10 Age 31.8 yr. 51.2 kg. 14.71 dm. F = 2.793	Reference Woman 20 to 24 yr. 56.8 kg. 16.38 dm F = 2.832		
Circumference	cm d Values	cm d Values	cm d Values		
	( cm/F)	(cm/F)	(cm/F)		
Shoulder	94.08 33.63	94.45 33.82	97.16 34.30		
Biceps	28.44 10.17	28.53 10.22	26.90 9.50		
Forearm	23.95 8.56	23.14 8.29	24.28 8.57		
Wrist	14.76 5.28	14.65 5.25	15.31 5.40		
Chest Waist (Abd.1) Abd. avg. Buttocks Thigh	81.79 29.24	81.02 29.00	83.17 29.39		
	(70.99)(25.37)	(72.30)(25.89)	(66.33)(23.42)		
	79.52 28.43	78.65 28.17	72.33 25.53		
	90.95 32.50	90.18 32.30	94.60 33.44		
	53.52 19.14	51.87 18.58	56.24 19.85		
Knee Calf Ankle	34.97 12.50 30.33 10.84 19.59 7.00 553 197.3	35.52 12.72 31.65 11.34 20.01 7.16 550 196.9	35.16 12.41 34.37 12.13 20.74 7.32 560 197.8		

<sup>\*</sup>Individual data on separate table. \*\* Factor (F)  $\sqrt{\frac{1}{W/h}}$  (Weight), h(height)

## SELECTED MEASUREMENTS FOR COMPARISON WITH U.S. DEPT. OF AGRICULTURE DATA

Average d values Groups 1 & 11

U.S.D.A. Age Group (35-39yr.) N = 1215, W(61.11 kg) h(16.04 dm, 63.3 in.)

U.S.D.A. Age Group 10yr N = 6253 W(31.90 kg) h(13.82 dm)

F = 2.960

F = 2.252

	d Values	cm	d Values	cm_	d Values
Chest	29.12	88.93	30.04	67.76	30.09
Waist(Abd.1)		74.85	25.29	57.77	25.65
Buttocks	32.40	99.34	33.56	71.88	31.92
Thigh	18.86	57.00	19.25	41.66	18.50
Calf	11.09	33.22	11.22	27.40	12.17
Knee	12.61	35.30	11.93	29.03	12.89
Forearm	8.42	24.89	8.41		
Wrist	5 <b>.27</b>	15.26	5 <b>.1</b> 6		
Ankle	7.08	23.60	6.98		
Sum	150.5		151.8		

## INDIVIDUAL DATA

	Young Wome				into two group	ps
Grou	ip 1 N = 10	Body Weig	ght = D <sup>2</sup>	x h·7 x <u>.2</u>	D = Sum	ll cm/100
No.	Age	Height decim.	Weight	Weight Calc.*	Sum Circum.	h is height in dm
14	35	15.13	57•7	56.1	574	
18	36	15.49	49.3	49.5	534	
24	23	14.92	40.9	41.8	497	
1001	30	14.92	58.8	59 <b>.7</b>	594	
1050	30	15.67	62.7	63.0	60 <b>0</b>	
1502	25	15.49	56.4	53.9	557	
71	38	14.41	56.6	55.7	588	
829	25	15.37	50.4	49.8	537	
51	35	14.90	45.0	40.2	523	
832	26	14.07	45.9	46.2	526	
		<del></del> -				
Mean	30.3	15.10	52.4	52.2	553	

# INDIVIDUAL DATA CONT'D

	Group 11	N = 10				
	No.	Age	Height Decim.	Weight Ops.	Weight Calc.	Sum Circum.
	835	30	14.61	43.6	43.5	511
	841	31	16.07	61.8	59.5	5 <b>78</b>
	843	35	14.61	58.4	57-4	587
	865	31	15.18	44.1	42.5	504
	867	36	15.03	52.7	55.8	5 <b>7</b> 3
	895	34	15.18	54.5	54.6	565
	896	24	12.59	45.5	43.5	538
	932	29	14.48	47.3	46.4	529
	934	29	14.73	64.3	64.4	620
	945	39	14.61	40.0	40.5	493
Мє	ean	31.8	14.71	51.2	50.8	550

* Ca	alc. Wei	ght (kg) =	(Sum Circ	um./100)	2 x h.7 x	.255				<b></b>
Grav	id? 49	25	15.49	75.5	74.2	739	(12	circum.	Abd(1	<b>) &amp;</b> 2
11 17	61	18	15.37	76.4	74.6	742	н	10	11	**
11 11	74	26	15.43	82.0	81.2	773	"	11	н	**

Calc. Weight (kg) =  $(Sum 12 \text{ circum/112.9})^2 \times \text{h}^{\cdot 7} \times .255$ 12 Circumferences = 10 circum. + Abd (1) and Abd (2) (11 " = 10 circum. + Abd (avg.)

## RONGELAP MALES

Height	Weigh	nt -	Calc. Wt.	F 7/w/n	0.7	Sum 11 Circum.	Sum 11 Circum	
Group 1 _N	<u> = 19</u>	<u>.</u>	Age 30 (20	to_39)			r	
16.27	63.7		64.6	3.007		590	196.2	
Group 11 N	= 10		Age 48 (4	<u>0 - 53)</u>				
16.15	70.8		70.6	3.178		616	193.8	
Group 111	<u>N</u> = _10		Age 58 (5	<u>4 - 64)</u>				
15.58	61.3		63.0	2.995	•	588	196.3	
Group 1V N	10_		Age 73 (6	<u>5 - 88)</u>				
15.80	61.6		62.7	2.987		586	196.1	
Circum.	Group Mean cm	p 1 Mean/F	Gro Mean cm	oup 11 Mean/F	Gro Mean cm	oup 111 Mean/F	Group 1V Mean Mean/F	_
Circum.  Shoulder Biceps Forearm Wrist	Mean	Mean/F	Mean	Mean/F d ———— 34.60	Mean	Mean/F d 34.35 10.53 9.18	Mean Mean/F	
Shoulder Biceps Forearm	Mean cm 107.1 31.65 27.64	Mean/F d 35.92 10.65 9.30	Mean cm 109.6 33.11 28.54	Mean/F d 34.60 10.42 8.98 5.49 29.92	Mean cm 102.9 31.53 27.47	Mean/F d 34.35 10.53 9.18 5.84 30.49	Mean Mean/F cm d  103.4 34.60 29.12 10.32 25.75 8.63	

194.11

196.31

196.92

196.14

## RONGELAP MALES - INDIVIDUAL DATA

Group 1 N = 19 Av. age 30

Group 111 N = 10 Av. Age 58

Number	Sum 11 Circum.	Weight Obs.	Weight Calc.*	Number	Sum 11 Circum.	Weight Obs.	Weight Calc.*
845	604	70.0	67.6	41	550	52.7	55.1
864	622	70.4	71.4	80	58 <b>2</b>	57.3	58.9
881	642	77.0	77.2	973	583	58.7	60.9
882	555	55.7	56.2	94 <b>7</b>	549	50.0	53.1
885	592	63.2	65.3	840	619	70.9	71.4
966	600	67.3	67.8	853	625	70.4	68.7
1501	617	66.8	70.1	11	549	51.1	53.7
823	588	63.2	65.1	910	559	54.5	55.8
77	558(h,15.50)	(55.8)**	55.8	82	- 587	60.0	61.4
10	600	63.2	65.2	878	679	87.7	87.7
27	592	64.1	65.8	010	019	91.1	91.1
37	59 <b>7</b>	66.4	66.9				
40	568	56.8	57.8	Group	1V N = 10 Av. Age '	73	
73	610	71.6	71.9		<del></del>	-	
827	5 <b>71</b>	57.7	59.4	29	· 540	50.2	51.3
828	551	54.0	53.6	856	553	54.1	55.7
830	604	68.6	67.4	860	55 <b>1</b>	51.8	54.6
833	591	61.5	65.4	884	593	69.0	66.9
836	554	57•3	57.5	897	668	77.7	77.5
·		<u> </u>		915	559	56.8	. 55.9
Group 11	N = 10 Av. Age 44	5		918	684	85.5	87.8
842	612	70.0	67.8	964	603	61.4	63.5
50	660	84.1	82.4	. 5 <b>5</b>	559(h, <b>1</b> 5.36)	(55.6)***	55.6
917	657	83.6	81.2	899	558	56.8	57.1
7	5 <b>78</b> .	58.2	60.2				
4	602	65.0	67.5		•		
16	569	56.4	58.0		ssumed stature 15.50		
849	720	99.1	96.5		tature left blank i		
1007	616	70.4	69.9		eight based on assu	med(H) = 1	L5.36
68	575	60.0	61.4	đ	ecimeters.		

Remarks

The equation, D<sup>2</sup> x Height 1.0 x.lll = Weight (kg) gives a good approximation also of weight. With this equation, calculated weights are lower. For the Rongelap group, the correct power of height lies between 0.7 and 1.0

Calculation of Weight.
Sum 11 Circum./100 = D

D<sup>2</sup> x Height. x .263 = Weight (kg)

Interpretation of Data.

The d values for Group 1 reflect good muscular development and leanness based on a comparison with the d values of a Reference (Military Man)\* and other groups.

The d values for Group IV reflect loss of lean tissue and fattening that accompanies the aging process.

The d values of Group 11 are somewhat puzzling. This group does not have the muscular development, for example, of the older age Group 111, despite the increased weight of this group. The number of individuals in each group except Group 1, is small, however. There should be at least 30 men in each group. Nevertheless, there is no question about the excellent muscular development of Group 1. The relatively small ankles compared with Reference Man\* may be a physical characteristic of the males of this race.

d Values for Reference Man
Shoulder (36.00), Biceps (10.32), Forearm (8.72), Wrist (5.62),
Chest (29.84), Abdomen Avg. (25.49), Buttocks (30.36),
Thigh (17.80), Knee (11.90), Calf (11.64), Ankle (7.31)

<sup>\*</sup> Reference (Military Man) Age group 20 - 24 years. Weight 70.0 kg.

Height 17.40 decimeters (68.5 inches).

Sum of 11 Circumferences = 600 F = 3.078

Sum 11 Circum./F = 194.9

### Conclusions.

- 1. The men in the Group 20 to 29 years, especially, reflect excellent physical development. The d value for biceps girth is 10.65 compared with 10.32 for a reference military (young) man. (A difference greater than 0.20 is highly significant).
- 2. By contrast, the women (ages 24 to 39) with the exception of the arm measurements are either physically immature, or they have lost a considerable amount of lean tissue.

The striking immaturity is reflected in the girths of hips and thigh. The d values for these measurements are much lower than the comparable d values for a reference woman and for the mean values for a group of American women measured about 1937 - 1939 by the Dept. of Agriculture in connection with garment patterns. The relatively small size of the calf musculature is noteworthy. The d values for arm size compare favorably with those of a reference woman and with those of the USDA (35-39 yr) group.

APPENDIX 10

Nausea and Vomiting in Marshallese Following Exposure to Fallout,

March 1, 1954

		-	Nau	sea	
Subject No.	Age (1954)	Sex	Onset	Duration	Vomiting, Onset
2	2	М	3/1 (1200)	?	
3	1	M	3/2	3 days	3/2 and 3/3
4	38	M	3/2	1 day	
5	2	М	3/2	l day	3/3
9	22	M	3/2	?	3/2
10	24	M	3/1 (1600)	1 day	•
11	50	М	3/2	?	
14	25	F	3/2 (1200)	2 hours	
15	7	F	3/2	?	
19	3	M	3/2	?	
20	7	M	3/2	1 day?	
21	3	F	3/1 or 3/2	?	3/1 or 3/2
22	17	F	3/2 (0700)	5 hours	3, 2 02 3, 2
24	13	F	3/2 (0700)	?	
27	26	M	3/1 or 3/2	?	
32	3	M	3/2	?	3/2
33	1	F	3/2	3 days	3/2
34	45	F	3/2 (1200)	12 hours	
36	7	M	3/2 (1200)	2 days	3/2
36 37	20	M	3/2	1 days	3/2
39	15	F	3/1?	1-2 days	
40	29	r M	3/1 (1200)	1-2 days 2 days	
42	3	r F			2 (2
43	66	r F	3/2	2 day <b>s</b>	3/2
			3/2	1 day	
49	15	F	3/1 or 3/2	1 day	
54 5.0	1	M	3/1 or 3/2	?	
58	59	F	3/2 (0800)	4 hours	
61	8	F	3/2 (1200)	4 hours	
62	57	F	3/2 (0600)	6 hours	
63	36	F	3/2 (0800)	4 hours	
64	30	F	3/2	1 hour	
65	1	F	3/1 or 3/2	1 day	
66	29	F	3/2 (1800)	12 hours	
67	14	F	3/2 (1200)	1 hour	•
68	45	M	3/2 (0800)	4 hours	
69	4	F	3/1	2 days	
71	28	F	3/2 (1000)	5 hours	
72	6	F	3/1 or 3/2	?	
74	16	F	3/2	?	
75	12	F	3/2	1 day	
77	26	M	3/1 or 3/2	1 day	
78	37	F	3/2 (0800)	4 hours	
80	46	M	3/1 (1800)	1 day	
82	50	M	3/2	l day	

NOTE: Total of 44 cases (69%) of 64 people receiving 175 r reported nausea in the first 2 days after exposure. No nausea was reported in the 18 Ailingnae people (receiving 69 r) or in the 157 Utirik people (receiving 14 r).

APPENDIX 11

Pediatric Anthropometric Data (Height and Weight) on Rongelap Control (Unexposed) Children,

1957 through 1964

			19	57	19	58	19	59	19	60	19	61	19	62	19	63	19	64
No.	Sex	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b
801	M	6/29/56	69	17	81	21	87	25	92	23	97	31	100	34	104	35	108	30
802	M	3/16/56	66	19	79	24	88	28			101	35	106	38	111	4í	118	39 48
803	M	3/18/56	71	20	85	26	91	29	100		104	37	108	38	112	43	118	46
go/t	M	/56	74	23			-											
805	F	2/25/54	88	27	<del>9</del> 6	36	104	40	112	49	119	49	121	52	126	<b>5</b> 6	130	61
806	M	1/ /55	79	25	89	30	96	34	104	39	108	40			118	48		
807	M	6/13/55	84	25	9ó	29	95	28	100	37	104	34	108	38	112	40	117	41
808	F	3/29/55	81	23	<b>8</b> 8	28	96	32	104	36	109	39	113	43	118	49		
809	M	6/18/56	76	22	84	25	99	29	102	32	107	36	113	38	118	43	124	48
<b>810</b>	F	2/5/55	91	27	<b>9</b> 9	32	105	34	112	39	118	بلبآ	121	46	126	52	132	57
811	F	2/14/54	<b>8</b> 5	28	93	32	<b>9</b> 9	34	105	38	111	42	114	46	118	50	125	57
812	F	2/ /54	ଞ୍ଚ	27	96	<b>3</b> 3	102	37	-		115	42			124	54	130	59
813	M	1/2/54	89	29	95	33	102	35	109	40	113	بلبل	117	48	122	52	126	55
814	M	4/5/52	99	36	105	40	112	43	118	50	122	53	125	57	130	62	134	69
815	M	5/4/50	113	43	119	46	125	50	129	57	133	63	136	<b>6</b> 6	141	71	149	89
816	F	10/31/49	116	47	122	52	127	<del>59</del>	133	70	138	76	بلبلًا	80	150	94	152	104
817	M	10/19/50	116	49	121	50			130	69	138							
818	M	3/4/51	$11/_{4}$	43	119	48	125	51	130	58	134	65	138	70	142	<b>7</b> 5	146	82
819	M	12/15/48	132	57		66	135	71	140	78	145	89	بَلَةِ 9لَلة	95	155	iii	165	123
820	M	10/25/48	124	53	128	56	128	61	134	72	146	<del>7</del> 9	152	90	157	106	161	109
821	F	8/1/47	122	58	129	68	135	76	143	93	146	103	148	107	148	114	148	127
822	M	12/26/45	132	<b>6</b> 6	136	69	141	79	146	<b>9</b> 1	154	10L	158	112	<b>1</b> 59	120	160	169
823	M	8/11/43	145	84	152	95	158	109	162	124	165	126	165	126				
82Ĺ	M	4/3/44	านุ่า	77							16ó	124	16Ú	131				
825	F	3/9/42	151	101	152	107	150	336	162	aol.		•					_	_
826	F	/37	154	78	172	-	152	115	153	124								
827	М	4/20/40	157	121		100	3.56	107	-	-								
828	M	8/26/40	150	106	157 151	122	158	123										
829	F	/39	152	104	-	103							<del></del> -					
830	M	9/9/ <b>3</b> 8	160	128	162	nl.n		***										
831	M	6/21/39	152	98	157	141 113	160	100	360					_				
863	M	6/25/50	112	44	117	49	160	122	160	125	177	<u></u>	126	70	140	75		95
866	F	7/ /55	81	19	85 85	49 25	123 91	55 30	127	60	133	64	136 110	70 41	140 114	75 44	147 119	85 47
869	м	4/ 9/46	130	57	134	64	140 91	30 74	147	<b>5</b> 8	105 155	37 98	110	41	117		119	71

ഗ്ര				19	57	195	58	19	59	19	60	190	51	19	62	190	53	19	64
0 0	No.	Sex	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., lb	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b
-0 -0	870	M	2/21/56	76	19	82	24	92	27	100	31	106	<del></del> 35	111	38	116	42	121	47
	872	M	8/4/43	149	83	159	102	167	124					***					
CO ·	874	M	8/ /46	133	59	138	68	145	81			-				168	119		
	876	F	/39	160	120								_						
	879	F	4/ /54	81	2/1	93	29						-					126	54
	885	M	10/17/38	164	120	165	135	3.53		3/0		 3/5	105						
	887		10/19/14	141	67	146	 -l	153	86 57	160	104	165	105	169	116			150	
	891	F	5/15/48	122	46	126	54 64	130	57 70•5	135	65 €Li	143 3 Ch	74		300	150	90	152	91
	892 404	M F	7/17/46	128	53 90	132 139	100	138 139	100	145 139	108	154	9H	156	102			161	115
	896	F	5/6 /38 7/ /57	137	90	139 68	18	129 82	23	129	100					223			
	900 901	F	7/12/57			67	16	78	23			94	31	100	38	111 105	<b>3</b> 8	111	42
	901	F	10/23/57			63.5	12	75 75	21			93	30	99	34	103	36	110	42
	902		11/19/57			57	10	71	19			7) 	30	97	34 34	101	35 35	107	38
	904		12/22/57			) l	13	79	22			96	32	101	35	107	39	113	45
135	905	M	10/23/57			62	Ĭ,	74	19			91	27	95	30	102	39 30	106	35
Çi	906	F	3/1/58					68	<u>1</u> 5			90	25	96	28	102	32	107	35
	909	F	3/11/50		-	109	40			120	50	125	51	<del></del>		137	74	141	35 35 78
	911	F	3/8/53			101	38	108	41		50	119	55	125	61	129	66	135	77
	912	M	6/1/53			101	<b>3</b> 7	109	38	114	بلبل	120	48	124	51	127	54	131	77 58
	913	M	3/27/51	-		114	43	120	47	126	55	129	56	131	60	135	65	138	70
	919	M	3/9/48		-	125	47		<del></del>			136	58	141	63	148	71	150	78 56 47
	921	M	10/11/53			98	38	105	39	111	42	115	48	118	51	122	54	125	56
	923	F	6/9/55			82	25	88	<b>2</b> 9	98	38	102	36	106	37	111	42	116	47
	924	M	/55			84	29	<del></del>						107	J1				
	925	F	5/4/50			115	بأبيا	120	48	124	55	131	57	136	68	140	78	146	85
	926	F	2/26/51			114	44			125	52	128	56			136	66	141	71
	930	F	4/4/56			<b>6</b> 7	26	95	30		<i></i>	106	36	110	41	116	44	121	51
	931	М	4, 4, 2			90	30	7) <del></del>	,-	104	37	109	41	=-		118	50	123	53
	937	F	/53	-		101	39					122	54	128	63	133	69	137	77
	939	M	1/10/46		***	141	86	146	97	152	118	159	117	162	134	162	133	164	149
	940	М	9/19/48			124	54	130	57	135	66	139	<b>7</b> 2	147	82				
	946	F	10/6/50			114	7-	<del></del>				130	67	<del></del> ,		144	78	148	92
	950	F	7/29/44		-	151	109	-	****			135	126	-		<b>1</b> 55	134	155	159
	952	M	9/26/56			<b>8</b> 7	26	92	29	99	<b>3</b> 2	103	35	107	38	112	42	115	44
	954	F	6/ /56					<b>7</b> 9	23	-		92	28					109	<b>3</b> 9

		19	57	19	58	19	59	19	60	196	61	19	62	19	63	19	64	
No.	Sex	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., lb	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b
955	F	5/11/52			112	43	118	48			129	65	133	71	139	82	145	98
959	F	8/30/48			128	65	134	74	<b>140</b>	95	148	107	149	119	150	132	150	127
960	F	12/5/51			115	47	121	51	126	59	133	63	138	74	144	86	148	97
962	F	11/3/52			102	39	108	42			118	49	122	53	125	55	130	61
965	F	/ /44			145	91					148	95	150	101				
967	M	8/10/43	·		152	104	158	117		-	160	133	160	145				
971	M	8/13/43			151	93	158	106	161	116	164	124	165	126				
972	M	7/1/55	-		92	30	98	32	104	36	110	38			117	46		
976	M	10/19/47			137	74	141	90	-							<b>_</b> -		
977	F	2/9/46		-	143	74	150	102		-	155	112					158	110
978	F	10/20/50		*****	118	50	123	50	129	66	135	70					151	102
979	F	6/5/55			84	23	91	28	96	31	102	32	108				115	43
980	F	10/3/52			108	39	113	44	118	50	123	53	•				144	85
981	M	8/8/54			94	31	101	33			112	40			120	47	125	52
985	F	5/20/52			102	<b>3</b> 5			-									
986	F	10/51/24			92	29				-	110							
987	M	/57									98			-				
988	F	7/ /54		-	94	31	<del>9</del> 6	33	105	38	110	41						
989	M	1/23/46		~~	134													
990	F	/54			8/1	514				-								
992	F	8/14/57					77	20			94	28	9 <b>9</b>	32				
993	F	2/25/47			132	59	<b>1</b> 40	67	148	81	153	<b>9</b> 9	154	117	155	120	155	115
995	F	3/19/57		-	73	20	81	25	***		95	34	101	36	106	37	111	42
996	F	1/16/53			102	31	108	35	112	43	118	44	122	49	127	54	133	63
997	M	/52		-	111	44	*****		-									
998	F	6/12/47			135	65	142	72	-		154	99	155	106	156	113	156	119
1002	М	3/22/55			-		91	28		-	101	34			108	. 40	113	43
1003	M	3/28/58			***		75	21										
100L	M	5/31/58			-		72	20	-		ජිජි	27	93	31	99	34	104	36
1006	M	8/12/58			-		70	15			87	25	94	28	100	32	106	<b>3</b> 6 <b>3</b> 6
1009	M	1/22/59	-	-	***		58	12		-	79.8		87	31	94	34	99	37
1010	M	1/27/59		-			53	9		***	****	22		26	93	31	100	33
1011	F	3/9/59				-		7			-	24					97	34
1012	F	Age 4'62									94	3Ì	100	33	105	37	íiı	42
101/1	M	Age 6'62								<b>-</b>	98	30			108	36	113	39
1015	M	12/31/60				***	****	-					78	24		29		

			19	57	19	58	19	59	19	60	19	61	19	62	19	63	19	64
No.	Sex	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b								
10	M	Age 4'62		-							a	22	90	29	96	29		
1018	¥	3/17/60							-		****		78	22			93	31
1019	F	1/18/60											80				95	31
1020	F	7/15/59												23	89	27	95	29
1021	F	5/11/59										22						
1022	F	11/20/59									-		84	<b>2</b> 6		30	99	32
1024	M	11/13/59									76	25	85	31	92	35	100	39
1025	F	6/13/59		-								18	81	24	87	26	94	29
1026	F	5/28/60				-		-				-	<b>8</b> 0	21	90	<b>2</b> 6	97	. 30
1027	M	12/7/60			****								71	18	82	23	87	27
1028	M	2/22/61		-	-								71	16		22		
1029	F	3/8/61	-		-	-					-		-	17		26	91	32
1030	M	3/26/61			-								72	22		26	91	29
1031	F	1/5/61											75	20	86	<b>2</b> 6		31
1033	M	/50	-										87	78	143	86	150	105
1034	F	Age 4'62				-							96	32	106	<b>3</b> 6	113	39
1035	F	Age 12'62											145	92	146	98	146	107
1036	M	Age 10'62											127	56	131	60	134	67
1037	M	9/18/61				***	-						65	14		20		25
1038	M	10/31/61											66	17	74	24	84	27
1039	M	12/18/61				-					_		***	11				22
1040	M.	9/24/61	***						***	-			66	17		25	87	29
1,008	F	6/24/58								•							95	32
1013	M	9/23/60																
1044	F	9/17/62														16		20
1046	М	10/ 9/62														14		18
1047	M	12/28/62																19
1051	F	/ /55															124	59 68
1052	M	/, /53															132	68
1053	М	/ /56													'		<del>9</del> 9	34
1054	М	11/29/63																15
1056	M	3/4/64								·								9
1057	F	8/ 4/63																15
1058	M	1/16/64																9
1503	M.	/ /58													89	27	96 95	30 05
1504	M	/ /62														21	85	25

APPENDIX 12

Pediatric Anthropometric Data (Height and Weight) on Children Born to Exposed Parents,

1956 through 196	64	9	1	zh	oug	th	56	9	1
------------------	----	---	---	----	-----	----	----	---	---

			19	57	19	<b>5</b> 8	19	59	19	60	19	61	19	62	19	63	19	64
No,	Sex	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., lb	Ht.,	Wt., 1b	Ht.,	Wt., 1b
<b>67</b> *	F	10/17/54	76	21		થા			97	30	105	36	112		115	43	118	48
8 <b>8</b> *	M	9/ 8/55	70	21	<b>8</b> 1	26	89	31	98	36	103	39	108	43	113	48.	118	52
<i>*</i> 9	M	12/28/55	ģ1	21		عاب	87	28	95	22	100	<b>3</b> 5	105	38	109	40	115	52 46
90 * 91 *	M	11/29/55	71	22	<b>8</b> 6	28	94	32	101	36	108	41	113	45	120	51	120	54
91 *	M	1/ 3/55	85	26	90	29	97	31.	104	38	110	43	116	Ţę́	129	51	124	56
92	F	3/16/56	71	22	źĭ	26	97 86	34 28	94	33	101	36	106	41	111	45	117	49
92 93 94 95 96 97	M	2/17/57	50	8	74	21	86	27	93	32	100	36	106	39	110	41	116	49 46
94	F	10/ /56	6Ŭ	16	, <del>, , ,</del>		8L	26			95	34	100	<u>3</u> 5	105	38	107	40
95	F	2/ 5/56	69	18	83	25	91	28	98	32	105	35	109	38	114	41		
96	M	2/12/58	• ,		51	-9	71	23	<b>8</b> 3	29	90	31	97	38			106	41
97	M	10/31/57				16	78	23		-/	90 96	34 31					113	41
98	M	3/ 5/58					71	20	-		85	28	91	38	95	33	101	37
100	F	4/26/56	71	22	83	25	88	33	96	35	102	40					117	
101	F	4/24/58	, -		-,	-,		"	,-		89	27			101	33	106	<b>3</b> 8
102	M	3/16/58					75	18	84	24	93	28	99	30	105	33	111	51 38 37 36
103	F	5/28/58					70	16				26	بلَاوَ	30	99	31	106	36
104	. M	10/ 2/58					68	17			86	26			<u>9</u> 8	31	105	35
105	F	10/ 9/58					65	16			85	26	92	29	99	34	107	40
106	F	3/11/59					-						89	26	96	33	103	35
107 108	F	1/22/59										22						
108	F	12/16/58										ᆀ	87	-	95	32	98	34
109	M	1/ 7/60										21			95	33	114	39
110	M	12/ 5/59											84	26	90	31	98	39 34
111	M	5/24/59											83	23	<b>8</b> 8	26	96	30
112	F	6/ 8/59											80	23	87	27	93	30
113	M	2/27/61												2ó		24		30
115	M	8/16/60											***	21	80	28	87	33

<sup>\*</sup>Data for 1956 on the first five children are as follows: No. 87, 16 1b; No. 88, 58 cm, 15 1b; No. 89, 13 1b; No. 90, 62 cm, 11 1b; No. 91, 75 cm, 22 1b.

No.	Sex	Birth date	1957		1958		1959		1960		1961		1962		1963		1964	
			Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b								
117	F	3/28/61											71	16	<b>7</b> 8 82	20	89	25
118	M	11/25/60											68 76	18	82	26	92	29
120	F	6/27/60											76	22		27	93	32
116	M	5/15/60														28	95	33 32
119	F	7/19/60													85.8	29	92	32
119 121	F	6/7/60																
122	F	4/12/60											77	22		<b>2</b> 6	94	30
123	F	11/26/61											56				81	24
124	F	10/23/61											56 66	16	74	23		
125	F	6/ <b>/61</b>											71	17	8i	23	88	29
126	M	9/26/61											71 64	16	73	21	81	24
127	F	5/17/62											~-			17		21
128	F	1/30/63																17
130	M	4/19/63																
131	M	10/28/63																13
132	M	/ /63																13
134	F	5/ /63																18

APPENDIX 13

Pediatric Anthropometric Data (Height and Weight) on Rongelap Exposed Children,

1954 through 1964

			1954	(Mar.)	1954	(Sept.)	19	55	19	56	1957	
No. ⊄ sex	Age at exposure	Birth date	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b
83 M	In utero	6/8/54	~~		66	15	74	20	क्षां	28	90	31
84 M	** **	5/31/54				-	86					28
85 M	m te	9/17/54			-	. 7	66	17	86		88	27
86 F	P# F#	10/17/54	-			-	58	16		'	83	25
54 M	1 y	2/21/53		23			కం	28	90	36	98	39
65 F	1 y 2 m	12/52		21		23	79	21+	83	27	<b>8</b> 8	26
5 M	1 y 4 m	10/52		20	80	25	85	27	ජිජි	29	93	31
3 M	1 y 5 m	9/52	Ratura	22	83	25	تلع	28	90	31	93	31
2 M	1 y 4 m	10/52	•	22		<b>2</b> 6	85	29	90	31	95	34
6*M 8*F	1 y 4 m 1 y 8 m	10/52 6/52		2년		<del></del>	<b>81</b>	27	90	30	95	32
33 F	1 y 7 m	7/52		23 22		25	87†	26	91	30 70	99	35
42 F	3 y	3/51	•	25		25 27	88 92	28 28	95 07	<b>3</b> 2	.99	33 74
21 F	3 y	3/51	81	29			92 91	32	97 98	31 35	100 101	36 39
17 F	3 y 4 m	10/50	90	31		32	98	35	102	38	101	41
23 M	3 y 5 m.	9/50	,,,	3 <del>8</del>	<del>9</del> 5	37	100	46	105	47	110	49
32 M	3 y 6 m	8/50		29		. 29	95	32	100	36	105	38
44*M	4 y	3/50		32	99	32	<del>-</del> -	-	107	40	112	40
69 F	3 y 7 m	7/50	95	33	100	34	100	37	105	42	113 .	
19 M	5 y 2 m	1/49	99	33	104	32	105	37	109	39	113	42
48*F	5 y 8 m	6/48		41	116	43	117	444	121	48	126	52
	7 y	3/47	108	74/4	113	40	112	44	116	49	121	53
	7 y	3/47	106	35	114	37	113	41	116	48	123	47
20 M	6 y 9 m.	5/47	110	43	111	43	115	49	118	57	125	59
36 M	7 y 4 m	10/46	116	50	120	51	119	- 57	124	64	129	6 <u>l</u> t
61 F	8 y	3/46	124	66	120	70	130	79	139	99	145	115
47 M	8 y 5 m	9/45	120	55	123	54	124	56	130	64	133	68
81*F 53*F	8 y 2 m 8 y 2 m	12/45 12 <b>/</b> 45	114	43	100	48	119	50	124	55	130	56
76 M	10 y 7 m	7/43	118 128	48 63	122 130	<b>61</b> 116	126	49 45	130	51	133	56 20
75 F	11 y 6 m	8/42	135	79	138	82	135 145	65 91	138 145	73 100	143 146	79 108
26 M	12 y 4 m	10/41	1))	19	143	104	150	110	155	138	163	140
	13 y 5 m	9/40		96	142	100	טעב	99	344	100	165 145	103
	13 y 5 m	9/40	138	98	147	94	155	105	155	111	156	114
67 F	13 y 7 m	7/40	151	115	152	117	152	108	152	116	156 154	123
39 F	13 y 5 m	9/40	148	104	149	102	150	103	150	108	151	109
	15 y	/38	142	96	<del></del> /	104		108			150	116
74 F	15 y 9 m	5/38			151	134	151	142	151	137	151	141
	15 y 9 m	5/38	151	120	154	120	154	116	154	110	-/-	
49 F	15 y 11 m	3/38	150	120	150	123	150	127	150	145	150	146
73 M	18 y	3/36	170	160	170	158	170	156	-		-/-	
	19 y 19 y	/35	147	96	741	112	•	-				
	4.7 T	/35	155	128	165	132						

<sup>\*</sup>Ailingnae group.

1958		1959		1960		1961		1962		1963		1964	
Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b	Ht.,	Wt., 1b
98	34	105	<b>3</b> 9	113	45	117	48	123	55	127	<u>5</u> 8	131	64
بلاو	<b>33</b> .	99	35	105	39	110	44					124	58
96	30	101	33	108	37	113	40			121	48		
91	28	97	30	104	33	108	36	112	41	116	ĵ <sup>‡</sup> ĵ <sup>‡</sup>		
107	45	113	47	118	55	124	57	127	62	134	73	140	82
93	<b>31</b>	98	33	103	38	109	40	114	بلبل	119			
96	35	99	36	102	40	105	44			111	48	114	5 <b>1</b>
99	37	102	40	107	44	109	50	110	51	114	65	114	68
103	40	108	42	116	46	120	52	125	56	128	61	133	65
100	38	106	41	112	747	116	50	120	<b>53</b>	124	59	128	6 <b>1</b>
105	39	111	43	118	45	122	52	125	57	132	63	140	75
107	39	116	بلبل	121	50	127	55	132	60	141	72	147	81
108	40	113	42	118	47	123	50	127	54	132	58	139	68
110	بلي	115	49	121	56	127	76			140	79	145	87
117	48	122	53	128	60	133	6 <b>L</b> t	139	70	146	81	152	100
119	52	123	60	129	68	134	75	138	79	142	87	147	97
113	43	118	46	121	54	125	56	129	58	132	64	137	71
117	47	122	52	127	58	131	6 <b>L</b>	-					
120	50	126	54	130	62	138	69	1744	77	150	90	155	101
119	48	123	51	128	60	132	63	137	66	141	76	149	84
133	61	139	69	145	82	151	92	بلا15	96	154	103	155	104
132	63	139	75	148	<b>93</b>	153	115	154	118	160	126	157	137
130	5 <b>8</b>	136	65	<u> 1</u>	75	152	86	155	99	157	113	158	120
132 134	9tt	135	67	140	80	ъц <b>8</b>	87	155	104	158	112	159	118
152	76	139	80	146	<b>8</b> 8	149	97	156	115	163	124		
140	124	152	142	154	152	153	156	154	161				
	77	145	79	152	98	160	119	165	130	167	137		
135	66	145	83	152	92	154	107	155	108				
142	67	149	83	<b>1</b> 53	90	154	92	154	94	154	98	155	102
153	97	162	113	166	127				138				
151	103	149 149	.99	150	94								
173	153	175	154 04	175	165	175	168						
	109	148 143	96	149	100								
156	123	163	122		117								
	121	7 ~~		158	118	160	127						
155 152	116	155		155	106								

APPENDIX 14
Supplementary Anthropometric Data on Rongelap Control Children

1957										
Subject No.	Sitting ht., in.	Lower extremity length, in.	Upper extremity length, in.	Arm span, in.	Biacromial width, in.	Intercristal width, in.	Head circ.,	Chest circ., in.	Left calf circ., in.	Buttock circ. in.
801	16	12.5	10.2	26	6.5	5	17.0	17	7.0	17
£02	17	11	11.5	33	7	5	16.5	17	6•5	18
803	18	يلا	11	27	6.5	4.5	18	17•5	7	18
80L	17	15.5	12	29	7	5∙5	18	18	8	19
805	2 <b>0</b>	18	<b>Щ.5</b>	33	8	6.5	18	19.7	<b>6∙</b> 5	19
806	19.5	16	13	31	8	6	19.5	19	7•7	19
807	19	17	13.2	32.5	g	6	18.7	18.7	7•7	18.5
808	19	15	12	30	7•5	6	18	18.5	7•5	$\mathfrak{I}$
809	19	14	12	28	6.5	<b>5•</b> 5	17.5	19	6.7	17
810	20.5	19	14	33•5	8	6	<b>1</b> 9	<b>1</b> 9	7.2	19
811	19.5	19	14	31.5	7•7	6	19	19.5	7•7	19.5
812	20	18.5	14.2	<b>3</b> 5	8.5	6	19	21	7•5	19.5
813	19.5	18.5	14.5	34.5	8.0	6.5	19	19.5	8	19.5
814	21	21.7	16.7	38	9	7	19	22	8	21
815	23.5	25	19	42 <b>.</b> 5	10	7.5	19	<b>2</b> 2	9	52
816		26 <b>.</b> 5	19	<del>Щ</del>	9•5	7	19•7	21.7	9	22.5
	25.2			44	10.5	6.5	20	22.2	9	24.5
817	24.5	26.5	19	42			20	22.2		23.5
818 819	ટ્યા 27	26 25•2	19 20•7	43 47•5	10 10•5	7 8.5	19.7	24.5	9 <b>1</b> 0	25.5 24.5
	21 05									24.5
820	25	29.5	21.5	49	12	7•5	19.5	23.5	9•5	
821	26	28	20.5	46	10.5	8	20.7	24.5	10.5	26.5
822	25.5	30	22	51	11.7	9	20.5	25	10.5	33
823	30	34	25	59•5	13	10	20.2	<b>26.</b> 5.	12	29.7
824	27.7	33	5/1	55	13	9	20	25.5	11	28
825	31	<b>3</b> 5	<b>25.</b> 5	59	<u>זוְ</u> י	9	21	30.5	11.2	28
<b>8</b> 26	30	37	25	57	<u> 1</u> /1	<b>.</b>	21	26	10	30
827	32.5	37	28	6Jt	15.5	9•5	22.5	34.5	13.5	34
828	26	34	· 26.5	58.5	14.5	10	20.7	34	<b>1</b> 2•5	32
830	33	37	28.5	65	16	11	21.5	33.5	٦/t	36
831	30.5	36	<b>2</b> 6	60	14.5	8	22	30	12.5	<b>3</b> 2.5
863	22.5	25	18	43.2	9	6.5	19.5	24	9	22
<b>86</b> 6	19	14.5	12	29•2	7•5	<b>5</b> ∙5	18	18	7	17.5
869	<b>2</b> 6	30∙5	22.2	50	11	7•5	20	24.7	10	26
570	- 18	14.5	12.5	29	7	5	17.5	18	7	17
872	29.5	37	27	61.5	13.5	9	20.5	28.5	11	29
874	26.5	31	23.5	الم	12	. 8	20	24.2	. 10	29 26
876	33.5	37	28	63.5	13.5	10	21	30	13.5	34
879	19.5	17	12.5	31	8	6	18	18.5	7	19.5
885	33	37 <b>.</b> 7	29.5	67	15	10.5	<b>2</b> 2	33.5	13.5	36.5
<b>8</b> 87	28.5	33.5	علب ع	54.2	12.5	8	20	25•5	10.5	27.2
891	25	27	20	47	10	9	20	23.5	9	29
<b>#</b> 02	27.2	28.5	-0	47 14.5	17	<i>5</i> 8	20.5	2J.5	10	26

## Chest Head Head Head Sitting circ., Left calf Biacromial Bi-iliac Buttocks width. length, Subject circ. circ., cm No. cm cm CM ht., cm cm circ., cm dia., cm dia., cm 45.7 13.5 15.2 47.0 45.5 18.2 Ь6 17.4 13.3 801 47.3 47.6 802 45.2 12.6 15.4 45.5 18.2 17.3 14.1 16.8 48.5 13 48 803 19 15.1 13.7 4.7 56.5 49 47.5 13.6 15.4 21 17.6 20.7 805 17.1 53.3 49 49.5 49.8 13.4 15.9 **806** 20.2 18.5 48 807 47.2 13.1 16.3 49.6 49 19.5 15.3 18.5 49.7 46.2 12.7 16 53.2 50.3 20 808 19.7 15.2 47 4625 12 16.7 50 50.5 18.5 809 15.7 19.7 56.9 12.6 49.4 51.5 47.7 16.7 16 810 20 21.2 54.0 **811** 49.4 12.7 17.2 53.5 51.4 21.2 15.6 19.8 52.3 12.2 17.4 53.7 812 48.8 52.5 21.5 20.4 16 52.2 16.1 47.5 13.6 53.8 52.1 20.7 15.7 813 20.9 54.2 14 16.4 58.3 55.7 16.6 48.7 22.4 23.9 877 58 62.5 57 815 49.3 13.7 16.5 22.9 23.2 18.3 62.5 13.6 66.6 57 24.1 19.5 816 50.2 17.5 24.8 14 17.3 67 57 60.8 817 50.3 25.2 18.7 23.5 58 60.5 818 51.2 13.9 18 65.6 23.3 24.6 18 65.8 14.9 17.1 66.4 819 51.4 72.2 27.8 27.3 20.4 14 63.3 16.4 66.7 **820** 48.3 60.7 24.2 27.1 18.7 53 52•5 13.9 18.7 67 \$21 71.4 62.8 26.6 22.4 28.5 822 14.6 18.0 72.5 63.6 69.9 28.8 23.1 27.4 13.4 17.7 78.8 823 52 78.3 70.2 > 30 25.4 30.7 53.1 13.6 18 **825** 84 31.6 >30 25.3 \_--14.4 18.8 82 827 54 85.8 33.9 > 30 25.5 14.3 77 86.4 77.7 828 52.4 18.2 81.7 31.2 > 30 24.9 14.5 55•9 55•7 19.3 84.8 830 36.3 27.2 15 79 831 19.1 76 83.1 32.5 >30 25.7 14.3 17.1 59.2 59.4 863 50.5 62.9 23.9 25.2 18.7 13.1 16.1 49 866 46.4 52.7 48.4 19.1 18 14.4 14.2 869 16.3 63 67.2 50.6 70 26 27.3 21.1 870 46 13 15.5 47 46.4 46.5 19 19.3 14.5 14.7 872 53.2 17.7 78.6 75.6 79.4 31.4 > 30 25.3 874 14.6 16.9 51 71.4 62.9 69.1 26.5 28.5 20.8 46.8 879 12.3 16.g 49 53.9 50 20.2 21 16.2 15.2 هلا 89 885 56 18.9 85 34.6 28.6 69 887 51.3 13.8 17.9 75.8 67.7 28.3 28.5 21.0 64 891 13.1 17.5 50.3 67.3 59 24.3 24.9 19.5 66.5 14.2 892 52 18 71.4 64.5 25.5 27.2 20.5 51.6 896 17.2 13.8 75.6 31.4 11.8 900 43 14.8 42.5 16 12 16.7 901 41.7 12.1 13.8 41 17 13.6 12.9 902 11.3 14.0 40.6 39.4 18.2 13.7 12.4 903 36.5 10.5 12.4 36 13.5 10.5 **90L** 37.5 39

1958

1958	(cont	_)

					-	1936 (COIII.)				
500	Subject No.	Head circ.,	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
$\overline{C}$	905	40				40				
-0	909	50.3	13.4	17.1	61.1	51	22	21.5	18.0	
~	911	49	13.8	16.3	56.2	53.5	22.5	22.1	17.0	
	912	49.3	13.2	17.5	59•7	52.3	21.3	20.7	17.9	54 53
	913	49.6	13.4	17.3	62.8	52	22.3	23.2	19.2	57.8
	919	48	12.5	16.7	67.1	55•3	22.6	26.4	20.2	59
	921	49•9	12.8	17.8	56.7	55.8	22.6	21.6	17.0	55∙8
	923	47.8	13.1	16.7	48.5	47.0	17.4	18.2	14.0	
	924	48.8	13.2	16.8	50.7	48	19	17.8	14.5	
	925	51.0	13.5	17.8	63.1	55	21.8	25	18.2	56.5
	926	49.4	12.5	17.6	63.2	54.5	21.5	23.3	12.7	57.5
	930	47.2	13.3	16.2	50	48	19	18.7	14.0	***
	931	48.7	13.7	16.5	51.5	51.5	21.2	20.6	15.5	5 <b>0.5</b>
	937	48.4	13	16.6	55•3	52.5	21.5	21.2	16.4	56.7
	939	51. <sup>1</sup> 4	14.2	17.7	74.9	67.5	31	30	21.7	7h
	0بلو	48.6	13.4	16.7	65.5	61	25.2	26	20	74 62
	946	49.7	13.0	17.2	63.1	54	22.5	23.7	18.4	57
	950	54.7	и́.9	18.2	80.6		31.5	>30	21.6	85.5
144	952	47	12.8	15.9	51.3	47	19.2	18.5	14.5	47
	955	48.5	13.1	16.3	62.2	52.7	23.2	22.9	18.5	56
	959	51.2	14.4	17.0	69.1	61.3	26.8	27.9	20.4	68 68
	959 960	50•3	13	17.8	63.5	56.6	24.2	23.4	18.7	60
	962	51.0	13.3	17.9	58.4	54.5	21.6	21.9	18	57•5
	965	52.7	13.1	18.0	76.2		29.1	25.2		79
	967	52.5	14.4	17.8	79•7	78	32.7	> 30	23.5	
	971	51.1	13.9	18.0	78.9	69.6	30	> 30	22./1	75.5
	972	48.9	12.4	17.7	53.3	52	19	20.8	15.8	10.0 
	976	51.3	14.1	17.4	71.9	52 <b>6</b> 5	27.4	28	21.8	70.5
	977	51.7	$y_{4.1}$	17.3	76	60.5	27.5	29.5	23.8	69.9
	978	50.14	13.5	16.7	66.1	56 <b>.</b> 5	24	24.7	18.0	60
	979	47	12.6	16.6	48.3	45	17.8	18.0	14.3	46.5
	980	50.7(hair)		17.1	58.4	51	22.3	21	18	57
	981	45.8	12.7	16	52.9	49	21	20.4	14.3	51.5
	985	49.5	13.8	16.8	56.3	<u>5</u> 2	20.2	22.1	16.5	53.5
	986	46.8(hair)	12.9	16.2	54.5	48.5	20.2	20.1	15.2	49
	988	45.8	12.8	15.0	52.5	48	21	21	15.1	50•5
	989	52.3	14.3	18	72	66.9	27.6	29.4	20.6	69.7
	990	47.2	12.9	16.2	48.8	47 ·	18.0	19	13.9	47.5
	993	52.2	14.5	17.6	71.2	59	24.6	26.5	19.8	63
	995	43.6	<del></del>		7	42.5		~~	19.0	<del></del>
	996	47.4	13.0	16.2	55.8	49.2	20.8	21.7	16.8	<del>-</del> 52
	997	48.7	13.2	16.5	61.2	55	23.2	24.3	17.3	55•5
	998	52	17 7	10.0	73	63	25.3	26.5	22.0	22•2 68
		/-	-		17	9)	-7.7	£0.9	An è a	00

	1959										
Subject No.	Head circ., cm	Head width, cm	Head length,	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm		
<b>5</b> 01	- 46.6	13.9	15.5	50.9	47.5	19.0	18	14.8	47		
502	46.3	13	15.7	50.4	49.1	19.8	19.6	15.7	49.5		
803	48.6	13.5	17.1	54.4	49.4	19.6	20.5	ıμ.9	49.4		
805	48.3	13.8	15.5	58.8	54.2	21.4	21.2	18.0	55.5		
<b>806</b>	50.3	14	17.5	57•3	51.5	21.5	20	17	52.5		
<b>807</b>	47.7	13.3	16.5	52 <b>.5</b>		19.7	20	16.3			
<b>පි</b> 0පි	46.8	12.8	16.2	56.6	50•4	20.6	21.4	17.2	53.5		
<b>809</b>	47.2	12.2	17.2	54.8	49	19.5	19.4	16.4	47.2		
<b>810</b>	48.2	_	16.9	58.3	50	20.1	21.4	16.5	52.5		
811	49.6	13.0	17.5	55.5	50.7	20.8	20.6	16.6	52		
812	49.5	12.3	17.8	5€.€	53	22	22.2	17.6	52 54		
813	48	13.5	16.4	56.7	52 <b>.7</b>	20.6	22.3	17	<del>5</del> 1.7		
gบ์เ	49	<b>1</b> 4	16.5	61.4	56	22.3	23.9	18	56		
815	49.2	13.7	16.7	68.6	56 56•7	23.9	25	18.1	58		
8 <b>16</b>	51.3	13.8	17.6	68.2	59•4	25.5	25.6	21.5	56 58 64		
818	51.2	13.9	18	68.5	58.3	23.6	24.7	19.4	61.5		
819	51.5	14.8	17.1	74.6	<b>6</b> 6.5	28.4	28.5	21.9	66		
820	48.5	14	16	69	63	25.5	27.9	19.8	59		
821	54.3	14	19.1	73.7	6Ú•8	29.4	28	22.2	71		
822	52 <b>.</b> €	14.7	18.2	74.3	<b>6</b> 6.5	28.9	30•1	23.7	66		
823	52.4	13.4	18.6	83.1	76.5	<b>3</b> 2 <b>.</b> 9	> 30	28.5	83.8		
<b>8</b> 25	53.0	13.8	18.2	<b>83.</b> 0	70.5	32.8	- Ju	26	86 86		
<b>8</b> 27	53 <b>-</b> 5	Й•5	18.5	83.1		34.0	> 30	> 30	<del></del>		
831	56.2	15	19.1	<b>85.</b> 1	 79	33.6	- 50	25.0	<b>5</b> 5		
863	50.6	14.2	17.1	65.4	67.2	24.1	25.8	19.1	60.5		
<b>866</b>	47.4	13.3	16.3	52.8	51	19.8	20	15.2	51.0		
869	51.3	14.4	17.2	72.3	66.7	27.6	28.2	22	65.6		
870	46.6	13	15.7	5 <b>2.</b> 5	<u>⊬</u> 8•7	19.7	19.4	15•7	47.8		
874	51.8	ર્યો6	17.6	74.4	68 <b>.</b> 5	28.2	30	22.5	74		
887	51.3	13.8	17.8	78•7	69.6	29.7	30 <b>.</b> 1	22.0	72		
891	50•5	13	17.3	70.1	59.5	24.7	25 <b>.</b> 4	19.8	64.6		
892	52.2	ปั๋₊.2	18.1	73.5	66.2	27	27.7	21	69		
896	52.2	13.8	17.3	73•7		32.1	31	25.0	84.5		
900	45.7	12.14	16.0	1/4/ 	46.2		16.8	13.7			
901	45.5	13	15.2		44.5	17.3	. 17	14.5	47.3		
902	44.5	12.2	15.7		41.3	18	16.6	13.2	46.9		
903	42.7	12.1	14.6		43.1	16.0	16.5	12.0	40.7		
90Ú	45.€	12.7	15.5		45.6	17.5	16.2	14.2	بلبا		

bject No.	Head circ.,	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
905	44.8	12.4	15.7	-	ع. بلبا	16.3	15.7	13.3	42.5
906	42	13	13.8		40.5	39•5	16	12.6	39•5
911	49.5	14.0	16.7	61	53•7	23	23.7	18.0	56.0
912	49.8	13.2	17.7	63.5	51.2	21.2	23.1	17.8	5 <b>5</b>
913	50.5	13.6	17.5	65.6	54.4	23.0	24.4	20.2	59•4
921	49.8	12.9	17.9	59•3	55•7	22	<b>22.6</b>	18.0	54.5
923	49•3	13.3	17.0	49•5	48.8	19.2	19	15.5	49 <b>•7</b>
925	51.7	<b>13.</b> 6	17.8	65.4	57	22.7	25	19.5	59•0
930	48.2	13.3	16.5	54.€	48.9	20.4	19.7	14.6	49•5
939	51.7	IJ₄•3	17.6	78	72.5	<b>32.</b> 4	30.3	23.5	75•5
940	48.7	13.5	16.8	68∙8	62	25.6	24.1	20.4	63.8
952	47.4	12.7	16.6	53+3	48.3	19.4	19.1	15.4	47
954	47	12.6	16.5		46	18.2	16.2	и.6	<del></del>
955	49•4	13.5	16.8	63.4	<b>5</b> 5•5	24	23	18.8	59•5
959	51.6	14.3	17	71.6	65.5	28.5	28∙8	21.7	69
960	50.4	13.2	17.8	66	57	24.7	25.3	19.5	61
962	51.9	13.4	18 <b>.1</b>	62.5	54.9	22.5	22.4	18.0	58.8
967	52∙€	14.6	18.0	83.5	82.5	34.Í	> 30	23.7	83.5
971	51.6	14	18	82.3	74.3	31.1	>30	23	83
972	49•4	12.6	17.9	55•3	52.6	<b>19•</b> 5	21	16.5	51.2
976	52	14.2	17.5	75•5	71.8	30.1	29.6	22.8	76.5
977	53.1	14.5	17.6	81.5	<del></del>	30.9	30	24.4	81.2
978	51	13.9	17.1	68.1	57.8	26.2	25.2	19	65
<b>9</b> 79	47	12.7	17.2	50	47	19.6	19.5	15.3	48
980	51	٠ بلا	17.4	60.2	52.5	23.8	21.5	1 <b>8.</b> 8	57.2
981	46.3	12.7	16.0	58	50.5	21.5	21	16.2	51.5
988	46.5	12.9	15.6	54.5	49.5	21.3	21.4	16 ·	52.5
992	45•3	12.9	15.5		45	16.2	17	13.5	بليل
993	52.7	14.5	17.5	75•6	61.5	26.4	27.7	21	لبلا 66
995	49	12.7	17.5		49.3	18.6	16.4	14.6	46.5
996	47.8	13.0	16.4	<b>57.</b> 8	50.2	21.1	22.7	17.8	52.7
998	52.5	13.7	18.1	75.4	65	26.5	27.3	23.4	70
1002	47	$\mathcal{U}_{4}$	15.5	53	50.3	19	21.2	15.9	49.9
1003	44.2	12.5	15.5		44.5	-	-		
1004	45•3	12.4	15.8		43		16.2	13.0	-
1006	42•€	12.2	14•5		41.5		15.0	11.8	
1009	<b>38∙2</b>	10.8	12.6		38.7		13	11.7	-
1010	37	9•8	12.6	₩ <b>.</b>	35.8		- <del>-</del>		
		<b>/</b> -			2700			<del></del>	

Subject No.	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., c
801	47•5	Щ.2	15.7	54.7	49•5	20.3	20.2	16.3	50∙0
80	47.4	13.5	16	56	52	22	22.1	17.5	52
<b>3</b> 3	50.2	13.9	17.4	<del>5</del> 9	52.7	21.7	21.7	16.8	53•5
807	48.3	13.8	16.7	55.2	50∙8	20.6	22	17	<b>51</b> -
808	47.8	13.1	16.6	62.4	52.6	<b>2</b> 2•5	23.2	17.5	<b>56.5</b>
<b>ĕ</b> 09	48.5	12.7	17.2	60	51.5	20.5	21	18.1	50.5
810	48.6	12.9	17.2	61.9	53.2	22	24.2	18.4	58
<b>811</b>	50.2	13.2	17.7	62.1	54.5	22.5	<b>20.</b> 6	17.7	<b>5</b> 5•5
<b>812</b>	50.1	12.7	17.9	6H*5	56 <b>.</b> 4	23.0	24.7	18.2	57.0
813	49	14.1	16.7	62	<b>5</b> 5•3	22.7	24.4	17.9	57
814	50	1/4	16.7	64.6	60	24.4	26.3	19•3	62.5
<b>81</b> 5	50 52	13.9	16.9	71	62	25.6	27.5	20	66.5
<b>£16</b>	52	13.9	17.€	74	64	27.€	27.6	23	73•5
<b>517</b>	52.3	14.3	17.5	<b>75•</b> 5	72.8	29.2	29	<b>22.</b> 6	78.5
818	51.5	1/4	18.1	71.2	63	25 <b>.</b> 9	26.7	20.7	68.0
<b>81</b> 9	52.3	15	17.2	79	70.3	31	<b>3</b> 0	23.3	77
<b>820</b>	49.3	14.3	16.4	74.3	<b>6</b> 8	28.2	30	21.3	71.5
<b>821</b>	55	14.3	19.2	gl		<b>3</b> 3	31	با.26	83.5
822	54	14.7	18.7	79	74•5	32.5		27.2	<b>5</b> 0•5
<b>E</b> 23	53 • 5	13.7	19	87.3	81.5	34.4		29	87.5
824	53	<b>1</b> /1•5	18.2	85.2	80	33.6		25.2	85.8
863	51.5	14.4	17.3	69.4	61.5	26.3	27 <b>.</b> &	20.3	<b>6</b> 6
866	48.8	13.8	16.4	60.2	52.2	21.1	22	17	54.4
869	52.3	14.5	17.5	78.5	73.5	30.5	31	5H•8	77.5
870	47.9	$\mathbf{n}^{\dagger}$	16.1	57•5	51.5	21	22.5	17.5	51.5
557	52.5	14	18	5 • بلغ	77•5	32		25.5	<b>8</b> 0∙5
891	51.2	13.4	17.7	75•4		27	28	21.8	74
892	53 • 3	<b>14.</b> 5	18.6	81.3	72.6	30.3	31.0	23.8	76.7
901	47•5	13.4	16.5	<b>5</b> 5	49	20.5	19.9	16.2	51.0
902	47	13	16.4	51.5	49.2	21.1	18.6	15.0	51.0
903	45.7	12.7	16					-	*****
904	48.7	13.4	16.5	54.4	50.5	20.4	20.4	16.0	49
905	47.3	13.2	16.5	<b>5</b> 2.5	49	19.3	18.3	15.2	45.5
906	45.5	13.5	ni•9	50	46.8	18.5	19	15.3	46.5
909	51.8	13.6	18.0	69.7	57.1	25.5	23.8	20.0	67.2
911	51	14.2	17.1	68.2	60.5	26.7	26.1	19.0	63.2
912	50.5	13.5	17.5	68.8	55•5	23.4	ड्यों•प	19.7	59.0
913	50.7	13.7	17.7	70	57	24.5	26.2	21.5	65.0
9 <b>19</b>	48.8	12.5	17	71	60.5	24.6	27.3	21	67.8
921	49.8	13.2	17.8	65.2	<del>59</del>	23.6	23.7	18.6	59•5
923	50•4	13.6	17.8	57•2	50.5	20.5	21.3	16.9	53•5

## 1961 (cont.) Head Head Head Chest . Subject circ., width, length, Sitting circ., Left calf Biacromial Bi-iliac Buttocks No. CM. CIM cm ht., cm CEN I circ., cm dia., cm dia., cm circ., cm 925 51.7(hair) 13.8 68.6 63.2 17.6 59.5 24.2 19.5 27.5 926 70.6 64 50.6 17.7 58.0 24.2 12.2 25.2 19.7 930 . 49 53 13.6 58.5 16.5 52.2 22 16 22.5 931 50 13.9 17.2 55.5 23.3 17.5 60.3 55.2 23.5 937 50.0(braid)15.3 17.0 65.6 64.0 58.2 24.5 18.2 25.3 939 18.2 52.8 14.6 83.5 77.8 33.7 27 85.0 940 49.4 13.7 27.9 27.2 17.0 70 66.7 21.7 70 946 950 952 954 13.3 17.6 70.4 65.8 51.3 59.5 25 25.9 20.7 85 52 49 55 48 15.2 18.3 81.9 33.5 21 26.8 \_\_ 13.1 16.7 58.2 51.0 21.6 17.0 48.5 13.1 55.4 16.7 48 18.9 19.1 16.3 955 959 960 962 49.5 13.3 68.8 69 17.2 27 60.5 25.5 20.5 53 84.5 14.5 17.5 77.7 32.2 24 31 51.3 63.5 27.7 66 71.2 13.3 18.0 25.7 21.1 62 52 13.5 64.5 15.5 56.5 24.8 18.8 23.5 965 52(braids) 81.5 30 35 13 18.1 78.3 26.5 967 971 88.3 58 53.5 14.5 18.4 84.9 24.5 ~~ 52.2 87 14.2 18.1 86 79 31.5 \_\_\_ 25.3 972 53.3 17.9 55 22.5 17 50.2 13.1 61.2 20.7 977 14.2 82 27 87.0 53.5 17.7 31.5 \_\_ 978 51.5(hair) 13.8 63.1 27.8 26.2 70 17.4 73.7 20.8 979 980 18.5 50.5 48.3 16.4 55.1 50 20.5 21.1 13 56 19.6 61 14.2 67.2 25.1 23.6 51.7 17.7 55.7 981 986 987 52.1 22.4 17.7 22.9 47.4 12.9 16.3 62.8 55 55 57 48 61.6 23.3 23.3 18 13.2 16.5 21.3 48.5 16.6 58 53.2 21.5 20.5 12.5 17 48.3 988 60 17.6 46.5 15.7 53.5 23 23.1 13 992 993 52 **81** 47.6 13.5 16.4 19 15.5 50 20.3 72.5 23.2 80 29.9 14.7 17.8 31 54(hair) 995 996 52.5 18.2 56 15.6 51 21 20.6 50.5 13.2 59.5 61.2 18.9 49 16.7 55.2 23 25.1 13.3 79 998 54 18.4 53.5 29.7 26.3 29.6 14 1002 53 48•5 16.8 51.2 47.8 14 15.7 58.2 23.2 20.2 47.5 15.8 1004 48.5 13.3 17.1 51 19.2 19.6 16.2 44 1006 46.9 13.2 50.5 46.5 18.5 19.0 15.0 50 49 15 13.5 20.5 18 1009 45.8 16.5 1010 47 50.5 50 50 48 54 20.5 19.9 16.8 1012 47.6 12.5 17.4 49 57.2 16.6 1014 48.5 13 17.2 19 20.6 12.3 17.9 1017 45.4 16 16.6 46.2 12.0 1025

C	Л
C	$\supset$
$\subset$	$\supset$
C	<b>;</b> –
_(	
L	ر،
-	٠,

					1962				
Subject No.	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
gol	48.2	14.3	15.8	<b>5</b> 5•4	51.3	20.4	21.1	16.7	51.0
802	47.8	13.5	16.4	<b>57</b> • 4	54.4	22.5	22.5	18.5	53.0
<b>8</b> 03	50.4	14	17.5	60	53•4	21.5	22.5	17.4	52
805	49.8	14	16	62.8	57.2	23.6	24.5	20.1	
807	48.6	13.7	16.5	56.6	52	21	22.8	17.8	51.3
<b>ජ0</b> ජ	48	13.2	16.8	63.8	55.0	22.8	23.2	17.6	57.8
809	48.8	12.6	17.5	62	53	20.5	<b>2</b> 2.5	17.6	51.2
810	49.3	12.9	17.2	63	54.7	22	23.7	18.3	59
811	50.7	13.2	17.6	63.5	56	23	23.8	18.2	59 57•9
<b>81</b> 3	49.2	1 <u>/</u> i	16.7	62.7	57•4	23.6	25.1	18.5	57
81Ĺ	50.4	14.3	16.7	64.4	60.5	علٰه. ع	26.8	19.4	61.3
815	50.2	14	16.9	71	63.2	26.2	27.5	20.9	66
<b>816</b>	52.2	14	17.9	75.1		27.8	<b>2</b> 9	23.6	74.5
818	52	14.2	18.2	71.5	66	26.2	27.5	21.4	68.5
819	52.9	15	17.5	79.9	71.5	31.5	31	24.6	78.8
820	50	14.3	16.6	76.4	71	29.1		21.7	76.5
821	55.4	ν.í	19.3	80	<u>.</u>	32.9	31	. 26	79•5
822	54.2	15	19.7	83	76.5	32.9		26.7	85.0
823	53.5	13.6	18.6	86.5	81.5	34.5		28.5	87.5
863	51.8	14.5	17.4	67.6	65.6	26.8	29.1	21.3	68.5
866	48.9	13.6	16.8	61.5	54	21.8	22.7	17.2	56
870	48.4	13.5	16.4	60.9	52.7	21.3	23.6	18.0	51.9
892	54	14.5	18.5	80.5	73.3	31.1		24.4	74.7
900	48.1	13.5	16.2	55•5	51	21.5	20.7	17.7	53.6
902		aid)13.2	16.3	55.2	48.9	21.4	2 <b>0.</b> 3	16.2	51.5
903	46.5	13	16.1	53.2	53.2	2065	20	16.5	52
904	49.2	13.7	17	55	52.5	21	20.2	17	51.5
905	48.2	13.4	16.s	53.5	49.3	20.1	20.6	16.0	47.4
906	46.2	13.6	14.4	52.5	49.1	19.6	19	16.2	48.3
9 <b>1</b> 1		aid)Li.1	17.1	67.8	61.5	27.2	26.7	20	64
912	50.7	13.5	17.2	69.8	56	23.3	25.5	19.6	60
913	51	13.9	17.7	<b>6</b> 9 <b>.</b> 6	50 50	25	27.0	22.0	65.0
921	50.7	13.2	18.0	65	60.3	Si2	<b>25.</b> 2	19.5	62.3
923	50.6	13.6	17.5	58.4	51.5	20.4	22.4	17.5	53.9
925	52 <b>.</b> 4	13.7	18.0	70	63.5	25.5	27.2	21.3	67•5
930	49.5	13.7	16.8	62.2	53.9	22.0	23.0	16.3	54

1962 (cont.)										
Subject No.	Head circ., cm	Head width, cm	Head length,	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm	
939	53.6	и.6	18.4	87	81.3	35.5	-	27.7	86	
940	50	13.5	17.1	72.8	69.6	29	30 <b>•</b> 3	23.8	73.0	
952	48.2	13.1	16.5	58.2	53.6	21.8	22.6	20.5	70 <b>.0</b>	
955	50.2	13.4	17	69.2	63.2	27.6	26 <b>.6</b>	20.5	70 <b>.0</b>	
959	53.4	14.5	17.6	78.4		33.8		<b>26.</b> 5	<b>8</b> 6	
960	51.7	13.4	18.1	74.8	<b>6</b> 5	28.9	28.7	21.8	72	
962	52.6	13.6	18.3	67	58.5	23.5	25.1	19.5	63.0	
971	52.5	14	18.2	85.5	78.5	32.2		25.5	87	
992	48.3	13.7	16.6	<b>5</b> 5•7	50.2	19.2	21	16.2	51	
993	54.2	บุ๋.8	17.8	82.3		31.8	31	26	86	
995	50.6	13	18.4	57•7	54.2	21.1	21	16	53.0	
996	48.8	13.3	16.6	62.2	<b>5</b> 7•5	23.8	25.5	19.0	60.0	
998	54	14	18.6	81.3		30.3	<b>30.</b> 5	27.0	83.0	
1004	49.6	13.2	17.3	50.2	50	20	20.3	16.8	50	
1006	48	13.2	16.6	52	48.3	19	20.2	16	50 47	
1009	49.7	13.5	<b>16.</b> 8	50.2	51.5	21.3	19.1	16.2	50.3	
1012	48.4	12.5	17.1	55•7	50.2	20	21.4	17.5	51.8	
1015	47.2	12.6	16.6		46.5	18.5	17.8	13.7	47	
1017	46.1	12.3	15.9	52	46.8	18.6	19.1	15.8	45•7	
1018	47.1	12.5	16.5	-	45	17.5	18.5	<b>1</b> / <sub>4</sub>	بليل	
1022	45	12.7	15.2		48	19.1	18.8	14.1	48	
1025	48.1	<b>1</b> 2 <b>.5</b>	17.5		47	17.3				
1026	44.2	12.5	14.9		43.5	17	17.3	¥•5	43	
1027	46.2							~~		
1028	43.3	10.8	15.1		42.4					
1029	43.3									
1030	46	12.0	16.5		46.5	18.2	16.6	13.0	43.4	
1031	45.8	12.7	15.7				-			
1033	53.8	14.7	18.3	69•7	66.5	28 <b>.7</b>	26∙8	23.0	73.0	
1034	48.5	12.9	17	53•5	50	19.1	20	16	50	
1035	51.0	13.9	15.8	74.5		28.9	31.2	23.2	78∙0	
1036	52.2	14.3	17.8	67.7	62	25	25.3	20.4	63.0	
1037	40.8	12.0	13.3		38 <sub>•</sub> 5		-			
1038	42	11.4	14.6		42.2			<del>-</del>		
1040	41.7	11.5	14.0			43				

Subject No.	Head circ., cm	Head width,	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf circ., cm	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
801	48.3	14.3	15.6	57.0	52.0	21.0	22.1	17.1	53.3
802	48.2	13.6	16.5	56.7	55.3	22.5	23.5	18.7	56.3
803		14.0	17.6	58.5	55.5	22.6	24.0	17.9	56.0
805	43.5	14.1	16.3	62.5	58.7	24.1	25.0	20.9	63.0
806	52.0	14.1	18.0	63.1	57.3	23.0	23.8	19.0	5 <b>7•7</b>
807	48.7	13.9	16.7	59.4	53.5	22.0	23.5	18.5	55.0
808	48.4	13.2	15.9	60.9	57.0	24.8	24.7	18.6	59.0
809	49.2	12.7	17.4	62.1	54.7	21.3	23.7	18.5	54.5
810	50.2	13.0	17.4	67.5	57.7	23.4	24.6	<b>1</b> 9.5	62.2
811	51.1	13.5	17.8	61.8	56.5	24.0	23.5	19.0	59.0
815	51.1	12.7	18.1	66.7	57.5	25.0	26.5	18.6	63.0
813	49.8	14.1	16.8	63.5	58.3	24.1	25.9	19.0	60.0
814	50.5	14.2	16.9	68.7	63.0	50.4	27.0	20.4	66.0
815	50.5	13.9	17.0	71.5	64.5	27.7	28.2	22.0	68.0
8 <b>1</b> 6	53.2	14.0	17.9	80.5		30.0	27.0	25.5	84.0
818	52 <b>.</b> 2	14.2	18.3	72.1	65.0	26.8		21.5	71.0
819	53.5	15.0	17.6	81.0	76.5	33.5	> 30.0	25.4	80.2
820	50.7	14.5	16.7	78.6	74.7	31.4		24.6	81.2
821	55 <b>.</b> 8	14.3	19.3	80.3	1741	34.8		27.8	90.0
822	55.0	15.0	18.9	82.0	77.5	35.0		28.5	83 <b>.</b> 5
863	51.8	14.4	17.5	70.5	68.2	27.9	29.5	21.6	70.4
866	49.2	14.4	17.0	63.5	55.4	22.3	23.4	18.2	56.8
870	49.2	14.0	16.7	60.0	54.0	22.4	24.7	19.1	55.2
874	54.0	14.8	18.3		79.0	31.7		27.0	84.3
	52.5	13.4	17.7	78.5	17.0	28.2	28.7	23.0	80.5
89 <b>1</b> 900	48.8	13.0	17.0	10.7	53.5	21.2	23.1	18.0	54.5
901	48.6	13.3	16.5	58.5	51.3	21.3	21.4	17.3	53.5
902	48.2	13.3	16.6	57.5	50.0	21.5	21.0	<b>1</b> 6.0	52.5
902	46.8	13.0	16.0	55.5	53.0	20.7	20.6	16.5	54.0
903 904	49.8	13.8	16.4	58.4	54 <b>.</b> 8	21.5	22.0	18.0	54.0
90 <del>4</del> 905	48.6	13.5	16.9	58 <b>.</b> 2	50.0	20.8	20.3	16.9	49.5
			14.5	55.0	49.4	20.2	21.2	17.0	51.0
9 <b>0</b> 6	46.8	14.3		73.3	47.4	27.6	26.2	22.0	75.0
909	52.0	13.6	18.1	68.5	62.2	28.2	26.8	20.0	68.0
911	51.2	14.2	17.2 18.1	69.7	58.8	24.3	26.3	20.6	63.0
912	51.2	13.5		69.0	61.5	25.6	26.9	22.7	67.8
913	51.4	13.1	17.8	77.0	62.5	27.7	31.0	23.7	72.5
919	49.3	12.6	17.0	66.0	62.8	24.0	26.2	20.0	62.3
921	50.8	13.3	18.2 18.0	58.4	52.1	21.5	22.5	17.6	56.6
923	50.7	13.2	18.1	74.2	72.1	27.2	29.5	23.3	71.0
925	63.0	13.9			61.7	25.3	27.1	20.5	68.5
926	51.0	12.8	17.9	73.0	54.0	. 22.9	23.0	17.6	59.0
930	48.6	13.9	16.7 16.9	60.9 62.5	57.2	24.8	26.0	18.6	58.7
931	50.4	14.1	-	69.0	61.8	25.1	26.5	21.2	72.0
937	50.5	13.5	17.0	09.0	01.0	- J. I	~~, /	weeds 2 has	1

Subject No.	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf circ., cm	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
939	53.6	14.6	18.4	87.0	81.3	35.5		27.7	86.0
946	52.2	13.5	17.8	74.1	01.5	28.0	27.2	23.4	73.0
950	56.5	15.2	18.6	82.3					
						33.5	00.0	30 5	91.0
952	48.3	13.1	16.7	58.8	53.8	21.8	22.9	18.5	55.3
955	51.2	13.5	17.4	71.6	68.5	29.1	27.5	21.7	74.5
959	54.0	14.8	17.8	80.6		32.0	31.0	26.5	92.4
960	52.1	13.5	18.3	77.0		30.7	28.3	23.1	77-5
962	53.0	13.6	18.4	67.0	58.8	24.1	26.0	20.0	61.5
972	50.4	13.0	18.3	62.1	57.1	22.5	24.2	18.4	57.5
981	47.7	13.0	16.3	65.0	54.6	23.2	24.9	18.5	59.0
993	54.5	14.9	18.0	85.0		32.6	31.0	25.0	84.0
995	51.6	13.4	18.2	59.3	54.0	21.5	21.9	17.0	55.0
996	49.7	13.2	17.0	62.0	58.4	25.5	26.4	20.4	63.0
998	54.0	14.1	18.5	81.9		31.5	30.6	27.1	84.5
1002	48.4	14.3	16.2	59.0	56.2	21.2	24.7	17.5	53.3
1004	50.0	13.5	17.5	54.9	50.0	20.5	21.5	17.6	50.8
1006	49.0	13.5	+1.7	55.8	50.0		21.3	16.3	50.8
1009		13.8				20.5			
	50.2		17.0		51.7	21.7	19.6	16.5	53.3
1010	49.0	12.6	17.3	53.0	50.5	20.1	18.1	16.7	50.5
1012	49.0	12.7	17.4	57.0	52.0	21.2	20.5	18.2	54.0
1014	48.9	13.0	17.3	58.0	52.7	19.8	<b>22.</b> 6	17.1	50.8
1015					49.6				
1017	46.5	12.6	16.5	54.2	50.3	19.3	20.0	16.3	47.5
1020	48.5	12.7	17.0		47.5	19.0	19.0	14.3	47.1
1022	45.9	12.7	15.5		52.0				
1024	50.0	13.4	17.7	54.2	51.0	22.2	20.0	17.5	50.5
1025	49.2	12.5	17.6		46.5	18.1	17.8	<b>15.</b> 6	45.3
1026	45.0								
1027	47.7	12.1	17.1		45.2	18.2			
1028	45.0				47.3				
1030	47.7								
1031	47.6	13.1	16.8		48.7	19.2	17.5	15.0	47.0
1033	54.3	14.7	18.3	72.4	68.6	27.4	29.0	23.8	77.6
1034	49.6	13.0	17.1	57.8	51.2	20.0	21.6	16.5	53.2
1035	51.6	14.2	16.8	74.9	71.2		30.0	23.7	73.6
1036	52.8					29.3			<i></i>
		14.5	18.0	69.3	60.5	24.7	26.6	20.5	66.5
1037	44.6					·			
1038	45.5								
1044	41.7				41.0		,		
1045	41.9				40.4				
1046	40.6				40.0				
1503	48.2	<b>13.</b> 6	16.4		48.2		19.3	15.5	48.2
1504	11K 2				46.5				

1963 (cont.)

APPENDIX 15
Supplementary Anthropometric Data on Children Born to Exposed Parents

					1957					
Subject No.	Sitting ht., in.	Lower extremity length, in.	Upper extremity length, in.	Arm span, in.	Biacromial width, in.	Intercristal width, in.	Head circ., in.	Chest circ., in.	Left calf circ., in.	Buttocks circ., in.
87	18	14.5	12	29,5	7.5	5	18.5	18.5	7	17
88	16.5	15	12	27	7.5	9	17.7	18	7.5	17.5
89	17	14	11	27.5	6.5	5.5	16	18	7	17.7
90	18	15	12.2	30	8	5.5	18.5	19	7.5	17.5
91	20	16.5	13.0	31.5	7.5	6.0	19.0	20	7.5	8
92	17.5	13.5	11	27	6.5	6.0	17.2	18.5	7.2	19.7
93		9	8	20	5	4	14.7	12.5	4.5	11.5
94	15	12.5	10	24.5	5.5	4.5	16	14.7	5.2	15
95	17	14	11	25	6	5.5	17.2	16.5	7	17
100	18.5	12.7	10.5	27	7	6	17.5	19	7.2	18.5

		1958									
Subject No.	Head circ., cm	Head width,	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm		
87	47.5	13	16.2		47.1	18.1	16	13.7	47		
88	47.0	13.5	16.1	47.9	49.8	20.5	19.0	15.0	48.2		
89	48.5	12.9	17.0	47.3	46.5	18.5	18.5	14.1	44.6		
90	48.5	13.3	16.8	50.7	49	20.5	19.8	15.2	48		
991	49.3	13.5	16.6	52.2	51.3	20.0	20.5	15.3	48.2		
92	46	12.5	16	***	48.3	19.0	18	14.5			
93	46.3	13.1	15.5	44.8	44.5	17.5	16	13.5			
95	45.9	12.7	15.5		48.5	20.1	17.6	14.7			
96	36.0										
97	40.2	12.0	13.2		42.2	16.5	16	13			
100	46	13.5	15		48.5	18.2	17	14.3			

					195	9			
Subject No.	Head circ., cm	Head width,	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf circ., cm	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., c
88	48.4	13.4	16.7	50.9	52.0	21.3	20.0	16.0	50.3
89	49.6	13.3	17.6	49.4	48.4	19.4	19.8	15.7	46.4
90	49	13.4	17.2	52.0		21.4	20	16.2	
91	49.5	13.6	17.0	56.3	54.0	21.4	21.6	16.8	50.5
92	46.7	12.7	16.3	50.0		19.5	19.4	15.3	
93	48	13.6	16.2	51.9	48.9	19.4	19.2	15.0	48.0
94	46.7	12.2	16.7	49.2	47.5	19.2	18.8	14.3	49.3
95	47	12.8	15.8	51.1	48.2	20.2	18.8	16.4	48.5
96	44.8	13.1	14.8		46.6	19.7	18.0	13.6	47.0
97	44.5	12.5	14.7		46	18.4	16.6	13.2	44
98	45.2	12.7	15.4		44.5	18.7	17.4	14.2	47
100	47.8	14.2	15.7	52	52.1	21.2	19.6	16.3	52.8
102	42.1	12.9	13.4		44.8		17.0	13.7	
103	43.2	12.2	15.0		41.5		14.5	12.8	
104	41.5	11.3	13.8		39		13.8	13	
105	40.5	11.3	14		41		15.0	12.1	
··					196	51			
87	49.5	13.5	16.7	59.6	51.5	20.7	22.5	15.9	53.0
88	49.5	14.0	17.2	<b>57</b>	55 <b>.</b> 5	22.8	23.0	<b>17.</b> 5	54.5
89	51.0	13.7	17.8	55.5	50.5	21	20.6	17.3	53.0
90	50.5	13.8	17.6	60	55.5	23.6	23.7	18.4	54.5
91	50.8	14.2	17.5	60.7	57	23.6	24.2	18.5	55.5
92	48.5	13.3	16.9	<b>57.</b> 3	53.3	21.6	22	16.8	54.0
93	50	14.2	16.9	56.3	52	21.3	21.5	17	53.0
94	48.3	12.2	16.9	53.5	51	21.3	19.9	16.3	53.5
95	47.4	13.0	16.5	58.8	51.4	21.1	18.5	17.0	55.0
96	48	14	15.8	52.3	54	23	20.6	16.2	53
97	46.3	13.3	15.4	53	50	21.1	21.3	16	53.5
98	47.7	13.5	15.5		48.8	20.4	19	14.7	50.5

					196	2			
Subject No.	Head circ.,	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
87	49.5								
88	49.7	14.0	17.2	58.2	56.8	23.5	23.7	17.8	56.0
89	51.0	13.7	18.1	57.8	<b>52.</b> 6	21.2	23.0	18.0	53.0
90	51.2	14.0	17.6	60.6	58.0	24.2	25.3	19.0	55.5
91	51.4	14.2	17.5	63.0	58.8	24.2	25.0	18.7	56.5
92	49.0	13.5	16.8	59.9	55.0	22.3	23.5	17.7	57.0
93	50.3	14.2	17.0	57.7	53.1	21.5	22.0	17.7	53.2
94	48.4	12.5	17.1	56.3	52.5	21.7	21.1	16.6	52.2
95	48.0	13.2	16.1	60.5	52.8	21.2	22.1	18.0	54.0
96	48.9	14.3	16.1	53.5	55.5	23.2	21.4	16.7	56.3
98	48.2	13.5	16.0	52.0	51.5	21.0	19.8	16.5	52.0
102	46.8	14.1	14.8	53.4	50.9	19.4	22.6	16.8	49.8
103	48.0	13.1	12.0		46.5	20.1	19.8	15.4	48.5
105	46.8	13.0	<b>1</b> 6.5	52.6	49.0	20.0	20.1	15.8	49.5
106	48.0	13.1	17.0		48.1	20.1	20.5	15.1	46.4
108	46.5		15.3	46.0	52.0	19.0			
110		13.3	<b>1</b> 6.9		46.0	19.7	19.0	15.0	46.0
111	47.0	12.8	16.0	47.9	46.3	17.0	17.6	14.9	43.8
112	46.0	12.2	16.2		48.1	18.4	18.0	14.5	45.0
113	45.6				44.0				
117	42.0	13.5			42.0				
118	45.0	12.3	15.2		43.5	16.8	17.2	13.2	42.0
120	46.3	12.3	16.3		46.0	17.8			
122	46.8	12.4	16.6		44.0	18.2	15.8	13.0	44.O
124	41.3	11.3	13.9		42.5				
125	44.7	11.7	16.3		41.0				
126	42.5	11.2	15.1		39.7				*

1963									
Subject No.	Head circ.,	Head width, cm	Head length,	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
87	50.2	13.5	17.3	63.5	54.7	22.2	24.0	18.2	56.0
88	50.2	14.1	17.3	58.2	59.0	25.0	24.2	18.3	58.5
89	51.5	14.0	18.2	58.0	54.0	21.8	25.3	18.0	52.0
90	51.5	14.1	17.7	62.3	60.0	25.7	26.5	20.0	59•7
91	51.5	14.5	17.6	65.1	60.4	24.9	26.1	19.3	59•9
92	49.1	13.5	17.0	61.0	56.0	23.0	23.4	18.8	57.2
93	50.8	14.3	16.7	58.1	55.0	22.0	21.4	18.5	54.3
94	48.5	12.5	17.2	56.7	51.7	21.5	22.0	16.6	53.5
95	48.3	13.4	16.4	61.0	54.0	22	24.0	18.5	56.7
98	48.5	14.7	16.0		51.3	21.2	20.0	17.3	53.4
101	48.4	12.8	16.8	57.0	50.2	20.8	20.9	15.2	54.5
102	47.2	14.2	15.6	54.8	50.6	20.0	22.5	17.0	50.5
103	48.7	13.2	17.0	56.0	47.8	20.2	21.2	15.8	47.0
104	47.1	13.0	16.0		49.1	20.2	21.0	16.0	51.0
105	47.7	13.2	16.7	<b>55.</b> 8	51.4	21.2	21.3	16.8	<b>51.</b> 8
106	49.5	13.4	17.6		50.7		22.1	15.7	48.5
108	47.9	12.5	17.1	56.2	49.7	19.5	18.9	17.5	53.0
109	49.0	13.7	<b>1</b> 6.5	55.2	<b>51.</b> 8	20.8	22.3	15.9	51.2
110	49.8	13.7	17.0		51.4	20.5	17.8	<b>1</b> 6.3	49.8
111	47.7	13.0	15.6		48.3	18.0	19.5	15.6	45.5
112	46.8	12.3	16.4		47.4	19.5	19.0	16.0	48.0
113	48.0				48.0				
115	47.2	12.9	16.1		52.0	20.3	19.4	15.1	
117	44.3	12.0	15.4		46.5				46.0
118	47.2	13.0	16.5		47.8				
119	46.8	12.1	16.8		47.6	20.2	17.2		
120	48.0				49.0				
122	47.7								
124	45.0				48.2				
125	48.2	12.2	16.7		44.5				
126	47.4	12.6	17.0		46.7				
127	44.0				40.0				

APPENDIX 16
Supplementary Anthropometric Data on Rongelap Exposed Children

			Septem	ber 1954			
Subject	Sitting ht., in.	Lower extremity length, in.	Arm span, in.	Biacromial width, in.	Upper extremity length, in.	Chest circ., in.	Left calf
2	18.2	9	27.5	6.2	21.2	19.5	7.2
<b>3</b> .	20.2	12.2	30.2	7.2	23	20	7.7
5	20	12	31.5	6.0	25.5	19.5	8.0
5 15	22.5	23	لَلِلُ	7.0	37	21	8.0
17	21	21	37.5	7•5	30.5	20.7	8.0
19	22	19.5	39•5	7.0	32.5	21.0	8.5
20	24	20	بَلْلُ	7.5	36.5	23.1	9.5
21	19.7	15.7	34.5	7.2	27.2	21.5	7•5
22	31	30.2	63.2	10	53.2	32.7	13
23	17.5	21	37.5	7	30.5	22	9•5
ર્સ	30.5	26.2	57	ıi	46	31.7	12.3
26	30	27	58	. 9	49	31	13
32	22	15	58 37•2	9 6•7	30 <sub>•</sub> 5	19.7	g.2
33	21	21	42	5•5	37 <b>.</b> 5	20	8
33 35 36	29.2	29.2	62.7	11.2	51.5	29.5	11.5
36	23	25.5	47	8	39	र्घा,	10
39	31.7	27.7	62	8.5	53•5	32.5	12
39 42	21	14.7	35•5	5.2	30 <b>.</b> 2	19.2	
47	26,2	23.2	48.2	8.5		1702	7•5
61	27.2	23.2	50•5	8	39•7	23	9•5
<b>61</b> 65	17	7	30•5	5• 5	42.5	27.5	11.5
67	32 <b>.</b> 5	28.2	62 <b>.</b> 5	7•7 11•5	25 53	18.5	8
69	21.5	18.5	40		51	32.5	12.5
72	23.2	22.2		6.5	34.5	20.5	9
75	23.5	31.7	39 52. 7	8	31	21.5	8.5
76	26.7		57 • 7	11.2	46.5	28.7	11
		25.2	53 • 7	9•2	44.5	25.5	10.5
83*	13	13	25	4•5	20.5	17	7
	,		<u>Ai</u>	lingnae		•	
8	25	15	30	5•5	24.5	19.5	· • • • • • • • • • • • • • • • • • • •
لمله	2 <u>1</u>	18	39	5•5	34.5	20.5	7•5
48	25	20.5	47	7•5	39•5	20 <b>.</b> 5	ఠ• <u>5</u>
5 <b>3</b>	25 25	23	45•5	7.2	38 <b>.</b> 2	<b>2</b> 2	9•0
70	29.7	27.7	47•7 58.5	9.7			9•5
81	र्घा•5	23	58•5 47•2	9	49•2 38•2	32 <b>.</b> 5 20 <b>.7</b>	11.5 9

<sup>\*</sup>Exposed in utero.

			1	1955			
Subject No.	Sitting ht., in.	Lower extremity length, in.	Arm span, in.	Biacromial width, in.	Upper extremity length, in.	Chest circ., in.	Left calf circ., in.
2	21	17.7	34	7 <b>.7</b>	12.5	19.5	7.7
3	20.7	15.7	32	8.5	13.5	21	7•5
5	19.0	17.5	31.5	7.0	12.5	19.5	7.0
3 5 15	26	26.5	45	9.2	18.0	21.0	8.0
17	22	21	37	8.5	16	20.2	7.2
19	22	22	38	9•5	14.5	22	8.0
20	25 22	25•5	بليل	10	16.5	22.5	9
21	22	19	35	8.5	13	20.5	6.5
22	30	35•7	35 61.5	13	26.7	33	12.7
23 24 26 32 33 35 36 39 42 47	21.5	20	39	20.7	16	23.5	9•2
2나	32	35∙5	39 60 <b>.2</b>	13 13 8 7	23.5	29.5	10.2
26	31	Marie	62	13	26.5	31.5	12.7
32	22 22	19.5	38	ğ	14	20	8
33	22	18	62 38 32	7	13.2	18.7	క క
35	33 24.5	35 2 <b>6.</b> 5	<b>61.</b> 5	13.7	24.5	31	12
36	24.5	2 <b>6.</b> 5	47.2	11	19.2	بالواق	
<b>3</b> 9	<b>30</b> 22	36	60	12.2	علب	31	11.2
42	<b>2</b> 2	19	32	7•7	12	19	7
47	*****	27.7	50 31 52 28 56	10.4	20.7	و.5	9•5
54 61 65 67 69 72 75 76	19	18	31	7.7	12	20	7.7
61	30	31	52	11.5	20.5	27	11.7
65	19.5	16	28	7.2	11	19	7.2
67	34	34	56	14	23	31	10
69	2 <b>3</b> 26	22.5	39 Цц.5	<b>8.</b> 5	18	20.5	8.7
72	26	22.2	44.5	9•5	. 18	21.5	8.5
75	31 26.5	32	<b>55</b>	12	23	27	10.5
	26.5	29.5	55 55•5	10.5	23	26.5	10.5
53* 54* 55* 86*	16	12.2	23	6.5	9•5	18	5•2
84*	19•5	17.5	32.5	7	13.5	20	フ•≤ 8
<b>85</b> *	*****	12.5	26.5	5 <b>∙7</b>		17•5	6.5
<b>86</b> *	12.2	10	20	5.2	9•5 8	15.5	6.5
					_	±)•/	0.,
			Ai	lingnae			•
6 8 4 <b>8</b> 53	20.5	17	30	<b>f</b>	12	20	7•25
8	18	18	30 3 <b>1</b> 46∙2	6.5 .	12	18.5	7•5
48	21,	26.7	46.2	10	18.2	21.5	8 <b>.</b> 2
72 70	25.5	2 <b>8</b>	48	10	19	27	9•2
70 81	32 26	33	48 56 47	13.5	23 18	27 33 23	11
OT	20	27	47	10.5	18	23	8.5

		1956								
Subject No.	Sitting ht., in.	Lower extremity length, in.	Arm span, in,	Biacromial width, in.	Upper extremity length, in.	Chest circ., in.	Left calf			
2	21.5	14.0	33	<b>క</b> •5	10.5	20.0				
3 4	40m	17	34	9•5	14	21	<b>€</b> •5			
4	21	to the second	33.5	8.5	13.5	20	8.0			
15	25•5	26 2나 2년 26	47	9	18.5	21	9•5			
17	23.5	<u> کاب</u>	43.5	10.2	18	21	8.5			
19	25.5	ર્યા	40.5	9•5	16.5	21	8.5			
20	25.5	26	47	10	20	23	9 <b>•5</b>			
21	23	-	36.5	8	15.5	20.5	έ			
<b>2</b> 2	23 31	38∙5	62	14.5	27.5	33	12.5			
23	25	21	39.5	9•5	16.5	22	9.5			
2ĺ4	25 <b>3</b> 1	34.5	61	14	27	31	12			
26	31	36.5	64	14	28.5	32	<u>1</u> 4.5			
	عل	21	38	8	16.5	20.5	8.5			
32 33 35 36	22.5	18	37		14.5	20	8			
35	31	36	67 <sup>†</sup>	16	27		13			
36	29	27 <b>.</b> 5	49	12.5	21	31 26	11			
30	32	34·5	62 <b>.</b> 5	13	27 <b>.</b> 5	32 32				
39 42	22 <b>.</b> 5	21	35•5	±5 8•5			15			
42 47	27	21 29	22•2		15.5	<b>1</b> 9	8			
			50.5	9•5	22	24.5	10			
<b>54</b> 61	Tribera.	17	24	<b>.</b> 5	13.5	.21	.9			
	00.5	32	56	13 8	2 <u>1</u> ,	27.5	13			
65	20.5	16	34 56 31 61		12.5	19.5	7.7			
67		35•5	61	15	26	32	12			
69	21.4	डा डा इ	75	10.5	18	21.5	9•5			
72		54	<del>Щ.</del> 5	9	18.5	22	9			
75	31 2	32	58 57	10	26	30	11.5			
76	28	31	57	10	25•5	25•5	10.5			
83*	21	17	30	<b>7∙</b> 5	12	20.5	8₀5			
<b>8</b> 5*		16	31	8	12	19	7•5			
		·	Ai1	ingnae						
6	22	17.5	34	9	14	20	8			
. 8	-	19	34	Ŕ	13.5	21	8			
44	23.5	22.5	34 42•5	-	18	22.5	9			
48	26.5	<b>2</b> 9	48	10.5	•	23	9 <b>∙</b> 5			
5 <b>3</b> ·	27.5	27.5	51	9.2	22	- <i>&gt;</i> 23				
81		26.5	51 50	10	21	23 23	9•5 9•5			

<sup>\*</sup>Exposed in utero.

S
$\Box$
$\Box$
0
<b>-</b> O
-{
w

		Lower extremity length, in.	Upper extremity length, in.	Arm span, in.	Biacromial width, in.	Intercristal width, in.	Head circ., in.	Chest circ., in.	Left calf	
2	22	21.2	15.7	37	7•5	6.5	20•5	20.5	8.5	20.5
<b>3</b> 5	21	20	15	26.5	<b>5</b> •5	5•7	19	20	8.0	,
5	20	20.5	15	35.5	9	7	19	20.5	8.0	20
15	24.7	29	21.2	49	11	7.5	19.2	22	9.0	23.2
17	23.5	ڪل	18	43.5	10.2	6.7	19.7	22	<b>8.</b> 5	23.2
19	ध्य	26	19	43.5	9•5	<b>8.0</b>	19.2	22	8•5	22.7
20	26.2	30.2	20	50 7.4 5	12	<b>5.</b> 0	20.5	54.5	10	26
21	22.5	23	17	38.5 61	10.5	<b>8.</b> 0	19 10.7	21.5	9 11	22.5
22 23	32 07 5	36.2	27	42	13 11•5	9 8•5	19.7	27•5 23	10	23.7
	23.5	24.5	18		11.05 11.05		20.5 21	30	12	
26 24	29.2	36 30	26 <b>.</b> 5	59 67•5	14.5	9 10	21.7		12 14	33
<i>2</i> 6 32	33.2 22.2	39 97	30 18∙5	41	10	6	19	33•5 21	8.7	36 21
33	21.5	23 22•5	17	38.5	±0 8•5	7	19	20	9	50
35 35	32.2	36 <b>∙</b> 5	28 28	63.5	15.5	9	21	32 <b>.</b> 5	12•5	<b>3</b> 2
36	25 25	30 30	22	50.5	11.5	9 8.5	19•7	25.5	10.5	26
30 30	31.5	37	28	62	14 14	9.2	21	29	11.5	==
39 42 47 <b>54</b> <b>61</b>	22	22	16	37.5	9•5	7	19.5	20	8	21
1.7	27	31.5	23	53	12.5	( 	21	24.5	10	26
54	22	21.2	16.5	38	8.2	7	19.5	22	ž	21.7
61	31	34	26	58	14	9•5	21	29	13.5	35
65	20.5	19	1/4	33	7.7	6	18	20	7	<b>2</b> 0
67	32	37·5	27.5	60	$\eta_{\downarrow}$	10	22.5	32.5	12	34
69	24.2	26	20	45	9	8	19	21.5	9•5	23.5
72	26.5	28	21	47	11	7	20.2	22.5	9.5	25
75	31.7	34	25.5	58	13.5	8.5	21.2	31	12	35
76	28.7	35.2	26	58.5	12	<b>8.</b> 5	20	27	11	28.5
<b>83</b> *	21.2	19	J/†	34 34•5	9	6•5	19	19	8.5	20
811×		18.5	14.5	34.5	8.5	6.5	19	20.5	8	20
<b>85</b> *	19	19	14	35	7∙5	6•5	18	19.5	7 <b>•</b> 5	19.5
86*	18.7	17•5	12.5	31	7•5	5• <b>7</b>	18.2	19.2	8	
					Ailingnae	<u> </u>				
6	21.5	20.5	15	23	9•5	6	19.2	20.5	8	21
8	22	19.5	15	35	7	6.5	19.5	19.5	8	21
44,	23	24.5	19.7	43	10.5	7.5	19.5	23.5	<b>9.</b> 5	23.5
48	24.2	30	21.2	49	11.5	8	20	23.5	9.2	25
53	27	32	22.5	49 52 57	10.5	7	19.2	31	. 10	24.5
70	29.5	36	25	57	<b>1</b> /4	10.5	21.5	32	12	35
81	26	30	22.5	50	11.5	క	20	24	9•5	26

	2 5 15 17 19 20 21 22 24 Preg. 26	52.4 49.2 48 49.5 51 49.1 52.5 49.5 50.5 51.5 52 55.6	14.0 12.7 13.2 13.6 14.1 15.1 13.5 13.3 13.8	18.2 17.4 16.8 17.1 17.5 16.5 17.0 17	59.2 56.3 53.9 69 64.7 66.9 70.9 61	54.5 54.0 53.3 58 57 58 64 55.8	22.5 21.7 21.8 25 23.2 23.0 26.5	21.5 20.5 20.6 25.5 24.3 24.5	17.0 15.9 16.3 19.5 18.3	55.0 52.9 51.5 62.5 59.5
	3 5 15 17 19 20 21 22 23 24 Preg. 26	49.2 48.5 51.1 52.5 49.5 50.5 51.5 55.6	12.7 13.2 13.6 14.1 15.1 13.5 13.3	17.4 16.8 17.1 17.5 16.5 17.0 17	56.3 53.9 69 64.7 66.9 70.9 61	54.0 53.3 58 57 58 64	21.7 21.8 25 23.2 23.0	20.8 20.6 25.5 24.3 24.5	15.9 16.3 19.5 18.3	52•9 51•5 62•5 59•5
	5 15 17 19 20 21 22 23 24 Pre <b>g.</b> 26	48 49•5 51 49•1 52•5 49•5 50•5 51•5 55•6	13.2 13.6 14.1 15.1 13.5 13.3	16.8 17.1 17.5 16.5 17.0 17	53.9 69 64.7 66.9 70.9 61	53•3 58 57 58 64	21.8 25 23.2 23.0	20.6 25.5 24.3 24.5	16.3 19.5 18.3	51.5 62.5 59.5
	15 17 19 20 21 22 23 24 Pre <b>g.</b> 26	49.5 51 49.1 52.5 49.5 50.5 51.5 52 55.6	13.2 13.6 以。1 15.1 13.5 13.3 13.8	17.1 17.5 16.5 17.0 17 17.4	69 64.7 66.9 70.9 61	58 57 58 64	25 23•2 23•0	25•5 24•3 <b>2</b> 4•5	19.5 18.3	62•5 59•5
	17 19 20 21 22 23 24 Preg. 26	51 49.1 52.5 49.5 50.5 51.5 52 55.6	13.6 14.1 15.1 13.5 13.3 13.8	17.5 16.5 17.0 17 17.4	64.7 66.9 70.9 61	57 58 64	23 <b>.2</b> 23.0	24.3 24.5	18.3	59•5
2 2 2	19 20 21 22 23 24 Preg. 26	52.5 49.5 50.5 51.5 52 55.6	14.1 15.1 13.5 13.3 13.8	16.5 17.0 17 17.4	66.9 70.9 61	58 64	23.0	24.5		
·	20 21 22 23 24 Preg. 26 32	52.5 49.5 50.5 51.5 52 55.6	15.1 13.5 13.3 13.8	17.0 17 17.4	70.9 61	64				iāΩ. Ā
2 2	21 22 23 24 Preg. 26 32	49.5 50.5 51.5 52 55.6	13.5 13.3 13.8	17 17•4	61			27.7	20	59•3 26•5
2 2	22 23 24 Preg. 26 32	50.5 51.5 52 55.6	13.3 13.8	17.4		7,700	22.7	24.2	18	59
2	23 24 Pre <b>g.</b> 26 32	51.5 52 55.6	13.8				27.3	> 30	23∙8	
,	24 Pre <b>g.</b> 26 32	52 55.6		1001	65.8	61	27.5	25	19•4	62
	26 32	55.6	374	17.1	7 <b>5.</b> 5	<del></del>	30 <b>.3</b>	>30.	19•4 24•7	
	32	22•0	14.4	19.1	90.3	85 <b>.</b> 9	36			•••
	76 33	48.8		16.9	62 <b>.</b> 9	56 <b>.</b> 5	23 <b>.3</b>	≥30 >30	28.6 17.6	 56
-			13.2		60.6	51.5	23	22.9		
7	)) 10	49.1	13	17.5		82 82			17.3	<b>5</b> 5
	33 35 36	53.2	14.7	17.7	8년.6		32•5 29•6	> 30	25•2	
7	20 30	50.5	14.8 14.8	16.5	74.1 82.8	65.8		26.9	21.8	72
i	39. 42	53.4	14.1	17.9	61.1		32 <b>.</b> 1	> 30	21.4	
	42 47	50•2		16.5		51.5	21.5	22.2	17.4	55 10 2
	4 / <del>c</del> l.	54.2	14.4	19.0	74.3	66 55	27.3	29	21.7	70.3
3	61	50.7	13.4	17.5	61.3	58	2년	23.5	17.5	58.7
		53.5	14.2	18 25 (	क्र <sup>1</sup> •5		34.7	30.2	21.5	86
2	65 67	46.7	12.9	15.6	52·5	52	19•7	19.3	15.5	<b>53</b>
	67	55	14.2	18.0	क्षां-ां		32	> 30	27.2	<del></del>
9	<b>69</b>	49.4	13	17.3	65	57	25	24.9	19.1	60
1	72	51.5	14.1	17.5	72.7	61	25.6	27.6	21	61
3	75	53.7	14.4	17.5	81.3		29.9	>30	<b>2</b> 6	<del></del>
. 1	76	50.6	개•1	17.1	79.4	75	31	> 30	<u>श</u> ्	74
	83 <b>*</b>	49.6	12.9	17.6	54.6	50.7	22.8	21.2	15.9	53
{	×بلع	48.2	14	16.2	53.3	51.5	21	21.5	16.4	51.5
1	85*	45.7	12.7	15.6	53.1	50.8	20.2	20.3	16.9	51
1	86*	47.5	13	16.3	52	49.7	20	21.2	15.8	****
•						Ailingn	a.e			
	6	49	υı	16.4	57	54.3	22	21.7	16	55•7
	6	49 50•7	13.4	17.7	58 <b>.</b> 9	51•5	21.2	21.5	16.9	57
1	44,		14.3	16.0	63.6	56 56	23.5	24.6	18.6	59•4
1	78 <del>111</del>	49 52•1	14.1	17.5	68.9	60.7	25	26.6	20.9	67.5
		49.3	13.2	16.7	75.4	62.7	27.3	28.5	21.4	67.5
	53 70	49.5 53.8 (hai:		18.1	81.6		30	<30	28	
	/0 <b>8</b> 1			16.0	72.1	63	26.3	27.5	21	67.5
1	OΤ	50.5	14.7	10.0	100+	<del>-</del> 59	-,00,	-147		31.07

<sup>\*</sup>Exposed in utero.

					1959				
Subject	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cr
2	52.7	14.2	18.4	<b>6</b> 0 <b>.</b> 3	54.5	22.6	22.8	18.0	54.6
3	49.3	12.9	17.4	57 <b>-</b> 4	56	22.6	22.3	16.9	56
5	48.3	13.2	16.7	54.6	54.5	22.0	21.6	17.0	53.4
5 15	49.6	13.2	17.1	72.3	60	26.1	26•5	21.3	<b>6</b> 8
17	51 <b>.1</b>	13.7	17.7	66.1	58.1	23.5	25.7	19.5	62.5
19	49.6	IJ <sub>4</sub> •1	16.5	67.3	58.5	23.4	25.7	20	60
20	52.6	15.3	17.1	71	64.5	26.1	29	20.8	66.5
21	50	13.6	16.9	64.3	59	23.6	25.3	18.8	61
23	51.9	13.7	18.1	68.1	61.7	27.7	26.2	20.5	65
23 24	51.5	13.7	17.2	76		29.4	> 30	25.4	
26	55•3	ป4.5	19.4	90.8	87	34.4		28	92.5
32	49.1	13.3	16.9	64.2	56	23.7	25.2	18.2	57
33	49.8	13.2	17.7	63.8	<b>5</b> 2 <b>.</b> 6	24.1	21	18.1	56
36	50.8	14.7	16.4	75 <b>•</b> 5	68.4	30	29.1	22.2	7 <u>1</u>
1.2	50.5	14.2	17	63.9	52 <b>.</b> 7	22	23.1	18.1	71 54.8
33 36 42 47	54.2	14.5	18.8	75•5	66 66	27.7	30.5	22.4	74•°
다.	51.1	13.9	17.5	63.1		St.5	24.6		
54 61	54.3	山。5	18	84	59°4	36.4		19.3	59• <sup>1</sup> 4
65	47.2	13.2	16.1	55 <b>.</b> 8	50.5	20.1	> 30	<del></del>	93 52
65 69 72	50	13	17.4	67 <b>.</b> 2		2 <b>5.</b> 6	20∙8 25 5	17.5	
72	52 <b>.</b> 2	14.3	17.9	76 <b>.</b> 9	57 65		25.5	20.3	60.5
75	72.2	14.3	17.2	/0•9 81	65	27•9 28	27.8	22	68 <b>.7</b>
75 76	51.5	14.5	17.2	83.5	<del></del>		31 70	25.2	<del></del>
10	71.0	щ•э	1/•2	o)• j	76.1	33	> 30	25.8	74.2
<b>8</b> 3*	50	13	17.9	59•5	53.1	23.6	22.3	17	53•5
81 <sup>1</sup> *	48.3	13.9	16.3		53.2	21.3	21.6	16.5	51.5
85*	46	13	. <b>1</b> 5•9	55 56	51	20.5	22	17.8	52
86*	48.4	13.5	16.2	54.5	49.4	20.1	22	16.6	48.4
					Ailingna	<u>e</u>			
6	49.3	14.1	16.6	59•3	55	22.4	07	17	<b>54.0</b>
8 -	51.6	13.7	17.9	62 <b>.</b> 3	22 53•5	22.1	23 22•8	17 18.6	56•2
-	49.3	14-4	16.3	66.5	.22•2 56•5	54•5 55•1			55 <b>.</b> 4
718 1717	52 <b>.</b> 1	14.1	17.8	72.2	50•5 61•2	24•2 25•6	26.3	19.3	61.5
53	49.7	13.5	16.9	79.2			28.3	21.5	69.5
53 81	51.3	14.8	15.9	76 <b>.</b> 2	68.4	29•7 28•0	29•0 29•9	22 <b>.</b> g 22 <b>.</b> g	74 74•0

<sup>\*</sup>Exposed in utero.

					1961				
Subject No.	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ., cm	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
2	53.6	14.4	18.8	63	59•4	24.5	25•5	19.0	60.0
3	50.3	13.2	17.6	60.3	60.8	25.0	23.5	19.0	62
5	49.5	13.4	17.0	59.1	57•5	23.7	22.9	17.4	57•4
15	50.5	13.3	17.4	78.4	-	28.3	29.2	21ં,	73
17	51.3	13.8	18.0	71.3	62.6	25.9	27.5	20.1	66.5
19	50.7	14∙2	17.0	71.5	63.5	25.4	27.2	21.2	67.0
20	54	15.5	18	74	70.3		30-4	<b>2</b> 2.5	75
21	51	13.7	17.2	68.3	62	25.2	26.4	20.8	67
23	53.3	וּענ י	18•4	72.4	66	30	28.1	22	71
26	56.1	ນຸ.ຮ	19.5	91.8	88.5	37.2		30	97
32	49.5	13.4	17.0	67.6	60 -	25.5	27	19.2	6i
33	50.3	13.2	17.9	68.6	57	25.8	25.2	19.5	62.7
36	52	15	16.8	80.5	74.2	32	30.8	23.5	75
42	51	14.4	17.2	68	56	<b>23.</b> 5	25	19.5	60.2
33 36 42 <b>4</b> 7	56.2	14.4	19.5	83	> 80	32	<del></del>	24.3	84.7
54 61	51.6	<b>1</b> /₄	18	68.7	62.5	25.8	26.5	20	64
61	54	14.4	18.4	85.5		39			100
65	48.5	13.2	16.4	60.9	妈	źi.2	22	17.8	57
69	50.5	13.2	17.7	72.5	60.5	28.1	27.4	22	67.9
72	53•5	14.5	18.2	82.4	-	32	31	26.7	85
83*	51.1	13.2	18.2	65.3	56	25 <b>•5</b>	24.1	18	59
8/1×	49•4	14.5	16.8	60•7	58.2	<b>2</b> 2.5	23.7	18	57
85*	47.1	13.2	15.8	61.3	53•7	22	23 <b>.7</b>	19.3	57 54
86*	49	15.5	16.5	58.5	51.5	21.3	23.5	17.5	53
					Ailingnae				
6 8	50•4	14.3	16.4	64.5	57•9	24.5	<b>⊴</b> 4.8	18.1	61.4
8	52.5	14.1	18.1	67	56.5	24.2	25.8	19.8	61.5
44	50•6	14.5	16.3	70.1	63	25.8	28.3	20.6	67
48	52.8	14.3	18.1	78	-	<b>2</b> 9	31	24.3	79 <b>•</b> 5
53 81	50 53	13.5	17	81.5		<b>30</b> ∙5	30•5	23.2	76
<b>51</b>	53	15.1	16.3	82.8		<b>30.</b> 5	30.4	25.1	85•4

<sup>\*</sup>Exposed in utero.

					1962				
Subject No.	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
2	53.5	Щ.6	19.0	66.0	59•3	24.8	26.2	19.1	61.5
3	50•2	13.2	17.8	61.6	61.1	24.2	24.5	19.8	62
15	51.5	13.5	17.5	80.2		<b>30.0</b>	29.1	25.1	79 <b>.0</b>
17	52.4	13.8	17.8	. 73.1	63.4	26.3	28.5	21.4	68.4
19	<b>5</b> 0•6	14.3	17 <b>.1</b>	72.2	63.1	24.7	28	21.6	67.0
20	54.3	15.7	18.0	79•2	76.5	31		24.7	79
23	52.7	13∙8	18.5	71.1	67	30	29.3	22.8	72.5
23 32 33 36	50.1	13.4	17.1	67.7	59•3	26	27.7	20.0	62
33	50.7	13.3	18.0	69.4			27.5	20.6	
	52.7	15	16.9	81.5	79.2	34•5		25	83.5
42	51.5	14.5	17.1	68.2	56	23.5	25.6	19.4	60.7
54 61	52.3	14.1	18.1	66.6	62.8	26.3	27.4	21	61
61	54.5	14.4	18	با و باق		39.3	-104		99•2
65 69	48.6	13.2	16.5	60	55.5	21.8	23.5	19.2	58.0
69	51	1362	17.7	73.7	64.6	29	28.7	25.4	72
72	54.5	14.5	18.0	80.7	ph-m	33.2	31	26	80.0
83 * 86 *	51•4	13.5	18.3	67•3	58∙8	27	25.6	18.8	61.5
86*	49•3	13	16.6	<b>59•</b> 5	53	21.8	र्धाः ।	17.6	55.1
					Ailingna	<u>e</u>			
6	50•5	14.4	16.9	65.1	59.8	24.3	25•7	19	61.5
<b>క</b>	52.9	14	18.3	68.2	58.3	24.9	26.5	18.4	63.9
48	53 • 4	14.2	18	75•5		29	31	25	80
53	50•4	12.4	16.9	82.5		30.7	<b>3</b> 0	24.6	<b>7</b> 5
81	52.4	15	16.5	83		<b>30.1</b>	***	26	83.5

<sup>\*</sup>Exposed in utero.

					1963				
Subject	Head circ., cm	Head width, cm	Head length, cm	Sitting ht., cm	Chest circ.,	Left calf	Biacromial dia., cm	Bi-iliac dia., cm	Buttocks circ., cm
2 3 5 15 17 19 20 21 23 32 33 36 47 54 65 69 72	53.7 51.6 49.5 52.8 51.5 52.3 53.2 50.0 51.7 53.8 57.0 51.8 57.7 51.8 57.6	14.7 13.4 13.6 13.7 13.9 14.3 15.8 14.1 14.0 13.5 13.3 15.2 14.5 15.0 14.2 13.5 13.2 14.5	18.9 18.0 17.4 17.7 18.4 17.4 18.0 17.7 18.4 17.2 18.2 17.2 17.1 19.6 18.4 16.6 18.0	65.3 62.8 60.3 81.8 73.7 71.0 79.2 72.0 73.5 68.7 74.5 87.3 70.3 89.1 65.0 76.4 83.8	62.0 70.3 59.0  66.0 77.5 63.0 69.2 63 50.9 79.0 57.0 79.8 69.5 56.5	25.5 26.7 23.6 31.4 28.0 27.0 31.1 27.2 28.2 34.5 24.8 34.5 28.1 22.9 30.3 34.0	26.2 26.2 24.0 30.4 29.8 29.7  30.0 29.0 28.4  25.4  29.0 23.6	20.7 21.5 18.8 26.0 20.3 22.4  23.8 24.0 20.4 21.2 27.2 21.4 26.8 21.8 20.0 24.5 26.0	63.0 70.3 59.3 83.8 73.0 72.0 81.0 74.5 74.0 65.3 68.5 85.0 64.0 89.0 70.5 62.5 76.0 85.0
83* 85* 86*	51.7 47.5 49.3	13.4 13.3 13.7	18.3 15.7 16.8	87.5 61.0 62.3	59.5 57.5 53.6	26.7 23.0 23.0	26.2 25.3 24.5	19.1 20.4 18.2	62.5 58.0 56.3
6 8 48 53	50.9 53.0 53.5 50.0	14.4 14.0 14.3 13.5	17.1 18.6 18.1 17.0	67.2 70.0 77.5 81.0	61.3 58.5 	25.0 25.5 30.0 30.8	26.1 26.1  30.0	19.2 20.8 25.5 25.0	65.0 66.9 83.2 79.0

<sup>\*</sup>Exposed in utero.

APPENDIX 17

Serum Folic Acid Levels, 1963

(normal = 7 to 20 mµg/ml; borderline = 4 to 7 mµg/ml)

Subject		Subject		Subject	
No .	mµg/m1	No.	mµg/m1	No.	mug/m
1	12.2	72	10.5	895	19.0
1 3 4 5 7	30.0	73	5.8	896	9.3
4	17.0	75	2.8	900	25.0
5	7.5	77	15.0	906	4.2
7	58.0	81	6.8	915	2.6
10	10.7	83	5.8	9 <b>1</b> 6	16.0
11	10.0	87	1.4	9 <b>1</b> 9	19.0
13	13.0	95	11.0	9 <b>2</b> 4	22.5
14	9.4	8 <b>í</b> 3	16.0	92 <del>6</del>	11.0
16	13.0	814	27.0	928	29.0
18	9.9	817	9.7	932	3.0
19	18.ó	819	11.0	932 938	6.2
21	2.1	821	18.0	940 940	
23	30.0	823	<1.0	942	37.0
24	8.6	824	3.1	942 943	5.0
26	22.0	825	22.0	ծ <del>րի</del> ծ <del>դ</del>	16.0
27	5.4	826	8.2		4.8
28	9 <b>.1</b>	828	19.0	946	11.7
29	21.0	8 <b>29</b>		948	18.0
30	11.0	830	7.9	950	14.0
32	12.0	833	8.7	953	7.7
33	37.0		<1.0	955	28.0
33 34		834 835	17.0	956	5.2
3 <del>4</del>	14.0	835	17.0	959	13.0
37	11.0	841	6.5	961	10.0
39 42	12.5	842	5.4	963	6.9
42	18.5	844	6.5	964	4.0
43 44	10.0	846	4.1	965	22.0
	33.5	852	4.0	967	3.7
45 1.6	6.5	853	16.0	969	10.5
46	3.8	856	15.0	9 <b>70</b>	10.5
48	5.1	859	<b>7.2</b>	975	2.2
49	22.5	860	24.0	991	10.5
50	<1.0	864	25.0	993	37.0
52	8.2	865	13.0	996	61.5
53	4.7	867	17.0	998	14.0
55	5.4	868	9•5	1001	1.7
58	8.9	876	<1.0	1005	12.0
59	12.0	882	14.0	1007	2.0
60	17.0	883	<1.0	1035	10.3
61	15.0	884	3.1	1036	47.5
66	20.0	885	12.2	1041	15.0
68	11.0	886	7.6	- <b>-</b> · <b>-</b>	
69	10.0	887	12.3		
70	25.0	892	4.5		
71	10.3	893	23.5		

APPENDIX 18

Bone Marrow Differential Counts

1 1	Subject No.									
	4	63	68	73	948	1007				
SEG PMN	9.8%	14.2%	15.0%	19.8%	16.8%	22.2%				
SEG PMB	0.2	0.8			0.4	0.2				
SEG PME	0.6	1.8	2.6	2.8	2.2	0.4				
BAND NEUT	10.6	6.4	6.6	10.0	5.8	10.6				
BAND BASO										
BAND EOS	0.6	0.2		0.6	0.4	0.2				
META NEUT	16.2	6.4	11.8	13.2	9.8	18.8				
META BASO										
META EOS			0.4							
MYEL. NEUT	10.0	4.6	9.8	7.2	5.2	7.0				
MYEL. BASO			0.4							
MYEL. EOS	2.0	0.2	1.0	0.8	0.2	0.4				
MYELOBLAST			0.8			0.6				
LYMPHOCYTE	18.0	33.0	14.8	21.2	27.0	16.4				
LYMPHOBLAST	0.8	0.2		0.2	0.2					
MONOCYTE		0.2	0.6	0.2	0.6	0.8				
MONOBLAST				- <b></b>						
NORMOBLAST ORTHO	18.0	23.2	24.2	21.0	21.6	17.0				
NORMOBLAST BASO	8.2	6.8	5.4	2.0	5.0	2.8				
☐ ☐ERYTHROBLAST	0.4	1.2	1.8	0.2	1.0	0.6				
□ CMEGALOBIAST	1.6		1.4		0.8	0.6				
PLASMA CELL	2.4	0.8	1.8	0.4	2.0	1.2				
R. E. CELL	0.6		1.6	0.4	1.0	0.2				